{
  "questions": [
    {
      "body": "Concizumab is used for which diseases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37341887",
        "http://www.ncbi.nlm.nih.gov/pubmed/35869698",
        "http://www.ncbi.nlm.nih.gov/pubmed/37146647",
        "http://www.ncbi.nlm.nih.gov/pubmed/37646676",
        "http://www.ncbi.nlm.nih.gov/pubmed/30137664",
        "http://www.ncbi.nlm.nih.gov/pubmed/28594458",
        "http://www.ncbi.nlm.nih.gov/pubmed/31394258",
        "http://www.ncbi.nlm.nih.gov/pubmed/30614620",
        "http://www.ncbi.nlm.nih.gov/pubmed/33570646",
        "http://www.ncbi.nlm.nih.gov/pubmed/33819375",
        "http://www.ncbi.nlm.nih.gov/pubmed/35465188",
        "http://www.ncbi.nlm.nih.gov/pubmed/25641556",
        "http://www.ncbi.nlm.nih.gov/pubmed/31444162",
        "http://www.ncbi.nlm.nih.gov/pubmed/30146094",
        "http://www.ncbi.nlm.nih.gov/pubmed/29931593",
        "http://www.ncbi.nlm.nih.gov/pubmed/29517971",
        "http://www.ncbi.nlm.nih.gov/pubmed/35290453",
        "http://www.ncbi.nlm.nih.gov/pubmed/35088769",
        "http://www.ncbi.nlm.nih.gov/pubmed/32008381",
        "http://www.ncbi.nlm.nih.gov/pubmed/29845491",
        "http://www.ncbi.nlm.nih.gov/pubmed/31676141",
        "http://www.ncbi.nlm.nih.gov/pubmed/34581771",
        "http://www.ncbi.nlm.nih.gov/pubmed/30408848",
        "http://www.ncbi.nlm.nih.gov/pubmed/30559263"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 599,
          "text": "Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Some non-factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are currently ongoing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869698"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 299,
          "text": "A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646676"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 174,
          "text": "Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646676"
        },
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 598,
          "text": "In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887"
        },
        {
          "offsetInBeginSection": 599,
          "offsetInEndSection": 736,
          "text": "This article summarizes the milestones in the development of concizumab leading to this first approval for the treatment of hemophilia B.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887"
        },
        {
          "offsetInBeginSection": 2086,
          "offsetInEndSection": 2226,
          "text": "Conclusion explorer™3 data support further clinical development of concizumab for use in people with hemophilia, with or without inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient\u0027s Perspectives.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33570646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "text": "Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 446,
          "text": "Prophylaxis with subcutaneous long-acting non-factor products that improve in vivo thrombin generation is now under intensive investigation (concizumab, fitusiran) or successfully employed (emicizumab) in haemophilia patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31676141"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 585,
          "text": "Concizumab is a monoclonal antibody (mAb) against tissue factor pathway inhibitor (TFPI), currently in clinical development as a subcutaneous prophylactic therapy for hemophilia A/B with and without inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30614620"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 656,
          "text": "A monoclonal antibody (concizumab) targeting tissue factor pathway inhibitor (TFPI) that can be administered subcutaneously (s.c.) has the potential to alter current concepts of prophylaxis in hemophilia.OBJECTIVES: To evaluate the safety and describe the pharmacokinetics and pharmacodynamics of single-dose concizumab in healthy volunteers and patients with hemophilia A or B.METHODS: In this first human dose, phase 1, multicenter, randomized, double-blind, placebo-controlled trial escalating single i.v.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25641556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 599,
          "text": "Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341887"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 739,
          "text": "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and blocking the factor Xa (FXa) active site. When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis. On the basis of this mechanism of action, concizumab is expected to be equally effective in hemophilia A and B, regardless of inhibitor status. Moreover, the concizumab mechanism of action does not interfere with the regulation of coagulation downstream of TFPI. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33570646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "BACKGROUND: Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous admi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37646676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 564,
          "text": "Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. Concizumab may represent a new opportunity for the treatment of persons with hemophilia, so there is much anticipation for the results of the ongoing trials still.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Concizumab is a humanized monoclonal antibody in clinical investigation directed against membrane-bound and soluble tissue factor pathway inhibitor (mTFPI and sTFPI) for treatment of hemophilia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31394258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "BACKGROUND: The anti-tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33819375"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29931593"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33570646"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 419,
          "text": "development of concizumab in people with hemophilia. SUMMARY: Background Concizumab is a humanized mAb targeting tissue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30137664"
        }
      ],
      "id": "65cfad2d1930410b13000014",
      "ideal_answer": [
        "Concizumab is developed for hemophilia A and B."
      ],
      "exact_answer": [
        [
          "hemophilia A"
        ],
        [
          "hemophilia B"
        ]
      ]
    },
    {
      "body": "What type of extracolonic tumors does the PMS2 germline mutation cause?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30161022",
        "http://www.ncbi.nlm.nih.gov/pubmed/25856668",
        "http://www.ncbi.nlm.nih.gov/pubmed/15256438",
        "http://www.ncbi.nlm.nih.gov/pubmed/19132747",
        "http://www.ncbi.nlm.nih.gov/pubmed/27435373",
        "http://www.ncbi.nlm.nih.gov/pubmed/29758216",
        "http://www.ncbi.nlm.nih.gov/pubmed/34357101",
        "http://www.ncbi.nlm.nih.gov/pubmed/18273873",
        "http://www.ncbi.nlm.nih.gov/pubmed/22714864",
        "http://www.ncbi.nlm.nih.gov/pubmed/15077197",
        "http://www.ncbi.nlm.nih.gov/pubmed/26110232",
        "http://www.ncbi.nlm.nih.gov/pubmed/18602922",
        "http://www.ncbi.nlm.nih.gov/pubmed/31056861",
        "http://www.ncbi.nlm.nih.gov/pubmed/17258725",
        "http://www.ncbi.nlm.nih.gov/pubmed/31860975"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 1516,
          "offsetInEndSection": 1675,
          "text": "Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30161022"
        },
        {
          "offsetInBeginSection": 454,
          "offsetInEndSection": 569,
          "text": "PMS2 mutation carriers had more extracolonic cancers although these differences were not statistically significant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22714864"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 553,
          "text": "pectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30161022"
        },
        {
          "offsetInBeginSection": 45,
          "offsetInEndSection": 158,
          "text": "PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25856668"
        }
      ],
      "id": "65f7736fc4010b4d78000024",
      "ideal_answer": [
        "Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer.",
        "The PMS2 germline mutation is associated with an increased risk of developing colorectal cancers (CRCs) that differ from sporadic CRCs in genetic and histologic features. In addition, tumors from patients with PMS2-associated Lynch syndrome have been found to be distinct from colorectal tumors associated with defects in other mismatch repair genes. , However, the PMS2 germline mutation does not cause extracolonic tumors, such as brain tumors, haematological malignancies, and signs of neurofibromatosis type 1, which are more commonly associated with biallelic MMR gene mutations. , In summary, the PMS2 germline mutation is primarily linked to the development of colorectal cancers with unique genetic and histological features, whereas extracolonic tumors are more frequently observed in individuals with biallelic MMR gene mutations.",
        "PMS2 is a mismatch repair gene that plays a critical role in maintaining genomic integrity. A germline mutation in PMS2 is associated with Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer syndrome). This mutation increases the risk of colorectal cancer and other extracolonic malignancies such as endometrial, ovarian, gastric, small bowel, pancreatic, ureter, and renal pelvis cancer",
        "The PMS2 germline mutation leads to café-au-lait macules, colonic polyps, and a unique range of tumors.",
        "PMS2 is one of the four DNA mismatch repair proteins, which plays a significant role in maintaining genomic stability. PMS2 germline mutation results in Lynch syndrome, which predisposes to various extracolonic tumors, including endometrial, ovarian, gastric, and urothelial cancers.",
        "PMS2 is a gene associated with Lynch syndrome, which is a hereditary predisposition to colorectal and extracolonic cancers. The extracolonic tumors associated with PMS2 germline mutation include gynecologic (endometrial and ovarian), urologic (urinary tract and renal pelvis), small bowel, pancreas, stomach, biliary tract, and skin (sebaceous neoplasms).",
        "PMS2 germline mutation causes extracolonic tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas small bowel and brain.",
        "The PMS2 gene is one of the mismatch repair genes that play a crucial role in maintaining genomic stability. Germline mutations in the PMS2 gene can lead to Lynch syndrome, which is an autosomal dominant disorder characterized by an increased risk of developing colorectal and other types of cancer. However, compared to other MMR genes such as MLH1 and MSH2, PMS2 germline mutations are less common and associated with a lower risk of cancer development. , Extracolonic tumors associated with PMS2 germline mutations include endometrial, gastric, small bowel, biliary tract, pancreatic, brain (usually glioblastoma), sebaceous skin tumors, and transitional cell carcinomas of the ureter and renal pelvis. However, it is important to note that the risk of developing extracolonic tumors in individuals with PMS2 mutations is lower than in those with MLH1 or MSH2 mutations. , It is also worth mentioning that PMS2 germline mutations have be",
        "The PMS2 germline mutation causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. The patient presented with multiple gastrointestinal tumors, which could not be distinguished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis. In addition, the cumulative incidence of extracolonic tumors was higher in females than males (p \u003d 0.001), including uterus and breast cancers. However, path_MLH1 variants are significantly more associated with the development of colorectal cancer than extracolonic tumors, while path_MSH2 variants show a greater frequency of extracolonic cancers, including ovarian cancer.",
        "PMS2 germline mutations are associated with an increased risk of extracolonic tumors, including tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas, small bowel, and brain in individuals with Lynch Syndrome.",
        "Germline mutations of the PMS2 gene are associated with an increased risk of colorectal cancer in individuals with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. However, PMS2 germline mutations are rarely associated with extracolonic tumors in familial aggregation of colorectal cancers.",
        "The PMS2 germline mutation is associated with an increased risk of developing various extracolonic malignancies, including but not limited to endometrial cancer, ovarian cancer, stomach cancer, small intestine cancer, hepatobiliary tract cancers (liver and bile duct), urinary tract tumors (kidney and ureter), brain tumors such as gliomas, skin cancers like melanoma, and pancreas cancer. The exact spectrum of extracolonic tumors can vary among different studies and populations, but these are the most commonly reported types associated with PMS2 mutations.",
        "Lynch syndrome, which can be caused by PMS2 germline mutations, predisposes to various extracolonic cancers including endometrial cancer, ovarian cancer, stomach cancer, renal pelvis and ureteral cancer, small bowel cancer, hepatobiliary tract cancer, pancreatic cancer, glioblastoma multiforme (in Turcot\u0027s variant), sebaceous skin tumors (in Muir-Torre variant), and more recently identified, breast and prostate cancers.",
        "The PMS2 germline mutation is associated with an increased risk of colorectal and endometrial cancer, but not with other Lynch syndrome-associated cancers. Heterozygous PMS2 mutation carriers have a small increased risk for colorectal and endometrial cancer. However, the mutation does not seem to increase the risk of other extracolonic tumors. Therefore, the answer is that PMS2 germline mutation causes colorectal and endometrial cancer, but not other Lynch syndrome-associated cancers.",
        "The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome. Lynch syndrome is a genetic disorder that increases the risk of many types of cancer, particularly cancers of the colon (colorectal cancer) and endometrium.",
        "The PMS2 germline mutation is associated with a slightly increased risk for colorectal and endometrial cancer. However, it does not appear to increase the risk for any other types of cancer associated with Lynch syndrome.",
        "The PMS2 germline mutation does not cause any extracolonic tumors.",
        "The PMS2 germline mutation is associated with an increased risk of developing extracolonic tumors, specifically endometrial cancer.",
        "The PMS2 germline mutation can cause several extracolonic tumors. These include cancers of the ovary, stomach, liver and biliary system, bladder, kidney, brain, breast, and prostate, as well as small bowel cancer. It is essential to monitor individuals with PMS2 mutations closely for these potential malignancies.",
        "Based on the provided abstract, a study was conducted to determine the age-specific cumulative risk (penetrance) of various cancers for carriers of heterozygous pathogenic PMS2 variants. The research involved a large dataset from a global collaboration and used modified segregation analysis while considering both genotyped and nongenotyped relatives. , The results showed that PMS2 mutation carriers had an increased risk for colorectal cancer and endometrial cancer compared to the general population. However, there was no clear evidence of an elevated risk for ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. , In conclusion, the PMS2 germline mutation primarily causes an increased risk for colorectal and endometrial cancers. The study did not find a significant association between PMS2 germline mutations and other Lynch syndrome-associated extracolonic tumors.",
        "The PMS2 germline mutation is predominantly associated with colorectal and endometrial cancer within the Lynch tumor spectrum. However, there is no clear evidence of an increased risk of other extracolonic tumors such as ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer.",
        "The PMS2 germline mutation causes extracolonic tumors, including endometrial cancer and colorectal and endometrial cancer."
      ],
      "exact_answer": [
        [
          "endometrial cancer",
          "ovarian cancer",
          "gastric cancer",
          "small bowell cancer",
          "ureter cancer",
          "urothelial cancers"
        ]
      ]
    },
    {
      "body": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37443640",
        "http://www.ncbi.nlm.nih.gov/pubmed/36889030",
        "http://www.ncbi.nlm.nih.gov/pubmed/31231783",
        "http://www.ncbi.nlm.nih.gov/pubmed/20075361",
        "http://www.ncbi.nlm.nih.gov/pubmed/18927265",
        "http://www.ncbi.nlm.nih.gov/pubmed/26731604",
        "http://www.ncbi.nlm.nih.gov/pubmed/23914326",
        "http://www.ncbi.nlm.nih.gov/pubmed/37849347",
        "http://www.ncbi.nlm.nih.gov/pubmed/22215237",
        "http://www.ncbi.nlm.nih.gov/pubmed/19122572",
        "http://www.ncbi.nlm.nih.gov/pubmed/17324369",
        "http://www.ncbi.nlm.nih.gov/pubmed/23666861",
        "http://www.ncbi.nlm.nih.gov/pubmed/24395523",
        "http://www.ncbi.nlm.nih.gov/pubmed/16299668",
        "http://www.ncbi.nlm.nih.gov/pubmed/19275628",
        "http://www.ncbi.nlm.nih.gov/pubmed/33204196",
        "http://www.ncbi.nlm.nih.gov/pubmed/12800780",
        "http://www.ncbi.nlm.nih.gov/pubmed/32755811",
        "http://www.ncbi.nlm.nih.gov/pubmed/29060173",
        "http://www.ncbi.nlm.nih.gov/pubmed/30680373",
        "http://www.ncbi.nlm.nih.gov/pubmed/37388591"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Sleep-Disordered Breathing and Prognosis after Ischemic Stroke: It Is Not Apnea-Hypopnea Index That Matters.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37443640"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 147,
          "text": " Sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37443640"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Post-stroke sleep disturbance and recurrent cardiovascular and cerebrovascular events: A systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889030"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 339,
          "text": "The relationship between sleep and stroke is complex: sleep disturbances are likely both a contributor to, and consequence of, stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "BACKGROUND AND PURPOSE: Obstructive sleep apnea (OSA) is seldom considered in the diagnostic investigation in the poststroke period although it is a stroke risk factor and has adverse prognostic implications after stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075361"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 628,
          "text": "Following stroke, patients have a high prevalence of OSA, which diminishes the potential for rehabilitation, increases the risk of secondary stroke, and heightens mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "More of the half of the stroke patients have sleep-disordered breathing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16299668"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 287,
          "text": "Obstructive sleep apnea, a form of sleep-disordered breathing, is associated with multiple major stroke risk factors but is also an independent risk factor for stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23914326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "The majority of stroke patients have clinically significant obstructive sleep apnea (OSA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395523"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke, but the impact of OSA on wake-up stroke (WUS) is not well studied. We aimed to determine the relationship between OSA and WUS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Obstructive Sleep Apnea (OSA) is a prevalent disease that has emerged as a new cerebrovascular disease (CVD) risk factor, which is independent of its association to hypertension, age and other known conditions that increase CVD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Obstructive sleep apnea (OSA) has been found to be an independent risk factor for stroke in large epidemiological studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666861"
        },
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 181,
          "text": "Obstructive sleep apnea (OSA) is prevalent after stroke and associated with recurrent stroke, prolonged hospitalization, and decreased functional recovery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37849347"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "The majority of stroke patients have clinically significant obstructive sleep apnea (OSA). Also, recent evidence demonstrates that OSA serves as an independent risk factor for stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395523"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 622,
          "text": "Obstructive sleep-disordered breathing (SDB), which includes primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compromise of respiratory gas exchange during sleep, related to transient upper airway narrowing disrupting ventilation, and causing oxyhemoglobin desaturation and poor sleep quality. SDB is common in chronic disorders and has significant implications for health. With prevalence rates globally increasing, this condition is causing a substantial burden on health care costs. Certain populations, including people with sickle cell disease (SCD), exhibit a greater prevalence of OSAS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33204196"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1548,
          "text": "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke, but the impact of OSA on wake-up stroke (WUS) is not well studied. We aimed to determine the relationship between OSA and WUS. We prospectively recruited 71 patients with mild to moderate ischemic stroke during hospitalization. Patients were classified into WUS and non-WUS. A full-night sleep respiratory study was performed between 3 and 14 days after stroke onset. Demographic data, sleep respiratory data, heart rate variability, stroke risk factors, stroke classification and sleep-related scales were recorded. We compared the differences in the variables between the two groups and determined the independent variables associated with WUS. Of the 71 patients, 26 (36.6%) had WUS. The patients with WUS had a significantly higher apnea-hypopnea index (23.1 ± 19.4 vs. 12.5 ± 11.9, p \u003d 0.016), obstructive apnea index (7.8 ± 9.7 vs. 3.0 ± 4.0, p \u003d 0.021) and lower mean blood oxygen saturation (95.1 ± 1.5 vs. 95.8 ± 1.3, p \u003d 0.046) than the non-WUS patients. There were no significant differences in demographic data, stroke risk factors, sleep-related scales or heart rate variability. Logistic regression revealed that severe sleep-disordered breathing (apnea-hypopnea index ≥30) was the only independent variable associated with WUS (OR 6.065, 95% CI 1.451-25.350; p \u003d 0.014). We conclude that in patients with mild to moderate ischemic stroke, OSA is the only risk factor associated with WUS, which cannot be distinguished clinically from n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319,
          "text": "Sleep-related breathing disorders are strongly associated with increased risk of stroke independent of known risk factors. The direction of causation favors sleep-disordered breathing leading to stroke rather than the other way around, although definitive proof of this awaits the results of prospective cohort studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12800780"
        },
        {
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1397,
          "text": "Based on a meta-analysis of the cohort studies, treatment with CPAP was associated with a lower incidence of stroke and cardiac events with relative risks of 0.27 [0.14-0.53], and 0.54 [0.38-0.75], respectively, although this could not be reproduced in the RCT and the studies using administrative data.CONCLUSIONS: Treating with CPAP in patients with OSA might decrease the risk of stroke, although there is some conflicting evidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26731604"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "BACKGROUND AND PURPOSE: Obstructive sleep apnea (OSA) has been shown to increase the risk of stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26731604"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 872,
          "text": "CPAP) treatment in these patients. Observational studies have shown an increased risk of ischemic stroke in patients with untreated OSA when compared with patients treated with CPAP; however, results",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231783"
        },
        {
          "offsetInBeginSection": 487,
          "offsetInEndSection": 710,
          "text": "The relationship between sleep-disordered breathing and stroke risk factors is complex, and likely part of the risk for cerebrovascular events is because of higher cardiovascular risk factors in patients with increased RDI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12800780"
        },
        {
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1585,
          "text": "poor functional prognosis.CONCLUSIONS: Severe OSA is an independent risk factor for a poor functional prognosis in patients with acute ischemic stroke, and quantitative EEG during sleep showed a significant slow wave enhancement, su",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36516602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Obstructive sleep apnea (OSA) increases the risk of stroke independent of known vascular and metabolic risk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18927265"
        },
        {
          "offsetInBeginSection": 18,
          "offsetInEndSection": 157,
          "text": "apnea (OSA) is a common disorder and the major sleep-related risk factor for cerebrovascular disease. There is a dose-response relationship",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17324369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 406,
          "text": "Obstructive Sleep Apnea (OSA) is a sleep disorder with a high prevalence in the general population. It is a risk factor for many cardiovascular diseases, and an independent risk factor for cerebrovascular diseases such as stroke. After an apnea episode, both arterial blood pressure and cerebral blood flow velocity change in function of the apnea duration (AD). We hypothesized that the relative excursion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29060173"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 341,
          "text": "Obstructive Sleep Apnea (OSA) is a common co-morbid condition in stroke patients. It represents a very important risk factor for stroke in addition to the other established ones such as hypertension, cardiovascular disease (CVD), hyperlipidemia, atrial fibrillation (AF), type 2 diabetes mellitus (T2DM), stress, smoking, and heavy drinking.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30680373"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Obstructive sleep apnea (OSA), prevalent in patients with stroke, increases the risks of cardiovascular events and stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32755811"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 248,
          "text": "OSA is an independent risk factor for acute ischemic stroke (AIS) and a contributor to other key risk factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37388591"
        },
        {
          "offsetInBeginSection": 370,
          "offsetInEndSection": 679,
          "text": "Obstructive sleep apnea (OSA), one of the most common and serious sleep disturbances, manifests itself in almost 50% of all stroke patients. Sleep apnea patients who experience a stroke may be at a greater impairment in their rehabilitation potential and have increased risk of secondary stroke and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19122572"
        }
      ],
      "id": "65f7080fc4010b4d78000019",
      "ideal_answer": [
        "Obstructive sleep apnea (OSA) is a common sleep disorder characterized by repetitive cessation or reduction in airflow during sleep and stroke patients have a higher risk of OSA.",
        "No, stroke patients do not have a lower risk of obstructive sleep apnea (OSA). In fact, studies suggest that the prevalence of OSA is higher among stroke patients compared to the general population. One study found that 79% of acute ischemic stroke patients had OSA, and another study found that 58% of stroke patients had OSA. Additionally, a study found that the severity of OSA was associated with poorer functional outcomes in stroke patients. This suggests that stroke patients are at higher risk for OSA and that proper screening and treatment of OSA may be important for their recovery and overall health. ",
        "Actually, stroke patients tend to have a higher risk of developing Obstructive Sleep Apnea.",
        "No, the majority of stroke patients have clinically significant obstructive sleep apnea (OSA). Observational studies have shown an increased risk of ischemic stroke in patients with untreated OSA, but results are not statistically significant. RCTs and meta-analyses have shown no significant ischemic stroke risk reduction in CPAP treated patients with OSA.",
        "There are no studies suggesting that stroke patients have a lower risk of Obstructive Sleep Apnea",
        "No, the fact that stroke patients have a higher risk of sleep-disordered breathing (SDB) and atrial fibrillation (AF) suggests that they have an increased, not decreased, risk of Obstructive Sleep Apnea.",
        "No, stroke patients have a higher risk of Obstructive Sleep Apnea.",
        "No, the majority of stroke patients have clinically significant obstructive sleep apnea (OSA), which indicates that stroke patients actually have a higher risk of OSA rather than a lower risk.",
        "No, sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes.",
        "Yes, obstructive sleep apnea is associated with stroke risk.",
        "No, stroke patients do not have a lower risk of Obstructive Sleep Apnea.",
        "No, stroke patients actually have a higher risk of sleep-disordered breathing, including obstructive sleep apnea, which is considered a risk factor for poor post-stroke outcomes.",
        "”We conclude that there is a significant association between stroke and OSA, and that the occurrence of stroke in patients with OSA is approximately 3 times higher than in the general population.\"}",
        "No, stroke patients do not have a lower risk of Obstructive Sleep Apnea (OSA). In fact, sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes.",
        "No, in fact, stroke patients have a higher risk of Obstructive Sleep Apnea. Sleep-disordered breathing, which includes Obstructive Sleep Apnea, is highly prevalent after a stroke and is considered a risk factor for poor post-stroke outcomes.",
        "No, stroke patients do not have a lower risk of Obstructive Sleep Apnea. In fact, they may have a higher risk due to the increased prevalence of sleep-disordered breathing after an ischemic stroke."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Should all babies diagnosed with spina bifida be operated within the first week of life?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35735913",
        "http://www.ncbi.nlm.nih.gov/pubmed/30486637",
        "http://www.ncbi.nlm.nih.gov/pubmed/36964773",
        "http://www.ncbi.nlm.nih.gov/pubmed/37970655",
        "http://www.ncbi.nlm.nih.gov/pubmed/2012704",
        "http://www.ncbi.nlm.nih.gov/pubmed/27179533",
        "http://www.ncbi.nlm.nih.gov/pubmed/37975651"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 324,
          "offsetInEndSection": 475,
          "text": "treatment for spina bifida has made great advancements, from surgical closure of the defect after birth to the now state-of-the-art intrauterine repair",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35735913"
        },
        {
          "offsetInBeginSection": 363,
          "offsetInEndSection": 479,
          "text": "Advances in fetal treatment have made minimally invasive prenatal surgery a realistic consideration for spina bifida",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637"
        },
        {
          "offsetInBeginSection": 571,
          "offsetInEndSection": 770,
          "text": "Prenatal surgery for spina bifida via open fetal surgery with hysterotomy decreases the rate of ventriculoperitoneal shunt placement and improves motor function compared to standard postnatal surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637"
        },
        {
          "offsetInBeginSection": 1643,
          "offsetInEndSection": 1673,
          "text": "fetoscopic spina bifida repair",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637"
        },
        {
          "offsetInBeginSection": 2124,
          "offsetInEndSection": 2158,
          "text": "prenatal treatment of spina bifida",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30486637"
        },
        {
          "offsetInBeginSection": 323,
          "offsetInEndSection": 401,
          "text": "Spina bifida should be found in utero for the immediate operation after birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2012704"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 334,
          "text": "Babies born with spina bifida require early closure surgery, done within the first 2-3 days after birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36964773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 555,
          "text": "OBJECTIVES: To determine if the lower extremity motor function of a fetus with open spina bifida deteriorates within a four-week interval between their first prenatal motor assessment at 22 weeks of gestation and second presurgical evaluation in cases operated at later gestational age (26-27 weeks of gestation), and to compare prenatal and postnatal motor function to the anatomical level of the lesion.METHODS: Multicenter cohort study involving cases from two centers that perform percutaneous fetoscopic repair of open spina bifida (SAFER technique).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37970655"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "PURPOSE: Clinical guidelines recommend repair of open spina bifida (SB) prenatally or within the first days of an infant\u0027s life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179533"
        },
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1522,
          "text": "Infants born in lower level nursery care hospitals with were less likely to have timely repairs (aPR \u003d 0.71, 95 % CI 0.52-0.98) than those born in higher level nursery care hospitals.CONCLUSIONS: Most infants with SB had surgical repair in the first 2 days of life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179533"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 219,
          "text": "To determine simple prenatal imaging parameters that can easily be acquired to predict the need for postnatal CSF diversion (PCD) surgery in fetuses undergoing open fetal surgery for open spina bifida (OSB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37975651"
        }
      ],
      "id": "65f859b2c4010b4d78000050",
      "ideal_answer": [
        "No, not all babies diagnosed with spina bifida should be operated on within the first week of life. The recommendation for treatment depends on the type and severity of spina bifida. Myelomeningocele, the most severe form, may benefit from prenatal surgery, which involves operating on the fetus while it is still in the uterus, before the 26th week of gestation. This approach can decrease the need for ventriculoperitoneal shunt placement and improve motor function compared to standard postnatal surgery. , On the other hand, spina bifida occulta, a milder form, usually does not require any surgical intervention, as many people with this condition do not experience symptoms. For some forms of spina bifida, such as meningocele, surgery may be recommended after birth to prevent infection and aid in protecting the spinal cord. , In summary, the decision for spina bifida treatment, including the timing and type of surgery, should be made on a case-by-case basis, taking into account various factors such as gestational age, lesion level, associated defects, and family considerations. Therefore, it is essential to consult with medical professionals specializing in fetal and pediatric care for personalized recommendations and guidance."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33805441",
        "http://www.ncbi.nlm.nih.gov/pubmed/35942670",
        "http://www.ncbi.nlm.nih.gov/pubmed/14526187",
        "http://www.ncbi.nlm.nih.gov/pubmed/29725764",
        "http://www.ncbi.nlm.nih.gov/pubmed/32842713",
        "http://www.ncbi.nlm.nih.gov/pubmed/34225694",
        "http://www.ncbi.nlm.nih.gov/pubmed/7795598",
        "http://www.ncbi.nlm.nih.gov/pubmed/22249111",
        "http://www.ncbi.nlm.nih.gov/pubmed/37634163",
        "http://www.ncbi.nlm.nih.gov/pubmed/25426070",
        "http://www.ncbi.nlm.nih.gov/pubmed/17110089",
        "http://www.ncbi.nlm.nih.gov/pubmed/31743248",
        "http://www.ncbi.nlm.nih.gov/pubmed/35025870",
        "http://www.ncbi.nlm.nih.gov/pubmed/16333769",
        "http://www.ncbi.nlm.nih.gov/pubmed/18432080",
        "http://www.ncbi.nlm.nih.gov/pubmed/37926637",
        "http://www.ncbi.nlm.nih.gov/pubmed/12619777",
        "http://www.ncbi.nlm.nih.gov/pubmed/12944420",
        "http://www.ncbi.nlm.nih.gov/pubmed/37923656",
        "http://www.ncbi.nlm.nih.gov/pubmed/37849345",
        "http://www.ncbi.nlm.nih.gov/pubmed/37519616",
        "http://www.ncbi.nlm.nih.gov/pubmed/3584810",
        "http://www.ncbi.nlm.nih.gov/pubmed/11742947",
        "http://www.ncbi.nlm.nih.gov/pubmed/10711989",
        "http://www.ncbi.nlm.nih.gov/pubmed/25860803",
        "http://www.ncbi.nlm.nih.gov/pubmed/9084936",
        "http://www.ncbi.nlm.nih.gov/pubmed/9585341",
        "http://www.ncbi.nlm.nih.gov/pubmed/15645184",
        "http://www.ncbi.nlm.nih.gov/pubmed/9601650",
        "http://www.ncbi.nlm.nih.gov/pubmed/16648376",
        "http://www.ncbi.nlm.nih.gov/pubmed/31537606",
        "http://www.ncbi.nlm.nih.gov/pubmed/36462961",
        "http://www.ncbi.nlm.nih.gov/pubmed/17296297",
        "http://www.ncbi.nlm.nih.gov/pubmed/5940325",
        "http://www.ncbi.nlm.nih.gov/pubmed/8689911",
        "http://www.ncbi.nlm.nih.gov/pubmed/25283883",
        "http://www.ncbi.nlm.nih.gov/pubmed/28575395",
        "http://www.ncbi.nlm.nih.gov/pubmed/30412104",
        "http://www.ncbi.nlm.nih.gov/pubmed/20184794",
        "http://www.ncbi.nlm.nih.gov/pubmed/16319127",
        "http://www.ncbi.nlm.nih.gov/pubmed/18577654",
        "http://www.ncbi.nlm.nih.gov/pubmed/16642034",
        "http://www.ncbi.nlm.nih.gov/pubmed/28361972",
        "http://www.ncbi.nlm.nih.gov/pubmed/20207626",
        "http://www.ncbi.nlm.nih.gov/pubmed/25831437",
        "http://www.ncbi.nlm.nih.gov/pubmed/30894671",
        "http://www.ncbi.nlm.nih.gov/pubmed/10555658",
        "http://www.ncbi.nlm.nih.gov/pubmed/21199860",
        "http://www.ncbi.nlm.nih.gov/pubmed/27980005",
        "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
        "http://www.ncbi.nlm.nih.gov/pubmed/11139982",
        "http://www.ncbi.nlm.nih.gov/pubmed/9392018",
        "http://www.ncbi.nlm.nih.gov/pubmed/12945950",
        "http://www.ncbi.nlm.nih.gov/pubmed/28590779",
        "http://www.ncbi.nlm.nih.gov/pubmed/27854203",
        "http://www.ncbi.nlm.nih.gov/pubmed/23399899",
        "http://www.ncbi.nlm.nih.gov/pubmed/30860873",
        "http://www.ncbi.nlm.nih.gov/pubmed/19484687",
        "http://www.ncbi.nlm.nih.gov/pubmed/19101703",
        "http://www.ncbi.nlm.nih.gov/pubmed/15864313",
        "http://www.ncbi.nlm.nih.gov/pubmed/21602480",
        "http://www.ncbi.nlm.nih.gov/pubmed/36691350",
        "http://www.ncbi.nlm.nih.gov/pubmed/19080757",
        "http://www.ncbi.nlm.nih.gov/pubmed/30837270",
        "http://www.ncbi.nlm.nih.gov/pubmed/9296168",
        "http://www.ncbi.nlm.nih.gov/pubmed/34380753",
        "http://www.ncbi.nlm.nih.gov/pubmed/35859342",
        "http://www.ncbi.nlm.nih.gov/pubmed/32804098",
        "http://www.ncbi.nlm.nih.gov/pubmed/35112761",
        "http://www.ncbi.nlm.nih.gov/pubmed/23815790",
        "http://www.ncbi.nlm.nih.gov/pubmed/21204267",
        "http://www.ncbi.nlm.nih.gov/pubmed/23793615",
        "http://www.ncbi.nlm.nih.gov/pubmed/25816335",
        "http://www.ncbi.nlm.nih.gov/pubmed/21316245",
        "http://www.ncbi.nlm.nih.gov/pubmed/31066242",
        "http://www.ncbi.nlm.nih.gov/pubmed/12673802",
        "http://www.ncbi.nlm.nih.gov/pubmed/11001936",
        "http://www.ncbi.nlm.nih.gov/pubmed/17138075"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33805441"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 210,
          "text": "Oculopharyngodistal myopathy (OPDM) is a rare adolescent or adult-onset neuromuscular disease that is characterized by progressive ocular, facial, pharyngeal and distal limb muscle weakness. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35942670"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37926637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare late-onset muscle disease associated with progressive dysphagia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37923656"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 201,
          "text": "Muscle weakness, and its association with mobility limitations, has received little study in oculopharyngeal muscular dystrophy (OPMD) using quantitative and standardized assessments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37849345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping, swallowing difficulties and proximal limb weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110089"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant muscular dystrophy which presents typically after the age of 50 with progressive eyelid drooping and an increasing difficulty in swallowing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7795598"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset neuromuscular degenerative disease characterized by ptosis, dysphagia, and proximal muscle weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25283883"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscular dystrophy characterized by late onset ptosis, proximal muscle weakness and swallowing difficulties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9601650"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16333769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Oculopharyngeal muscular dystrophy is a localized or restricted variety of muscular dystrophy, characterized by bilateral ptosis, myopathic facies, external ophthalmoplegia and dysphagia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5940325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late adult onset, autosomal dominant muscular dystrophy characterized by ptosis and dysphagia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9585341"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 930,
          "text": "OPMD is a unique disease sharing common pathogenic features with other polyalanine disorders, as well as with polyglutamine and dystrophic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110089"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a muscle disease of late onset associated with progressive ptosis of the eyelids, dysphagia, and unique tubulofilamentous intranuclear inclusions (INIs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14526187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic disorder with late-onset progressive myopathy affecting mainly head and neck striated muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8689911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37926637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant form of late-onset muscular dystrophy. Ptosis (droopy eyelids) and dysphagia (difficulty swallowing) are the most common presenting symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18432080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "RATIONALE: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset progressive muscle disorder typically characterized by ptosis, difficulty in swallowing, and proximal lim",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30412104"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a rare inherited muscular disorder, clinically characterized by late-onset, slowly progressive bilateral ptosis, dysphagia, and proximal limb weakness. A short polyalanine expansion in the polyadenylate binding-protein nuclear 1 (PABPN1) gene is a commonly report",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late onset neuromuscular disease characterised by proximal muscle weakness, ptosis, and swallowing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) belongs to the group of protein aggregation disorders and is caused by extensions of the N-terminal polyalanine stretch of the nuclear polyA-binding protein 1 (PABPN1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16319127"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late onset hereditary myopathy of autosomal dominant transmission characterised by ptosis, dysphagia and limb weakness. The disease is caused by short heterozygous expansions of a (GCN)(10) triplet located in the first exon of the PABPN1 gene at chromos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18577654"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "OBJECTIVE: Oculopharyngeal muscular dystrophy (OPMD) is a rare neuromuscular disorder characterized by late-onset development of bilateral eyelid ptosis, ophthalmoparesis and dysphagia with further progression to proximal limb muscle weakness that is an under recognized condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31743248"
        },
        {
          "offsetInBeginSection": 377,
          "offsetInEndSection": 1057,
          "text": "OPMD is caused by a short expansion of the alanine repeat (GCN trinucleotide) in the poly(adenylate)-binding protein nuclear1 (PABPN1) gene.METHODS: We performed a retrospective review of undiagnosed cases that initially presented with ptosis, diplopia, dysphagia, muscle weakness, muscular dystrophy and/or myasthenia gravis from 2000 to 2015 at two institutions in Southern California.RESULTS: Twenty-five patients were identified to have OPMD with genetic confirmation.CONCLUSIONS: Even though a rare condition, the prevalence is disproportionally frequent in certain ethnic groups and in certain regions; thus, we report our experience of OPMD patients in Southern California.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31743248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset syndrome characterized by progressive degeneration of particular muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16642034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361972"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37926637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 408,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset. OPMD is among the few triplet repeat diseases/ polyalanine (poly(A)) expansion diseases for which the function of the mutated gene is quite well established. The disease is characterised by slowly progressive bilateral ptosis, dysphagia and proximal limb weakness, appearing after the age of 40 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16333769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late onset neuromuscular disease characterised by proximal muscle weakness, ptosis, and swallowing difficulty. The only causative mutation described to date is a triplet repeat expansion consisting of two to seven additional base triplets in a repeat sequence in exon 1 of the polyadenine binding protein nuclear 1 (PABPN1) gene. This results in an increase in length of a polyalanine tract in the PABPN1 protein from 10 to 12-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "INTRODUCTION: Oculopharyngeal muscular dystrophy (OPMD) presents with progressive ptosis, dysphagia and limb girdle weakness, and is caused by expansion of a trinucleotide tandem repeat within the gene encoding poly-(A) bind",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) has long been characterized by a combination of bilateral ptosis and dysphagia and subsequent limb gird",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27854203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "OBJECTIVE: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset inherited neuromuscular disorder, with progressive ptosis and dysphagia as common mani",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant myopathy with almost benign course.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11139982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "It has been 10 years since the identification of the first PABPN1 gene (GCN)(n)/polyalanine mutations responsible for oculopharyngeal muscular dystrophy (OPMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19080757"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late onset myopathy usually presenting in the 5th or 6th decade of life with progressive ptosis, dysphagia and proximal muscle weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare progressive disease characterized by bilateral ptosis and dysphagia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3584810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease with worldwide distribution.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711989"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, primarily autosomal dominant disease caused by a short GCN expansion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30837270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal-dominant, adult-onset disorder defined by blepharoptosis, dysphagia, and proximal muscle weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a muscle disease of late onset associated with progressive ptosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14526187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy characterised by slowly progressive ptosis, dysphagia, and proximal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34225694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy caused by a polyalanine expansion mutation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199860"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping, swallowing difficulties and proximal limb",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110089"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive ptosis, dysphagia and p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12945950"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by ptosis, dysphagia and proximal limb",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207626"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619777"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 443,
          "text": "currently no cures. Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset, progressive disease that generally presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness. OPMD is caused by the abnormal expansion of a (GCG)n trinucleotide repeat in the coding region of the poly-(A) binding protein nuclear 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15864313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) has long been characterized by a combination of bilateral ptosis and dysphagia and subsequent",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27854203"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 539,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is caused by a small expansion of the polyalanine tract in the poly(A)-binding protein nuclear 1 (PABPN1). Aggregation of expanded PABPN1 into intranuclear inclusions (INIs) in skeletal muscle fibers is the pathological hallmark of OPMD. In this study what we have analyzed in muscle fibers of OPMD patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249111"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 291,
          "text": "OPMD is caused by a small expansion of a short polyalanine tract in the poly (A) binding protein nuclear 1 protein (PABPN1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17110089"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37519616"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disorder characterized by progressive dysphagia and bilateral ptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17138075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia), and proximal limb weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619777"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Oculopharyngeal muscular dystrophy (OPMD) is a muscle-specific, late-onset degenerative disorder whereby muscles of the eyes (causing ptosis), throat (leading to dysphagia), and limbs (causing proximal limb weakness) are mostly affected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25860803"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 168,
          "text": "utations in the gene encoding poly(A)-binding protein nuclear 1 (PABPN1) result in oculopharyngeal muscular dystrophy (OPMD). This disease is of late-onset",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 315,
          "text": "OPMD courses with muscle atrophy and weakness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574"
        }
      ],
      "id": "6446884b57b1c7a31500006f",
      "ideal_answer": [
        "Oculopharyngeal muscular dystrophy (OPMD) is a rare late-onset intractable neuromuscular disease, characterized by slowly progressive ocular, facial, pharyngeal and distal limb muscle weakness.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic disorder that affects the muscles in the eyes, throat, and limbs. It is caused by an abnormality in the PABPN1 gene, which codes for a protein involved in the development of muscle cells. The mutation leads to the accumulation of proteins in the nuclei of muscle cells, forming inclusions that disrupt normal cellular function. Symptoms typically begin in adulthood and progress slowly over time, affecting muscles responsible for eyelid movement, swallowing, and limb movement. Treatment options are limited, but research into the genetic mechanisms of OPMD is ongoing to develop potential therapeutic strategies.",
        "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset genetic disorder characterized by progressive eyelid drooping, difficulty swallowing, and proximal limb weakness. It typically manifests after the age of 50 and is caused by a mutation in the PABPN1 gene.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset progressive neuromuscular disorder, characterized by ptosis (droopy eyelids), dysphagia (difficulty swallowing), and limb-girdle weakness. It is inherited in an autosomal dominant manner due to mutations in the PABPN1 gene.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset, autosomal dominant muscular dystrophy characterized by ptosis, dysphagia, and proximal limb weakness. It is caused by an abnormal expansion of a GCG repeat in the PABPN1 gene.\n\nThe PABPN1 gene codes for a nuclear protein that is involved in RNA processing. OPMD is primarily a muscle disease, but it also presents in a minority of patients with sensorineural hearing loss. The age of onset, severity of symptoms, and the rate of progression are highly variable.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset genetic disorder characterized by progressive bilateral ptosis (drooping of the upper eyelids), dysphagia (difficulty swallowing), and limitation of extraocular movements, which can lead to diplopia (double vision). The disease may also progress to proximal limb muscle weakness. OPMD is caused by an expansion of a GCN trinucleotide repeat in the poly(adenylate)-binding protein nuclear1 (PABPN1) gene, leading to the accumulation of mutated PABPN1 protein and formation of intranuclear inclusions in affected tissues. It is inherited in an autosomal dominant or recessive manner, with variable penetrance and expressivity. While OPMD is considered a rare disorder, it may be underdiagnosed due to its nonspecific symptoms and the lack of awareness among healthcare professionals. Genetic testing can confirm the diagnosis and aid in appropriate clinical management.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness. It is caused by an abnormal alanine-encoding (GCN) trinucleotide repeat expansion in the first exon of the poly(A)-binding protein nuclear 1 (PABPN1) gene. OPMD can be inherited in an autosomal dominant or, rarely, autosomal recessive manner.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant inherited disorder characterized by progressive ptosis, dysphagia and proximal limb weakness. It is caused by an abnormal expansion of a trinucleotide repeat in the gene PABPN1, leading to aggregation of expanded protein into inclusions in muscle fibers.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness. It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1 of the PABPN1 gene. OPMD can be inherited in an autosomal dominant or recessive manner, with the dominant form being more common. The disease is characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, intractable myopathy characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset disease characterized by slowly progressive weakness in the eyelids (ptosis), difficulty swallowing (dysphagia), and weakness in the proximal limbs.",
        "OPMD is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness. It is an autosomal dominant disease caused by the expansion of a GCG trinucleotide repeat in exon 1 of the PABPN1 gene.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset intractable myopathy characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a genetic disorder characterized by a late-onset, slowly progressive muscle disease, or myopathy. It primarily affects the muscles of the upper eyelids (leading to ptosis or drooping of the eyelids) and the throat, causing difficulty in swallowing (dysphagia). Additionally, it can cause weakness in the proximal limbs, which are closer to the center of the body. The onset of this disease typically occurs in adulthood, often in individuals aged 40 to 60 years. OPMD is caused by mutations in the PABPN1 gene and is inherited in an autosomal dominant manner.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a genetic disorder characterized by muscle weakness that begins in adulthood, typically affecting the eyelids (leading to ptosis), throat muscles (causing dysphagia), and proximal limb muscles.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a type of late-onset myopathy, which is a disease that affects the muscles. It\u0027s characterized by slowly progressive symptoms such as ptosis, which is drooping or falling of the upper or lower eyelid, dysphagia, which is difficulty swallowing, and weakness in the proximal limbs, which are the limbs closest to the body\u0027s midline. This condition typically becomes apparent in adulthood",
        "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, incurable myopathy that affects the muscles of the eyelids, throat, and upper limbs. It causes progressive ptosis, difficulty swallowing, and weakness in the arms and legs. OPMD is an inherited disorder caused by mutations in the SGCB gene, which encodes a protein involved in maintaining muscle structure and function. The condition typically presents in individuals aged 50 to 69 years old and progresses slowly over time, leading to significant functional impairment and disability.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset neuromuscular disease characterized by progressive muscle weakness in the ocular, facial, pharyngeal, and distal limb muscles. It is caused by mutations in four genes, including CGG repeats in the 5\u0027-untranslated region of LRP12, GIPC1, NOTCH2NLC, and RILPL1. The disease is characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness, and patients may also experience suffocation, regurgitation of food, and aspiration pneumonia. Autologous myoblast transplantation has been suggested as a potential therapeutic approach to reduce swallowing problems in OPMD patients. Recent studies have shed light on the genetic and molecular mechanisms underlying OPMD, but more research is needed to fully understand its pathogenesis and develop effective treatments.",
        "Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, late-onset, and progressive muscle disorder characterized by ptosis, dysphagia, and proximal limb weakness."
      ]
    },
    {
      "body": "What is the mechanisms of action of Dersimelagon?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37043653",
        "http://www.ncbi.nlm.nih.gov/pubmed/37060458",
        "http://www.ncbi.nlm.nih.gov/pubmed/37078227",
        "http://www.ncbi.nlm.nih.gov/pubmed/36840969",
        "http://www.ncbi.nlm.nih.gov/pubmed/36050717",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665216"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 422,
          "text": "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Absorption, metabolism, and excretion of [14 C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36050717"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 719,
          "text": "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.METHODS: We conducted a randomized, placebo-controlled, phase 2 trial to investigate the efficacy and safety of dersimelagon with respect to the time to onset and the severity of symptoms associated with sunlight exposure in patients with erythropoietic protoporphyria or X-linked protoporphyria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 644,
          "text": "PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).METHODS: In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.RESULTS: Dersimelagon was generally well tolerated in healthy participants, with the most common TEAEs being lentigo (52.8%) and skin hyperpigmentation (50.0%) after multiple doses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 291,
          "text": "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 506,
          "text": "The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic sclerosis (SSc).METHODS: The effects of dersimelagon phosphoric acid (MT-7117) on skin fibrosis and lung inflammation were evaluated in bleomycin (BLM)-induced SSc murine models that were optimized for prophylactic and therapeutic evaluation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36050717"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840969"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 423,
          "text": "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "BACKGROUND: Activation of melanocortin 1 receptor (MC1R) is known to exert broad anti-inflammatory and anti-fibrotic effects. The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic scle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36050717"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36840969"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 472,
          "text": "xcruciating phototoxic attacks after exposure to visible light. Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.METHODS: We conducted a randomized, placebo-contr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37043653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37078227"
        }
      ],
      "id": "65d144731930410b13000040",
      "ideal_answer": [
        "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 that is being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis."
      ]
    },
    {
      "body": "What proportion of risk is attributable to obesity in colorectal cancer women development?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17823417",
        "http://www.ncbi.nlm.nih.gov/pubmed/37264099",
        "http://www.ncbi.nlm.nih.gov/pubmed/32791859",
        "http://www.ncbi.nlm.nih.gov/pubmed/23481261",
        "http://www.ncbi.nlm.nih.gov/pubmed/29259258",
        "http://www.ncbi.nlm.nih.gov/pubmed/30326010",
        "http://www.ncbi.nlm.nih.gov/pubmed/12117878",
        "http://www.ncbi.nlm.nih.gov/pubmed/17696248",
        "http://www.ncbi.nlm.nih.gov/pubmed/11169969",
        "http://www.ncbi.nlm.nih.gov/pubmed/19207714",
        "http://www.ncbi.nlm.nih.gov/pubmed/22312135",
        "http://www.ncbi.nlm.nih.gov/pubmed/33070559",
        "http://www.ncbi.nlm.nih.gov/pubmed/28703702",
        "http://www.ncbi.nlm.nih.gov/pubmed/17855691",
        "http://www.ncbi.nlm.nih.gov/pubmed/20843489",
        "http://www.ncbi.nlm.nih.gov/pubmed/27196525",
        "http://www.ncbi.nlm.nih.gov/pubmed/32868317"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1586,
          "text": "Colon cancer risk increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33).CONCLUSIONS: The association between obesity and colon and rectal cancer risk varies by sex and cancer site",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17823417"
        },
        {
          "offsetInBeginSection": 999,
          "offsetInEndSection": 1177,
          "text": " The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio \u003d 1.13 [1.10-1.17] in men, and hazard ratio \u003d 1.04 [1.01-1.18] in women, P \u003d 0.001). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264099"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 1015,
          "text": "Compared with individuals with normal weight, overweight and obese young adults had a significantly higher risk of CRC (relative risks (RR):18%, 95% CI:1.08, 1.28； RR:32%, 95% CI: 1.11, 1.56, respectively).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32791859"
        },
        {
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1210,
          "text": "cant from a BMI of 23.4 kg/m2 [spline analysis]) and women (HR for overweight, 1.54; 95% CI, 1.22-1.93; HR for obesity, 1.5",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736986"
        },
        {
          "offsetInBeginSection": 906,
          "offsetInEndSection": 1060,
          "text": "r association than females. Population attributable fraction for colorectal cancer by BMI ≥ 25 kg/m(2) was 3.62% (95% CI 1.91-5.30) for males and 2.62% (9",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21597097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1558,
          "text": "OBJECTIVE: Excess body weight, defined by body mass index (BMI), may increase the risk of colorectal cancer. As a prerequisite to the determination of lifestyle attributable risks, we undertook a systematic review and meta-analysis of prospective observational studies to quantify colorectal cancer risk associated with increased BMI and explore for differences by gender, sub-site and study characteristics.METHOD: We searched MEDLINE and EMBASE (to December 2007), and other sources, selecting reports based on strict inclusion criteria. Random-effects meta-analyses and meta-regressions of study-specific incremental estimates were performed to determine the risk ratio (RR) and 95% confidence intervals (CIs) associated with a 5 kg/m(2) increase in BMI.RESULTS: We analysed 29 datasets from 28 articles, including 67,361 incident cases. Higher BMI was associated with colon (RR 1.24, 95% CIs: 1.20-1.28) and rectal (1.09, 1.05-1.14) cancers in men, and with colon cancer (1.09, 1.04-1.12) in women. Associations were stronger in men than in women for colon (P \u003c 0.001) and rectal (P \u003d 0.005) cancers. Associations were generally consistent across geographic populations. Study characteristics and adjustments accounted for only moderate variations of associations.CONCLUSION: Increasing BMI is associated with a modest increased risk of developing colon and rectal cancers, but this modest risk may translate to large attributable proportions in high-prevalence obese populations. Inter-gender differences point to potentially important mechanistic diffe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19207714"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 938,
          "text": "The proportion of all cancers attributable to overweight has, however, never been systematically estimated. We reviewed the epidemiological literature and quantitatively summarised, by meta-analysis, the relationship between excess weight and the risk of developing cancer at the 6 sites listed above. Estimates were then combined with sex-specific estimates of the prevalence of overweight [body mass index (BMI) 25-29 kg/m(2)] and obesity (BMI \u003e or \u003d 30 kg/m(2)) in each country in the European Union to obtain the proportion of cancers attributable to excess weight. Overall, excess body mass accounts for 5% of all cancers in the European Union, 3% in men and 6% in women, corresponding to 27,000 male and 45,000 female cancer cases yearly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11169969"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1206,
          "text": "s would be avoided by 2040. The population attributable fractions (PAF) for excess weight were much higher for males (between 13.5% and 18.2%) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843489"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 1079,
          "text": "Among men, when the highest and lowest fifths were compared, BMI (HR \u003d 1.35, 95%CI: 1.13-1.61; Ptrend \u003c 0.0001), waist circumference (HR \u003d 1.66, 95%CI: 1.39-1.99; Ptrend \u003c 0.0001), waist-to-hip ratio (HR \u003d 1.58, 95%CI: 1.31-1.91; Ptrend \u003c 0.0001), total body fat percentage (HR \u003d 1.27, 95%CI: 1.06-1.53; Ptrend \u003d 0.002), and trunk fat percentage (HR \u003d 1.31, 95%CI: 1.09-1.58; Ptrend \u003d 0.002) were associated with greater colorectal cancer risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29259258"
        },
        {
          "offsetInBeginSection": 1632,
          "offsetInEndSection": 2377,
          "text": "Similar associations were observed among women without a family history of CRC and without lower endoscopy within the past 10 years. Both BMI at 18 years of age and weight gain since 18 years of age contributed to this observation. Compared with women with a BMI of 18.5 to 20.9 at 18 years of age, the RR of early-onset CRC was 1.32 (95% CI, 0.80-2.16) for women with a BMI of 21.0 to 22.9 and 1.63 (95% CI, 1.01-2.61) for women with a BMI of 23.0 or greater at 18 years of age (P \u003d .66 for trend). Compared with women who had gained less than 5.0 kg or had lost weight, the RR of early-onset CRC was 1.65 (95% CI, 0.96-2.81) for women gaining 20.0 to 39.9 kg and 2.15 (95% CI, 1.01-4.55) for women gaining 40.0 kg or more (P \u003d .007 for trend).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30326010"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 948,
          "text": " Compared to women with normal BMI, women who were obese had HRs of 1.39 (95%CI 1.12-1.74) and 1.64 (95%CI 1.24-2.16) for CRC and CC respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30448606"
        },
        {
          "offsetInBeginSection": 712,
          "offsetInEndSection": 1475,
          "text": " Compared with the reference group (WC 65-75), the HRs [95% confidence interval (CI)] of colorectal cancer in WC \u003c65, 75-85, 85-95, and \u003e95 groups were 1.01 (0.91-1.11), 1.02 (0.97-1.07), 1.09 (1.00-1.18), and 1.31 (1.12-1.52), respectively, in premenopausal women and 1.01 (0.95-1.17), 1.09 (1.07-1.12), 1.19 (1.00-1.18), and 1.30 (1.25-1.35), respectively, in postmenopausal women. Compared with the reference group (BMI 18.5-22.9), HRs (95% CI) for colorectal cancer in BMI \u003c18.5, 23-25, 25-30, and \u003e30 groups were 0.99 (0.87-1.14), 0.99 (0.94-1.06), 0.98 (0.92-1.04), and 1.06 (0.92-1.20), respectively, in premenopausal women. In postmenopausal women, those values were 0.99 (0.93-1.05), 1.05 (1.03-1.08), 1.11 (1.09-1.13), and 1.20 (1.16-1.25), respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868317"
        }
      ],
      "id": "65f7728fc4010b4d78000021",
      "ideal_answer": [
        "The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio \u003d 1.13 [1.10-1.17] in men, and hazard ratio \u003d 1.04 [1.01-1.18] in women, P \u003d 0.001).",
        "The population attributable fractions (PAFs) for excess weight were 24.3% for colon and 18.9% for rectum among women. This means that approximately 24.3% of colon cancer cases and 18.9% of rectum cancer cases in women are attributable to obesity.",
        "The study found that approximately 15.8% of the total costs in obesity-related cancers among women can be reduced, with a significant portion of this reduction coming from post-menopausal breast, liver, and colorectal cancers. However, the study does not provide a specific proportion of risk attributable to obesity in colorectal cancer women development.",
        "The exact proportion of colorectal cancer risk that is attributable to obesity can vary depending on the study and the population being considered. However, research has consistently shown that there is a positive association between excess body weight and an increased risk of developing colorectal cancer, particularly in women. Studies have estimated that approximately 3-5% of all colorectal cancers may be attributable to obesity among women. It\u0027s important to note that these estimates are based on observational studies and can fluctuate due to factors such as study design, sample size, and the specific measures used to define obesity.",
        "The population attributable fraction (PAF) for obesity in colorectal cancer in women is 9%.",
        "According to the provided information, the proportion of colorectal cancer risk attributable to obesity in women varies by population:\n\n- In Italian women, a decrease in waist-to-hip ratio below 0.82 might reduce colorectal cancer by 19%.\n\n- In Pacific women, the population attributable fraction (PAF) for obesity was 19%. \n\n- In Maori women, the PAF for obesity was 14%.\n\n- In European/other women, the PAF for obesity was 8%.\n\nOverall, obesity increases the risk of colorectal cancer in women by around 19%, but this varies from 8-19% depending on the specific population. The relative risk is estimated to be about 1.5 times higher in obese women compared to normal-weight women.",
        "1.04 [1.01-1.18]",
        "According to the provided snippets, the risk of colon cancer in women is associated with increasing waist circumference and waist-hip ratio, with a higher risk observed in men compared to women. Specifically, the hazard ratio for colon cancer in women was found to be 1.04 (95% CI: 1.01-1.18) per 10-cm increase in waist circumference, and 1.20 (95% CI: 1.08-1.33) per 0.1-unit increase in waist-hip ratio. However, the proportion of risk attributable to obesity in colorectal cancer women development is not explicitly stated in the provided snippets. , Therefore, we cannot provide a specific proportion of risk attributable to obesity in colorectal cancer women development based on the given information. However, it is clear that obesity is a significant risk factor for colon cancer in both men and women, and that the association between obesity and colon cancer risk varies by sex and cancer site.",
        "The hazard ratio for colon cancer risk in obese women is 1.04 [1.01-1.18], indicating a slight increase in risk associated with obesity.",
        "The proportion of risk attributable to obesity in the development of colorectal cancer among women is 1.04 (95% CI: 1.01-1.18).",
        "”BMI and/or the number of CTCs were significantly associated with the risk of CRC (P values of less than 0.001 for all). The proportion of risk attributable to BIM was 31% (95% confidence interval: 27% to 35%). The proportion of risk attributable to the number of CTCs was 49% (95% confidence interval: 43% to 55%).”}\u003c/s\u003e",
        "The proportion of risk attributable to obesity in colorectal cancer women development is 1.20 for each 0.1-unit increase in waist-hip ratio.",
        "16% of risk of colorectal cancer in women development is attributable to obesity.",
        "The exact proportion of risk attributable to obesity in colorectal cancer development in women is not specified in the provided documents. However, they do provide relative risk (RR) values for increases in waist circumference and waist-hip ratio, which are measures often associated with obesity. For every 10-cm increase in waist circumference, the RR is 1.16, and for every 0.1-unit increase in waist-hip ratio, the RR is 1.20. Additionally, the hazard ratio for colon cancer in obese women is 1.04, suggesting that obesity increases the risk of colon cancer in women by 4%. It\u0027s important to note that these are not direct measures of the proportion of risk attributable to obesity, but rather indications of the relative risk compared to non-obese individuals.",
        "Obesity increases the risk of developing colorectal cancer in women by a factor ranging from 1.04 to 1.18.",
        "According to the study, the proportion of risk attributable to obesity in colorectal cancer women development is 1.04 (hazard ratio) [1.01-1.18] in women, which means that obesity increases the risk of colorectal cancer in women by 4% (1.04-1.00) compared to non-obese women. This suggests that obesity plays a role in the development of colorectal cancer in women, but the effect size is relatively small compared to other risk factors.",
        "The specific proportion of risk attributable to obesity in colorectal cancer development in women is not explicitly stated in the provided snippets. However, it is indicated that an increase in waist circumference and waist-hip ratio is associated with an increased risk of colon cancer in women. For every 10-cm increase in waist circumference, the relative risk (RR) increases by 1.16. Similarly, for every 0.1-unit increase in waist-hip ratio, the RR increases by 1.20. Furthermore, women in the obese group had a hazard ratio of 1.04 for colon cancer, indicating a slightly increased risk compared to non-obese women. It\u0027s important to note that the association between obesity and colon and rectal cancer risk varies by sex and cancer site",
        "The risk of colon cancer increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33). The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio\\u2009\u003d\\u20091.13 [1.10-1.17] in men, and hazard ratio\\u2009\u003d\\u20091.04 [1.01-1.18] in women, P\\u2009\u003d\\u20090.001).",
        "Obesity contributes to an increased risk of colorectal cancer development in women, with a hazard ratio of 1.04 to 1.18. This indicates that a proportion of the risk of colon cancer in women can be attributed to obesity.",
        "The proportion of risk attributable to obesity in colorectal cancer development in women varies depending on the cancer site. For colon cancer, a 5-unit increase in body mass index (BMI) is associated with a 12% increased risk in women. However, for rectal cancer, there is a weak or no association between BMI and risk in women. Therefore, the proportion of risk attributable to obesity in colorectal cancer development in women is higher for colon cancer compared to rectal cancer.",
        "The proportion of risk attributable to obesity in colorectal cancer development in women is approximately 1.13-1.17 times that of men.",
        "The exact percentage may vary, but providing an approximate range or qualitative description would be helpful.   The study found that approximately 10-25% of colorectal cancer cases in women are attributable to obesity.",
        "In women, colon cancer risk increased by 16% per 10-cm increase in waist circumference (RR: 1.16; 95% CI: 1.09, 1.23) and by 20% per 0.1-unit increase in waist-hip ratio (RR: 1.20; 95% CI: 1.08, 1.33). Obese women had a 4% higher risk of colon cancer compared to non-obese women (hazard ratio \u003d 1.04; 95% CI: 1.01-1.18).",
        "In women, 1.04 times higher risk of colorectal cancer development is attributable to obesity.",
        "In women, obesity is associated with a 16% increased risk of developing colorectal cancer. This means that approximately 16% of the risk of colorectal cancer in women can be attributed to obesity."
      ],
      "exact_answer": [
        [
          "Hazard Ratio 1.04",
          "4%",
          "HR 1.04 (1.01-1.18) p\u003c0.001"
        ]
      ]
    },
    {
      "body": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37611653",
        "http://www.ncbi.nlm.nih.gov/pubmed/37484678",
        "http://www.ncbi.nlm.nih.gov/pubmed/36184377",
        "http://www.ncbi.nlm.nih.gov/pubmed/12691208",
        "http://www.ncbi.nlm.nih.gov/pubmed/26579955",
        "http://www.ncbi.nlm.nih.gov/pubmed/35272210",
        "http://www.ncbi.nlm.nih.gov/pubmed/34150406",
        "http://www.ncbi.nlm.nih.gov/pubmed/37987270",
        "http://www.ncbi.nlm.nih.gov/pubmed/29524515",
        "http://www.ncbi.nlm.nih.gov/pubmed/36311515",
        "http://www.ncbi.nlm.nih.gov/pubmed/38004320",
        "http://www.ncbi.nlm.nih.gov/pubmed/26371762",
        "http://www.ncbi.nlm.nih.gov/pubmed/34465250",
        "http://www.ncbi.nlm.nih.gov/pubmed/34855694",
        "http://www.ncbi.nlm.nih.gov/pubmed/30949077",
        "http://www.ncbi.nlm.nih.gov/pubmed/36713926",
        "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
        "http://www.ncbi.nlm.nih.gov/pubmed/35230652",
        "http://www.ncbi.nlm.nih.gov/pubmed/33972795",
        "http://www.ncbi.nlm.nih.gov/pubmed/36815187",
        "http://www.ncbi.nlm.nih.gov/pubmed/37404971",
        "http://www.ncbi.nlm.nih.gov/pubmed/36189781",
        "http://www.ncbi.nlm.nih.gov/pubmed/24648791",
        "http://www.ncbi.nlm.nih.gov/pubmed/30632995",
        "http://www.ncbi.nlm.nih.gov/pubmed/28741031",
        "http://www.ncbi.nlm.nih.gov/pubmed/28635375",
        "http://www.ncbi.nlm.nih.gov/pubmed/37709999",
        "http://www.ncbi.nlm.nih.gov/pubmed/30529341",
        "http://www.ncbi.nlm.nih.gov/pubmed/35700643"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment of posttraumatic stress disorder (PTSD). Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37611653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 381,
          "text": "Post-traumatic stress disorder (PTSD) is a prevalent psychiatric condition that significantly impacts daily functioning in patients but lacks adequate treatment options. 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for the treatment of PTSD has been studied increasingly for the last two decades and has shown promising results through quantitative data.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37484678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorde",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36184377"
        },
        {
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1112,
          "text": "MDMA-assisted psychotherapy has emerged as an innovative approach to treating PTSD, leading to sustained reductions in symptoms and even promoting post-traumatic growth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38004320"
        },
        {
          "offsetInBeginSection": 751,
          "offsetInEndSection": 907,
          "text": "MDMA can reduce PTSD symptoms even in treatment-resistant cases by increasing certain neurohormones, i.e., dopamine, serotonin, norepinephrine, and oxytocin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37987270"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 375,
          "text": "MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524515"
        },
        {
          "offsetInBeginSection": 1437,
          "offsetInEndSection": 1680,
          "text": "These findings suggest that MDMA enhances fear memory extinction through a BDNF-dependent mechanism, and that MDMA may be a useful adjunct to exposure-based therapies for PTSD and other anxiety disorders characterized by altered fear learning.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26371762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524515"
        },
        {
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1464,
          "text": "Based on the pharmacology of MDMA and the available translational literature of memory reconsolidation, fear learning, and PTSD, this review suggests a neurobiological rationale to explain, at least in part, the large effect sizes demonstrated for MDMA in treating PTSD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "3,4 Methylenedioxymethamphetamine (MDMA)-assisted therapy has been recently found to be highly effective for treatment of posttraumatic stress disorder (PTSD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34465250"
        },
        {
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1721,
          "text": "Finally, the amount of recovery from PTSD after MDMA-AT correlated with changes in four functional connections during autobiographical memory recall: the left amygdala-left posterior cingulate cortex (PCC), left amygdala-right PCC, left amygdala-left insula, and left isthmus cingulate-left posterior hippocampus.Discussion: Amygdala-insular functional connectivity is reliably implicated in PTSD and anxiety, and both regions are impacted by MDMA administration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36713926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524515"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 495,
          "text": ". A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose participants no longer met the diagnosis of PTSD after two MDMA sessions, compared to 23% in the control grou",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689"
        },
        {
          "offsetInBeginSection": 751,
          "offsetInEndSection": 908,
          "text": "MDMA can reduce PTSD symptoms even in treatment-resistant cases by increasing certain neurohormones, i.e., dopamine, serotonin, norepinephrine, and oxytocin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37987270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "BACKGROUND AND OBJECTIVE: Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35230652"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 552,
          "text": "We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33972795"
        },
        {
          "offsetInBeginSection": 613,
          "offsetInEndSection": 755,
          "text": "MDMA therapy for PTSD is now entering the final Phase 3 stage of drug development, with a target set for licensing by the FDA and EMA in 2021.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30949077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36311515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "INTRODUCTION: 3,4-Methylenedioxymethamphetamine (MDMA/\"ecstasy\") is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36189781"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 324,
          "text": "Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30949077"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 403,
          "text": "der (PTSD). A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for treating patients with severe PTSD compared to a therapy with placebo group (N",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36815187"
        },
        {
          "offsetInBeginSection": 1255,
          "offsetInEndSection": 1428,
          "text": "3,4-Methylenedioxymethamphetamine, which activates 5-HT2A receptors, has been successful in the treatment of PTSD and has recently achieved status as a breakthrough therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632995"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 374,
          "text": "The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12691208"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 290,
          "text": "nical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promisin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35272210"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 552,
          "text": "We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37404971"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) persistently improves symptoms of post-traumatic stress disorder (PTSD) when combined with psy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28741031"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 315,
          "text": "Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28635375"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37709999"
        },
        {
          "offsetInBeginSection": 805,
          "offsetInEndSection": 959,
          "text": "o have anxiolytic effects, whereas 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855694"
        },
        {
          "offsetInBeginSection": 2011,
          "offsetInEndSection": 2242,
          "text": "Finally, even though MDMA is listed as a Schedule I compound by the Drug Enforcement Agency, MDMA-assisted psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder is currently under investigation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24648791"
        },
        {
          "offsetInBeginSection": 55,
          "offsetInEndSection": 212,
          "text": "(MDMA, \u0027ecstasy\u0027) has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26371762"
        },
        {
          "offsetInBeginSection": 726,
          "offsetInEndSection": 1009,
          "text": "has shown that MDMA, used as a catalyst in psychotherapy, is effective in treating posttraumatic stress disorder (PTSD). This review also examines the psychopharmacological basis for the efficacy of MDMA-assisted psychotherapy. Specifically, the brain regions involved with both PTSD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26579955"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 416,
          "text": "FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the only ones in the world",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12691208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1445,
          "text": "Background: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as \"Molly\" or \"Ecstasy\", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the potential benefits in clinical trials for post-traumatic stress disorder (PTSD). A larger amount of data has been provided for the push in support of MDMA-assisted psychotherapy in these patients.  Objective: The aim of this article is to compute a meta-analysis and conduct a systematic review of the effects of MDMA on PTSD, discussing the potential benefits and adverse events relative to dosing and stability of treatment. Methods: Articles were collected and analyzed for systematic review: 16 articles were included in the systematic review that met the criteria for the use of MDMA in the treatment of PTSD as well as assessing the safety and efficacy of the drug in human participants. Ten studies were used for the meta-analysis, with a cumulative sample size of 168 patients. The significance of the findings on dosing and efficacy of MDMA in healthy human participants was quantified based on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD symptom scores. Results: The disorders for which MDMA demonstrated a net positive o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34150406"
        },
        {
          "offsetInBeginSection": 1286,
          "offsetInEndSection": 1511,
          "text": "These findings are consistent with a general memory-disrupting effect of MDMA and suggest that MDMA could augment psychotherapy by modifying fear memories during reconsolidation without necessarily enhancing their extinction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30529341"
        },
        {
          "offsetInBeginSection": 1551,
          "offsetInEndSection": 1785,
          "text": "These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33972795"
        },
        {
          "offsetInBeginSection": 974,
          "offsetInEndSection": 1124,
          "text": "In recent human-subject studies MDMA-assisted therapy resulted in significant improvement in PTSD symptoms with a good safety and side effect profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35700643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Clinical trials have demonstrated that 3,4-methylenedioxymethamphetamine (MDMA) paired with psychotherapy is more effective at reducing symptoms of post-traumatic stress disorder (PTSD) than psychotherapy or pharmacotherapy, alone or in combination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30529341"
        }
      ],
      "id": "65f490fac4010b4d78000010",
      "ideal_answer": [
        "Yes MDMA, a compound belonging to the family of entactogens, has been demonstrated to be useful to treat post-traumatic stress disorders.",
        "Yes, MDMA-assisted psychotherapy has shown promise in treating PTSD",
        "Yes, MDMA-assisted therapy has shown high efficacy in treating PTSD.",
        "MDMA (ecstasy) has been used in conjunction with psychotherapy to treat PTSD disorder and preliminary studies suggest that MDMA-assisted psychotherapy can be a safe and effective treatment approach for PTSD.",
        "Yes, MDMA-assisted psychotherapy has shown promise in addressing PTSD disorder among female subgroups.",
        "Yes, MDMA-assisted therapy (MDMA-AT) has been successfully used to treat PTSD disorder.",
        "Yes, 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with Phase III clinical trial evidence.",
        "Yes, MDMA has been successfully used to treat PTSD disorder.",
        "Yes, MDMA-assisted psychotherapy is effective for posttraumatic stress disorder.",
        "No, MDMA (ecstasy) has not been successfully used to treat PTSD disorder.",
        "Yes, clinical trials have shown promising safety and efficacy for the use of MDMA (ecstasy) in conjunction with psychotherapy for the treatment of posttraumatic stress disorder (PTSD). However, the mechanisms underlying this treatment form remain largely unestablished.",
        "Yes, MDMA has been successfully used as an adjunct to psychotherapy for treating PTSD, showing promising results in clinical trials over the last two decades.",
        "”Three patients with severe, treatment-resistant post-traumatic stress disorder (PTSD) were successfully treated with a single high-dose (300-mg) of 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, in a controlled clinical trial\"}",
        "Yes, MDMA-assisted psychotherapy has shown promising safety and efficacy in the treatment of PTSD.",
        "Yes, MDMA has been successfully used to treat PTSD disorder in conjunction with psychotherapy. Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.",
        "Yes, MDMA has been successfully used in treating PTSD.",
        "Yes, 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for the treatment of PTSD has been studied increasingly for the last two decades and has shown promising results through quantitative data.",
        "Yes, MDMA has been used successfully in conjunction with psychotherapy to treat PTSD. Clinical trials have shown promising results, although the exact mechanisms underlying this treatment are still being studied.",
        "Yes, MDMA (ecstasy) has been successfully used to treat PTSD disorder. Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is a spillover event?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37367190",
        "http://www.ncbi.nlm.nih.gov/pubmed/37672628",
        "http://www.ncbi.nlm.nih.gov/pubmed/28555073",
        "http://www.ncbi.nlm.nih.gov/pubmed/36379648",
        "http://www.ncbi.nlm.nih.gov/pubmed/29134435",
        "http://www.ncbi.nlm.nih.gov/pubmed/36169531",
        "http://www.ncbi.nlm.nih.gov/pubmed/35537080",
        "http://www.ncbi.nlm.nih.gov/pubmed/31401953",
        "http://www.ncbi.nlm.nih.gov/pubmed/31401965",
        "http://www.ncbi.nlm.nih.gov/pubmed/25667339",
        "http://www.ncbi.nlm.nih.gov/pubmed/16358422",
        "http://www.ncbi.nlm.nih.gov/pubmed/15540144",
        "http://www.ncbi.nlm.nih.gov/pubmed/32427175",
        "http://www.ncbi.nlm.nih.gov/pubmed/30096035",
        "http://www.ncbi.nlm.nih.gov/pubmed/37786724",
        "http://www.ncbi.nlm.nih.gov/pubmed/37007505",
        "http://www.ncbi.nlm.nih.gov/pubmed/35632729",
        "http://www.ncbi.nlm.nih.gov/pubmed/37321337",
        "http://www.ncbi.nlm.nih.gov/pubmed/29351657",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864994",
        "http://www.ncbi.nlm.nih.gov/pubmed/34018336"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1166,
          "text": "importance of assessing the zoonotic potential of widely distributed batborne CoV in order to monitor changes in genomic composition of viruses and prevent spillover events",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37367190"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 420,
          "text": "Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus and the leading cause of pediatric encephalitis in the Asian Pacific region. The transmission cycle primarily involves Culex spp. mosquitoes and Ardeid birds, with domestic pigs (Sus scrofa domestica) being the source of infectious viruses for the spillover of JEV from the natural endemic transmission cycle into the human population",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37672628"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 471,
          "text": "Spillover events, which involve the physical transfer of viral particles across species, could therefore be directly promoted by conditions of host ecology and environment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29134435"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Bats are the natural reservoir host for many pathogenic and non-pathogenic viruses, potentially spilling over to humans and domestic animals directly or via an intermediate host.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35537080"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 820,
          "text": "Here we aim to provide a synthetic explanation by arguing that domestication, horizontal gene transfer even between superkingdoms as well as gradual exchange of microbiome (microbiome succession) are essential in the whole scenario. We present a new perspective at the molecular level which can explain the observations of frequent pathogen spillover events at the ecological level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37007505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "H5N1 highly pathogenic avian influenza viruses (HPAIV) emerged in wild birds in Chile in December 2022 and spilled over into poultry, marine mammals, and one human.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37786724"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "Forecasting the risk of pathogen spillover from reservoir populations of wild or domestic animals is essential for the effective deployment of interventions such as wildlife vaccination or culling. Due to the sporadic nature of spillover events and limited availability of data, developing and validating robust, spatially explicit, predictions is challenging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33657095"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Nipah virus is a zoonotic virus harbored by bats and lethal to humans. Bat-to-human spillovers occur every winter in Bangladesh.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29351657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "INTRODUCTION: The increasing incidence of pathogen transmission from animals to humans (zoonotic spillover events) has been attributed to behavioural practices and ecological and socioeconomic change.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36379648"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 370,
          "text": "In the simplest form of human exposure, spillover occurs from the enzootic cycle when humans enter zoonotic foci and/or enzootic amplification increases circulation near humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358422"
        },
        {
          "offsetInBeginSection": 735,
          "offsetInEndSection": 993,
          "text": "Some viruses, such as Rift Valley fever, Japanese encephalitis and Venezuelan equine encephalitis viruses (VEEV) undergo secondary amplification involving replication in livestock animals, resulting in greater levels of spillover to humans in rural settings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358422"
        },
        {
          "offsetInBeginSection": 535,
          "offsetInEndSection": 699,
          "text": "Pathogen spillover occurs when epidemics in a host population are driven not by transmission within that population but by transmission from a reservoir population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15540144"
        },
        {
          "offsetInBeginSection": 433,
          "offsetInEndSection": 597,
          "text": "The detection of a virus in bats does not imply that spillover will occur and several biological, ecological and anthropogenic factors play a role in such an event.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32427175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Zoonotic spillover, which is the transmission of a pathogen from a vertebrate animal to a human, presents a global public health burden but is a poorly understood phenomenon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555073"
        },
        {
          "offsetInBeginSection": 905,
          "offsetInEndSection": 1066,
          "text": "Further surveillance of spillover events is warranted to assess the emergence and potential onward transmission of mammalian adapted H5N1 HPAIV in South America.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37786724"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 437,
          "text": "Emerging infectious diseases have posed growing medical, social and economic threats to humanity. The biological background of pathogen spillover or host switch, however, still has to be clarified. Disease ecology finds pathogen spillovers frequently but struggles to explain at the molecular level. Contrarily, molecular biological traits of host-pathogen relationships with specific molecular binding mechanisms predict few spillovers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37007505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "Zoonotic spillover is a phenomenon characterized by the transfer of pathogens between different animal species. Most human emerging infectious diseases originate from non-human animals, and human-related environmental disturbances are the driving forces of the emergence of new human pathogens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36169531"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 554,
          "text": "Despite their importance, little is known about their enzootic cycles of transmission, amplifying hosts and vectors, and biotic and abiotic factors involved in spillover events to humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35632729"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 268,
          "text": "Molecular data suggest that spillover from other hosts may be responsible for the emergence of this infectious disease, but the scale of such studies is limited.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30096035"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "The concept of environmental \"spillover\" of pathogens to humans is widely used in the scientific literature about emerging diseases with the idea that it is scientifically proven.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321337"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Zoonotic spillover is a phenomenon characterized by the transfer of pathogens between different animal species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36169531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "For pathogens known to transmit across host species, strategic investment in disease control requires knowledge about where and when spillover transmission is likely.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401965"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Pathogen spillover between different host species is the trigger for many infectious disease outbreaks and emergence events, and ecosystem boundary areas have been suggested as spatial hotspots of spillover.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401953"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 437,
          "text": "Investigating the processes that lead to spillover fundamentally involves interactions between animals, humans, pathogens and the environments they inhabit.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34018336"
        }
      ],
      "id": "65f843cbc4010b4d78000042",
      "ideal_answer": [
        "A spillover event is the transmission of a pathogen from one host species to another. It involves the physical transfer of viral or other infectious particles across species boundaries, and is often the trigger for infectious disease outbreaks and emergence events. Spillover events can be influenced by factors like host ecology, environment, habitat fragmentation, biodiversity loss, livestock density, and human-animal interactions.",
        "A spillover event is a situation in which a pathogen or disease agent is transmitted from one species to another, often through an intermediate host or vector. This can occur in various contexts, including between wildlife and domestic animals, or between humans and animals. The main cause of spillover events is habitat loss and fragmentation, which can lead to increased contact between different species and create opportunities for transmission."
      ]
    },
    {
      "body": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30506906",
        "http://www.ncbi.nlm.nih.gov/pubmed/28214269",
        "http://www.ncbi.nlm.nih.gov/pubmed/27179216",
        "http://www.ncbi.nlm.nih.gov/pubmed/21496632",
        "http://www.ncbi.nlm.nih.gov/pubmed/17567779",
        "http://www.ncbi.nlm.nih.gov/pubmed/10838246",
        "http://www.ncbi.nlm.nih.gov/pubmed/23349612",
        "http://www.ncbi.nlm.nih.gov/pubmed/17217858",
        "http://www.ncbi.nlm.nih.gov/pubmed/16550925",
        "http://www.ncbi.nlm.nih.gov/pubmed/12424964",
        "http://www.ncbi.nlm.nih.gov/pubmed/36897110",
        "http://www.ncbi.nlm.nih.gov/pubmed/37251241",
        "http://www.ncbi.nlm.nih.gov/pubmed/17013557",
        "http://www.ncbi.nlm.nih.gov/pubmed/22480903",
        "http://www.ncbi.nlm.nih.gov/pubmed/10732816",
        "http://www.ncbi.nlm.nih.gov/pubmed/10220866",
        "http://www.ncbi.nlm.nih.gov/pubmed/10080180",
        "http://www.ncbi.nlm.nih.gov/pubmed/10711990",
        "http://www.ncbi.nlm.nih.gov/pubmed/11731280",
        "http://www.ncbi.nlm.nih.gov/pubmed/1998333",
        "http://www.ncbi.nlm.nih.gov/pubmed/16585054",
        "http://www.ncbi.nlm.nih.gov/pubmed/37257496",
        "http://www.ncbi.nlm.nih.gov/pubmed/35607917",
        "http://www.ncbi.nlm.nih.gov/pubmed/10838245",
        "http://www.ncbi.nlm.nih.gov/pubmed/34026875",
        "http://www.ncbi.nlm.nih.gov/pubmed/9536090",
        "http://www.ncbi.nlm.nih.gov/pubmed/16804269",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622360",
        "http://www.ncbi.nlm.nih.gov/pubmed/3203701",
        "http://www.ncbi.nlm.nih.gov/pubmed/8042665",
        "http://www.ncbi.nlm.nih.gov/pubmed/19021551",
        "http://www.ncbi.nlm.nih.gov/pubmed/11930270",
        "http://www.ncbi.nlm.nih.gov/pubmed/22555292",
        "http://www.ncbi.nlm.nih.gov/pubmed/10814726",
        "http://www.ncbi.nlm.nih.gov/pubmed/3417305",
        "http://www.ncbi.nlm.nih.gov/pubmed/31645980",
        "http://www.ncbi.nlm.nih.gov/pubmed/11470279",
        "http://www.ncbi.nlm.nih.gov/pubmed/11503164"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 239,
          "text": "X-linked recessive EDMD patient ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30506906"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 713,
          "text": " Therefore, myoblast/fibroblast cultures from biopsy and tissue sections from a panel of nine Emery-Dreifuss muscular dystrophy patients (4 male, 5 female) including those carrying emerin and FHL1 (X-linked) and several lamin A (autosomal dominant) mutations were stained for the proteins linked to the disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28214269"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 581,
          "text": "he majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179216"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 429,
          "text": "EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion and is caused by mutations in proteins of the nuclear membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "BACKGROUND: Emery-Dreifuss muscular dystrophy (EDMD2) is a rare form of muscular dystrophy that is inherited as an autosomal dominant trait.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36897110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 207,
          "text": "The inheritance pattern of Emery-Dreifuss muscular dystrophy (EDMD) is X linked, whereas EDMD2 is autosomal dominant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349612"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 581,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD), a rare inherited disease, is characterized clinically by humero-peroneal muscle atrophy and weakness, multijoint contractures, spine rigidity and cardiac insufficiency with conduction defects. There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins. The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited disorder affecting skeletal and cardiac muscles and characterized by muscular atrophy, contractures, and cardiomyopathy with conduction defects. It can be X-linked or autosomal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480903"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 503,
          "text": "Emery-Dreifuss muscular dystrophy is characterized by the clinical triad of early onset contractures of elbows, Achilles tendons and spine, wasting and weakness with a predominantly humero-peroneal distribution and life-threatening cardiac conduction defects and/or cardiomyopathy. Two main types of inheritance have been described: the X-linked form is caused by mutations in the STA gene on locus Xq28 and the gene for the autosomal dominant form (LMNA gene) has been localized on chromosome 1q11-q23.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731280"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 359,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited disorder characterized by slowly progressive skeletal muscle weakness in a humero-peroneal distribution, early contractures and prominent cardiomyopathy with conduction block. Mutations in EMD, encoding emerin, and LMNA, encoding A-type lamins, respectively, cause X-linked and autosomal dominant EDMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17567779"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 577,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a muscular disorder characterized by 1) early contracture of the elbows. Achilles tendons and post-cervical muscles, 2) slowly progressive muscle wasting and weakness with a humeroperoneal distribution, and 3) life-threatening cardiomyopathy with conduction block. Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin. A rare autosomal dominant form of EDMD (AD-EDMD) is caused by mutations in lamin A/C gene (LMNA) on chromosome 1q21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424964"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 359,
          "text": "Mutations in EMD, encoding emerin, and LMNA, encoding A-type lamins, respectively, cause X-linked and autosomal dominant EDMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17567779"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Activation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery Dreifuss muscular dystro",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17567779"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 389,
          "text": "Autosomally inherited EDMD is caused by mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins associated with inner nuclear membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 139,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD2) is a rare form of muscular dystrophy that is inherited as an autosomal dominant trait",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36897110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner. X-linked EDMD is caused by mutations in EMD, which encodes an integral protein of the nuclear envelope inner membrane called emerin. Autosomally inherited EDMD is caused by mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins associated with inner nuclear membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 950,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is the third most common X-linked muscular dystrophy. This disorder is characterized by childhood onset of early contractures, humeroperoneal muscle atrophy, and cardiac conduction abnormalities. Weakness is slowly progressive, but there is a broad spectrum of clinical severity. Patients and carriers are at risk of sudden death. Regular cardiac evaluation is mandatory to assess the risk of cardiac arrhythmias. Unique atrial pathology is seen at autopsy. The mutated gene in EDMD is localized to the long arm of the X chromosome. Mutations in the gene lead to abolished synthesis of the gene product, emerin. Emerin is localized to the nuclear membrane of skeletal, cardiac, and smooth muscle. The term Emery-Dreifuss syndrome describes patients who have the EDMD phenotype without X-linked inheritance. There is no treatment for the underlying disease, but early placement of pacemakers may be lifesaving.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711990"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 429,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a progressive muscle-wasting disorder defined by early contractures of the Achilles tendon, spine, and elbows. EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion and is caused by mutations in proteins of the nuclear membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1310,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening. Two modes of inheritance exist, X-linked (OMIM 310300) and autosomal dominant (EDMD-AD; OMIM 181350). EDMD-AD is clinically identical to the X-linked forms of the disease. Mutations in EMD, the gene encoding emerin, are responsible for the X-linked form. We have mapped the locus for EDMD-AD to an 8-cM interval on chromosome 1q11-q23 in a large French pedigree, and found that the EMD phenotype in four other small families was potentially linked to this locus. This region contains the lamin A/C gene (LMNA), a candidate gene encoding two proteins of the nuclear lamina, lamins A and C, produced by alternative splicing. We identified four mutations in LMNA that co-segregate with the disease phenotype in the five families: one nonsense mutation and three missense mutations. These results are the first identification of mutations in a component of the nuclear lamina as a cause of inherited muscle disorder. Together with mutations in EMD (refs 5,6), they underscore the potential importance of the nuclear envelope components in the pathogenesis of neuromuscular disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10080180"
        },
        {
          "offsetInBeginSection": 75,
          "offsetInEndSection": 253,
          "text": "One family presented a rare autosomal dominant variant of Emery-Dreifuss muscular dystrophy, another with X-linked recessive inheritance showed unusual intrafamilial variability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042665"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 581,
          "text": "The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179216"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 302,
          "text": "Autosomal dominant EDMD caused by LMNA mutations is more common than the X-linked form and often more severe, with an earlier onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021551"
        },
        {
          "offsetInBeginSection": 575,
          "offsetInEndSection": 793,
          "text": "The most common etiology of autosomal dominant EDMD is an LMNA gene mutation; LMNA encodes the intermediate filament protein lamins A and C, which constitute the major scaffolding protein of the inner nuclear membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496632"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 460,
          "text": "Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner. X-linked EDMD is caused",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a progressive muscle-wasting disorder defined by early contractures of the Achilles tendon, spine, and elbows. EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is the third most common X-linked muscular dystrophy. This disorder is",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711990"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 581,
          "text": "There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins. The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "EDMD (Emery-Dreifuss muscular dystrophy) is caused by mutations in either the gene encoding for lamin A/C (LMNA) located at 1q21.2-q21.3 or emerin (EMD) located at Xq28. Autosomal dominant EDMD caused by LMNA mutations is more common than the X-linked form and often more severe, with an earlier onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021551"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 612,
          "text": "Clinically indistinguishable X-linked and autosomal forms of EDMD have been described. Mutations in the STA gene, encoding the nuclear envelope protein emerin, are responsible for X-linked EDMD, while mutations in the LMNA gene encoding lamins A and C by alternative splicing have been found in patients with autosomal dominant, autosomal recessive, and sporadic forms of EDMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11503164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 291,
          "text": "Emery-Dreifuss muscular dystrophy (EDMD) is a neuromuscular degenerative condition with an associated dilated cardiomyopathy and cardiac conduction defect. It can be inherited in either an X-linked or autosomal manner by mutations in the nuclear proteins emerin and lamin A/C, respectively. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17013557"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 398,
          "text": "Different subtypes of EDMD have been described, with the two most common forms represented by the X-linked EDMD1, caused by mutations in the EMD gene encoding emerin, and the autosomal EDMD2, due to mutations in the LMNA gene encoding lamin A/C. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37257496"
        }
      ],
      "id": "64467f8657b1c7a31500006d",
      "ideal_answer": [
        "EDMD can be inherited in an X-linked recessive, autosomal dominant or autosomal recessive fashion.",
        "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in an X-linked recessive, autosomal dominant, or autosomal recessive fashion.",
        "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion.",
        "Yes, EDMD can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion.",
        "Emery-Dreifuss Muscular Dystrophy can be inherited through X-linked, autosomal dominant, or autosomal recessive patterns."
      ],
      "exact_answer": [
        [
          "X-linked recessive"
        ],
        [
          "autosomal dominant"
        ],
        [
          "autosomal recessive"
        ]
      ]
    },
    {
      "body": "Can valproate be used during pregnancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36433783",
        "http://www.ncbi.nlm.nih.gov/pubmed/36287388",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401747",
        "http://www.ncbi.nlm.nih.gov/pubmed/37485793",
        "http://www.ncbi.nlm.nih.gov/pubmed/37294532",
        "http://www.ncbi.nlm.nih.gov/pubmed/36828241",
        "http://www.ncbi.nlm.nih.gov/pubmed/37684052",
        "http://www.ncbi.nlm.nih.gov/pubmed/38061552",
        "http://www.ncbi.nlm.nih.gov/pubmed/36381886",
        "http://www.ncbi.nlm.nih.gov/pubmed/18360539",
        "http://www.ncbi.nlm.nih.gov/pubmed/25400349",
        "http://www.ncbi.nlm.nih.gov/pubmed/19198722",
        "http://www.ncbi.nlm.nih.gov/pubmed/38062774",
        "http://www.ncbi.nlm.nih.gov/pubmed/35926210",
        "http://www.ncbi.nlm.nih.gov/pubmed/28953852",
        "http://www.ncbi.nlm.nih.gov/pubmed/21216127",
        "http://www.ncbi.nlm.nih.gov/pubmed/24161312",
        "http://www.ncbi.nlm.nih.gov/pubmed/27875769",
        "http://www.ncbi.nlm.nih.gov/pubmed/26329145",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460259",
        "http://www.ncbi.nlm.nih.gov/pubmed/19892633",
        "http://www.ncbi.nlm.nih.gov/pubmed/3114906",
        "http://www.ncbi.nlm.nih.gov/pubmed/18062721"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1038,
          "offsetInEndSection": 1279,
          "text": "Compared to lamotrigine, there was an increased risk of malformations associated with valproate (n \u003d 2,031, aRR \u003d 2.05, 95% CI \u003d 1.70-2.46) and topiramate (n \u003d 509, aRR \u003d 1.81, 95% CI \u003d 1.26-2.60), which increased in a dose-dependent manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36433783"
        },
        {
          "offsetInBeginSection": 1509,
          "offsetInEndSection": 1860,
          "text": "Valproate was associated with several malformation subtypes, including nervous system, cardiac, oral clefts, clubfoot, and hypospadias, whereas lamotrigine and carbamazepine were not.INTERPRETATION: Topiramate is associated with an increased risk of MCM similar to that associated with valproate, but lower doses may mitigate the risks for both drugs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36433783"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "INTRODUCTION: Prenatal exposure to valproate and related substances is associated with a risk of malformations and/or neurodevelopmental disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36287388"
        },
        {
          "offsetInBeginSection": 1647,
          "offsetInEndSection": 1793,
          "text": "Increased awareness and compliance among healthcare professionals regarding risk minimization measures could limit prenatal exposure to valproate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36287388"
        },
        {
          "offsetInBeginSection": 1792,
          "offsetInEndSection": 1947,
          "text": "CONCLUSIONS: Our proof-of-concept analysis based on GePaRD showed a strong association between intrauterine exposure to VPA and occurrence of spina bifida.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828241"
        },
        {
          "offsetInBeginSection": 439,
          "offsetInEndSection": 598,
          "text": "Major congenital malformations (MCMs) in offsprings of mothers exposed to valproate during pregnancy have been reported in international scientific literature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828241"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 1112,
          "text": "Valproate, in monotherapy and polytherapy, has been associated with elevated risk of major congenital malformations and neurodevelopmental disorders in children born to mothers who took it. Topiramate and phenobarbital are also associated with elevated risks of congenital malformations and neurodevelopmental disorders, though the risks are lower than those of valproate. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37684052"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 385,
          "text": "Valproic acid (VPA), a widely prescribed first-line antiepileptic drug for epilepsy and various neurological conditions, has been associated with a 4-fold increase in the risk of NTDs when used during pregnancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38062774"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 892,
          "text": "This finding suggests the need for reappraisal of the use of valproate in women who may become pregnant or are pregnant whilst the drug is taken.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18360539"
        },
        {
          "offsetInBeginSection": 430,
          "offsetInEndSection": 499,
          "text": "Valproate of sodium should be avoided, if possible, during pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216127"
        },
        {
          "offsetInBeginSection": 453,
          "offsetInEndSection": 604,
          "text": "At valproate doses of 1400 mg and below per day, the mean rate of pregnancies with fetal malformations was 6.42% and did not seem to be dose-dependent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18360539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "Valproic acid (VPA, valproate, Depakote) is a commonly used anti-seizure medication (ASM) in the treatment of epilepsy and a variety of other neurological disorders. While VPA and other ASMs are efficacious for management of seizures, they also increase the risk for adverse pregnancy outcomes, including neural tube defects (NTDs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35265619"
        },
        {
          "offsetInBeginSection": 820,
          "offsetInEndSection": 1293,
          "text": "Sodium valproate is a known teratogen, and is discouraged in pregnancy, but what choice is open to women who rely on this medication to stabilise their mood?CONCLUSIONS: The large majority of women of childbearing age with bipolar disorder should not be prescribed sodium valproate as the risks to the unborn fetus far outweigh the benefits of the medication, as other drugs have similar if not better efficacy to stabilize the mother\u0027s mood, with lower risks to the fetus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953852"
        },
        {
          "offsetInBeginSection": 481,
          "offsetInEndSection": 598,
          "text": "The use of valproate is contraindicated during pregnancy due to teratogenicity and neurocognitive delay and deficits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161312"
        },
        {
          "offsetInBeginSection": 764,
          "offsetInEndSection": 1278,
          "text": "Spina bifida is the only specific major congenital malformation significantly associated with exposure to Carbamazepine monotherapy Despite the small number of studies on the teratogenic effects of new antiepileptic drugs, the analysis of the literature shows that exposure of the fetus to the new antiepileptic drugs is associated with a lower risk of major congenital malformations compared to the use of older drugs.EXPERT OPINION: Where possible, Valproate should be avoided in women of childbearing potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26329145"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 443,
          "text": "BACKGROUND: The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress. In addition, intrauterine exposure to valproic acid has been associated with an increased risk of central nervous system abnormalities, primarily neural t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "PURPOSE: Valproate is an effective wide-spectrum anti-epileptic drug that is also known to be teratogenic. Its administration in epileptic women remains contr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27875769"
        },
        {
          "offsetInBeginSection": 701,
          "offsetInEndSection": 812,
          "text": "Therefore, we strongly recommend avoidance of valproic acid and supplementation of folic acid during pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400349"
        },
        {
          "offsetInBeginSection": 810,
          "offsetInEndSection": 958,
          "text": "Therefore, we recommend that valproic acid must be avoided during pregnancy, as new generation of anticonvulsant drugs have emerged into the market.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "BACKGROUND: The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460259"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 500,
          "text": "Women of childbearing age taking valproate should be warned of its teratogenicity and advised to plan pregnancies, take a higher dose of folate, discuss reducing the dose of valproate or changing the medication with their physician, and have antenatal screening.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892633"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 844,
          "text": "It also includes the importance of awareness among middle-aged women with mental illness regarding the teratogenic effects of sodium valproate use and the relevance of discussion by physicians with patients regarding the usage of this drug despite being aware of the complications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36381886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Sodium valproate is a teratogen responsible for a wide range of abnormalities, including neural tube defects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892633"
        },
        {
          "offsetInBeginSection": 594,
          "offsetInEndSection": 958,
          "text": "Sodium valproate, a widely used anticonvulsant and mood regulator, is a well-recognized teratogen that can result in severe limb deformities, craniosynostosis, neural tube defects and neurodevelopmental retardation. Therefore, we recommend that valproic acid must be avoided during pregnancy, as new generation of anticonvulsant drugs have emerged into the market.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198722"
        },
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 700,
          "text": "Sodium valproate, a widely used anticonvulsant and mood regulator, is a well-recognized teratogen that can result in facial dysmorphism, craniosynostosis, neural tube defects, and neurodevelopmental retardation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400349"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Valproic acid use during pregnancy results in an absolute risk for spina bifida of 1-2%. This increased risk is comparable to the recurrence risk for neural tube defects and warrants informed counselling and access to prenatal diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3114906"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "Within several years after receiving U.S. Food and Drug Administration (FDA) approval in the late 1970s, valproate was shown to increase the risk for major congenital malformations and learning disabilities in the offspring of women who used the drug during pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35926210"
        },
        {
          "offsetInBeginSection": 1034,
          "offsetInEndSection": 1152,
          "text": "The teratogenic effects of valproic acid appear to be dose dependent, with higher risks at dosage levels \u003e1000 mg/day.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18062721"
        }
      ],
      "id": "65d12b451930410b13000031",
      "ideal_answer": [
        "No. Valproate is associated with high risk of malformations and should no be used during pregnancy."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Which dietary compounds are associated with colorectal cancer incidence?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33591366",
        "http://www.ncbi.nlm.nih.gov/pubmed/34455534",
        "http://www.ncbi.nlm.nih.gov/pubmed/7576993",
        "http://www.ncbi.nlm.nih.gov/pubmed/29873077",
        "http://www.ncbi.nlm.nih.gov/pubmed/33596716",
        "http://www.ncbi.nlm.nih.gov/pubmed/21700901",
        "http://www.ncbi.nlm.nih.gov/pubmed/25954732",
        "http://www.ncbi.nlm.nih.gov/pubmed/37740374",
        "http://www.ncbi.nlm.nih.gov/pubmed/20400781",
        "http://www.ncbi.nlm.nih.gov/pubmed/12737716",
        "http://www.ncbi.nlm.nih.gov/pubmed/28205448",
        "http://www.ncbi.nlm.nih.gov/pubmed/24659930",
        "http://www.ncbi.nlm.nih.gov/pubmed/8381240",
        "http://www.ncbi.nlm.nih.gov/pubmed/17700421",
        "http://www.ncbi.nlm.nih.gov/pubmed/33410363",
        "http://www.ncbi.nlm.nih.gov/pubmed/8850441",
        "http://www.ncbi.nlm.nih.gov/pubmed/10422555",
        "http://www.ncbi.nlm.nih.gov/pubmed/23577027",
        "http://www.ncbi.nlm.nih.gov/pubmed/12718613"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 2093,
          "offsetInEndSection": 2288,
          "text": "This umbrella review found convincing evidence of an association between lower CRC risk and higher intakes of dietary fiber, dietary calcium, and yogurt and lower intakes of alcohol and red meat.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33591366"
        },
        {
          "offsetInBeginSection": 1826,
          "offsetInEndSection": 2134,
          "text": "high red meat intake was positively associated with risk of breast cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, and high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34455534"
        },
        {
          "offsetInBeginSection": 2135,
          "offsetInEndSection": 2276,
          "text": "Higher risk of colorectal, colon, rectal, lung, and renal cell cancers were also observed with high total red and processed meat consumption.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34455534"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 326,
          "text": "Epidemiological studies have shown that a high fat (or meat) intake is associated positively and a high starch, fibre (non-starch polysaccharide), vegetable and fruit intake negatively with colorectal cancer incidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7576993"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 401,
          "text": "Consumption of high amounts of red and processed meat and low intake of fiber and multiple protective phytochemicals found in fruits, vegetables, and whole grains might be responsible for the high incidence of this neoplasm in the Western world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2633,
          "text": "Although the etiology of colorectal cancer is multifactorial, experimental evidence suggests a role for dietary factors in the promotion of this disease. The complex interrelations governing energy balance and the consumption of fat, fiber, and micronutrients make it difficult to define the precise role of specific dietary factors in the etiology of colorectal neoplasms. Epidemiologic studies have demonstrated a correlation between the prevalence of colorectal cancer and per capita consumption of meat and fat. Case-control studies investigating the relation between colorectal cancer and dietary fat consumption have yielded inconsistent results. Prospective studies have failed to demonstrate a relation between fat consumption and subsequent risk for colorectal cancer. There is an inverse correlation between fiber intake and the prevalence of colorectal carcinoma. A more detailed analysis of the influence of various types of dietary fiber on the subsequent risk for colorectal cancer will provide a better understanding of this relation. Fiber derived from fruits and vegetables may provide more effective protection than cereal fibers. Correlational studies have established an association between total caloric intake and the prevalence of colorectal carcinoma. The design of future studies investigating the influence of individual dietary constituents on the risk for colorectal cancer must control for variations in energy balance as a confounding variable. Recent evidence suggests that a variety of micronutrients, including calcium, vitamin D, selenium, and vitamins A, C, and E, exert an anticarcinogenic effect. Studies designed to evaluate the influence of alcohol consumption on colorectal carcinogenesis have yielded inconclusive results. The potential influence of food preparation methods on colorectal carcinogenesis requires further evaluation. There is no conclusive evidence to support any of the hypotheses proposed to explain the role of dietary factors in colorectal carcinogenesis. Intervention trials designed to monitor intermediate markers for colorectal cancer such as increased epithelial-cell proliferation rates and the development of aberrant crypt architecture provide the opportunity for testing these hypotheses in relatively short-term studies. The results from such studies can be utilized in the design of large-scale, long-term prospective studies to evaluate the influence of dietary factors on the development of colorectal neoplasms. These trials should generate the information required to develop strategies for diet modification to reduce the incidence of colorectal carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8381240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1614,
          "text": "The association between diet and colorectal cancer has been studied in depth for many decades, with equivocal results. It has been hypothesized that cancers arising in the distal and proximal colon have different pathologies, and therefore different risk factors. As such, it is possible that diet-related factors might influence colorectal neoplasia differently depending on the subsite. Recent evidence indicates that women may be more likely to develop proximal cancers than men. Additionally, the link between certain dietary factors and colorectal neoplasia in women seems to vary by menopausal status. Given these observations, women may be affected differently than men by diet-related factors. The objective of this article was therefore to review the data for diet and colorectal adenomas and cancer, and then attempt to address the potential differences in the association of diet-related factors and colorectal neoplasia in men and women. For total energy intake, selenium, and fiber, it seems that there may be slightly stronger effects in men as compared with women, whereas calcium and folate seem to affect both sexes similarly. With regard to vitamin D and colorectal cancer, women may exhibit stronger associations than men. Perhaps the most evidence for a sex-specific effect is observed for obesity, where more substantial direct relationships between body size and colorectal neoplasia have been reported for men than for women. However, this observation may be influenced by the differential effects in women by menopausal status. Further research on sex-specific dietary effects is warranted.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17700421"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 321,
          "text": "Alcoholic beverages enhance the risk of cancer of the oral cavity, pharynx, larynx and oesophagus, while the relation is less well established for cancer in the stomach, pancreas, colon, rectum and breast.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10422555"
        },
        {
          "offsetInBeginSection": 715,
          "offsetInEndSection": 928,
          "text": "For alcohol, there seems to be a stronger association with rectal cancer than with colon cancer, and for meat a somewhat stronger association with distal colon and rectal cancer, relative to proximal colon cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23577027"
        },
        {
          "offsetInBeginSection": 443,
          "offsetInEndSection": 561,
          "text": "Further, meat consumption is associated with increased risk but this, too, is not explained solely by its fat content.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8850441"
        },
        {
          "offsetInBeginSection": 1173,
          "offsetInEndSection": 1509,
          "text": "Incidences of colorectal cancer were positively associated with fat and oil intake, of both plant and animal types; a positive link was noted with animal protein but the association with plant protein consumption was inverse, as was also the case for carbohydrate and cereals; no simple association was evident with total energy intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12718613"
        },
        {
          "offsetInBeginSection": 315,
          "offsetInEndSection": 602,
          "text": "The endogenous formation of N-nitroso compounds is a possible explanation because red and processed meat, but not white meat or fish, cause a dose-dependent increase in faecal ATNCs (apparent total N-nitroso compounds) and the formation of nitroso-compound-specific DNA adducts in humans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956350"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 921,
          "text": "High intakes of total lipid (ORT3 vs T1 \u003d 4.15, 95% CI: 1.33-12.96, p for trend \u003d 0.034), saturated fatty acid (ORT3 vs T1 \u003d 2.96, 95% CI: 1.24-7.04, p for trend \u003d 0.016) and monounsaturated fatty acid (ORT3 vs T1 \u003d 3.04, 95% CI: 1.23-7.54, p for trend \u003d 0.018) were significantly associated with increased incidence of colorectal cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954732"
        },
        {
          "offsetInBeginSection": 1721,
          "offsetInEndSection": 1867,
          "text": " eating a diet high in total lipid, saturated fatty acids and monounsaturated fatty acids is associated with higher incidence of colorectal cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954732"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 937,
          "text": "In conjunction with obesity and physical inactivity, which induce a state of insulin resistance, certain dietary patterns that stimulate insulin secretion, including high intakes of red and processed meats, saturated and trans-fats, and highly processed carbohydrates and sugars, may increase the risk of colon cancer. There is evidence suggesting that some component of red meat may independently increase the risk of colorectal cancer, and some micronutrients may be important as protective agents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12737716"
        },
        {
          "offsetInBeginSection": 957,
          "offsetInEndSection": 1077,
          "text": ". Conversely, acidic food, reheated food, meat, spicy food, and alcohol are associated with the increment case of cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33410363"
        },
        {
          "offsetInBeginSection": 751,
          "offsetInEndSection": 1026,
          "text": " Increased colorectal cancer risk regarding the lowest vs the highest intake quartile emerged for: vitamin B12 (3.41), cholesterol (3.15), total fat (2.87), saturated fat (1.98), animal protein (1.95), energy (1.85), alcohol (1.70), iron (1.49), refined carbohydrates (1.39).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15989062"
        }
      ],
      "id": "65f7725ec4010b4d78000020",
      "ideal_answer": [
        "Red and red processed meat, lower intakes of dietary fiber and alcohol are associated with colorectal cancer incidence",
        "Several dietary compounds have been associated with colorectal cancer incidence, including fiber, folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. A case-control study conducted in Melbourne, Australia found that high intakes of folate, methionine, vitamins B6 and B12, and selenium were associated with a lower risk of colorectal cancer. Additionally, dietary vitamins E and C, and lycopene showed protective effects against colorectal cancer. Other compounds such as phenolic compounds, carotenoids, iridoids, nitrogen compounds, organosulfur compounds, phytosterols, essential oil compounds, and polyunsaturated fatty acids have also been found to have chemopreventive properties against colorectal cancer in vitro, laboratory animals, and clinical trials. These compounds may act through various molecular and biochemical mechanisms, including inhibition of cell growth, apoptosis, interaction with gut microbiota, and regulation of cellular signal transduction pathways.",
        "There is a considerable consensus in the scientific community that colorectal cancer (CRC) is associated with the consumption of high levels of fat, processed and red meats and low intake of fruit, vegetables and fiber. Specific dietary components that have been identified to play a role in CRC carcinogenesis include heme iron, phosphatidylcholine, bile acids, heterocyclic amines (HCAs), polycyclic aromatic hydrocarbons (PAHs) and advanced glycation end products (AGEs).",
        "Dietary fiber, dairy products, calcium and folate are negatively associated with colorectal cancer risk, while processed red meat, alcohol, obesity and lack of physical activity increase the risk. Diets high in fruits, vegetables and fish are inversely associated with colorectal cancer.",
        "Dietary compounds associated with colorectal cancer incidence include red meat, saturated fats, bile acids, and fatty acids, which are linked to increased risk. Conversely, calcium, probiotics, and prebiotics are associated with a decrease in fecal water toxicity and potentially lower colorectal cancer risk. Additionally, a proinflammatory diet, high-DII diets, and specific dietary components like alcohol and certain types of fats have been linked to an increased risk of colorectal cancer, particularly for colon cancer. The insulin-like growth factor (IGF) system components and plasma IGF-I levels have also been correlated with colon cancer incidence rates.",
        "Several dietary compounds have been associated with colorectal cancer incidence, including vegetables, fiber, meat, folate, calcium, phytochemicals, and alcohol. Vegetables, particularly cruciferous vegetables, have been found to be associated with a lower risk of colorectal cancer. Fiber alone does not account for this association. Meat consumption, especially when cooked and producing mutagenic compounds like heterocyclic amines, is associated with an increased risk. Other dietary factors such as folate, calcium, and phytochemicals may also play a role. Alcohol consumption has been inconsistently associated with increased risk. It is important to note that personalized nutrition and protective diets are areas of ongoing research in colorectal cancer prevention.",
        "Dietary factors that have been associated with an increased risk of colorectal cancer include high intake of red and processed meats, as well as foods rich in saturated fats. Conversely, diets high in fiber, particularly from whole grains, fruits, and vegetables, are believed to reduce the risk of CRC due to their potential to modulate gut microbiota composition and improve bowel function. Additionally, some studies have suggested that certain dietary components such as folate, calcium, vitamin D, and antioxidants may also play a role in colorectal cancer prevention. However, it is important to note that the relationship between specific dietary compounds and CRC incidence can be complex and may vary depending on other factors like overall diet quality, lifestyle habits, genetic predisposition, and individual metabolic differences.",
        "Dietary compounds that have been associated with colorectal cancer incidence include red meat, processed meat, unprocessed red meat, total white meat, poultry and fish, and meat-related compounds such as heme iron, nitrate, nitrite, heterocyclic amines (HCAs), and benzo(a)pyrene (B(a)P). A meta-analysis of 18 studies found that specific flavonoid subclasses, such as procyanidins and isoflavones, showed protective effects against colorectal cancer risk. However, there was no enough evidence indicating that increased consumption of total flavonoids were significantly associated with reduced risk of colorectal cancer. The highest quintile of heme iron was associated with increased cancer risk only in the distal colon and rectum, while the highest quintile of HCAs and nitrate/nitrite were associated with increased risk of total colorectal cancer. Right and left subsites of the colon may have distinct susceptibilities to meat and possibly other dietary risk factors, suggesting that the causes of colorectal cancer may vary across anatomical subsites.",
        "High meat and fat diets, low starch, low fiber, low vegetable diets, high-meat diets that increase the level of nitrosatable material in the colon, processed or red meat, low dietary fiber, alcohol, low intake of fruits, vegetables and cereals, high intake of animal fat, low intake of polyphenols, low intake of spices, low intake of vitamin B12, cholesterol, total fat, saturated fat, animal protein, energy, iron, refined carbohydrates, low intake of n-3 fatty acids, insoluble fiber, folate, flavonoids, vitamin E, isoflavones, beta-carotene, selenium, copper, vitamin B6, low intake of deep-yellow vegetables, dark-green vegetables, onions and garlic.",
        "Dietary compounds associated with colorectal cancer incidence include: * Total lipid, saturated fatty acids, and monounsaturated fatty acids (increased incidence) * Dietary fiber and vitamin C (reduced incidence) * Traditional rice cake consumption (inversely associated with colorectal cancer incidence)",
        "Several dietary compounds are associated with colorectal cancer incidence:\n\nPositively associated (increased risk):\n- High intake of fat and oil (both plant and animal types)\n- High intake of animal protein \n- Diets high in animal fat\n- Consumption of processed or red meat, especially when cooked at high temperatures\n- Diets low in fiber and high in refined carbohydrates like sugar\n\nInversely associated (decreased risk):\n- High intake of plant protein\n- High intake of carbohydrates and cereals\n- High intake of total fiber, cereal fiber, calcium, and phosphorus \n- Diet high in vegetables like Brussels sprouts, cabbage and broccoli\n- Micronutrients involved in DNA methylation, synthesis and repair (folate, methionine, vitamins B6 and B12) \n- Micronutrients with antioxidant properties (selenium, vitamins E and C, lycopene)\n\nIn summary, a diet high in fiber, calcium, certain vitamins and minerals, and vegetables, but low in animal fat and red/processed meat, is associated with reduced colorectal cancer risk. Specific dietary components can influence colorectal cancer risk, likely through effects on inflammation and DNA damage/repair.",
        "Based on the provided snippets, there are several dietary compounds that have been associated with colorectal cancer incidence. These include: * High intake of red meat, which has been positively associated with risk of colorectal, colon, rectal, and lung cancers. * High intake of processed meat, which has been positively associated with risk of breast, colorectal, colon, rectal, and lung cancers. * Low intake of dietary fiber, which has been inversely associated with risk of colorectal cancer. * High intake of dietary calcium, which has been inversely associated with risk of colorectal cancer. * High intake of yogurt, which has been inversely associated with risk of colorectal cancer. , It is important to note that these associations are based on observational studies and further research is needed to confirm the findings and understand the underlying mechanisms. Additionally, it\u0027s worth mentioning that other factors such as lifestyle, genetics, and environmental factors may also play a role in colorectal cancer development.",
        "High intake of red meat and processed meat is associated with an increased risk of colorectal cancer. This includes both colon and rectal cancers. On the other hand, higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol, are associated with a lower risk of colorectal cancer. Therefore, a diet rich in fiber, calcium, and yogurt, and low in red and processed meat and alcohol, may help reduce the risk of developing colorectal cancer.",
        "High intake of red meat and processed meat is associated with an increased risk of colorectal, colon, and rectal cancers. This includes meats like beef, pork, and lamb, as well as processed meats such as sausages, hot dogs, and deli meats. On the other hand, higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol, are associated with a lower risk of colorectal cancer. Therefore, a diet rich in fiber, calcium, and yogurt, and low in red and processed meats and alcohol, may help reduce the risk of developing colorectal cancer.",
        "Dietary fiber, dietary calcium, and yogurt are associated with lower colorectal cancer incidence, while high red meat and processed meat intake is associated with higher colorectal cancer incidence.",
        "Dietary compounds associated with colorectal cancer incidence include dietary fiber, dietary calcium, and yogurt, which are associated with a lower risk of colorectal cancer. On the other hand, alcohol, red meat, and processed meat are associated with a higher risk of colorectal cancer.",
        "The incidence of colorectal cancer is associated with higher intakes of red and processed meats, and lower intakes of dietary fiber, dietary calcium, yogurt, as well as alcohol consumption.",
        "Some dietary compounds associated with colorectal cancer incidence are red meat, processed meat, and alcohol. A diet low in fiber and calcium may also increase the risk. However, consuming yogurt has been found to have a protective effect.",
        "The umbrella review of meta-analyses indicates that certain dietary factors are associated with colorectal cancer (CRC) incidence. Specifically, there is convincing evidence of an association between higher intakes of dietary fiber, dietary calcium, and yogurt, as well as lower intakes of alcohol and red meat, with a lower risk of CRC. On the other hand, high consumption of red meat and processed meat is associated with an increased risk of CRC, colon cancer, rectal cancer, and lung cancer. Moreover, total red and processed meat consumption is positively associated with greater risks of colorectal, colon, rectal, lung, and renal cell cancers. Therefore, these dietary compounds have been consistently linked to CRC incidence and should be considered in strategies for cancer prevention.",
        "The incidence of colorectal cancer (CRC) is associated with both dietary compounds and habits. According to the umbrella review, there is strong evidence that a higher intake of dietary fiber, dietary calcium, and yogurt is associated with a lower risk of CRC. On the other hand, higher consumption of alcohol and red meat is linked to an increased risk of CRC. Specifically, high red meat intake is positively associated with the risk of CRC, among other types of cancer. Similarly, high processed meat intake is also positively associated with the risk of CRC. Therefore, a diet rich in fiber, calcium, and yogurt, and low in alcohol, red meat, and processed meat, could potentially reduce the risk of developing CRC",
        "Higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. Conversely, high intake of alcohol and red meat, including processed meat, is associated with an increased risk of colorectal cancer.",
        "There is convincing evidence that higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. On the other hand, higher intakes of red meat and alcohol are associated with an increased risk of colorectal cancer.",
        "The dietary compounds associated with colorectal cancer incidence are red meat and processed meat. High red meat intake was positively associated with risk of breast cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, and high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers.",
        "The umbrella review of meta-analyses of prospective observational studies found convincing evidence of an association between lower colorectal cancer (CRC) risk and higher intakes of dietary fiber, dietary calcium, and yogurt. Additionally, there was evidence of an inverse association between moderate alcohol consumption and CRC risk. The review also found that high red meat intake was positively associated with risk of CRC, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, while high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers. Furthermore, higher risk of colorectal, colon, rectal, lung, and renal cell cancers were observed with high total red and processed meat consumption.",
        "Red meat, processed meat, yogurt, dietary fiber, dietary calcium, and alcohol are associated with colorectal cancer incidence.",
        "Based on the evidence, the following dietary factors are associated with colorectal cancer (CRC) risk:\n\nHigher CRC risk is associated with higher intakes of alcohol and red/processed meat.\n\nLower CRC risk is associated with higher intakes of dietary fiber, dietary calcium, and yogurt.\n\nIn summary, diets high in fiber, calcium and yogurt, and low in alcohol and red/processed meats are linked to reduced colorectal cancer incidence.",
        "Higher intakes of dietary fiber, dietary calcium, and yogurt are associated with a lower risk of colorectal cancer. Conversely, higher intakes of alcohol and red meat are associated with an increased risk of colorectal cancer.",
        "Lower intake of dietary fiber, dietary calcium, and yogurt are associated with higher risk of colorectal cancer. On the other hand, higher intake of alcohol and red meat, particularly processed meat, is associated with an increased risk of colorectal cancer."
      ],
      "exact_answer": [
        [
          "Red meat"
        ],
        [
          "Red processed meat",
          "Red meat intake"
        ],
        [
          "Lower intakes of dietary fiver",
          "Low fiver level"
        ],
        [
          "Alcohol"
        ],
        [
          "Polyphenols",
          "Dietary polyphenols"
        ],
        [
          "Total lipid",
          "Fatty acid",
          "Saturated fatty acid",
          "Monounsaturated fatty acid",
          "Total fat"
        ],
        [
          "Highly processed carbohydrates",
          "Sugars"
        ],
        [
          "Spicy food"
        ],
        [
          "Vitamin B12"
        ],
        [
          "Total caloric intake"
        ],
        [
          "Nitroso compounds",
          "Nitrate",
          "Nitrite"
        ]
      ]
    },
    {
      "body": "What is the relationship between  Electroporation (EP) and DNA vaccines?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36992261",
        "http://www.ncbi.nlm.nih.gov/pubmed/38063059",
        "http://www.ncbi.nlm.nih.gov/pubmed/15110305",
        "http://www.ncbi.nlm.nih.gov/pubmed/19619001",
        "http://www.ncbi.nlm.nih.gov/pubmed/21180650",
        "http://www.ncbi.nlm.nih.gov/pubmed/38034030",
        "http://www.ncbi.nlm.nih.gov/pubmed/37860767",
        "http://www.ncbi.nlm.nih.gov/pubmed/17961089",
        "http://www.ncbi.nlm.nih.gov/pubmed/18847301",
        "http://www.ncbi.nlm.nih.gov/pubmed/21530212",
        "http://www.ncbi.nlm.nih.gov/pubmed/25535102",
        "http://www.ncbi.nlm.nih.gov/pubmed/18353952",
        "http://www.ncbi.nlm.nih.gov/pubmed/18989354",
        "http://www.ncbi.nlm.nih.gov/pubmed/24510831",
        "http://www.ncbi.nlm.nih.gov/pubmed/24510835",
        "http://www.ncbi.nlm.nih.gov/pubmed/22284894",
        "http://www.ncbi.nlm.nih.gov/pubmed/31174938",
        "http://www.ncbi.nlm.nih.gov/pubmed/36365078",
        "http://www.ncbi.nlm.nih.gov/pubmed/28646234",
        "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
        "http://www.ncbi.nlm.nih.gov/pubmed/17239494",
        "http://www.ncbi.nlm.nih.gov/pubmed/21752954",
        "http://www.ncbi.nlm.nih.gov/pubmed/22644389",
        "http://www.ncbi.nlm.nih.gov/pubmed/22894954",
        "http://www.ncbi.nlm.nih.gov/pubmed/23684840",
        "http://www.ncbi.nlm.nih.gov/pubmed/20951666",
        "http://www.ncbi.nlm.nih.gov/pubmed/23085605"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 260,
          "text": "Electroporation (EP) is an effective way to increase the immunogenicity of DNA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38063059"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 378,
          "text": "n this study, we challenged this concept by characterizing the immunological response induced by a plasmid DNA vaccine delivered using electroporation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36992261"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Intradermal delivery of DNA vaccines via electroporation (ID-EP) has shown clinical promise, but the use of needle electrodes is typically required to achieve consistent results",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38034030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "In vivo electroporation (EP) has been shown to augment the immunogenicity of plasmid DNA vaccines, but its mechanism of action has not been fully characterized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18353952"
        },
        {
          "offsetInBeginSection": 1445,
          "offsetInEndSection": 1559,
          "text": "These data establish EP as a potent method for stimulating humoral responses induced by DNA vaccination in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19619001"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 655,
          "text": "Electroporation (EP), a promising approach that dramatically enhances expression of the encoded antigen as well as the potency and immunogenicity of DNA vaccines, could facilitate clinical implementation of DNA vaccination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17961089"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 347,
          "text": "Electroporation (EP) has emerged as an effective method for delivering DNA vaccines, significantly enhancing humoral and cellular responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15110305"
        },
        {
          "offsetInBeginSection": 639,
          "offsetInEndSection": 865,
          "text": "DNA Electroporation may prove to be the \"missing link\" in the evolution of DNA vaccines allowing for enhanced immune responses from DNA vaccination in humans thereby resulting in protection from disease post-pathogen exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510831"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 919,
          "text": "In vivo EP has the key features of improved DNA uptake, increased antigen expression and a local inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21180650"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 717,
          "text": "DNA vaccines have been proposed as a promising approach for introducing foreign antigens into the host for inducing protective immunity against infectious and cancer diseases. Nevertheless, because of their poor immunogenicity, plasmid DNA vaccination strategies need further implementations. Recent data suggest electrotransfer as a useful tool to improve DNA-based vaccination protocols, being able to stimulate both the humoral and cellular immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510835"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 561,
          "text": "Importantly, EP dramatically enhanced the neutralizing potency of the humoral response, since antibodies induced by low DNA dose (10 μg) were able to highly neutralize DHBV and to recognize ten antigenic regions, including four neutralization epitopes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22284894"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989354"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 488,
          "text": "Herein, we report a screening system based on DNA vaccines and a micro-electroporation/electrophoresis system (MEES), which greatly improved the efficacy of DNA vaccines, elevating humoral and cellular immune responses by over 400- and 35-fold respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37860767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1010,
          "text": "Electroporation can improve intramuscular DNA vaccination efficacy but the exact antigen presentation mechanism remains unclear. We reported here that a similar immuno-potentiation effect was also observed by stimulating the skeletal muscles with electric pulses (EP) a few days prior to DNA inoculation (EP + n days + DNA). The application of EP by itself activated proinflammatory chemokine genes and stress genes. It also triggered an influx of inflammatory monocytes/macrophages (MPs). After DNA inoculation, the plasmids were seen taken up by these inflammatory MPs, which migrated to the draining LNs subsequently. The antibody responses results were fast and strong. Furthermore, MPs isolated from the draining LNs of EP + n days + DNA treated mice were capable of stimulating Ag specific CD4+ T cell proliferation in vitro. Based on these observations, we proposed that the local inflammation resulted from EP treatment played an important role in facilitating antigen presentation of the DNA vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17239494"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 642,
          "text": "One of the uses of EP in vivo is plasmid DNA electrotransfer to the skin for DNA vaccination. EP of tissues induces reduction of blood flow and, in combination with plasmid DNA, induction of an immune response. One of the EP protocols for plasmid DNA electrotransfer to the skin is a combination of high-voltage (HV) and low-voltage (LV) pulses. However, the effects of this pulse combination on skin-vessel blood flow are not known.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22644389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "text": "In vivo electroporation (EP) is used to enhance the uptake of nucleic acids and its association with DNA vaccination greatly stimulates immune responses to vaccine antigens delivered through the skin. However, the effect of EP on cutaneous cell behavior, the dynamics of immune cell recruitment and local inflammatory factors, have not been fully described.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28646234"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 484,
          "text": "Recent delivery techniques such as the gene gun and in vivo electroporation (EP)/electrotransfer (ET) have completely changed the efficiency of DNA vaccines in humans. In vivo EP exerts multiple effects that contribute to its efficiency. The two central factors are most likely the increased DNA uptake due to the transient membrane destabilization, and the local tissue damage acting as an adjuvant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 661,
          "text": "Non-viral in vivo administration of plasmid DNA for vaccines and immunotherapeutics has been hampered by inefficient delivery. Methods to enhance delivery such as in vivo electroporation (EP) have demonstrated effectiveness in circumventing this difficulty. However, the contact-dependent nature of EP has resulting side effects in animals and humans. Noncontact delivery methods should, in principle, overcome some of these obstacles. This report describes a helium plasma-based delivery system that enhanced humoral and cellular antigen-specific immune responses in mice against an intradermally administered HIV gp120-expressing plasmid vaccine (pJRFLgp120).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894954"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 529,
          "text": "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol. Principally, EP increases the transfection of plasmid DNA (pDNA) into the resident skin cells. In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 583,
          "text": "Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36365078"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 1039,
          "text": "Our laboratory has been evaluating DNA plasmid based Pfs25 vaccine in mice and non-human primates. Previously, we established that in vivo electroporation (EP) delivery is an effective method to improve the immunogenicity of DNA vaccine encoding Pfs25 in mice. In order to optimize the in vivo EP procedure and test for its efficacy in more clinically relevant larger animal models, we employed in vivo EP to evaluate the immune response and protective efficacy of Pfs25 encoding DNA vaccine in nonhuman primates (olive baboons, Papio anubis). The results showed that at a dose of 2.5mg DNA vaccine, antibody responses were significantly enhanced with EP as compared to without EP resulting in effective transmission blocking efficiency. Similar immunogenicity enhancing effect of EP was also observed with lower doses (0.5mg and 1mg) of DNA plasmids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23684840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "In vivo electroporation (EP) has proven to significantly increase plasmid transfection efficiency and to augment immune responses after immunization with plasmids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752954"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 404,
          "text": "Two main strategies to increase DNA-based vaccine potency are the employment of immuno-adjuvants such as heat shock proteins (HSPs) and a method of improving the delivery of naked plasmid DNA by electroporation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085605"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 529,
          "text": "In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 329,
          "text": "electroporation (EP) has been shown to generate potent and efficacious immune responses in the clinic. Needle-free jet injection has also been reported to improve DNA vaccine delivery over standard needle and syringe in clinical trials. Here",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31174938"
        },
        {
          "offsetInBeginSection": 460,
          "offsetInEndSection": 685,
          "text": "Of these, EP mediated delivery has generated considerable enthusiasm and appears to have had a great impact in vaccine immunogenicity and efficacy by increasing antigen delivery upto a 1000 fold over naked DNA delivery alone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21530212"
        },
        {
          "offsetInBeginSection": 477,
          "offsetInEndSection": 818,
          "text": "One novel in vivo delivery method for plasmid vaccines is electroporation, which is the application of short pulses of electric current immediately after, and at the site of, an injection of a genetic vaccine. This method has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20951666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18847301"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 177,
          "text": "ecruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18353952"
        }
      ],
      "id": "65f494d7c4010b4d78000013",
      "ideal_answer": [
        "Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity.",
        "Electroporation (EP) is a physical method used to facilitate the entry of DNA vaccines (plasmid DNA molecules) into cells, significantly improving their efficacy by inducing humoral and cellular immune responses by over 400- and 35-fold respectively.",
        "Electroporation (EP) is a method of delivering DNA vaccines that significantly increases transfection efficacy and the subsequent vaccine-specific immune responses.",
        "Electroporation (EP) is a method that has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses of DNA vaccines.",
        "Electroporation allows efficient delivery of DNA into cells and tissues, improving the expression of therapeutic or immunogenic proteins that are encoded by plasmid DNA, which is used in DNA vaccines.",
        "Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines.",
        "Yes, electroporation is an effective way to increase the immunogenicity of DNA.",
        "Electroporation (EP) is a method that increases the immunogenicity of DNA vaccines, particularly plasmid DNA vaccines.",
        "Electroporation (EP) is a method used to increase the immunogenicity of DNA vaccines.",
        "Electroporation (EP) is an effective way to increase the immunogenicity of plasmid DNA vaccine.",
        "Electroporation (EP) is associated with increasing the immunogenicity of DNA vaccines.",
        "Electroporation (EP) is a technique used to increase the immunogenicity of DNA vaccines. It involves the use of an electric field to create temporary pores in the cell membrane, allowing the DNA to enter the cell and be expressed as antigens, which can stimulate an immune response.",
        "Electroporation (EP) effectively enhances the immunogenicity of DNA vaccines.",
        "Electroporation (EP) increases the immunogenicity of DNA vaccines.",
        "Electroporation (EP) is an effective way to increase the immunogenicity of DNA vaccines. EP is used to deliver plasmid DNA vaccines, enhancing the immune response induced by the vaccine.",
        "Electroporation (EP) is used to enhance the effectiveness of DNA vaccines by increasing their immunogenicity. This means it helps to boost the immune response triggered by the DNA vaccines."
      ],
      "exact_answer": [
        [
          "increase immunogenicity of the vaccine"
        ]
      ]
    },
    {
      "body": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36680212",
        "http://www.ncbi.nlm.nih.gov/pubmed/37971951",
        "http://www.ncbi.nlm.nih.gov/pubmed/28673424",
        "http://www.ncbi.nlm.nih.gov/pubmed/34953518",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590128",
        "http://www.ncbi.nlm.nih.gov/pubmed/28646947",
        "http://www.ncbi.nlm.nih.gov/pubmed/22298303",
        "http://www.ncbi.nlm.nih.gov/pubmed/8034506",
        "http://www.ncbi.nlm.nih.gov/pubmed/21855993",
        "http://www.ncbi.nlm.nih.gov/pubmed/31009080",
        "http://www.ncbi.nlm.nih.gov/pubmed/36414136",
        "http://www.ncbi.nlm.nih.gov/pubmed/3811010",
        "http://www.ncbi.nlm.nih.gov/pubmed/31622151",
        "http://www.ncbi.nlm.nih.gov/pubmed/12721887",
        "http://www.ncbi.nlm.nih.gov/pubmed/33303011",
        "http://www.ncbi.nlm.nih.gov/pubmed/28966000",
        "http://www.ncbi.nlm.nih.gov/pubmed/26562349",
        "http://www.ncbi.nlm.nih.gov/pubmed/11435120",
        "http://www.ncbi.nlm.nih.gov/pubmed/30156949",
        "http://www.ncbi.nlm.nih.gov/pubmed/2867355",
        "http://www.ncbi.nlm.nih.gov/pubmed/26065443"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1540,
          "offsetInEndSection": 1713,
          "text": "renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Measles is a highly contagious, vaccine-preventable disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951"
        },
        {
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1170,
          "text": "an estimated 57 million measles deaths were averted by vaccination during 2000-2022",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971951"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Measles is a highly contagious, but vaccine-preventable disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680212"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 223,
          "text": "the administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680212"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1205,
          "text": "The use of early measles vaccination at 4 months of age could be an effective strategy to prevent severe morbidity and death from both measles and RSV infections in many LMICs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34953518"
        },
        {
          "offsetInBeginSection": 619,
          "offsetInEndSection": 795,
          "text": "Measles is best prevented through vaccination, and the major reductions in measles incidence and mortality have renewed interest in regional elimination and global eradication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28673424"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 307,
          "text": "Since 2000, vaccination campaigns against measles, which is highly contagious but preventable through the measles-mumps-rubella (MMR) vaccine, have reduced both the global incidence of the disease and measles deaths by 80 percent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009080"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 557,
          "text": "In other parts of the world the incidence of this disease has been dramatically reduced following effective measles immunisation programmes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3811010"
        },
        {
          "offsetInBeginSection": 420,
          "offsetInEndSection": 512,
          "text": "This achievement attests to the enormous importance of measles vaccination to public health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21855993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "text": "Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more than 2 million deaths annually before the introduction and widespread use of measles vaccine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28673424"
        },
        {
          "offsetInBeginSection": 1461,
          "offsetInEndSection": 1586,
          "text": "This highly effective and well-tolerated vaccine has greatly reduced the number of measles cases and saved millions of lives.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36414136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Worldwide during the 1980s remarkable progress was made in controlling measles through increasing routine measles vaccination to nearly 80%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721887"
        },
        {
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1590,
          "text": "Measles immunization has dramatically reduced measles occurrence, but improved control is necessary to prevent the estimated 1 million deaths still occurring each year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8034506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "The global measles vaccination program has been extraordinarily successful in reducing measles-related disease and deaths worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590128"
        },
        {
          "offsetInBeginSection": 722,
          "offsetInEndSection": 946,
          "text": "Routine immunization with MCV has been the cornerstone for the control and prevention of measles. Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "BACKGROUND: Measles is a highly contagious and serious infection. Before the introduction of vaccination, measles caused yearly epidemics putting vulnerable children at risk of brain damage and death. Despite safe and cost-effective vaccines, measles remains a leading cause of death in childr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33303011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 497,
          "text": "INTRODUCTION: One of the goals of the Global Measles and Rubella Strategic Plan is the reduction in global measles mortality, with high measles vaccination coverage as one of its core components. While measles mortality has been reduced more than 79%, the disease remains a major cause of childhood vaccine preventable disease burden globally. Measles immunization requires a two-dose schedule and only countries with strong, stable immunization programs can rely on routine services to deliver th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "In 2000, the United Nations General Assembly adopted the Millennium Development Goals (MDG), with MDG4 being a two-thirds reduction in child mortality by 2015, and with measles vaccination coverage being one of the three indicators of progress toward this goal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26562349"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 481,
          "text": "In 2001, to accelerate the reduction in measles cases achieved by vaccination, the World Health Organization (WHO) and the United Nations Children\u0027s Fund (UNICEF) developed a strategy to deliver 2 doses of measles-containing vaccine (MCV) to all children through routine services and supplementary immunization activities (SIAs) and improved disease surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22298303"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 528,
          "text": "Health care and community collaboration led to coverage rates of measles vaccination increasing from 80% to 95% within three months and a significant decline in incidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31622151"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 419,
          "text": "Remarkable progress in reducing the number of people dying from measles has been made through measles vaccination, with an estimated 164,000 deaths attributed to measles in 2008.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21855993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "An immunisation programme to eliminate measles, mumps, and rubella from Finland within 10 years was",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2867355"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 401,
          "text": "Measles vaccination programs have been among the greatest public health achievements reducing, eliminating endemic measles in the whole of the Americas and across much of the globe.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28646947"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "Vaccination is one of history\u0027s most successful public health interventions. Since 2000, vaccination campaigns against measles, which is highly contagious but preventable through the measles-mumps-rubella (MMR) vaccine, have reduced both the global incidence of the disease and measles deaths by 80 percent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Increased measles immunization has led to a significant decline in measles incidence and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30156949"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 358,
          "text": "The incidence of measles worldwide has decreased dramatically since the introduction of effective vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11435120"
        },
        {
          "offsetInBeginSection": 820,
          "offsetInEndSection": 946,
          "text": "Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590128"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1409,
          "text": "Because measles is one of the most contagious human diseases, maintenance of high (≥95%) 2-dose MCV coverage is crucial for controlling the spread of measles and successfully reaching measles eliminatio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590128"
        },
        {
          "offsetInBeginSection": 786,
          "offsetInEndSection": 961,
          "text": "Strengthening immunization programs and keeping vaccination coverage rates above 95% with a two-dose schedule will be necessary for measles control strategies in the Americas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26065443"
        }
      ],
      "id": "65f84d20c4010b4d7800004a",
      "ideal_answer": [
        "Measles immunisation is considered to be the best public health approach to reduce the incidence of measles worldwide.",
        "Yes, measles immunisation is the best public health approach to reduce incidence of measles worldwide.",
        "Yes. Measles immunisation is the best public health approach to reduce incidence of measles worldwide.",
        "Measles immunization is considered the best public health approach to reduce the incidence of measles worldwide. Routine vaccination supplemented by planned campaigns has been the core strategy for measles control and elimination efforts. Vaccination helps to build immunity against the measles virus, preventing infection and reducing the risk of transmission. It is a cost-effective intervention that has been proven to be highly effective in reducing measles cases and outbreaks. However, it is important to note that the success of measles immunization programs also depends on factors such as vaccine coverage, access to healthcare, and public awareness. Therefore, a comprehensive approach that includes vaccination, surveillance, and public health education is crucial in achieving global measles control and elimination.",
        "The administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles.",
        "Yes, measles immunization is the best public health approach to reduce incidence of measles worldwide.",
        "Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide.",
        "Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. By renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, measles outbreaks can be prevented and progress towards measles elimination can be accelerated.",
        "Yes, the administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles.",
        "Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. It is highly effective and has been proven to prevent outbreaks and accelerate progress toward measles elimination.",
        "Yes, measles immunisation is the best public health approach to reduce the incidence of measles worldwide. By renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, outbreaks can be prevented and progress toward measles elimination can be accelerated."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What type of DMD can golodirsen be used for?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025945",
        "http://www.ncbi.nlm.nih.gov/pubmed/33407808",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
        "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/32139505",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/34092651"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 455,
          "text": "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 505,
          "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027"
        },
        {
          "offsetInBeginSection": 377,
          "offsetInEndSection": 482,
          "text": "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 514,
          "text": "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 649,
          "text": "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 506,
          "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027"
        },
        {
          "offsetInBeginSection": 783,
          "offsetInEndSection": 901,
          "text": "Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 352,
          "text": "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.METHODS: Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505"
        },
        {
          "offsetInBeginSection": 1259,
          "offsetInEndSection": 1982,
          "text": "Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p \u003c 0.001) and a positive correlation (Spearman r \u003d 0.663; p \u003c 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry.CONCLUSION: Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization.CLINICALTRIALSGOV IDENTIFIER: NCT02310906.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 285,
          "text": "golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD). Part 1 was a 12-week, randomized, double-blind, placebo-controlled,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 386,
          "text": "DMD gene. In particular, PMOs for skipping exon 44 have been developing in clinical trials, such as the drug NS-089/NCNP-02. Two exon 53 skipping PMOs, golodirsen and viltolarsen,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027"
        },
        {
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1078,
          "text": "Very recently, golodirsen and viltolarsen, for treatment of DMD patients amenable to skipping exon 53, have been approved by regulatory agencies in the USA and Japan, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34092651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 5",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505"
        },
        {
          "offsetInBeginSection": 330,
          "offsetInEndSection": 544,
          "text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786"
        }
      ],
      "id": "64179034690f196b5100002b",
      "ideal_answer": [
        "Patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen is used for treating Duchenne muscular dystrophy that can benefit from exon 53 skipping.",
        "Golodirsen is approved by the FDA for the treatment of Duchenne Muscular Dystrophy (DMD) patients who are amenable to exon 53 skipping.",
        "Golodirsen is approved for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen (VYONDYS 53TM) can be used for specific types of Duchenne Muscular Dystrophy (DMD) that are amenable to exon 53 skipping.",
        "Golodirsen can be used for Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping.",
        "Golodirsen can be used for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen can be used to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen can be used for Duchenne muscular dystrophy (DMD) with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen (Vyondys 53™) is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen is approved for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen (Vyondys 53™) can be used for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen is used for treating DMD in patients who have a specific mutation that can be treated by skipping exon 53.",
        "Golodirsen can be used for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen (Vyondys 53™) can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen is a drug that can be used for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.",
        "Golodirsen (Vyondys 53™) is an antisense oligonucleotide designed to induce exon 53 skipping in patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene that is amenable to this specific form of therapy.",
        "Golodirsen can be used for DMD with a confirmed mutation amenable to exon 53 skipping.",
        "Golodirsen can be used for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping."
      ],
      "exact_answer": [
        [
          "exon 53"
        ]
      ]
    },
    {
      "body": "What are active ingredients of Trikafta?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36653239",
        "http://www.ncbi.nlm.nih.gov/pubmed/37503734",
        "http://www.ncbi.nlm.nih.gov/pubmed/37222401",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831163",
        "http://www.ncbi.nlm.nih.gov/pubmed/34026156",
        "http://www.ncbi.nlm.nih.gov/pubmed/34356748",
        "http://www.ncbi.nlm.nih.gov/pubmed/32853178",
        "http://www.ncbi.nlm.nih.gov/pubmed/34357110",
        "http://www.ncbi.nlm.nih.gov/pubmed/31784874",
        "http://www.ncbi.nlm.nih.gov/pubmed/33775603",
        "http://www.ncbi.nlm.nih.gov/pubmed/35021019"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36653239"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "CONTEXT: Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37503734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "INTRODUCTION: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222401"
        },
        {
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1408,
          "text": "The method has been validated following international (EMA) guidelines for bioanalytical method validation and has been tested on plasma samples from 62 CF patients treated with the three-drug combination IVA/TEZ/ELX, marketed as Kaftrio® or Trikafta®, in steady-state condition. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831163"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272,
          "text": "Trikafta, a triple-combination drug, consisting of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor) and the gating potentiator VX-770 (ivacaftor) provided unprecedented clinical benefits for patients with the most common cystic fibrosis (CF) mutation, F508del.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34357110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32853178"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Trikafta, the combination of elexacaftor (VX-445), tezacaftor (VX-661) and ivacaftor (VX-770), was approved for therapy of cystic fibrosis (CF) patients with at least one allele of the CFTR mutation F508del.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33775603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "We present a novel case of an urticaria multiforme-type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34026156"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34356748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. These drugs have complicated metabolic profiles that make the potential for drug interactions an important consideration for prescribers, care providers and patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36653239"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 891,
          "text": "CONTEXT: Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF).OBJECTIVE: This longitudinal case-control study assessed changes in β-cell function and secretory capacity measures over two visits in individuals with PI-CF who were initiated on ETI after the baseline visit (2012-2018) and 1) restudied between 2019-2021 (ETI group) vs. 2) those restudied between 2015-2018 and not yet treated with CFTR modulator therapy (controls).METHODS: Nine ETI participants (mean ± SD age 25 ± 5 years) and eight matched controls were followed up after median(IQR) 5(4-7) and 3(2-3) years, respectively (p \u003c 0.01), with ETI initiation a median of 1 year before follow-up.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37503734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "text": "A fixed-dose combination tablet of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector tezacaftor and the CFTR potentiator ivacaftor with the next-generation CFTR corrector elexacaftor (hereafter referred to as elexacaftor/ivacaftor/tezacaftor) [Trikafta™] has been developed by Vertex Pharmaceuticals Inc. to treat patients with the most common cystic fibrosis mutation (F508del).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31784874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "Based on its clinical benefits, Trikafta - the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) - was FDA approved for treatment of patients with cystic fibrosis (CF) carrying deletion of phenylalanine at position 508 (F508del) of the CF transmembrane conductance regulator (CFTR) on at least 1 allele.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32853178"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36653239"
        },
        {
          "offsetInBeginSection": 32,
          "offsetInEndSection": 169,
          "text": "Trikafta - the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32853178"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 409,
          "text": "pyrin domain-containing protein 3) inflammasome. Objectives: To explore the effect of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (Trikafta)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35021019"
        }
      ],
      "id": "65d137871930410b1300003e",
      "ideal_answer": [
        "Trikafta includes elexacaftor/tezacaftor/ivacaftor."
      ],
      "exact_answer": [
        [
          "elexacaftor"
        ],
        [
          "tezacaftor"
        ],
        [
          "ivacaftor"
        ]
      ]
    },
    {
      "body": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36914665",
        "http://www.ncbi.nlm.nih.gov/pubmed/28174090",
        "http://www.ncbi.nlm.nih.gov/pubmed/36041373",
        "http://www.ncbi.nlm.nih.gov/pubmed/34402529",
        "http://www.ncbi.nlm.nih.gov/pubmed/31567189",
        "http://www.ncbi.nlm.nih.gov/pubmed/36077692"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1154,
          "text": " In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914665"
        },
        {
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1456,
          "text": "The proportion of patients with targets for genetically matched therapies differed among subtypes (salivary duct carcinoma: 82%, adenoid cystic carcinoma 28%, mucoepidermoid carcinoma 50%, acinic cell carcinoma 33%)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36077692"
        },
        {
          "offsetInBeginSection": 782,
          "offsetInEndSection": 935,
          "text": "Of 15,223 patients analyzed, 38 (0.25%) had NTRK gene fusions in 11 tumor types, the most common were breast cancer, colorectal cancer (CRC), and sarcoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36041373"
        },
        {
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1135,
          "text": "TRK positivity was observed in 11 of 58 (19%) MLH1-methylated MSI-high CRCs, 4 of 23 (17%) sessile serrated lesions with dysplasia (SSLDs), and 5 of 132 (4%) sessile serrated lesions (SSLs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34402529"
        },
        {
          "offsetInBeginSection": 772,
          "offsetInEndSection": 1020,
          "text": "colorectal cancers, prevalence of the NTRK fusions is well below 5%. Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations. Currently,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28174090"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 298,
          "text": "Of the 7008 tumors screened for NTRK expression using a pan-Trk antibody, 16 (0.23%) had Trk immunoreactivity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31567189"
        }
      ],
      "id": "65f77397c4010b4d78000025",
      "ideal_answer": [
        "In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.",
        "According to the literature review, NTRK gene fusions are found in approximately 0.2% to 0.3% of colorectal cancers. This means that out of every 100 colorectal cancers, 2 to 3 cases will have an NTRK gene fusion. Therefore, the proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, but still significant enough to consider testing for these fusions in certain subgroups of patients.",
        "The proportion of alteration in NTRK genes attributable to colorectal cancer (CRC) is around 10% in the pan-cancer population, and 0.2% of CRCs (9/4569) were positive for Pan-Trk IHC. Additionally, the prevalence of NTRK fusion in CRC was 0.18%, with 46 unique NTRK-fusion partner pairs, of which 33 were not previously reported. TRK positivity was observed in 19% of MLH1-methylated MSI-high CRCs, 17% of sessile serrated lesions with dysplasia (SSLDs), and 4% of sessile serrated lesions (SSLs). However, NTRK gene alterations are not enriched in gastric cancer (GC) with dMMR but are specifically enriched in cases of GAHED.",
        "0.25% of patients analyzed had NTRK gene fusions and the most common were breast cancer, colorectal cancer (CRC), and sarcoma.",
        "The exact proportion of NTRK gene alterations attributable to colorectal cancer (CRC) is not provided in the text. However, the text does mention that NTRK gene fusions are found in approximately 0.16-0.3% of CRCs and that they are more frequent in MMR-deficient/BRAFV600E wild-type tumors (5.3%). Additionally, the study found that 7% of MSI-high CRC cohort had NTRK gene fusions. It is important to note that these frequencies are based on specific patient populations and may not be generalizable to all patients with CRC.",
        "The proportion of alterations in NTRK genes attributable to colorectal cancer is relatively low, with NTRK gene fusions occurring in approximately 1% of colorectal cancer cases.",
        "According to the provided text, approximately 7% of colorectal cancers (CRCs) have NTRK gene fusions. This means that about 7% of alterations in NTRK genes are attributable to CRC. However, it\u0027s important to note that not all NTRK alterations are necessarily driver mutations or functional, and some may be passengers or non-pathogenic variants. Therefore, the actual proportion of NTRK alterations that contribute to the development and progression of CRC is likely lower than 7%.",
        "The prevalence of NTRK gene fusions in colorectal cancer is generally low, ranging from approximately 0.23% to 0.7% in most studies. However, one study found a higher prevalence of around 7% specifically in the microsatellite instability-high (MSI-high) colorectal cancer subgroup.",
        "Based on the information provided in the snippet, it is not possible to directly determine the proportion of alterations in NTRK genes that are attributable to colorectal cancer. The snippet discusses the rates of cancers in general and mentions rare morphological subtypes, microsatellite instability, and driver mutation exclusion cancers having higher rates, but it does not provide specific details about NTRK gene alterations or their association with colorectal cancer. , However, it is known that NTRK gene fusions can occur across various tumor types, including colorectal cancer, but they are considered rare events. According to a study published in Cancer Discovery, the frequency of NTRK gene fusions in colorectal cancer is estimated to be around 0.18-0.23% (Cancer Discov. 2017 Aug;7(8):824-836). , Therefore, while it\u0027s challenging to provide an exact proportion based on the given snippet, it can be inferred that alterations in NTRK genes attributable to colorectal cancer are relatively rare events.",
        "Alterations in NTRK genes attributable to colorectal cancer account for 0.5% of cases, with higher rates observed in rare morphological subtypes and those with microsatellite instability.",
        "The proportion of alteration in NTRK genes attributable to colorectal cancer is below 0.5%.",
        "Alterations in NTRK genes attributable to colorectal cancer account for approximately 0.5% and are associated with colorectal microsatellite instability.",
        "The text does not provide specific information on the proportion of alteration in NTRK genes attributable to colorectal cancer. It mentions that common cancers have rates consistently below 0.5%, and that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates. However, it does not specify the rate for colorectal cancer or NTRK gene alterations.",
        "Rates of NTRK gene alteration were consistently below 0.5% in common cancers, but in rare morphological subtypes and colorectal microsatellite instability, and driver mutation exclusion cancers, higher rates of NTRK gene alteration were reported.",
        "The proportion of alteration in NTRK genes attributable to colorectal cancer is 0.0001%.",
        "Approximately less than 0.5% of alterations in NTRK genes are associated with colorectal cancer. NTRK gene fusions have been identified as oncogenic drivers across various tumor types; however, they are relatively rare in colorectal cancer, making up a very small proportion of genetic changes observed in this cancer type.",
        "According to the systematic review, the proportion of NTRK gene fusions attributable to colorectal cancer is not specifically stated. However, it is mentioned that rare morphological subtypes, such as colorectal microsatellite instability, and driver mutation exclusion cancers have higher rates of NTRK fusions. The review also notes that the prevalence of NTRK fusions in common cancers, including colorectal cancer, is consistently below 0.5%. Therefore, it can be inferred that the proportion of NTRK alterations attributable to colorectal cancer is likely low, but further large-scale, standardized genomic data are needed to characterize NTRK fusion epidemiology in this specific cancer type.",
        "In common cancers, rates of NTRK gene alterations were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.",
        "In colorectal cancer, the proportion of alterations in NTRK genes is consistently below 0.5%. However, rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers show higher rates of alterations in NTRK genes.",
        "The proportion of alteration in NTRK genes attributable to colorectal cancer is not well established in the literature. However, it is known that NTRK gene alterations are relatively rare in colorectal cancer, occurring in approximately 1-3% of cases. Therefore, the proportion of alteration in NTRK genes attributable to colorectal cancer is likely to be small.",
        "The rate of alterations in NTRK genes among common cancers is generally below 0.5%, with rare morphological subtypes, colorerectal microsatellite instability (MSI) tumors, and driver mutation exclusion cancers having higher rates. Colorectal cancer specifically has been found to have a higher prevalence of NTRK gene alterations compared to other common cancers, although the exact rate can vary depending on factors such as MSI status and the presence or absence of certain driver mutations.",
        "The rates of NTRK gene alterations were consistently below 0.5% in common cancers. However, colorectal cancers with microsatellite instability had higher rates of NTRK alterations compared to common cancers overall.",
        "The proportion of alterations in NTRK genes attributable to colorectal cancer is below 0.5%.",
        "The proportion of alterations in NTRK genes attributable to colorectal cancer is consistently below 0.5%. However, it is important to note that rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers may have higher rates of NTRK gene alterations.",
        "0.5% or less."
      ],
      "exact_answer": [
        [
          "Less than 0.5%",
          "0.5%"
        ]
      ]
    },
    {
      "body": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36936239",
        "http://www.ncbi.nlm.nih.gov/pubmed/36515243",
        "http://www.ncbi.nlm.nih.gov/pubmed/36913180",
        "http://www.ncbi.nlm.nih.gov/pubmed/37004800",
        "http://www.ncbi.nlm.nih.gov/pubmed/37855324",
        "http://www.ncbi.nlm.nih.gov/pubmed/37036140",
        "http://www.ncbi.nlm.nih.gov/pubmed/29938545",
        "http://www.ncbi.nlm.nih.gov/pubmed/26608188",
        "http://www.ncbi.nlm.nih.gov/pubmed/32873116",
        "http://www.ncbi.nlm.nih.gov/pubmed/35505771",
        "http://www.ncbi.nlm.nih.gov/pubmed/37226522",
        "http://www.ncbi.nlm.nih.gov/pubmed/37977068",
        "http://www.ncbi.nlm.nih.gov/pubmed/29225517",
        "http://www.ncbi.nlm.nih.gov/pubmed/33207299",
        "http://www.ncbi.nlm.nih.gov/pubmed/34089259",
        "http://www.ncbi.nlm.nih.gov/pubmed/31227590",
        "http://www.ncbi.nlm.nih.gov/pubmed/32440190",
        "http://www.ncbi.nlm.nih.gov/pubmed/31879750",
        "http://www.ncbi.nlm.nih.gov/pubmed/35018293",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884361",
        "http://www.ncbi.nlm.nih.gov/pubmed/35300073",
        "http://www.ncbi.nlm.nih.gov/pubmed/37480322"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1323,
          "text": "Although there are currently no approved JAK inhibitors for Crohn\u0027s disease, upadacitinib and filgotinib have shown increased remission rates in these patients. Other JAK inhibitors, including gut-selective molecules, are currently being studied IBD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36936239"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 151,
          "text": "he Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36515243"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 533,
          "text": "Tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36913180"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 323,
          "text": "Tofacitinib, a pan-JAK inhibitor, has spearheaded the new JAK class for IBD treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37004800"
        },
        {
          "offsetInBeginSection": 532,
          "offsetInEndSection": 1404,
          "text": " We conducted a comparative phosflow study of four JAKinibs (filgotinib, upadacitinib, tofacitinib, and deucravacitinib) to observe subtle mechanistic differences that may dictate their clinical behavior. Resected mesenteric lymph node (MLN) cells from 19 patients (9 CD, 10 UC) were analyzed by flow cytometry in the presence or absence of different cytokine stimuli and titrated JAKinibs.RESULTS: We found a higher potency of the JAK 1/3-preferential inhibitor, tofacitinib, for JAK 3-dependent cytokine signaling pathways in comparison to filgotinib, but a higher potency of the JAK 1-preferential inhibitors, filgotinib and upadacitinib, for JAK 3-independent cytokine signaling pathways. Deucravacitinib, a TYK2-preferential inhibitor, demonstrated a much narrower selectivity by inhibiting only IL-10 and IFN-βpathways, albeit more potently than the other JAKinibs .",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37855324"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 157,
          "text": "Upadacitinib, a novel and selective inhibitor of Janus kinase 1, has demonstrated promising efficacy in managing inflammatory bowel disease (IBD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37977068"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 447,
          "text": "Tofacitinib was the first pan-Janus kinase (Jak) inhibitor approved for the treatment of IBD, targeting the 4 isoforms of cytokine-associated Jaks (Jak1, Jak2, Jak3, and tyrosine-protein kinase 2).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505771"
        },
        {
          "offsetInBeginSection": 1399,
          "offsetInEndSection": 1805,
          "text": "Tofacitinib, dosed orally, intracecally, or applied to the colonic lumen in vitro, produced dose-dependent, and maximal inhibition of oxazolone or IFNγ-induced STAT1 phosphorylation in the colon.CONCLUSIONS: Localized colonic JAK inhibition, by intracecal delivery of tofacitinib, provides colonic target engagement and efficacy in a mouse colitis model at doses which do not impact splenic NK cell counts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29225517"
        },
        {
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1207,
          "text": "Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608188"
        },
        {
          "offsetInBeginSection": 801,
          "offsetInEndSection": 905,
          "text": "Tofacitinib, a pan-JAK inhibitor, has been recently approved for the treatment of moderate-to-severe UC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31227590"
        },
        {
          "offsetInBeginSection": 1242,
          "offsetInEndSection": 1397,
          "text": ". Tofacitinib, a pan-JAK inhibitor, has shown good efficacy and safety in UC clinical trials and has been recently approved for the treatment of UC patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32440190"
        },
        {
          "offsetInBeginSection": 685,
          "offsetInEndSection": 864,
          "text": "Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32873116"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 258,
          "text": "The oral formulation of tofacitinib has recently been approved for the treatment of moderate-to-severe ulcerative colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Tofacitinib is the only medicine in the class of Janus kinase (JAK) inhibitors that has been approved for use in moderate-to-severely active ulcerative colitis (UC). The potential of other JAK inhibitors to treat UC has not been fully explored.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35018293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32873116"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "INTRODUCTION: Janus Kinase inhibitors (JAKi) are a new class of oral therapies for the treatment of moderate-severe ulcerative colitis with additional potential for the treatment of moderate-severe Cr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37226522"
        },
        {
          "offsetInBeginSection": 731,
          "offsetInEndSection": 907,
          "text": "Tofacitinib, inhibiting signaling via different types of JAKs, has been already approved for ulcerative colitis, and several other small-molecule are still under investigation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884361"
        },
        {
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1045,
          "text": "Tofacitinib has been shown to be therapeutically efficacious, to have a tolerable safety profile, and to be available for adult patients with moderate-to-severe UC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35300073"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1442,
          "text": "The inflammatory diseases ulcerative colitis and Crohn\u0027s disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608188"
        },
        {
          "offsetInBeginSection": 1284,
          "offsetInEndSection": 1521,
          "text": "Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34089259"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 596,
          "text": "Currently, in Japan, three Janus kinase inhibitors, namely tofacitinib, filgotinib, and upadacitinib, are available for the treatment of patients with active ulcerative colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37036140"
        },
        {
          "offsetInBeginSection": 447,
          "offsetInEndSection": 675,
          "text": "ass of drugs.AREAS COVERED: This review describes the JAK-STAT pathway and analyzes the efficacy and safety of new small molecules such as filgotinib, upadacitinib, TD-1473, peficitinib, and Pf-06651600/Pf-06700841, showing data",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29938545"
        },
        {
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1199,
          "text": "ld be preferred in first line, filgotinib, tofacitinib or ustekinumab in second line. A steroid-dependent course in both diseases requires azathioprine or vedolizumab, in second ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37480322"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 641,
          "text": "Tofacitinib is the first compound of a promising class of new small molecules approved for the treatment of IBD. This pan-Janus kinase (JAK) inhibitor (JAKi) targets the four isoforms of cytokine associated JAKs (JAK1, JAK2, JAK3 and TYK2). Next generations JAKi with marked selectivity for specific JAK isoforms or gut-restricted effect are in development, with promising results in phase I and II clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207299"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 534,
          "text": "Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease. Generally, Janus kinase inhibitors are being used for the treatment of rheumatoid arthritis and other immunological diseases, with the therapeutic promising effects. Currently, in Japan, three Janus kinase inhibitors, namely tofacitinib, filgotinib, and upadacitinib, are available",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37036140"
        }
      ],
      "id": "65f1d234c4010b4d78000005",
      "ideal_answer": [
        "Several small-molecule JAK inhibitors (JAKis) including abrocitinib, baricitinib, filgotinib,  peficitinib, tofacitinib, risankizumab upadacitinib, deucavacitinib are now approved for the treatment of various immune-mediated inflammatory diseases.",
        "The Janus Kinase inhibitors that are currently being used or investigated for the treatment of Inflammatory Bowel Disease (IBD) include: , 1. Tofacitinib, 2. Filgotinib, 3. Upadacitinib, 4. TD-1473, 5. Peficitinib, 6. Pf-06651600/Pf-06700841 , These JAK inhibitors target the JAK-STAT pathway, which is strongly involved in the pathophysiology of IBD. They are being evaluated for their efficacy and safety in treating patients with active ulcerative colitis.",
        "Tofacitinib is a Janus Kinase inhibitor used for treating Inflammatory Bowel Disease.",
        "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include:\n\n1. Tofacitinib\n2. Filgotinib\n3. Upadacitinib\n\nThese JAK inhibitors have been approved by the US Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis (UC) and are considered advanced therapies for IBD. Tofacitinib is a pan-JAK inhibitor, primarily of JAK1 and JAK3, while filgotinib and upadacitinib are selective JAK-1 inhibitors. These JAK inhibitors have shown increased remission rates in patients with Crohn\u0027s disease, although there are currently no approved JAK inhibitors for this indication.",
        "The Janus Kinase (JAK) inhibitors currently used or being investigated for the treatment of Inflammatory Bowel Disease (IBD) include: , 1. Tofacitinib (approved for moderate-to-severe active ulcerative colitis), 2. Upadacitinib (selective JAK-1 inhibitor, in late-stage clinical trials for IBD), 3. Filgotinib (selective JAK-1 inhibitor, in late-stage clinical trials for IBD), 4. TD-1473 (JAK3/Tyk2 inhibitor, under investigation in phase II trials for IBD), 5. Peficitinib (JAK inhibitor, under investigation in phase II trials for IBD), 6. Pf-06651600/Pf-06700841 (JAK inhibitors, under investigation in phase II trials for IBD)",
        "The following Janus Kinase (JAK) inhibitors are used to treat inflammatory bowel disease (IBD):, 1. Filgotinib, 2. Upadacitinib, 3. Tofacitinib, 4. Peficitinib, 5. Pf-06651600/Pf-06700841, 6. TD-1473",
        "The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD) are tofacitinib, upadacitinib, and filgotinib.",
        "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include tofacitinib and upadacitinib.",
        "The following are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD): , 1. Tofacitinib, 2. Filgotinib, 3. Upadacitinib, 4. GSK2586184 (Janus kinase 1 selective inhibitor)",
        "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include Tofacitinib and Upadacitinib.",
        "Upadacitinib, filgotinib, tofacitinib, and upadacitinib can be used to treat Inflammatory Bowel Disease (IBD).",
        "The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD) include Tofacitinib, Upadacitinib, Filgotinib, and Deucravacitinib.",
        "The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD) include upadacitinib, filgotinib, tofacitinib, and deucravacitinib.",
        "Upadacitinib, filgotinib, tofacitinib, and deucravacitinib are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease (IBD).",
        "The Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD) are Tofacitinib, Upadacitinib, Filgotinib and Deucravacitinib.",
        "Upadacitinib, filgotinib, tofacitinib and deucravacitinib are Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD).",
        "The Janus Kinase (JAK) inhibitors used to treat Inflammatory Bowel Disease (IBD) include tofacitinib, upadacitinib, filgotinib, and deucravacitinib."
      ],
      "exact_answer": [
        [
          "abrocitinib"
        ],
        [
          "baricitinib"
        ],
        [
          "filgotinib"
        ],
        [
          "peficitinib"
        ],
        [
          "tofacitinb"
        ],
        [
          "upadacitinib"
        ],
        [
          "risankizumab"
        ],
        [
          "deucavacitinib"
        ],
        [
          "brepocitinib"
        ],
        [
          "PF-06826647"
        ],
        [
          "Pf-06651600/Pf-06700841"
        ],
        [
          "TD 1473"
        ]
      ]
    },
    {
      "body": "Are only babies and young children at risk of severe malaria in endemic areas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37365258",
        "http://www.ncbi.nlm.nih.gov/pubmed/35916146",
        "http://www.ncbi.nlm.nih.gov/pubmed/34905777",
        "http://www.ncbi.nlm.nih.gov/pubmed/35382261",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465125",
        "http://www.ncbi.nlm.nih.gov/pubmed/15480963",
        "http://www.ncbi.nlm.nih.gov/pubmed/25300703",
        "http://www.ncbi.nlm.nih.gov/pubmed/17102547"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 168,
          "text": "malaria in pregnancy remains a significant cause of low birth weight, stillbirth, and severe anaemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37365258"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 205,
          "text": "mortality rates from severe malaria (SM) remain significantly high",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916146"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 571,
          "text": "SM in adults and children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916146"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 38,
          "text": "Cerebral malaria in adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34905777"
        },
        {
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1306,
          "text": "Brain involvement is common in adults with SNCM ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34905777"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 214,
          "text": "Cerebral malaria (CM) is a rapidly progressive and severe form of Plasmodium falciparum infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382261"
        },
        {
          "offsetInBeginSection": 480,
          "offsetInEndSection": 638,
          "text": "CM, often associated with fatal outcomes even in treated subjects, is usually diagnosed at autopsy.Case presentation: We present the case of a 36-year-old man",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382261"
        },
        {
          "offsetInBeginSection": 639,
          "offsetInEndSection": 914,
          "text": "Acute episodes of severe malaria, repeated malaria infections leading to severe anemia, and infection during pregnancy which predisposes to low birth weight, a major risk factor for neonatal death, account for the majority of malaria-related deaths in young African children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15480963"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 184,
          "text": "Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25300703"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Malaria is a potentially life-threatening disease with approximately half of the world\u0027s population at risk. Young children and pregnant women are hit hardest by the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465125"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "BACKGROUND: Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25300703"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 128,
          "text": "In India, both adults and children are affected by severe malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17102547"
        }
      ],
      "id": "65f83281c4010b4d78000040",
      "ideal_answer": [
        "No, everybody is at risk, though the people at highest risk are young children and pregnant women.",
        "While young children are particularly vulnerable to developing severe malaria in endemic areas, they are not the only ones at risk. In fact, anyone who is not immune to the disease can develop severe malaria if they become infected with the Plasmodium parasite. However, young children and pregnant women tend to be more susceptible to severe forms of the disease due to their weaker immune systems and other factors. For example, in areas where malaria is endemic, babies and young children are not yet immune to the disease, making them more vulnerable to severe symptoms. Similarly, pregnant women may experience altered B cell responses associated with changes in BAFF levels, which can increase their risk of developing severe malaria. Therefore, while anyone can develop severe malaria in endemic areas, young children and pregnant women are at particularly high risk.",
        "While babies and young children are indeed at a higher risk of severe malaria in endemic areas, they are not the only ones susceptible to the disease. Pregnant women, for instance, can also experience significant health issues due to malaria, such as low birth weight, stillbirth, and severe anaemia. Additionally, adults can contract severe forms of malaria, including cerebral malaria. Therefore, it is not accurate to say that only babies and young children are at risk of severe malaria in endemic areas.",
        "No, severe malaria can affect people of all ages in endemic areas, including pregnant women and their unborn babies."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35713895",
        "http://www.ncbi.nlm.nih.gov/pubmed/35723111",
        "http://www.ncbi.nlm.nih.gov/pubmed/35073949",
        "http://www.ncbi.nlm.nih.gov/pubmed/33053810",
        "http://www.ncbi.nlm.nih.gov/pubmed/12026233",
        "http://www.ncbi.nlm.nih.gov/pubmed/28823869",
        "http://www.ncbi.nlm.nih.gov/pubmed/33104035",
        "http://www.ncbi.nlm.nih.gov/pubmed/8289083",
        "http://www.ncbi.nlm.nih.gov/pubmed/8186713",
        "http://www.ncbi.nlm.nih.gov/pubmed/37927274",
        "http://www.ncbi.nlm.nih.gov/pubmed/18334131"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Prednisone and deflazacort in Duchenne muscular dystrophy: ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895"
        },
        {
          "offsetInBeginSection": 652,
          "offsetInEndSection": 766,
          "text": "Prednisone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for DMD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 354,
          "text": "Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35723111"
        },
        {
          "offsetInBeginSection": 444,
          "offsetInEndSection": 680,
          "text": "This analysis considered patients from the UK NorthStar database (2003-2020) on one of five regimes: \"GC naïve\", \"deflazacort daily\" (DD), \"deflazacort intermittent\" (DI), \"prednisolone daily\" (PD) and \"prednisolone intermittent\" (PI). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073949"
        },
        {
          "offsetInBeginSection": 851,
          "offsetInEndSection": 1202,
          "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 465,
          "text": "Glucocorticoid steroids, like prednisone, are known to delay loss of ambulation in patients with Duchenne muscular dystrophy but are accompanied by prominent adverse effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28823869"
        },
        {
          "offsetInBeginSection": 588,
          "offsetInEndSection": 694,
          "text": "Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334131"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 272,
          "text": "Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035"
        },
        {
          "offsetInBeginSection": 1575,
          "offsetInEndSection": 1748,
          "text": ": These results helped the researchers to learn more about the differences between how well prednisone and deflazacort work in males with DMD based on their medical records.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713895"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Prednisone (Pred) and Deflazacort (Dfz) are commonly used glucocorticoids (GCs) for Duchenne muscular dystrophy (DMD) treatment and management.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33053810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "In recent years, various clinical trials have documented the benefit of glucocorticoid therapy in the palliation of Duchenne muscular dystrophy (DMD). Prednisone therapy, daily or on alternate days, has been confirmed to be of value in enhancing muscle strength and function in DMD for up to two years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8289083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8186713"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 528,
          "text": "Glucocorticoids such as prednisone and deflazacort have powerful anti-inflammatory benefits and are the standard of care for DMD, but their long-term use can result in severe adverse side effects; thus, vamorolone was designed as a unique dissociative steroidal anti-inflammatory drug, to retain efficacy and minimise these adverse effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927274"
        }
      ],
      "id": "64414bdb57b1c7a315000058",
      "ideal_answer": [
        "The glucosteroids used for the management of Duchenne muscular dystrophy are prednisone, prednisolone and deflazacort.",
        "Deflazacort and prednisone are the types of glucocorticoids used for managing Duchenne muscular dystrophy.",
        "Glucocorticoids such as prednisone, prednisolone, deflazacort are used for the management of Duchenne muscular dystrophy.",
        "Glucocorticoids such as prednisone and deflazacort are used for the management of Duchenne muscular dystrophy.",
        "Glucocorticoids, such as prednisone and deflazacort, are commonly used for the management of Duchenne muscular dystrophy.",
        "Prednisolone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for Duchenne muscular dystrophy.",
        "Deflazacort, prednisone, and prednisolone are glucosteroids used for the management of Duchenne muscular dystrophy.",
        "Prednisone and deflazacort are the glucosteroids used for the management of Duchenne muscular dystrophy (DMD).",
        "The types of glucosteroids used for the management of Duchenne muscular dystrophy are deflazacort, prednisone, and prednisolone.",
        "Prednisone and deflazacort are two different types of corticosteroids. Prednisone is a glucocorticoid and deflazacort is a synthetic corticosteroid used for the management of Duchenne muscular dystrophy.",
        "Prednisone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for DMD.",
        "Prednisone and deflazacort are glucosteroids used for the management of Duchenne muscular dystrophy.",
        "Prednisone, Deflazacort, and Prednisolone are types of glucocorticoids used in the management of Duchenne muscular dystrophy. These glucocorticoids can be used in different regimes, including daily and intermittent.",
        "Prednisone and Deflazacort are the glucocorticoids used for treating Duchenne muscular dystrophy.",
        "The types of glucocorticoids used for the management of Duchenne muscular dystrophy (DMD) are deflazacort and prednisone/prednisolone.",
        "Prednisone and Deflazacort are the types of glucocorticoids used for the management of Duchenne muscular dystrophy.",
        "Prednisone and deflazacort are two types of glucosteroids used for the management of Duchenne muscular dystrophy."
      ],
      "exact_answer": [
        [
          "prednisone"
        ],
        [
          "prednisolone"
        ],
        [
          "deflazacort"
        ]
      ]
    },
    {
      "body": "Cilta-cel was developed for treatment of which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36411210",
        "http://www.ncbi.nlm.nih.gov/pubmed/36271807",
        "http://www.ncbi.nlm.nih.gov/pubmed/36269898",
        "http://www.ncbi.nlm.nih.gov/pubmed/37497629",
        "http://www.ncbi.nlm.nih.gov/pubmed/37272512",
        "http://www.ncbi.nlm.nih.gov/pubmed/34885106",
        "http://www.ncbi.nlm.nih.gov/pubmed/34840088",
        "http://www.ncbi.nlm.nih.gov/pubmed/35764490",
        "http://www.ncbi.nlm.nih.gov/pubmed/34175021",
        "http://www.ncbi.nlm.nih.gov/pubmed/37913909",
        "http://www.ncbi.nlm.nih.gov/pubmed/37716872",
        "http://www.ncbi.nlm.nih.gov/pubmed/37704875",
        "http://www.ncbi.nlm.nih.gov/pubmed/36720180",
        "http://www.ncbi.nlm.nih.gov/pubmed/37014590",
        "http://www.ncbi.nlm.nih.gov/pubmed/37750399",
        "http://www.ncbi.nlm.nih.gov/pubmed/35900317"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1407,
          "text": " Additional indirect treatment comparisons conducted separately for ide-cel and cilta-cel have demonstrated that these CAR-T therapies hold promise for substantial clinical benefit relative to currently available treatments for RRMM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 607,
          "text": "OBJECTIVE: This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450 × 106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807"
        },
        {
          "offsetInBeginSection": 1645,
          "offsetInEndSection": 1850,
          "text": "CONCLUSIONS: These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "PURPOSE: CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898"
        },
        {
          "offsetInBeginSection": 1776,
          "offsetInEndSection": 1978,
          "text": "CONCLUSION: These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36269898"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 323,
          "text": "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37497629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 432,
          "text": "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37913909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 602,
          "text": "BACKGROUND: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (MM) who previously received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 monoclonal antibody (triple-class exposed).PATIENTS AND METHODS: A dataset of US patients refractory to an anti-CD38 monoclonal antibody (MAMMOTH) was used to identify patients who would meet eligibility for CARTITUDE-1 and received subsequent non-CAR-T therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34840088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272512"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 765,
          "text": "BACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.METHODS: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34175021"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34885106"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 410,
          "text": "INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monocl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37014590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 557,
          "text": "INTRODUCTION: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part 2], and melphalan flufenamide plus dexamethasone [HORIZON]), each with distinct mechanisms of action, for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monocl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35764490"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 528,
          "text": "Two BCMA-directed CAR T-cell products - idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) - have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37750399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 433,
          "text": "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37913909"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 402,
          "text": "nancies. Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double B cell maturation antigen (BCMA) targeting binding domains, showed an 88% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (MM), which were carried out in our i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720180"
        },
        {
          "offsetInBeginSection": 712,
          "offsetInEndSection": 935,
          "text": "The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has approved two BCMA-targeting CAR T cell products, idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), for use in RRMM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37704875"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 975,
          "text": "The autologous CAR-T cell therapy against BCMA (ide-cel and cilta-cel) shows the best efficacy with an overall response rate and a median progression-free survival in RRMM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900317"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 413,
          "text": "eptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectiv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37716872"
        }
      ],
      "id": "65cfd4b21930410b13000020",
      "ideal_answer": [
        "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma."
      ],
      "exact_answer": [
        [
          "multiple myeloma"
        ]
      ]
    },
    {
      "body": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35173208",
        "http://www.ncbi.nlm.nih.gov/pubmed/8607008",
        "http://www.ncbi.nlm.nih.gov/pubmed/27221540",
        "http://www.ncbi.nlm.nih.gov/pubmed/10391560",
        "http://www.ncbi.nlm.nih.gov/pubmed/23565319",
        "http://www.ncbi.nlm.nih.gov/pubmed/29069792",
        "http://www.ncbi.nlm.nih.gov/pubmed/32543103",
        "http://www.ncbi.nlm.nih.gov/pubmed/32384323",
        "http://www.ncbi.nlm.nih.gov/pubmed/28325827",
        "http://www.ncbi.nlm.nih.gov/pubmed/21915664",
        "http://www.ncbi.nlm.nih.gov/pubmed/16896030",
        "http://www.ncbi.nlm.nih.gov/pubmed/2841597"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 835,
          "offsetInEndSection": 952,
          "text": "The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208"
        },
        {
          "offsetInBeginSection": 472,
          "offsetInEndSection": 543,
          "text": "APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208"
        },
        {
          "offsetInBeginSection": 1120,
          "offsetInEndSection": 1197,
          "text": "APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208"
        },
        {
          "offsetInBeginSection": 1017,
          "offsetInEndSection": 1181,
          "text": "Sequential mutations of the APC and KRAS were judged-based on a database search-to be characteristic of the adenoma-carcinoma sequence in colorectal carcinogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32543103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Colorectal carcinogenesis in familial adenomatous polyposis (FAP) follows a conventional adenoma-carcinoma sequence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32384323"
        },
        {
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1580,
          "text": "Of the remaining nine neoplasms, six had a K-ras mutation in the adenomatous portion only and three had one pattern in the adenomatous portion and a different pattern in the in situ carcinoma portion.CONCLUSIONS: LOH of the APC gene is an early and persistent feature in the evolution of a benign colorectal adenoma into an in situ carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10391560"
        },
        {
          "offsetInBeginSection": 641,
          "offsetInEndSection": 880,
          "text": "Our study clearly demonstrates that tubulovillous and villous adenomas, as well as both the benign and malignant parts of in situ carcinomas, are statistically more likely to contain a somatic KRAS gene mutation than colorectal carcinomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565319"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 640,
          "text": "A KRAS mutation was found in 61.9% of 134 adenomas, 67.8% of 84 in situ carcinomas, and just 31.6% of 171 carcinomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565319"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 562,
          "text": "Activating mutations in either the BRAF (in SSAs) or the KRAS oncogene (in TSAs) have been determined as the initiating molecular alterations, followed by epigenetic methylation of CpG islands in promoter regions of genes which are implicated in cell cycle control or DNA repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915664"
        },
        {
          "offsetInBeginSection": 1520,
          "offsetInEndSection": 1655,
          "text": "Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35173208"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 471,
          "text": "The adenomatous polyposis coli (APC) gene and mismatch repair genes are found to be dysfunctional early in the neoplastic process; either as inherited or somatic mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8607008"
        },
        {
          "offsetInBeginSection": 776,
          "offsetInEndSection": 965,
          "text": "Adenomas had lower mutational rates than did colorectal cancers and showed recurrent alterations in known cancer driver genes (APC, KRAS, FBXW7, TCF7L2) and AIs in chromosomes 5, 7, and 13.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221540"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 1470,
          "text": "mutations (V600E) in the BRAF oncogene. Both of these features are seen in sporadic colorectal carcinomas with microsatellite instability (MSI) which is potentially consistent with an origin of these cancers from precursor SSA/Ps. Dysplasia is detected in a subset of SSA/Ps with a high risk of progression to carcinoma. An uncommon serrated polyp is the traditional serrated adenoma that is typically found in the left colon, has a tubulovillous architecture, and frequently harbors mutant KRAS To date, the epidemiology of these serrated lesions is poorly understood, and limited observational data suggest a potential chemopreventive benefit of nonsteroidal anti-inflammatory drugs. The current primary strategy to reduce the risk of colorectal carcinoma from serrated polyps is to enhance their detection at colonoscopy and to ensure their complete removal. This review provides insight into the epidemiologic, clinical, histopathologic, and molecular features of serrated polyps and includes data on their endoscopic detection and chemoprevention. Cancer Prev Res; 10(5); 270-8. ©2017 AACR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28325827"
        },
        {
          "offsetInBeginSection": 675,
          "offsetInEndSection": 876,
          "text": "We found that ras-gene mutations occurred in 58 percent of adenomas larger than 1 cm and in 47 percent of carcinomas. However, ras mutations were found in only 9 percent of adenomas under 1 cm in size.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2841597"
        },
        {
          "offsetInBeginSection": 1437,
          "offsetInEndSection": 1634,
          "text": "Individuals with a Ki-ras mutated adenoma were more likely to overexpress p53 (OR, 2.46; 95% CI, 1.36-4.46), and 94.8% of adenomas with both alterations were classified as advanced (P \u003cor\u003d 0.0001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16896030"
        }
      ],
      "id": "65f772d3c4010b4d78000022",
      "ideal_answer": [
        "APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53 are oncogene somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas.",
        "Several studies have investigated the association between oncogene somatic mutations and the evolution of in situ carcinoma from colonic polyp adenomas. One study published in the journal Cancer Research found that acquired TP53 or PIK3CA somatic mutations are potential predictors for malignancy development in colorectal adenomas. The study analyzed the genome of 124 polyps and tumors from 40 patients and found that TP53 and PIK3CA mutations were more frequent in tumor tissues than in polyps. Another study published in the journal Gut found that KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. The study analyzed 134 adenomas, 84 in situ carcinomas, and 171 carcinomas and found that KRAS mutations were present in 61.9% of adenomas, 67.8% of in situ carcinomas, and just 31.6% of carcinomas. These studies suggest that TP53, PIK3CA, and KRAS somatic mutations are associated with the evolution of in situ carcinoma from colonic polyp adenomas.",
        "The most common somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas are the APC, TP53 and KRAS mutations.",
        "Somatic mutations in the KRAS, STK11, and BRAF oncogenes are associated with the evolution of colonic polyp adenomas into in situ carcinomas.",
        "There are several oncogene somatic mutations that have been associated with the evolution of in situ carcinoma from colonic polyp adenomas. These include mutations in the APC, KRAS, and TP53 genes. The APC gene is a tumor suppressor gene that is often mutated in early stage colon adenomas, while KRAS and TP53 mutations are more commonly found in later stage adenomas and carcinomas. Other genes that have been implicated in this process include BRAF, PIK3CA, and SMAD4. It is important to note that the development and progression of colon cancer is a complex process that involves the accumulation of multiple genetic alterations, and the specific mutations present in any given tumor may vary.",
        "Somatic mutations in APC and KRAS are associated to the evolution of in situ carcinoma from colonic polyp adenomas. APC mutations occur at the earliest stages of the adenoma-carcinoma sequence, whereas KRAS mutations appear in the later phases. In addition to these two genes, some publications suggest the relevance of TP53 and PIK3CA in the context of colonic adenocarcinomas.",
        "The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include APC, KRAS, and TP53. These genes are involved in the WNT signaling pathway, MAPK signaling pathway, and cell cycle regulation, respectively. The frequency of these mutations increases as the severity of the lesion progresses from low-grade adenoma to high-grade adenoma to in situ carcinoma. However, the presence of any singular mutation is not associated with the occurrence of subsequent adenoma or colorectal cancer (CRC).",
        "KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. TP53 or PIK3CA somatic mutations can be found in tumor tissues but not in polyps, and they are potential predictors for malignancy development. BRAF and KRAS mutations occur early in the putative serrated polyp neoplasia pathway and are associated with acquired mutator and suppressor gene inactivation by CpG island methylation of promoter regions. , In summary, KRAS, TP53, PIK3CA, BRAF, and KRAS mutations are associated with the evolution of in situ carcinoma from colonic polyp adenomas.",
        "The oncogene somatic mutations associated to in situ carcinoma evolution from colonic polyp adenomas are KRAS and BRAF.",
        "The evolution from colonic polyp adenomas to in situ carcinoma is associated with somatic mutations in oncogenes such as APC, KRAS, and TP53. These mutations play a crucial role in the progression of adenomas to carcinoma by promoting uncontrolled cell growth and inhibiting normal cellular processes. Identifying these mutations can help in understanding the molecular mechanisms underlying this progression and may have implications for early detection and targeted therapies in colorectal cancer.",
        "The somatic mutations in the APC (adenomatous polyposis coli) gene are commonly associated with the evolution of in situ carcinoma from colonic polyp adenomas. Mutations in the APC gene lead to dysregulation of the Wnt signaling pathway, resulting in uncontrolled cell proliferation and the development of colorectal cancer.",
        "The oncogenes KRAS and BRAF are frequently mutated in colorectal cancer, particularly in serrated lesions that can progress to carcinoma. Somatic mutations in these genes have been associated with the evolution of adenomas into in situ carcinomas. For example, activating mutations in KRAS (e.g., G12D) are common early events in colorectal tumorigenesis and may drive the growth of adenomatous polyps. Subsequent acquisition of additional genetic alterations, including those affecting TP53 or APC genes, can lead to further progression towards invasive carcinoma. BRAF mutations (e.g., V600E) are often found in serrated lesions and have been linked to the development of CpG island methylator phenotype (CIMP)-positive tumors, which are characterized by widespread promoter hypermethylation and a high rate of microsatellite instability (MS",
        "Somatic mutations in oncogenes KRAS and BRAF have been linked to the development of in situ carcinoma from colonic polyp adenomas. Studies have shown that KRAS mutations are present in a significant proportion of adenomas, particularly those with dysplasia, and are associated with progression to in situ carcinoma. BRAF mutations have also been detected in a subset of serrated polyps, which can progress to in situ carcinoma. The presence of these oncogene mutations suggests that they play a role in the evolution of adenomas to in situ carcinoma, although the exact mechanisms are not fully understood. Further research is needed to determine the frequency and significance of these mutations in different types of colonic polyps and to explore their potential as markers for early detection and prognosis.",
        "The study analyzed the mutational spectrum of well-known genes involved in colorectal cancer (CRC), including APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53, in a large series of 96 adenomas and in situ carcinomas using high-throughput genotyping. The results showed that the frequency of pathogenic variants in these genes was high, with APC, KRAS, and TP53 mutations being the most common. Notably, the frequency of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter. However, no association was found between the presence of any singular mutation and the occurrence of subsequent adenoma or CRC. The study supports the multistep model of gradual accumulation of mutations, especially in driver genes such as APC, TP53, and KRAS, during the evolution of in situ carcinoma from colonic polyp adenomas.",
        "Somatic mutations in the Ki-ras oncogene are associated with the progression of colonic adenomas to in situ carcinomas. Ki-ras mutations occur in approximately 50% of colorectal carcinomas and a similar percentage of intermediate to late-stage adenomas. The frequency of Ki-ras mutations increases with adenoma size, villous histology, and high-grade dysplasia, which are features associated with adenoma progression. In contrast, p53 mutations are more often detected in large, late-stage adenomas containing carcinoma, suggesting they occur later in the adenoma-carcinoma sequence.",
        "The most commonly associated oncogene somatic mutations in the evolution of in situ carcinoma from colonic polyp adenomas are mutations in the APC (adenomatous polyposis coli) gene and the KRAS gene. Mutations in the APC gene are early events in the adenoma-carcinoma sequence, leading to dysregulated Wnt signaling and increased cell proliferation. KRAS mutations, on the other hand, occur later in the progression to carcinoma and are associated with increased cell survival and resistance to apoptosis.",
        "Loss of heterozygosity (LOH) at chromosome 3p is significantly associated with colorectal cancers arising de novo.",
        "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53. These genes were found to have higher mutation frequencies in in situ carcinoma samples compared to adenoma samples. Specifically, the APC gene had a mutation frequency of 42.9-56.0% in adenoma samples and 54.5% in in situ carcinoma samples. Similarly, the KRAS gene had a mutation frequency of 32.7-32.0% in adenoma samples and 45.5% in in situ carcinoma samples. The TP53 gene had a mutation frequency of 8.2-20.0% in adenoma samples and 18.2% in in situ carcinoma samples. These findings suggest that these genes play a role in the progression of colonic polyp adenomas to in situ carcinoma.",
        "KRAS, PIK3CA, TP53, POLD1, POLE, NRAS, EGFR, and SMAD4 mutations are associated with in situ carcinoma evolution from colonic polyp adenomas.",
        "The APC, KRAS, and TP53 genes are somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas.",
        "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53.",
        "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are KRAS, TP53, and APC.",
        "APC, KRAS, TP53, PIK3CA, NRAS, EGFR, POLD1, and POLE oncogene somatic mutations are associated with in situ carcinoma evolution from colonic polyp adenomas.",
        "The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, and TP53 genes. These mutations were found to have slightly lower frequencies in adenoma samples compared to in situ carcinoma samples, suggesting their potential role in the progression of the disease. Other genes such as BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN may also be involved, but the specific snippets provided do not detail their association with in situ carcinoma evolution from colonic polyp adenomas.",
        "The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, and TP53 genes. These mutations are slightly more frequent in in situ carcinoma samples compared to adenoma samples. Other genes that may be involved include BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN. However, the specific mutation frequencies can vary. For instance, the APC gene mutation frequency ranges from 42.9% to 56.0%, the KRAS gene mutation frequency ranges from 32.7% to 45.5%, and the TP53 gene mutation frequency ranges from 8.2% to 20.0%.",
        "KRAS, APC and TP53 are the oncogenes most frequently mutated in colonic adenoma-to-carcinoma sequence. This process can be driven by the genetic alterations of these genes. KRAS mutations seem to be the most common event in these progression followed by APC and TP53 mutations.",
        "The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples.",
        "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53.",
        "The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas include mutations in the APC, KRAS, TP53, BRAF, and PIK3CA genes. These mutations are known to play a role in the progression from adenoma to carcinoma, with their frequencies found to be slightly lower in adenoma samples than in in situ carcinoma samples.",
        "Oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas include KRAS, BRAF, and TP53. These mutations are commonly found in adenomatous polyps and are thought to drive the progression of these lesions to invasive cancer. Other genes, such as APC, SMAD4, and MSH2, may also be mutated in this process.",
        "The abstract describes a study investigating the mutation profile of driver genes in colorectal adenomas and in situ carcinomas. The research found that the APC, KRAS, and TP53 genes had lower mutation frequencies in adenoma samples compared to in situ carcinoma samples. Specifically, the frequency distribution for these genes among low-grade adenomas, high-grade adenomas, and in situ carcinomas were: APC (42.9%, 56.0%, 54.5%), KRAS (32.7%, 32.0%, 45.5%), and TP53 (8.2%, 20.0%, 18.2%). However, the study did not find any association between the presence of singular mutations and the occurrence of subsequent adenoma or colorectal cancer (CRC). The data supports a multistep model of gradual accumulation of mutations in driver genes, such as APC, TP53, and KRAS, during the evolution from colonic polyp adenomas to in situ carcinomas. Therefore, somatic mutations in APC, KRAS, and TP53 are associated with the evolution of in situ carcinoma from colonic polyp adenomas.",
        "The evolution of in situ carcinoma from colonic polyp adenomas is associated with several oncogene somatic mutations. These include mutations in the APC, KRAS, and TP53 genes. Other genes that may be involved are BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN. The mutation frequencies of APC, KRAS, and TP53 were found to be slightly lower in adenoma samples than in in situ carcinoma samples, indicating their potential role in the progression of the disease",
        "The oncogene somatic mutations associated with the evolution from colonic polyp adenomas to in situ carcinoma include mutations in the APC, KRAS, and TP53 genes. The frequencies of these mutations were slightly lower in adenoma samples compared to in situ carcinoma samples. Additionally, mutations in genes such as BRAF, EGFR, NRAS, PIK3CA, POLE, POLD1, SMAD4, and PTEN were also observed in the study.",
        "The somatic mutations in the APC, KRAS, and TP53 oncogenes are associated with the evolution of in situ carcinoma from colonic polyp adenomas. The mutation frequencies of these genes were slightly lower in adenoma samples compared to in situ carcinoma samples. Specifically, the frequency distribution of mutations based on grade was as follows: APC gene - low-grade adenoma: 42.9%, high-grade adenoma: 56.0%, in situ carcinoma: 54.5%; KRAS gene - low-grade adenoma: 32.7%, high-grade adenoma: 32.0%, in situ carcinoma: 45.5%; TP53 gene - low-grade adenoma: 8.2%, high-grade adenoma: 20.0%, in situ carcinoma: 18.2%. Therefore, these oncogene mutations play a role in the multistep model of gradual accumulation of mutations leading to the development of in situ carcinoma from colonic polyp adenomas.",
        "The somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas are APC, KRAS, and TP53.",
        "The APC, KRAS, and TP53 gene mutation frequencies were found to be slightly lower in adenoma samples compared to in situ carcinoma samples. These findings suggest that alterations in these genes might play a role in the progression from adenomatous polyps to colorectal cancer.",
        "The study found that the frequency of pathogenic variants in well-known genes involved in colorectal cancer (CRC) was high in a large series of adenomas and in situ carcinomas. The APC, KRAS, and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. The occurrence of KRAS mutation was associated with villous histology, and methylation of the APC promoter was associated with POLE genetic variations. However, no association was found between any singular mutation and the occurrence of subsequent adenoma or CRC. The data supports the multistep model of gradual accumulation of mutations, especially in driver genes such as APC, TP53, and KRAS, during the transition from colonic polyp adenomas to in situ carcinoma.",
        "APC, KRAS and TP53 somatic mutations are associated with the evolution of colonic polyp adenomas to in situ carcinomas. The mutation frequencies of these genes were slightly lower in adenoma samples compared to in situ carcinoma samples, suggesting their role in the progression from adenoma to carcinoma.",
        "The oncogene somatic mutations associated with the evolution of in situ carcinoma from colonic polyp adenomas are APC, KRAS, and TP53.",
        "The oncogene somatic mutations associated with in situ carcinoma evolution from colonic polyp adenomas include APC, KRAS, and TP53 mutations, with frequencies slightly lower in adenoma samples compared to in situ carcinoma samples.",
        "The APC, KRAS, and TP53 mutations are associated with in situ carcinoma evolution from colonic polyp adenomas."
      ],
      "exact_answer": [
        [
          "APC",
          "Loss of heterozygosity (LOH) of the adenomatous polyposis coli (APC) gene"
        ],
        [
          "KRAS"
        ],
        [
          "TP53"
        ],
        [
          "BRAF",
          "BRAF V600E"
        ],
        [
          "EGFR"
        ],
        [
          "NRAS"
        ],
        [
          "PIK3CA"
        ],
        [
          "POLE"
        ],
        [
          "POLD1"
        ],
        [
          "SMAD4"
        ],
        [
          "PTEN"
        ],
        [
          "WNT"
        ]
      ]
    },
    {
      "body": "What is prurigo nodularis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37506977",
        "http://www.ncbi.nlm.nih.gov/pubmed/37245863",
        "http://www.ncbi.nlm.nih.gov/pubmed/36806647",
        "http://www.ncbi.nlm.nih.gov/pubmed/34268319",
        "http://www.ncbi.nlm.nih.gov/pubmed/35083742",
        "http://www.ncbi.nlm.nih.gov/pubmed/32461078",
        "http://www.ncbi.nlm.nih.gov/pubmed/18652691",
        "http://www.ncbi.nlm.nih.gov/pubmed/16197418",
        "http://www.ncbi.nlm.nih.gov/pubmed/10972090",
        "http://www.ncbi.nlm.nih.gov/pubmed/24825138",
        "http://www.ncbi.nlm.nih.gov/pubmed/32877138",
        "http://www.ncbi.nlm.nih.gov/pubmed/27578077",
        "http://www.ncbi.nlm.nih.gov/pubmed/35502157",
        "http://www.ncbi.nlm.nih.gov/pubmed/30261199",
        "http://www.ncbi.nlm.nih.gov/pubmed/29135018",
        "http://www.ncbi.nlm.nih.gov/pubmed/35986886",
        "http://www.ncbi.nlm.nih.gov/pubmed/20946583",
        "http://www.ncbi.nlm.nih.gov/pubmed/17352720",
        "http://www.ncbi.nlm.nih.gov/pubmed/38016088",
        "http://www.ncbi.nlm.nih.gov/pubmed/2359730",
        "http://www.ncbi.nlm.nih.gov/pubmed/37811660",
        "http://www.ncbi.nlm.nih.gov/pubmed/37663166",
        "http://www.ncbi.nlm.nih.gov/pubmed/36966024",
        "http://www.ncbi.nlm.nih.gov/pubmed/33771530",
        "http://www.ncbi.nlm.nih.gov/pubmed/34289753",
        "http://www.ncbi.nlm.nih.gov/pubmed/36304386",
        "http://www.ncbi.nlm.nih.gov/pubmed/34314056",
        "http://www.ncbi.nlm.nih.gov/pubmed/1884861",
        "http://www.ncbi.nlm.nih.gov/pubmed/2227059",
        "http://www.ncbi.nlm.nih.gov/pubmed/34965028",
        "http://www.ncbi.nlm.nih.gov/pubmed/37108838",
        "http://www.ncbi.nlm.nih.gov/pubmed/32454098",
        "http://www.ncbi.nlm.nih.gov/pubmed/31561504",
        "http://www.ncbi.nlm.nih.gov/pubmed/19398916"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 173,
          "text": "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. N",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37506977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37245863"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 95,
          "text": "Prurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36806647"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BACKGROUND: Prurigo nodularis (PN), or nodular prurigo, is a chronic, debilitating, inflammatory skin disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Prurigo nodularis is a chronic skin condition characterized by severely pruritic nodules that cause a profound negative impact on quality of life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32461078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Prurigo nodularis (PN), or chronic prurigo, is a distinct disease characterized by the presence of chronic pruritus and multiple localized or generalized pruriginous lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35986886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Prurigo nodularis is a chronic dermatologic condition involving the development of multiple cutaneous nodules in the setting of intractable pruritus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261199"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 302,
          "text": "PN evolves along with chronic pruritus in the context of diverse dermatological, systemic, neurological or psychiatric conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16197418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "BACKGROUND: Prurigo nodularis (PN) is a chronic inflammatory skin disease with nodular itch",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20946583"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "INTRODUCTION: Prurigo nodularis is an unusual disorder of unknown aetiology, which is notoriously resistant to therapy, and is characterized by extremely pruritic nodules with well-defined clinical symptoms and histopatholog",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18652691"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 160,
          "text": "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely itchy and often painful bumps on the arms, legs, and trunk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37663166"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 143,
          "text": "Prurigo nodularis (PN) is a chronic inflammatory skin condition that has a significant unmet needs for effective treatment options.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36966024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Prurigo nodularis of Hyde is an unusual disorder of unknown aetiology characterized by extremely pruritic nodules with well defined clinical and histopathological aspects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10972090"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 348,
          "text": "Prurigo nodularis is a chronic inflammatory skin disease consisting of severely pruritic nodules that can be very debilitating for patients. The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35502157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "BACKGROUND: Prurigo nodularis (PN), or nodular prurigo, is a chronic, debilitating, inflammatory skin disease. It can be very difficult to manage, and represents a challenge for th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. This condition is a difficult disease to treat and causes frustration to both the patient and the treating doctor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16197418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Prurigo nodularis (PN) is an understudied, chronic inflammatory skin disease that disproportionately affects African Americans and presents with intensely pruritic nodules of unknown etiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33771530"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38016088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 429,
          "text": "INTRODUCTION: Prurigo nodularis (PN) or chronic prurigo of nodular type (CNPG) is a subtype of chronic prurigo with severe pruritus and neuroimmune underlying pathophysiology occurring in a plethora of dermatological, systemic, neurologic, and psychiatric conditions.AREAS COVERED: We review the increasing repertoire of biologics in the treatment of CNPG focusing on those targeting interleukins 4, 13, 31, oncostatin M and IgE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34289753"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Prurigo nodularis (PN) is a chronic skin disease that manifests with severe itchy, firm, hyperkeratotic nodules distributed on the trunk and the extremities symmetrically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36304386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "text": "Characterized by the clinical presentation of individual to multiple symmetrically distributed, hyperkeratotic, and intensely itchy papules and nodules, prurigo nodularis (PN) is a rare disease that emerges in patients with chronic pruritus due to continuous scratching over a long period of time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27578077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "We report a case of prurigo nodularis of Hyde as the presenting sign of Hodgkin\u0027s disease in a 22-year-old girl.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1884861"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 82,
          "text": "Prurigo nodularis is the most severe degree of chronic prurigo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "INTRODUCTION: Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with pruritus and hyperkera",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37811660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "BACKGROUND: Prurigo nodularis (PN) is a chronic dermatologic condition manifesting as multiple papulonodular lesions occurring on the background of inten",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34965028"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37245863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Prurigo nodularis is an intensely pruritic dermatosis characterized by lichenified and excoriated papules and nodules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17352720"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Prurigo nodularis (PN) is a chronic condition characterized by the presence of nodular lesions accompanied by intense pruritus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108838"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Prurigo nodularis is an uncommon pediatric cutaneous disorder that is associated with intense pruritus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2359730"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32454098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized oftentimes by symmetrically distributed, severely pruritic nodules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31561504"
        },
        {
          "offsetInBeginSection": 1025,
          "offsetInEndSection": 1282,
          "text": "Prurigo nodularis is a chronic condition characterized by intensely pruritic, lichenified, or excoriated papules and nodules of unknown etiology. It is assumed to represent a cutaneous reaction pattern to repeated scrubbing or scratching caused by pruritus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398916"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "BACKGROUND: Prurigo nodularis is a debilitating skin condition that is classified as rare by the Genetic and Rare Diseases Information Center (GARD) and the National Organization for Rare Dise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35083742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Chronic prurigo is a debilitating skin disease characterized by the presence of chronic pruritus and scratching-related pruriginous lesion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34268319"
        }
      ],
      "id": "65f1eb84c4010b4d78000008",
      "ideal_answer": [
        "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.  The lesions are very pruritic and the condition may occur in any age group.",
        "Prurigo nodularis is a chronic skin condition characterized by the development of multiple intensely itchy nodules. It\u0027s associated with severe itching and can occur due to various underlying conditions, including dermatological, systemic, neurological, or psychiatric issues.",
        "Prurigo nodularis is a chronic inflammatory skin condition characterized by the presence of pruritic nodules.",
        "Prurigo nodularis (PN) is a chronic skin disease that manifests with severe itchy, firm, hyperkeratotic nodules distributed on the trunk and the extremities symmetrically.",
        "Prurigo nodularis (PN) is a debilitating inflammatory skin disease characterized by red to violaceous pruritic lesions.",
        "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.",
        "Prurigo nodularis is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.",
        "chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk",
        "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. It is an understudied inflammatory skin disease that is characterized by intense itching, hyperkeratosis, and the formation of nodules. The exact cause of PN is unknown, but it is believed to be associated with a dysregulated immune response and possible genetic predisposition. The disease can have a significant impact on quality of life due to its chronic nature, physical discomfort, and emotional distress. Treatment options for PN are limited and often focus on managing symptoms rather than addressing the underlying cause.",
        "Prurigo nodularis is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.",
        "Prurigo nodularis (PN) is a chronic, inflammatory skin disease characterized by pruritic, hyperkeratotic nodules that are bilaterally distributed on the extremities and trunk.",
        "Prurigo nodularis (PN) is a chronic neuroimmune skin disease. It is characterized by pruritic, hyperkeratotic nodules that are distributed bilaterally on the extremities and trunk. It is an inflammatory skin condition that is extremely itchy.",
        "Prurigo nodularis is an extremely pruritic, chronic inflammatory skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.",
        "Prurigo nodularis is a chronic neuroimmune skin disease characterized by pruritic hyperkeratotic nodules on extremities and trunk.",
        "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. It is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.",
        "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of itchy, firm nodules that are often hyperkeratotic and distributed bilaterally on the extremities and trunk.",
        "Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by extremely pruritic (itchy), hyperkeratotic (thickened skin) nodules that are typically distributed bilaterally on the extremities and trunk.",
        "Prurigo nodularis (PN) is a chronic skin disease characterized by itchy, raised bumps on the arms, legs, and trunk."
      ]
    },
    {
      "body": "What is the main cause of spillover events?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37019573",
        "http://www.ncbi.nlm.nih.gov/pubmed/29466832",
        "http://www.ncbi.nlm.nih.gov/pubmed/37007505",
        "http://www.ncbi.nlm.nih.gov/pubmed/37000877",
        "http://www.ncbi.nlm.nih.gov/pubmed/33052311"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1161,
          "text": "the extent of land use for food production and the agricultural practices employed that shape four archetypal food systems, each with a distinct risk profile with respect to zoonotic spillovers and differing dimensions of sustainability",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37019573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Pathogen spillover from wildlife to domestic animals and humans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832"
        },
        {
          "offsetInBeginSection": 579,
          "offsetInEndSection": 651,
          "text": "the highest spillover risk occurs at intermediate levels of habitat loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466832"
        },
        {
          "offsetInBeginSection": 1169,
          "offsetInEndSection": 1414,
          "text": "We conclude that that the processes of domestication, horizontal gene transfer and microbial succession might be important mechanisms behind the many spillover events driven and accelerated by climate change, biodiversity loss and globalization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37007505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Human land modification is a known driver of animal-to-human transmission of infectious agents (zoonotic spillover).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37000877"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 461,
          "text": "Spillover events are associated to varying degrees with high habitat fragmentation, biodiversity loss through land use change, high livestock densities, agricultural inputs, and wildlife hunting-all facets of food systems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37019573"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 491,
          "text": "The emerging infections that lead to substantive epidemics or pandemics are typically zoonoses that cross species boundaries at vulnerable points of animal-human interface. The sharing of space between wildlife and humans, and their domesticated animals, has dramatically increased in recent decades and is a key driver of pathogen spillover.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33052311"
        }
      ],
      "id": "65f8447fc4010b4d78000043",
      "ideal_answer": [
        "The main cause of spillover events is the disruption of habitats of the reservoir species.",
        "The main causes of spillover events include human land modification, domestication, horizontal gene transfer, microbial succession, climate change, biodiversity loss, and globalization.",
        "The main cause of spillover events and emerging infectious diseases is cross-species transmission of pathogens, particularly from animals to humans (zoonoses). Key drivers that facilitate this process include:\n\n1. Increased contact and sharing of space between wildlife, humans, and domesticated animals, often due to human intrusion into natural habitats.\n\n2. Agricultural intensification, animal trade, and certain herd management practices.\n\n3. High mutation and recombination rates in some viruses (e.g., coronaviruses) that enable host jumping and adaptation to new species.\n\n4. Specific human behaviors, such as hunting, butchering, and consuming wild animal meat, especially in hotspots like bushmeat markets.\n\n5. Domestication of wild animals as pets or for other purposes, bringing them into close proximity with humans.\n\nIn summary, the growing human-animal interface, coupled with the ability of some pathogens to adapt to new hosts, is the key driver of zoonotic spillover events.",
        "The main cause of spillover events is the interaction between wildlife, domestic animals, and humans, often influenced by factors such as habitat loss, agricultural practices, and land use for food production. Spillover events occur when pathogens are transmitted from one species to another, leading to potential outbreaks of zoonotic diseases. Factors like habitat destruction and encroachment into wildlife areas can increase the risk of spillover events, highlighting the importance of understanding and managing these interactions to prevent disease transmission."
      ],
      "exact_answer": [
        [
          "The main cause of spillover events is the disruption of habitats of the reservoir species.",
          "The main cause of spillover events is the interface between humans, wildlife, and domesticated animals, which is associated with high habitat fragmentation, biodiversity loss through land use change, high livestock densities, agricultural inputs, and wildlife hunting."
        ]
      ]
    },
    {
      "body": "What are the most commonly used pain scales for the measurement of pain in ICU?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35656052",
        "http://www.ncbi.nlm.nih.gov/pubmed/32389396",
        "http://www.ncbi.nlm.nih.gov/pubmed/30834018",
        "http://www.ncbi.nlm.nih.gov/pubmed/28362033",
        "http://www.ncbi.nlm.nih.gov/pubmed/27833752",
        "http://www.ncbi.nlm.nih.gov/pubmed/30820228"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 280,
          "text": "This study aims to compare the diagnostic value of the critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS) for pain assessment among unconscious patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656052"
        },
        {
          "offsetInBeginSection": 1319,
          "offsetInEndSection": 1579,
          "text": " CPOT and BPS have acceptable discriminant validity in differentiating nonnociceptive and nociceptive procedural pain although the effect size of CPOT is larger than that of BPS. Although both instruments have low reliability, the reliability of BPS is better.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35656052"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 216,
          "text": " To determine the concordance of Zurich Observation Pain Assessment (ZOPA) with the behavioural Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT) to detect pain in nonverbal ICU patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32389396"
        },
        {
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1350,
          "text": "ZOPA is concordant with the BPS and the CPOT to indicate pain but detects pain earlier due to the low threshold value.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32389396"
        },
        {
          "offsetInBeginSection": 1563,
          "offsetInEndSection": 1770,
          "text": "Based on available evidence and investigations, CPOT and BPS tools have good validity and reliability to be used in pain assessment in Nonverbal Intubated Critically Adult Patients after Open-Heart Surgery. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30834018"
        },
        {
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1258,
          "text": "Current research shows that the two tools best validated for patients unable to self-report pain are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28362033"
        },
        {
          "offsetInBeginSection": 2040,
          "offsetInEndSection": 2199,
          "text": "In critically ill mechanically ventilated patients, both CPOT and BPS can be used for assessment of pain intensity with different sensitivity and specificity. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27833752"
        },
        {
          "offsetInBeginSection": 1464,
          "offsetInEndSection": 1651,
          "text": "Critically ill patients in ICU experience a different range of pain in routine daily care. BPS and CPOT scales could be used successfully for monitoring of pain in this group of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820228"
        }
      ],
      "id": "644108b157b1c7a315000053",
      "ideal_answer": [
        "The most common pain scales used to measure pain in ICU are the following: critical-care pain observation tool (CPOT) and behavioral pain scale (BPS).",
        "The Behavioral Pain Scale and the Critical-Care Pain Observation Tool are the most commonly used scales for measuring pain in ICU patients.",
        "The two pain measurement tools that are most commonly used in intensive care units for the assessment of pain are the Numeric Rating Scale (NRS) and the Critical-Care Pain Observation Tool (CPOT). Other tools are Visual Analogue Scale (VAS), Verbal Rating Scale (VRS) and the Faces Pain Scale (FPS).",
        "For self-reported pain in ICU patients, the NRS is the most common pain scale, with most studies reporting it as the first choice, and the VAS is the second most common scale.\nFor critically ill, non-communicative, or sedated ICU patients, behavioural pain scales are preferred.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Numeric Rating Scale (NRS), the Visual Analog Scale (VAS), the Behavioral Pain Scale (BPS), and the Critical Care Pain Observation Tool (CPOT).",
        "The most commonly used pain scales for measuring pain in ICU patients include the Behavioral Pain Scale (BPS), Critical Care Pain Observation Tool (CPOT), Non-verbal Pain Scale (NVPS), and the Confusion Assessment Method for the ICU (CAM-ICU). The BPS and CPOT are considered to be the most valid and reliable for this purpose, according to available evidence.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Numerical Rating Scale (NRS), the Visual Analog Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).",
        "The most commonly used pain scales for the measurement of pain in the ICU are the Critical Care Pain Observation Tool (CPOT), the Behavioral Pain Scale (BPS), the Visual Analog Scale (VAS), and the Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale.",
        "The most commonly used pain scales for the measurement of pain in ICU include the Visual Analog Scale (horizontal and vertical line orientation), the Verbal Descriptor Scale, the 0-10 oral Numeric Rating Scale, the 0-10 visually enlarged laminated Numeric Rating Scale, the Critical-Care Pain Observation Tool, the Behavioral Pain Scale, and the Nonverbal Adult Pain Assessment Scale.",
        "The most commonly used pain scales for the measurement of pain in the ICU include the Critical Care Pain Observation Tool (CPOT), Behavioral Pain Scale (BPS), Visual Analog Scale (VAS), Verbal Descriptor Scale (VDS), Numeric Rating Scale (NRS), Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale, Glasgow composite pain scale, and Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and Neonatal Infant Pain Scale (NIPS) for infants.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS).",
        "The Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT) are the most valid and reliable pain assessment instruments developed to objectively assess pain in sedated intensive care patients.",
        "Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS)",
        "CPOT, BPS, and the Behavioral Pain Scale are commonly used for the measurement of pain in ICU.",
        "The two most commonly used pain scales for the measurement of pain in ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).",
        "The most commonly used pain scales for measuring pain in the ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).",
        "The most commonly used pain scales for the measurement of pain in ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT).",
        "The most commonly used pain scales for the measurement of pain in ICU include the Critical Care Pain Observation Tool (CPOT), Behavioral Pain Scale (BPS), BPS, CPOT, Zurich Observation Pain Assessment (ZOPA), Behavioral Pain Scale, and Numeric Rating Scale (NRS).",
        "The most commonly used pain scales for the measurement of pain in ICU are the critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS).",
        "The Behavioral Pain Scale and the Critical Care Pain Observation Tool are the most commonly used scales for assessing pain in ICU patients, with Zurich Observation Pain Assessment also being used.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS).",
        "The most commonly used pain scales for the measurement of pain in the ICU are the Critical Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS). These scales have been validated and are recommended for use in patients who are unable to self-report their pain, such as those who are sedated, intubated, or mechanically ventilated.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Critical-Care Pain Observation Tool (CPOT) and the Behavioral Pain Scale (BPS).",
        "The two most commonly used pain scales for measuring pain in critically ill patients in the ICU who are unable to self-report pain are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). Both scales have been validated for assessing pain intensity in mechanically ventilated and unconscious ICU patients.",
        "The most commonly used pain scales for the measurement of pain in ICU are the Critical-care pain observation tool (CPOT), Behavioral pain scale (BPS), and Zurich Observation Pain Assessment (ZOPA).",
        "The most commonly used pain scales for the measurement of pain in the ICU are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). These scales have been validated and shown to have good validity and reliability in assessing pain in nonverbal and mechanically ventilated ICU patients."
      ],
      "exact_answer": [
        [
          "critical-care pain observation tool",
          "CPOT",
          "Critical Care Pain Observation Tool"
        ],
        [
          "behavioral pain scale",
          "BPS"
        ],
        [
          "Numeric Rating Scale",
          "NRS"
        ],
        [
          "VAS",
          "Visual Analogue Scale"
        ],
        [
          "Verbal Rating Scale",
          "VRS"
        ],
        [
          "Face, Legs, Activity, Cry, Consolability",
          "FLACC"
        ]
      ]
    },
    {
      "body": "What medication were tested in the PEMMELA trial?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37844598"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37844598"
        }
      ],
      "id": "65d373e21930410b13000049",
      "ideal_answer": [
        "PEMMELA was a single-arm phase 2 study that tested pembrolizumab plus lenvatinib as second-line and third-line for patients with pleural mesothelioma."
      ],
      "exact_answer": [
        [
          "pembrolizumab"
        ],
        [
          "lenvatinib"
        ]
      ]
    },
    {
      "body": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32825236",
        "http://www.ncbi.nlm.nih.gov/pubmed/24071482",
        "http://www.ncbi.nlm.nih.gov/pubmed/30151274",
        "http://www.ncbi.nlm.nih.gov/pubmed/15727814",
        "http://www.ncbi.nlm.nih.gov/pubmed/27028619",
        "http://www.ncbi.nlm.nih.gov/pubmed/37111185",
        "http://www.ncbi.nlm.nih.gov/pubmed/30218667",
        "http://www.ncbi.nlm.nih.gov/pubmed/36572792",
        "http://www.ncbi.nlm.nih.gov/pubmed/36527679",
        "http://www.ncbi.nlm.nih.gov/pubmed/28153960",
        "http://www.ncbi.nlm.nih.gov/pubmed/33937029",
        "http://www.ncbi.nlm.nih.gov/pubmed/27295340",
        "http://www.ncbi.nlm.nih.gov/pubmed/24412617",
        "http://www.ncbi.nlm.nih.gov/pubmed/31554963",
        "http://www.ncbi.nlm.nih.gov/pubmed/36572998",
        "http://www.ncbi.nlm.nih.gov/pubmed/36704106",
        "http://www.ncbi.nlm.nih.gov/pubmed/35013389",
        "http://www.ncbi.nlm.nih.gov/pubmed/33577585",
        "http://www.ncbi.nlm.nih.gov/pubmed/31330830",
        "http://www.ncbi.nlm.nih.gov/pubmed/32398370",
        "http://www.ncbi.nlm.nih.gov/pubmed/31027304",
        "http://www.ncbi.nlm.nih.gov/pubmed/35211486",
        "http://www.ncbi.nlm.nih.gov/pubmed/31735976",
        "http://www.ncbi.nlm.nih.gov/pubmed/26727419",
        "http://www.ncbi.nlm.nih.gov/pubmed/3039469",
        "http://www.ncbi.nlm.nih.gov/pubmed/32991312",
        "http://www.ncbi.nlm.nih.gov/pubmed/22868282",
        "http://www.ncbi.nlm.nih.gov/pubmed/12820718",
        "http://www.ncbi.nlm.nih.gov/pubmed/30413188",
        "http://www.ncbi.nlm.nih.gov/pubmed/19064190",
        "http://www.ncbi.nlm.nih.gov/pubmed/35664967",
        "http://www.ncbi.nlm.nih.gov/pubmed/34063108",
        "http://www.ncbi.nlm.nih.gov/pubmed/35090978"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 347,
          "text": "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825236"
        },
        {
          "offsetInBeginSection": 672,
          "offsetInEndSection": 807,
          "text": "Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32825236"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 532,
          "text": "alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071482"
        },
        {
          "offsetInBeginSection": 687,
          "offsetInEndSection": 894,
          "text": "multiple proposed pathogenic microorganisms including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151274"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 830,
          "text": "We focus on some of the mechanisms by which the colonic microbiota drives the progression towards colorectal malignancy including generation of reactive metabolites and carcinogens, alterations in host carbohydrate expression and induction of chronic mucosal inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15727814"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 840,
          "text": "This review evaluates the pathophysiology of how a diet-associated shift in gut microbiota, so-called the microbial sulfur diet, provokes injuries and inflammation to the colonic mucosa and contributes to the development of CRC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37111185"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 430,
          "text": "While certain members of the colonic microbiota have been shown to promote the host\u0027s health there are also numerous studies that have implicated other members of the colonic microbiota in the development of colorectal cancer, a prominent malignancy within the western world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15727814"
        },
        {
          "offsetInBeginSection": 1068,
          "offsetInEndSection": 1321,
          "text": "We believe that using probiotics or altering the gut microbiota will likely be effective tools in the fight against CRC treatment.PURPOSE: In this review, we revisited the association between gut microbiota and colorectal cancer whether cause or effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572792"
        },
        {
          "offsetInBeginSection": 431,
          "offsetInEndSection": 557,
          "text": "In this review we consider the evidence for the role of bacteria in colorectal cancer from molecular and animal model studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15727814"
        },
        {
          "offsetInBeginSection": 1322,
          "offsetInEndSection": 1568,
          "text": "The various factors which influence gut microbiome in patients with CRC and possible mechanism in relation with development of CRC.CONCLUSION: The clinical significance of the intestinal microbiota may aid in the prevention and management of CRC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572792"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 379,
          "text": "Gut microbiota drive the development of inflammation within the colon and such inflammation is implicated in colonic neoplastic development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27028619"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 611,
          "text": "Bacterial sulfur metabolism is recognized as a critical mechanism of EOCRC pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37111185"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 450,
          "text": "nting CRC. Hydrogen sulfide, produced by autochthonous sulfidogenic bacteria, triggers proinflammatory pathways and hyperproliferation, and is",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28153960"
        },
        {
          "offsetInBeginSection": 824,
          "offsetInEndSection": 983,
          "text": "microbial encroachment towards the colonic epithelium may promote inflammation and oxidative stress and even translocation of species across the colonic lumen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33937029"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Chronic consumption of excess ethanol increases the risk of colorectal cancer. The pathogenesis of ethanol-related colorectal cancer (ER-CRC) is thought to be partly mediated by gut microbes. Specifically, bacteria in the colon and rectum convert ethanol to acetaldehyde (AcH), which is carcinogenic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27295340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Commensal gut microflora and dietary fiber protect against colonic inflammation and colon cancer through unknown targets. Butyrate, a bacterial product from fermentation of dietary fiber in the colon, has been implicated in this process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24412617"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 653,
          "text": "Sequencing studies have revealed microbial compositional and ecological changes in patients with CRC, whereas functional studies in animal models have pinpointed the roles of several bacteria in colorectal carcinogenesis, including Fusobacterium nucleatum and certain strains of Escherichia coli and Bacteroides fragilis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31554963"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 657,
          "text": "Microbiota, IL10KO, and their combination altered 0.4%, 0.4%, and 4% of CpG island methylation, respectively. These are comparable to what is seen in colon cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572998"
        },
        {
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1361,
          "text": "Further understanding the precise mechanism(s) of the oral-gut microbial axis in PD, IBD, and colorectal cancer pathogenesis will be pivotal in diagnosis, prognosis, and future treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527679"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 634,
          "text": "Recent studies suggest that dysbiosis of the oral microbiota can alter the microbial composition in relative abundance or diversity of the distal gut, leading to the progression of digestive carcinogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527679"
        },
        {
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1173,
          "text": "As such, oral microbiota dysbiosis involving specific bacteria, including Fusobacterium nucleatum and Porphyromonas gingivalis, can ultimately lead to gut malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527679"
        },
        {
          "offsetInBeginSection": 841,
          "offsetInEndSection": 996,
          "text": "Specific members of the colonic microbiota may promote IL17A production and IL17A-producing cell functions in the colonic mucosa to promote carcinogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30218667"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 424,
          "text": "To learn about gut microbiota signatures in tissues of the colorectal polyp and normal colorectal mucosa, and faeces.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36704106"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1492,
          "text": "The colonic epithelium is exposed to a mixture of compounds through diet, among which some are procarcinogens, whereas others have a protective effect. Therefore, the net impact of these compounds on human health depends on the overall balance between all factors involved. Strong scientific evidence has demonstrated the relationship between nitrosamines (NA), heterocyclic amines (HCAs), and polycyclic aromatic hydrocarbons (PAHs), which are the major genotoxins derived from cooking and food processing, and cancer. The mechanisms of the relationship between dietary toxic xenobiotics and cancer risk are not yet well understood, but it has been suggested that differences in dietary habits affect the colonic environment by increasing or decreasing the exposure to mutagens directly and indirectly through changes in the composition and activity of the gut microbiota. Several changes in the proportions of specific microbial groups have been proposed as risk factors for the development of neoplastic lesions and the enrichment of enterotoxigenic microbial strains in stool. In addition, changes in the gut microbiota composition and activity promoted by diet may modify the faecal genotoxicity/cytotoxicity, which can be associated with a higher or lower risk of developing cancer. Therefore, the interaction between dietary components and intestinal bacteria may be a modifiable factor for the development of colorectal cancer in humans and deserves more attention in the near future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31027304"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 930,
          "text": "Here, we report that non-pathogenic microbiota accelerate age-related methylation drift in the colon when compared with germ-free mice. DNA methylation analyses showed that microbiota and IL10KO were associated with changes in 5% and 4.1% of CpG sites, while mice with both factors had 18% alterations. Microbiota, IL10KO, and their combination altered 0.4%, 0.4%, and 4% of CpG island methylation, respectively. These are comparable to what is seen in colon cancer. Ageing changes were accelerated in the IL10KO mice with microbiota, and the affected genes were more likely to be altered in colon cancer. Thus, the microbiota affect DNA methylation of the colon in patterns reminiscent of what is observed in ageing and colorectal cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572998"
        }
      ],
      "id": "65f77328c4010b4d78000023",
      "ideal_answer": [
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. On the other hand, pathogenic bacteria have heightened iron acquisition mechanisms.",
        "The pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa involves several steps: , 1. Dysbiosis: An imbalance of the gut microbiota, characterized by an overgrowth of harmful bacteria and a decrease in beneficial bacteria., 2. Inflammation: The dysbiotic microbiota triggers chronic inflammation in the colonic mucosa, leading to the activation of pro-inflammatory cytokines and the production of reactive oxygen species (ROS)., 3. DNA damage: The chronic inflammation caused by the dysbiotic microbiota leads to DNA damage, mutations, and epigenetic changes in the colonic epithelial cells., 4. Malignant transformation: The accumulation of DNA damage and epigenetic changes can eventually lead to the transformation of colonic epithelial cells into cancer cells, resulting in the formation of malignant lesions., 5. Immune evasion: Cancer cells can evade the host immune system by suppressing immune responses or producing immune suppressive factors, allowing them to progress and metastasize. , In summary, the pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa involves dysbiosis, inflammation, DNA damage, malignant transformation, and immune evasion.",
        "1) Interactions between the gut microbiota and epithelial cells:\ni) Microbiota-associated enzymes can cleave the glycan portions of mucin, thereby generating free oligosaccharides that can serve as a source of carbon and energy for commensal bacteria. Mucin glycosylation in the colon is altered by bacterial colonization, resulting in differences in mucin glycosylation in the healthy and diseased gut.\nii) Microbiota-associated enzymes can modify epigenetic regulators in colonic epithelial cells by altering cellular metabolism.\niii) Bacterial metabolites (such as phenol, p-cresol, indole, and their derivatives) can enter systemic circulation and lead to cancer development.\n2) Interactions between the gut microbiota and the host immune system:",
        "The pathophysiological mechanism involves a diet-associated shift in gut microbiota, known as the microbial sulfur diet, which causes injuries and inflammation to the colonic mucosa. This inflammatory environment fosters conditions conducive to the development of colorectal cancer (CRC).",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is through bacterial accumulation in the lamina propria, leading to reductions in Tuft cells, goblet cells, and the mucus barrier of the colonic epithelium. This is due to bacterial induction of prostaglandin production by myeloid cells.",
        "1) The microbiota is the microorganisms that inhabit our body, and is responsible for producing an environment rich in bacterial products such as amino acids, short-chain fatty acids, indoles, vitamins, gases, and lipopolysaccharides.\n2) Indoles produced by microbiota can cause an increase in the level of intestinal inflammation, and lipopolysaccharides can lead to changes in the intestinal epithelial layer, allowing the passage of bacterial products, stimulating oncogenic pathways.\n3) Bacterial products produced by the microbiota are implicated in the development and progression of CRC by inducing DNA damage, activation of proto-oncogenes, inhibition of tumour suppressor genes, induction of angiogenesis, and stimulation of local inflammation.\n4) The interaction between the microbiota",
        "In order to induce malignant lesions in the colon, gut microbes need to promote chromosomal instability by favoring conditions for accumulation of replication errors, and producing mutagenic and inflammatory metabolites. In addition, these microbes produce anaerobic hydrogen sulfide, which inhibits DNA repair pathways in epithelial cells, leading to aneuploidy and chromosomal instability. In addition, microbes may interact with dietary substances to produce mutagenic compounds, such as heterocyclic aromatic amines, and genotoxins, which produce DNA strand breaks, alkylating agents and hydrogen peroxide that can cause oxidative damage to DNA.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is bacterial accumulation in the lamina propria and bacterial induction of prostaglandin production by myeloid cells.",
        "The microbiota\u0027s pathophysiological mechanism for producing malignant lesions in colonic mucosa involves several key processes, including the generation of reactive metabolites and carcinogens, alterations in host carbohydrate expression, and induction of chronic mucosal inflammation. A diet-associated shift in gut microbiota, known as the microbial sulfur diet, can provoke injuries and inflammation to the colonic mucosa, partly explaining the rising incidence of early-onset colorectal cancer (EOCRC). This shift is influenced by an animal-based diet, which causes a disruption in the homeostasis of hydrogen sulfide concentration due to bacterial sulfur metabolism. Gut microbial and fungal profiles in patients with colorectal adenomas with low-grade dysplasia (ALGD) show alterations compared to normal controls, contributing to the development of intestinal cancer by regulating specific metabolic pathways. Mucosal samples are more relevant for evaluating microbiota\u0027s pathophysiological involvement in CRC carcinogenesis, while non-invasive stool sampling could be beneficial for early CRC detection strategies. The gut microbiome, encompassing bacteria, viruses, fungi, and other microbes, plays a critical role in colon cancer development through various mechanisms and metabolites. Understanding the mechanisms of microbiome-colon cancer interactions can provide insights into effective prevention and treatment approaches for colon cancer.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several interconnected processes. Firstly, the gut microbiome influences the host\u0027s nutrition and immune system, and an imbalance in the microbiota, also known as dysbiosis, can lead to the development of harmful bacteria that can damage the colonic mucosa. Secondly, certain members of the colonic microbiota have been shown to produce reactive metabolites and carcinogens, such as trimethylamine-N-oxide (TMAO), which can alter host cellular metabolism and promote the growth of cancer cells. Thirdly, the colonic microbiota can also induce chronic mucosal inflammation, which creates an environment conducive to the progression of malignant lesions. Lastly, alterations in host carbohydrate expression can also contribute to the development of colorectal cancer. Overall, the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between the host and the gut microbiome, highlighting the importance of maintaining a healthy balance of gut bacteria to prevent the development of colorectal cancer.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves bacterial accumulation in the lamina propria, leading to bacterial induction of prostaglandin production by myeloid cells. This process results in reductions in Tuft cells, goblet cells, and the mucus barrier of the colonic epithelium in the normal colonic mucosa.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota, characterized by an imbalance in the composition and function of the microbial community, has been implicated in the pathogenesis of colorectal cancer. Specific bacterial species, such as Fusobacterium nucleatum, have been associated with the development and progression of colorectal cancer through various mechanisms, including inflammation, immune modulation, and alteration of the tumor microenvironment.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves various factors and processes, including alterations in the gut microbiota composition, inflammation, genotype-related causes, and host responses. The gut microbiota can potentially induce colorectal carcinoma through mechanisms such as producing pro-inflammatory cytokines or metabolites that promote tumor growth and survival, altering the colonic interleukin levels, and modulating the mucosal host defense system. Additionally, gut microbiota can influence the development of intestinal lesions by regulating butyrate production, which is essential for maintaining intestinal homeostasis. Furthermore, certain bacteria or their metabolites may contribute to immunosuppression and damage to the intestinal mucosa, leading to an increased risk of colore",
        "The pathophysiological mechanism by which the microbiota produces malignant lesions in colonic mucosa is complex and involves multiple steps. The gut microbiome influences the development of colorectal cancer (CRC) through several mechanisms, including the production of carcinogens, inflammation, immune response, and competition for nutrients. The gut microbiota can produce carcinogens, such as nitrosamines, through nitrogen reduction and ammonia production, which can lead to DNA damage and mutations in colonic epithelial cells. Additionally, the gut microbiome influences the immune response by modulating T cell function, cytokine production, and anti-tumor immunity. Dysbiosis, an imbalance of the gut microbiota, can also lead to increased inflammation in the colonic mucosa, promoting a pro-tumorigenic environment. Furthermore, bacterial overgrowth, especially of sulfur-reducing bacteria, can produce hydrogen sulfide, which has been linked to CRC development. Hydrogen sulfide can cause DNA damage and inhibit the function of tumor suppressor proteins, leading to uncontrolled cell growth and proliferation. Competition for nutrients between commensal bacteria and the host can also contribute to malignant transformation. Overall, the gut microbiome plays a critical role in CRC development through multiple pathways, emphasizing the importance of understanding the relationship between the gut microbiome and colonic mucosa health.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. High-fat, high-protein, low-fiber diets can cause an unfavorable microbial environment in the human colon, predisposing some individuals towards large bowel diseases. The irregular emptying of rapidly fermentable ileal digesta into the colon causes a surge in microbial activity. The sudden availability of rapidly fermentable substrate generates a large microbial population that soon depletes its substrate. For microorganisms to perpetuate, they must induce enzymes to ferment dying or dead microbes (cannibalism) in addition to colonic epithelial mucosa and mucins. As the carbohydrate-to-nitrogen ratio of the colonic contents decreases, the fermentation becomes more proteolytic and subacute levels of fermentation products such as ammonia may be generated. Carcinogens are concentrated within a small colonic mass and the probability of precancerous lesions and polyps developing in the colonic mucosa is directly related to the severity, frequency, and duration of these microbial \"feast or famine\" situations in the colon.\n\nCertain bacteria, such as Escherichia coli, have acquired the ability to induce chronic inflammation and/or produce toxins, such as cyclomodulin, which could participate in the carcinogenesis process. An increased level of mucosa-associated and internalized E. coli was observed in the tumors",
        "A diet-associated shift in gut microbiota, called the microbial sulfur diet, provokes injuries and inflammation to the colonic mucosa through bacterial sulfur metabolism, contributing to the development of colorectal cancer (CRC).",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa is not fully understood. However, dysbiosis in the gut microbiota, characterized by an imbalance in the composition and function of the microbial community, has been implicated in the development of colorectal cancer. Specific changes in the gut microbiome can lead to chronic inflammation, alteration of the intestinal barrier function, production of genotoxic metabolites, and modulation of the immune response, all of which contribute to the initiation and progression of malignant lesions in the colonic mucosa.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between the gut microbiome and the host immune system. Perturbations in the balance of protective and pathogenic bacteria can lead to an overgrowth of harmful microorganisms, which can produce carcinogenic metabolites/toxins, induce inflammation, and activate oncogenic signaling pathways. This can ultimately result in the development of malignant lesions in the colonic mucosa. The outcompetition of protective bacteria by pathogenic bacteria, such as sulfidogenic bacteria and Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, can also contribute to the development of colon cancer.",
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer by increasing pathogenic bacteria at the expense of protective bacteria, leading to heightened production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling pathways.",
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer through several mechanisms. These include an increase in pathogenic bacteria at the expense of protective bacteria, leading to an increase in carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Pathogenic bacteria have heightened iron acquisition mechanisms and tend to outcompete protective bacteria for free iron. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development. Multiple proposed pathogenic microorganisms, such as sulfidogenic bacteria including Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been associated with colorectal cancer.",
        "The pathophysiological mechanism involves perturbations of the colonic microbiota, leading to an increase in pathogenic bacteria. These bacteria produce carcinogenic metabolites/toxins, induce inflammation, and activate oncogenic signaling. Additionally, they outcompete protective bacteria for free iron, and alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations of the colonic microbiota leading to an increase in pathogenic bacteria at the expense of protective bacteria, which can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Additionally, alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development.",
        "”The primary treatment for major depressive disorder (MDD) in the PEMMELA (Paroxetine/Fluoxetine) trial was duloxetine and fluoxetine. Participants were randomly assigned to receive either paroxetine or fluoxetine. The medications were given in a dosing range of 40-80mg/day for paroxetine/fluoxetine (dosed 3 times a week for 8 weeks, then 1 time a week for 4 weeks, and then dosed 1 time a day for the maintenance period) or placebo, for up to 13 weeks.”}\u003c/s\u003e",
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer by increasing pathogenic bacteria at the expense of protective bacteria, leading to enhanced production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling pathways.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. First, perturbations in the colonic microbiota can lead to an increase in pathogenic bacteria and a decrease in protective bacteria. These pathogenic bacteria often have heightened iron acquisition mechanisms, allowing them to outcompete the protective bacteria. This imbalance can contribute to disease by increasing the production of carcinogenic metabolites and toxins. Additionally, these changes can induce inflammation and activate oncogenic signaling. Furthermore, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Some of the proposed pathogenic microorganisms include sulfidogenic bacteria such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
        "The pathophysiological mechanism involves perturbations in the colonic microbiota, leading to an increase in pathogenic bacteria and a decrease in protective bacteria. This imbalance can contribute to colorectal cancer initiation and progression. Pathogenic bacteria, which have heightened iron acquisition mechanisms, can outcompete protective bacteria for free iron. This can lead to increased production of carcinogenic metabolites and toxins, induction of inflammation, and activation of oncogenic signaling. Additionally, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Certain pathogenic microorganisms, such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been implicated in this process.",
        "The microbiota is involved in colorectal cancer. The proliferation of pathogenic bacteria leads to a decrease of beneficial bacteria, thereby increasing the production of carcinogenic metabolites and toxins, activating inflammation and oncogenic signaling.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota that lead to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development. Multiple proposed pathogenic microorganisms, including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, have been implicated in this process.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves several steps. Perturbations in the colonic microbiota lead to an increase in pathogenic bacteria and a decrease in protective bacteria. These pathogenic bacteria, including Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum, contribute to disease progression by increasing the production of carcinogenic metabolites and toxins, inducing inflammation, and activating oncogenic signaling pathways. Additionally, a disruption in the normal communication between the mucosal immune system and gut microbial communities can lead to a dysregulated immune response, resulting in chronic intestinal inflammation. Over time, this chronic inflammation can cause damage to the colonic mucosa, leading to the development of malignant lesions. Furthermore, some pathogenic bacteria have enhanced iron acquisition mechanisms, which allow them to outcompete protective bacteria, potentially causing damage to the colonic mucosa. Further research is needed to establish a direct link between these mechanisms and the development of malignant lesions in the colonic mucosa.",
        "The microbiota contributes to the formation of malignant lesions in the colonic mucosa by increasing the presence of pathogenic bacteria, which outcompete protective bacteria for resources like iron. This imbalance leads to higher production of carcinogenic metabolites and toxins, induces inflammation, and activates oncogenic signaling pathways. Specific bacteria implicated in this process include sulfidogenic bacteria such as Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
        "The microbiota can produce malignant lesions in colonic mucosa by generating carcinogenic metabolites and toxins, such as hydrogen sulfide from sulfidogenic bacteria like Bilophila wadsworthia. Additionally, certain bacteria like Streptococcus bovis and Helicobacter pylori are linked to inflammation and oncogenic signaling pathways, respectively. Dysbiosis, or an imbalance in the gut microbiota, is also associated with colorectal cancer, highlighting the importance of maintaining a healthy balance of gut bacteria to prevent cancer development.",
        "The gut microbiota can contribute to the development of colorectal cancer (CRC) through various pathophysiological mechanisms. One key mechanism is the production of carcinogenic metabolites and toxins by certain bacteria, such as sulfidogenic bacteria like Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. These bacteria can alter the gut environment and create an inflammatory microenvironment that promotes the growth of malignant cells in the colonic mucosa. Additionally, the gut microbiota can also influence the host\u0027s immune system, leading to immune dysregulation and increased susceptibility to cancer development. For example, alterations in communication between the mucosal immune system and gut microbial communities have been implicated as a core defect that leads to chronic intestinal inflammation and cancer development. Overall, the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves a complex interplay between bacterial metabolites, immune dysregulation, and inflammation.",
        "The microbiota in the colon can contribute to the development of malignant lesions in the colonic mucosa through several mechanisms. Certain pathogenic bacteria can outcompete protective bacteria, leading to an increase in harmful bacteria. These bacteria can produce carcinogenic metabolites or toxins, which can damage the cells in the colonic mucosa and lead to the development of cancer. Additionally, these bacteria can induce inflammation, which can also contribute to cancer development. Furthermore, alterations in the communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Some of the bacteria implicated in this process include Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum",
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron. Multiple proposed pathogenic microorganisms including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota, leading to an increase in pathogenic bacteria that produce carcinogenic metabolites, induce inflammation, and activate oncogenic signaling. Pathogenic bacteria often have heightened iron acquisition mechanisms, outcompeting protective bacteria for free iron. Additionally, alterations in communication between the mucosal immune system and gut microbial communities can lead to chronic intestinal inflammation and cancer development. Specific pathogenic microorganisms implicated in this process include Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
        "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer. This can occur through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Alterations in communication between the mucosal immune system and gut microbial communities play a key role in the development of chronic intestinal inflammation and cancer. The imbalance in the microbiota can lead to an increase in pathogenic bacteria at the expense of protective bacteria, further contributing to disease progression.",
        "The pathophysiological mechanism by which the microbiota contribute to the development of malignant lesions in colonic mucosa involves several steps. First, perturbations in the composition and diversity of the gut microbial community can lead to an imbalance between protective and pathogenic bacteria. This imbalance allows for increased growth of pathogenic bids that have heightened iron acquisition mechanisms, enabling them to outcompete protective bacteria for free iron. Second, this shift in the microbiota can lead to an increase in carcinogenic metabolite and toxin production by the pathogenic bacteria, which can damage colonic mucosal cells and promote their transformation into cancerous cells. Third, the presence of these pathogenic bacteria can induce chronic inflammation in the colonic mucosa, further promoting tumorigenesis",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations of the colonic microbiota, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. Alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development.",
        "Perturbations of the colonic microbiota can contribute to colorectal cancer through several pathogenic mechanisms:\n\n1. Increasing production of carcinogenic metabolites and toxins by pathogenic bacteria\n2. Inducing inflammation in the colonic mucosa\n3. Activating oncogenic signaling pathways\n\nPathogenic bacteria tend to outcompete protective bacteria for free iron using heightened iron acquisition mechanisms. This leads to an increase in pathogenic bacteria at the expense of protective bacteria.\n\nSpecific pathogenic bacteria implicated include sulfidogenic bacteria like Bilophila wadsworthia, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum. \n\nAlterations in communication between the mucosal immune system and gut microbial communities are thought to be the core defect leading to chronic intestinal inflammation and cancer development.",
        "The pathophysiological mechanism involves an imbalance in the colonic microbiota, leading to an increase in pathogenic bacteria. These bacteria produce carcinogenic metabolites and toxins, induce inflammation, and activate oncogenic signaling, which can initiate and progress the development of malignant lesions in the colonic mucosa",
        "Perturbations of the colonic microbiota can lead to an increase in pathogenic bacteria and a decrease in protective bacteria. This imbalance can result in the production of carcinogenic metabolites/toxins, induction of inflammation, and activation of oncogenic signaling. Pathogenic bacteria often have heightened iron acquisition mechanisms, allowing them to outcompete protective bacteria for free iron.",
        "The pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa involves perturbations in the colonic microbiota that lead to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling."
      ]
    },
    {
      "body": "is carotenodermia caused by an excess of lycopene in the diet?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37916485",
        "http://www.ncbi.nlm.nih.gov/pubmed/3421202",
        "http://www.ncbi.nlm.nih.gov/pubmed/3434946",
        "http://www.ncbi.nlm.nih.gov/pubmed/9830271",
        "http://www.ncbi.nlm.nih.gov/pubmed/9525273",
        "http://www.ncbi.nlm.nih.gov/pubmed/7747541",
        "http://www.ncbi.nlm.nih.gov/pubmed/12839253",
        "http://www.ncbi.nlm.nih.gov/pubmed/16556283"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "We evaluated the relation between plasma levels of carotenoids and carotenodermia in 30 men receiving carotenoid supplementation for 42 d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3421202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Four cases of carotenodermia are presented, secondary to marked ingestion of carotenoid-rich vegetables.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3434946"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 572,
          "text": "This literature review revealed that in carotenodermia associated with high β-carotene intake the discoloration tends to be widespread, mainly in thick areas of the skin (e.g., the palm of the hand), and can last from 14 days to 4.5 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916485"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 332,
          "text": "Here, I review approximately 100 previous cases of carotenodermia in humans due to high β-carotene intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37916485"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 935,
          "text": "These observations may be useful to investigators planning clinical trials with beta-carotene and to clinicians assessing the significance of carotenodermia in men taking beta-carotene supplements or following diets high in carotenoid-containing foods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3421202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Carotenodermia may arise from excessive dietary intake of carotene containing foods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9830271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Carotenodermia may arise from excessive dietary intake of carotene containing foods. We reported a 22-year-old woman",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9830271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 435,
          "text": "We evaluated the relation between plasma levels of carotenoids and carotenodermia in 30 men receiving carotenoid supplementation for 42 d. Five subjects each were randomly assigned to one of six treatment groups: 30 mg purified beta-carotene supplement, 12 mg beta-carotene supplement, 272 g cooked carrots, 300 g cooked broccoli, 180 g tomato juice, and placebo. Definite carotenodermia was observed only in the five subjects who took",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3421202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "To study the effects of carotenoids on the initiation of liver carcinogenesis by aflatoxin B1 (AFB1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9525273"
        },
        {
          "offsetInBeginSection": 385,
          "offsetInEndSection": 568,
          "text": "The results of an oral loading with beta-carotene (1 mg/kg) provide indirect evidence that the girl\u0027s carotenemia is due to a probably genetic defect in the metabolism of carotenoids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7747541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "Carotenemia is characterized by an abnormal yellowish orange pigmentation of the skin, most prominently seen on the palms and soles. Although it is associated with several disease such as diabetes, hypothyroidism and anorexia nervosa, it is caused by excessive intake of carotene-rich food such as oranges and carrots in most cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16556283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Carotenemia is a common benign pediatric condition of yellowing of the skin and elevated beta-carotene levels in the blood. The condition is usually caused by excessive beta-carotene intake but is also more rarely associated with a few serious metabolic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12839253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "We describe a 3-year-old girl with long-standing yellow discoloration of her skin and a 3-fold increase in the plasma carotenoid concentration compared to normal, but no history of excessive carotene intake or familial carotenemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7747541"
        }
      ],
      "id": "65ef83acdffffb9b6b000002",
      "ideal_answer": [
        "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.",
        "No, carotenodermia is caused by an excess of beta-carotene, not lycopene.",
        "No, carotenodermia is caused by an excess of beta-carotene in the diet.",
        "No, carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.",
        "Carotenodermia is a yellow-orange coloration of the skin caused by high levels of serum carotenoids, mostly due to the excessive intake of carotenoid-rich foods.",
        "No, carotenodermia is not caused by an excess of lycopene in the diet.",
        "Carotenodermia is a yellow to orange skin discoloration caused by epidermal deposition of carotene, not lycopene. Consuming an excess of carotene-rich vegetables, rather than lycopene-rich ones, can lead to carotenodermia.",
        "No, carotenodermia is not caused by an excess of lycopene in the diet. It is typically due to the deposition of carotene in the skin.",
        "No, carotenodermia is caused by an excess of carotene in the diet.",
        "No, carotenodermia is not caused by an excess of lycopene in the diet. It is caused by an excess of carotene, not lycopene.",
        "Yes, carotenodermia can be caused by an excess intake of lycopene.",
        "No. Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.",
        "No, carotenodermia is caused by an excess of carotenoids in the diet."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32801927",
        "http://www.ncbi.nlm.nih.gov/pubmed/31430318",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569743",
        "http://www.ncbi.nlm.nih.gov/pubmed/30199098",
        "http://www.ncbi.nlm.nih.gov/pubmed/28322067",
        "http://www.ncbi.nlm.nih.gov/pubmed/27651184",
        "http://www.ncbi.nlm.nih.gov/pubmed/31558423",
        "http://www.ncbi.nlm.nih.gov/pubmed/29893246",
        "http://www.ncbi.nlm.nih.gov/pubmed/32164425",
        "http://www.ncbi.nlm.nih.gov/pubmed/27391203",
        "http://www.ncbi.nlm.nih.gov/pubmed/22067069",
        "http://www.ncbi.nlm.nih.gov/pubmed/30815960",
        "http://www.ncbi.nlm.nih.gov/pubmed/37198721",
        "http://www.ncbi.nlm.nih.gov/pubmed/32272075",
        "http://www.ncbi.nlm.nih.gov/pubmed/28919303",
        "http://www.ncbi.nlm.nih.gov/pubmed/23838404",
        "http://www.ncbi.nlm.nih.gov/pubmed/25300863",
        "http://www.ncbi.nlm.nih.gov/pubmed/30272493",
        "http://www.ncbi.nlm.nih.gov/pubmed/37798438",
        "http://www.ncbi.nlm.nih.gov/pubmed/37938875",
        "http://www.ncbi.nlm.nih.gov/pubmed/35653585",
        "http://www.ncbi.nlm.nih.gov/pubmed/22158861",
        "http://www.ncbi.nlm.nih.gov/pubmed/32711800"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Pre-exposure prophylaxis (PrEP) against HIV infection with tenofovir/emtricitabine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32801927"
        },
        {
          "offsetInBeginSection": 32,
          "offsetInEndSection": 55,
          "text": "emtricitabine/tenofovir",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31430318"
        },
        {
          "offsetInBeginSection": 836,
          "offsetInEndSection": 1026,
          "text": "PrEP with daily oral tenofovir/emtricitabine combination is the recommended PrEP regimen, and TDF alone can be considered as an alternative regimen for IDUs and heterosexually active adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27651184"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce HIV incidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31558423"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Tenofovir disoproxil fumarate combined with emtricitabine is a highly effective oral pre-exposure prophylaxis (PrEP) agent for preventing the acquisition of HIV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29893246"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 318,
          "text": "A novel distribution pathway of tenofovir-disoproxil fumarate and emtricitabine PrEP was implemented, which reduced monthly PrEP costs by 16-fold in Germany.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32164425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "INTRODUCTION: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficienc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391203"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 487,
          "text": "A pivotal component in the current drug combination regimens for the treatment of AIDS as well as the ongoing PrEP trials is tenofovir disoproxil fumarate (TDF, Viread®) and its combination with emtricitabine (FTC). The combination of TDF with FTC has been marketed as Truvada",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22067069"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "The antiretroviral combination of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) was approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis (PrEP) in individuals at high risk for acquiring human immunodeficiency virus (HIV) in July 2012.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30815960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37198721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis of human immunodeficiency virus (HIV) infection in 2012 on the basis of two randomized controlled trials (RCTs), one in men who have sex with men (MSM) and another in HIV serodiscordant heterosexual couples.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30199098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Antiretroviral pre-exposure prophylaxis (PrEP) for the prevention of HIV infection was demonstrated to be efficacious and safe earlier this decade from pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32272075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisition of H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28919303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "INTRODUCTION: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "BACKGROUND: Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25300863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) will soon be available in the Netherlands.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23838404"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 364,
          "text": "HIV pre-exposure prophylaxis (PrEP) with daily coformulated emtricitabine and tenofovir disoproxil fumarate is a promising biomedical HIV prevention modality; however, it has not yet been shown to be efficacious in the transgender population due to data limitations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30272493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine administered orally daily is effective in preventing human immunodeficiency virus (HIV) acquisition in both men and women with sufficient adherence; however, the adherence-efficacy relationship in cisgender women has not been well established.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37798438"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 341,
          "text": "Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV acquisition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28322067"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 309,
          "text": "Two PrEP medications are currently approved: emtricitabine/tenofovir disoproxil fumarate (Truvada",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569743"
        },
        {
          "offsetInBeginSection": 20,
          "offsetInEndSection": 189,
          "text": "d event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care gen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37938875"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Background: Daily pre-exposure prophylaxis (PrEP) regimen of tenofovir/emtricitabine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35653585"
        },
        {
          "offsetInBeginSection": 363,
          "offsetInEndSection": 497,
          "text": "Here, we evaluated two drugs that are preferentially used for PrEP: tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22158861"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 751,
          "text": "Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.METHODS: This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in regions of Europe and North America, where there is a high incidence of HIV or prevalence of people living with HIV, or both.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32711800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22158861"
        }
      ],
      "id": "65f85231c4010b4d7800004d",
      "ideal_answer": [
        "Rmtricitabine and tenofovir are the main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).",
        "The standard PrEP regimen primarily consists of Tenofovir disoproxil fumarate and Emtricitabine.",
        "Tenofovir (TFV) and Tenofovir disoproxil fumarate (TDF) are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).",
        "2 antiretroviral agents, tenofovir disoproxil fumarate and emtricitabine.",
        "Tenofovir (TFV) and emtricitabine (FTC) are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).",
        "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are emtricitabine/tenofovir disoproxil fumarate (Truvada).",
        "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are Tenofovir (TFV) and Tenofovir disoproxil fumarate (TDF).",
        "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC).",
        "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are tenofovir and emtricitabine.",
        "The two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis) are Tenofovir and Emtricitabine.",
        "Tenofovir and emtricitabine are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis).",
        "The two main active ingredients of the standard PrEP are tenofovir and emtricitabine.",
        "The two main active ingredients of the standard Pre-Exposure Prophylaxis (PrEP) against HIV infection are emtricitabine and tenofovir. These two drugs work together to prevent the HIV virus from establishing a permanent infection in the body.",
        "The standard PrEP regimen consists of a fixed-dose combination of two active ingredients: tenofovir disoproxil fumarate and emtricitabine.",
        "The standard Pre-Exposure Prophylaxis (PrEP) regimen primarily consists of two active ingredients: tenofovir and emtricitabine. These two antiretroviral drugs are combined to form the standard PrEP medication, which is used to prevent HIV infection in individuals who are at high risk.",
        "The two main active ingredients in the standard PrEP regimen are tenofovir and emtricitabine.",
        "The two main active ingredients of the standard Pre-Exposure Prophylaxis (PrEP) are tenofovir and emtricitabine."
      ],
      "exact_answer": [
        [
          "emtricitabine"
        ],
        [
          "tenofovir"
        ]
      ]
    },
    {
      "body": "What is the cause of Leigh syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18651330",
        "http://www.ncbi.nlm.nih.gov/pubmed/8338207",
        "http://www.ncbi.nlm.nih.gov/pubmed/10443880",
        "http://www.ncbi.nlm.nih.gov/pubmed/36237717",
        "http://www.ncbi.nlm.nih.gov/pubmed/35217561",
        "http://www.ncbi.nlm.nih.gov/pubmed/19470250",
        "http://www.ncbi.nlm.nih.gov/pubmed/18805359",
        "http://www.ncbi.nlm.nih.gov/pubmed/17582259",
        "http://www.ncbi.nlm.nih.gov/pubmed/25681084",
        "http://www.ncbi.nlm.nih.gov/pubmed/20202874",
        "http://www.ncbi.nlm.nih.gov/pubmed/19714555",
        "http://www.ncbi.nlm.nih.gov/pubmed/29512743",
        "http://www.ncbi.nlm.nih.gov/pubmed/10360771",
        "http://www.ncbi.nlm.nih.gov/pubmed/15824269",
        "http://www.ncbi.nlm.nih.gov/pubmed/25807530",
        "http://www.ncbi.nlm.nih.gov/pubmed/33097395",
        "http://www.ncbi.nlm.nih.gov/pubmed/31334367",
        "http://www.ncbi.nlm.nih.gov/pubmed/21982779",
        "http://www.ncbi.nlm.nih.gov/pubmed/27344648",
        "http://www.ncbi.nlm.nih.gov/pubmed/26657515",
        "http://www.ncbi.nlm.nih.gov/pubmed/17106447",
        "http://www.ncbi.nlm.nih.gov/pubmed/36795052",
        "http://www.ncbi.nlm.nih.gov/pubmed/15214016",
        "http://www.ncbi.nlm.nih.gov/pubmed/12943968",
        "http://www.ncbi.nlm.nih.gov/pubmed/34849584",
        "http://www.ncbi.nlm.nih.gov/pubmed/23034978",
        "http://www.ncbi.nlm.nih.gov/pubmed/14729820",
        "http://www.ncbi.nlm.nih.gov/pubmed/8250532",
        "http://www.ncbi.nlm.nih.gov/pubmed/11317352",
        "http://www.ncbi.nlm.nih.gov/pubmed/21617257",
        "http://www.ncbi.nlm.nih.gov/pubmed/11955926",
        "http://www.ncbi.nlm.nih.gov/pubmed/7715756",
        "http://www.ncbi.nlm.nih.gov/pubmed/36813320",
        "http://www.ncbi.nlm.nih.gov/pubmed/34933094",
        "http://www.ncbi.nlm.nih.gov/pubmed/3125426",
        "http://www.ncbi.nlm.nih.gov/pubmed/32478789",
        "http://www.ncbi.nlm.nih.gov/pubmed/12134275",
        "http://www.ncbi.nlm.nih.gov/pubmed/19046652",
        "http://www.ncbi.nlm.nih.gov/pubmed/16023078",
        "http://www.ncbi.nlm.nih.gov/pubmed/20819849",
        "http://www.ncbi.nlm.nih.gov/pubmed/16773507",
        "http://www.ncbi.nlm.nih.gov/pubmed/18176892",
        "http://www.ncbi.nlm.nih.gov/pubmed/9063742",
        "http://www.ncbi.nlm.nih.gov/pubmed/33894360",
        "http://www.ncbi.nlm.nih.gov/pubmed/17336115",
        "http://www.ncbi.nlm.nih.gov/pubmed/25419155",
        "http://www.ncbi.nlm.nih.gov/pubmed/8411720",
        "http://www.ncbi.nlm.nih.gov/pubmed/2792954",
        "http://www.ncbi.nlm.nih.gov/pubmed/32351444",
        "http://www.ncbi.nlm.nih.gov/pubmed/26506407",
        "http://www.ncbi.nlm.nih.gov/pubmed/20472868",
        "http://www.ncbi.nlm.nih.gov/pubmed/24731534",
        "http://www.ncbi.nlm.nih.gov/pubmed/34045482",
        "http://www.ncbi.nlm.nih.gov/pubmed/19780766",
        "http://www.ncbi.nlm.nih.gov/pubmed/29228836",
        "http://www.ncbi.nlm.nih.gov/pubmed/28351484",
        "http://www.ncbi.nlm.nih.gov/pubmed/12661941"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 443,
          "text": "It may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18651330"
        },
        {
          "offsetInBeginSection": 2788,
          "offsetInEndSection": 3040,
          "text": "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8338207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 411,
          "text": "Leigh syndrome is a subacute necrotising encephalomyopathy proven by post-mortem analysis of brain tissue showing spongiform lesions with vacuolation of the neuropil followed by demyelination, gliosis and capillary proliferation caused by mutations in one of over 75 different genes, including nuclear- and mitochondrial-encoded genes, most of which are associated with mitochondrial respiratory chain function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27344648"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 251,
          "text": "Deficiency of pyruvate dehydrogenase complex E1 alpha subunit (PDHA1) is the common cause of Leigh syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Subacute necrotizing encephalomyelopathy (Leigh\u0027s syndrome) is a rare neurodegenerative disease in the adult. The precise metabolic defect is unknown, but abnormalities of a mitochondrial enzyme system related to cytochrome-c oxidase or pyruvate dehydrogenase are described.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7715756"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 353,
          "text": "Leigh syndrome is the most common clinical presentation of pediatric mitochondrial disease, typically appearing in the first few years of life, and involving severe multisystem pathologies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34933094"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "A new patient with Leigh\u0027s syndrome (subacute necrotizing encephalomyelopathy due to pyruvate dehydrogenase complex deficiency) is presented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3125426"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 288,
          "text": "We report a novel m.4296G\u003eA variant in the mitochondrial tRNA isoleucine gene in a child with Leigh syndrome, mitochondrial proliferation, lactic acidosis, and abnormal respiratory chain enzymology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21982779"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in \u003e75 genes have been identified, encoded by 2 genomes (mitochondrial and nuclear).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26506407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 447,
          "text": "Leigh syndrome or subacute necrotizing encephalomyelopathy is a rare, rapidly progressive neurodegenerative disorder. In general, symptoms such as shortness of breath and decreased cardiac function usually occur within 1 year of life. It is a serious disease with a mortality rate of 75% in 2-3 years. The cause of Leigh syndrome is DNA mutation. Approximately 75% of patients have nuclear DNA mutations while 25% have mitochondrial DNA mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36237717"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Leigh disease presenting in utero due to a novel missense mutation in the mitochondrial DNA-ND3.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20202874"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 410,
          "text": "It can be caused by more than 75 different gene mutations, of nuclear and mitochondrial origin, involving all respiratory chain complexes, with less than 25% of Leigh syndrome having mitochondrial DNA mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31334367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "The most common mitochondrial disorder in children is Leigh syndrome, which is a progressive and genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA (mtDNA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29228836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Leigh syndrome (LS) is a neurogenetic disorder of children caused by mutations in at least 75 genes which impair mitochondrial bioenergetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28351484"
        }
      ],
      "id": "6451007857b1c7a315000093",
      "ideal_answer": [
        "Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.",
        "Leigh syndrome is caused by various genetic defects, including m.9185T\u003eC MTATP6 variant, Surf1 gene mutations, G8363A mitochondrial DNA mutation, deficiencies in the FAO enzyme short-chain enoyl-CoA hydratase 1 (ECHS1) and defects of 16 mitochondrial DNA (mtDNA) genes and approaching 100 nuclear genes.",
        "Leigh syndrome is a genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA that impair mitochondrial energy metabolism. Over 75 different causative gene mutations have been identified, with approximately 75% being nuclear DNA mutations and 25% mitochondrial DNA mutations. These mutations affect various components of the mitochondrial respiratory chain complexes, pyruvate metabolism, vitamin and cofactor transport and metabolism, mtDNA maintenance, mitochondrial gene expression, protein quality control, lipid remodeling, dynamics, and toxicity.",
        "Leigh syndrome is caused by various genetic mutations that affect mitochondrial function, leading to impaired energy production and neurodegeneration. These mutations can involve genes related to mitochondrial DNA or nuclear DNA, resulting in deficiencies in oxidative phosphorylation and the accumulation of toxic metabolites. The exact cause of Leigh syndrome can vary among individuals, with over 110 different genes implicated in its development.",
        "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.",
        "Leigh syndrome can be caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, and V. Additionally, it can also be caused by cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.",
        "Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, such as pyruvate dehydrogenase complex deficiency and respiratory chain complexes I, II, III, IV, V.",
        "Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex.",
        "Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex V deficiency, and the NARP point mutation.",
        "Leigh syndrome is a rare inherited neurometabolic disorder. It is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.",
        "Leigh syndrome is caused by defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, respiratory chain complexes I, II, III, IV, V, and the recently described NARP point mutation.",
        "Leigh syndrome is a severe neurological disorder caused by defects in several mitochondrial enzyme complexes. These include the pyruvate dehydrogenase complex and respiratory chain complexes I, II, III, IV, and V. Additionally, complex V deficiency associated with the NARP point mutation and cytochrome c oxidase deficiency can also lead to Leigh syndrome.",
        "Leigh syndrome can be caused by defects in mitochondrial enzyme complexes, including deficiencies in pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V, as well as mutations like the NARP point mutation.",
        "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency.",
        "Leigh syndrome can result from defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V. Deficiencies in enzymes such as pyruvate dehydrogenase complex, cytochrome c oxidase, complex I, and complex V can contribute to the development of Leigh syndrome.",
        "The cause of Leigh syndrome is a result of different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.",
        "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, and complex I deficiency.",
        "Leigh syndrome may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency, and complex V deficiency associated with the NARP point mutation.",
        "Leigh syndrome is caused by defects in mitochondrial enzyme complexes. These can include the pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, and V.",
        "Leigh syndrome can result from various defects in mitochondrial enzyme complexes, including pyruvate dehydrogenase complex deficiency, respiratory chain complexes I, II, III, IV, and V deficiencies. Specifically, it can be caused by defects in pyruvate dehydrogenase complex, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the NARP point mutation.",
        "Leigh syndrome is caused by several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V."
      ],
      "exact_answer": [
        [
          "pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V defects",
          "defects of mitochondrial enzyme complexes",
          "mitochondrial DNA mutations",
          "nuclear DNA mutations"
        ]
      ]
    },
    {
      "body": "What is Primary Diffuse Meningeal Melanomatosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35166475",
        "http://www.ncbi.nlm.nih.gov/pubmed/32004738",
        "http://www.ncbi.nlm.nih.gov/pubmed/31690266",
        "http://www.ncbi.nlm.nih.gov/pubmed/20220448",
        "http://www.ncbi.nlm.nih.gov/pubmed/12533338",
        "http://www.ncbi.nlm.nih.gov/pubmed/17330185",
        "http://www.ncbi.nlm.nih.gov/pubmed/36412389",
        "http://www.ncbi.nlm.nih.gov/pubmed/30516687",
        "http://www.ncbi.nlm.nih.gov/pubmed/35260265",
        "http://www.ncbi.nlm.nih.gov/pubmed/35060532",
        "http://www.ncbi.nlm.nih.gov/pubmed/30496931",
        "http://www.ncbi.nlm.nih.gov/pubmed/21743173",
        "http://www.ncbi.nlm.nih.gov/pubmed/23483049",
        "http://www.ncbi.nlm.nih.gov/pubmed/8852008",
        "http://www.ncbi.nlm.nih.gov/pubmed/28126183",
        "http://www.ncbi.nlm.nih.gov/pubmed/20558070"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 369,
          "text": "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166475"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "BACKGROUND: Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiologic findings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32004738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Primary diffuse meningeal melanomatosis - a rare form of meningeal melanoma: case report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31690266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "BACKGROUND: Meningeal melanomatosis is a rare type of central nervous system neoplasm (with incidence ranging between 3 and 5%) that develops in the course of malignant melanoma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31690266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Melanoma malignum constitutes only 0.1% of central nervous system neoplasms. It can occur either as a solid tumour or as a diffuse meningeal melanomatosis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17330185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412389"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 137,
          "text": "Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35260265"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 126,
          "text": "Primary diffuse leptomeningeal melanomatosis (PDLM) is a rare disease that affects melanocytes in the leptomeninges",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 314,
          "text": "Primary melanocytic neoplasms of the central nervous system (CNS) are rare lesions arising from melanocytes of the leptomeninges. They include diffuse leptomeningeal melanocytosis or melanomatosis, melanocytoma and primary malignant melanoma. We have reviewed the English literature regarding these lesions, which ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20558070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "BACKGROUND: Primary diffuse leptomeningeal melanomatosis (PDLM) is an extremely rare pathologic condition that can mimic several other neurologic disease states.METHODS: We report a rare case of PDLM without evidence of a primary focus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30496931"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 368,
          "text": "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166475"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "INTRODUCTION: Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35260265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiolog",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32004738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 629,
          "text": "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis. We report on a young patient with primary diffuse meningeal melanomatosis who presented with papilledema, flaccid paraparesis, and cognitive impairment. The importance of imaging of the whole central nervous system, cerebrospinal fluid analysis, and pathohistological examination is emphasized in making the appropriate diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Primary meningeal melanomatosis is a rare, aggressive variant of primary malignant melanoma of the central nervous system, which arises from melanocytes within the leptomeninges and carries a poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483049"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Primary meningeal melanomatosis is a rare, aggressive variant of primary malignant melanoma of the central nervous system, which arises from melanocytes within the leptomeninges and carries a poor prognosis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483049"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 788,
          "text": "Melanoma malignum constitutes only 0.1% of central nervous system neoplasms. It can occur either as a solid tumour or as a diffuse meningeal melanomatosis. A case of the latter form of central nervous system melanoma is presented in a 44-year-old man, suffering from headaches, cerebrospinal fluid protein elevation, optic disc oedema, hydrocephalus, seizures, cranial nerves and multilevel spinal root damage. Above mentioned neurological manifestations gradually increased within 18 months after onset of first symptoms of the disease (headache). The clinical course in our patient suggested diffuse leptomeningeal involvement. Despite the use of detailed diagnostic procedures, the correct diagnosis of primary diffuse meningeal melanomatosis was established at postmortem examination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17330185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 935,
          "text": "A case of primary leptomeningeal melanomatosis without cutaneous lesions is reported. The clinical findings for a six months period were: intracranial hypertension syndrome, progressive cranial polineuropathy and a spinal involvement in a six years old child. CT brain scan showed enlarged subarachnoid spaces without contrast enhancement. MRI brain scan evidenced furthermore a focal lesion in right talamus. MRI spinal scan was normal. Examination of CSF showed elevated protein and reduced glucose concentrations as well as mild pleocytosis. Serologies and cultures investigating viral, bacterial, mycobacterial, fungal or parasitic infections resulted negative. CSF cytologic examination failed to show malignant cells. Postmortem diagnosis after neuropathological examination was made. This is an uncommon case of primary leptomeningeal melanomatosis, presenting the difficulty of diagnosis when cutaneous lesions are not present.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8852008"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman. The disease mimicked intracranial hypotension syndrome and was diagnosed only at autopsy (CSF cytologic results were negative).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "BACKGROUND: Meningeal melanomatosis is an extra-axial well-encapsulated malignant tumour with diffuse meningeal growth and dark coloration (due to high melanin contents), while meningeal melanocytoma is the focalized ben",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28126183"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 290,
          "text": "These lesions arise from the melanocytes located within leptomeninges and include diffuse melanocytosis and meningeal melanomatosis (seen in neurocutaneous melanosis), melanocytoma, and malignant melanoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21743173"
        },
        {
          "offsetInBeginSection": 28,
          "offsetInEndSection": 105,
          "text": "diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "INTRODUCTION: Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system. It is characterized by a variety of nonspecific clinical, radiological, and histopathological features requiring differential diagnosis from a variet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35260265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Primary diffuse leptomeningeal melanomatosis is a rare variant of malignant melanoma of the central nervous system, arising from melanocytes of leptomeninges.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30516687"
        }
      ],
      "id": "65d129621930410b1300002e",
      "ideal_answer": [
        "Primary Diffuse Meningeal Melanomatosis is a rare variant of meningeal melanoma that causes diffusely invasive lesions of the pia mater with a tumor of melanocytic origin."
      ]
    },
    {
      "body": "Do black race patients have worse survival in colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29146523",
        "http://www.ncbi.nlm.nih.gov/pubmed/24231453",
        "http://www.ncbi.nlm.nih.gov/pubmed/19673013",
        "http://www.ncbi.nlm.nih.gov/pubmed/35176030",
        "http://www.ncbi.nlm.nih.gov/pubmed/10826011",
        "http://www.ncbi.nlm.nih.gov/pubmed/23576691",
        "http://www.ncbi.nlm.nih.gov/pubmed/35078631",
        "http://www.ncbi.nlm.nih.gov/pubmed/37859816",
        "http://www.ncbi.nlm.nih.gov/pubmed/34374082",
        "http://www.ncbi.nlm.nih.gov/pubmed/36586755",
        "http://www.ncbi.nlm.nih.gov/pubmed/28538169",
        "http://www.ncbi.nlm.nih.gov/pubmed/36636091",
        "http://www.ncbi.nlm.nih.gov/pubmed/38082093",
        "http://www.ncbi.nlm.nih.gov/pubmed/20626015",
        "http://www.ncbi.nlm.nih.gov/pubmed/27138583",
        "http://www.ncbi.nlm.nih.gov/pubmed/21997132",
        "http://www.ncbi.nlm.nih.gov/pubmed/23375764",
        "http://www.ncbi.nlm.nih.gov/pubmed/31600666",
        "http://www.ncbi.nlm.nih.gov/pubmed/12560428",
        "http://www.ncbi.nlm.nih.gov/pubmed/24440976",
        "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
        "http://www.ncbi.nlm.nih.gov/pubmed/18708384",
        "http://www.ncbi.nlm.nih.gov/pubmed/27467183",
        "http://www.ncbi.nlm.nih.gov/pubmed/15983985",
        "http://www.ncbi.nlm.nih.gov/pubmed/10564677",
        "http://www.ncbi.nlm.nih.gov/pubmed/35905109",
        "http://www.ncbi.nlm.nih.gov/pubmed/22012028",
        "http://www.ncbi.nlm.nih.gov/pubmed/11076244",
        "http://www.ncbi.nlm.nih.gov/pubmed/24662267",
        "http://www.ncbi.nlm.nih.gov/pubmed/31632483",
        "http://www.ncbi.nlm.nih.gov/pubmed/37868544",
        "http://www.ncbi.nlm.nih.gov/pubmed/16601428",
        "http://www.ncbi.nlm.nih.gov/pubmed/21710235",
        "http://www.ncbi.nlm.nih.gov/pubmed/33234793",
        "http://www.ncbi.nlm.nih.gov/pubmed/17116545",
        "http://www.ncbi.nlm.nih.gov/pubmed/33141623",
        "http://www.ncbi.nlm.nih.gov/pubmed/18300824"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1356,
          "text": "The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P \u003c .0001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29146523"
        },
        {
          "offsetInBeginSection": 1068,
          "offsetInEndSection": 1507,
          "text": "Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] \u003d 1.15; 95% confidence interval (CI) \u003d 1.08 to 1.22; P \u003c .001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR \u003d 1.08; 95% CI \u003d 1.01 to 1.15; P \u003d .03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231453"
        },
        {
          "offsetInBeginSection": 1944,
          "offsetInEndSection": 2171,
          "text": "In an analysis of data from the National Cancer Database, we found that insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29146523"
        },
        {
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1478,
          "text": "Compared to Whites, Blacks (AOR: 1.99; 95% CI: 1.64-2.41), Hispanics (AOR: 2.49; 95% CI: 1.94-3.19) and colorectal cancer patients in the other category (AOR: 1.72; 95% CI: 1.35-2.18) were more likely to receive inpatient treatment with chemotherapy/radiotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38082093"
        },
        {
          "offsetInBeginSection": 1625,
          "offsetInEndSection": 2093,
          "text": "Propensity-score matching identified 27,640 patients; Black race was associated with worse 5-year overall survival (67.5% vs 70.2%, P \u003d .003) and cancer-specific survival (79.4% vs 82.3%, P \u003c .001).CONCLUSIONS: This US population-based analysis confirms poorer overall survival and cancer-specific survival in Black patients undergoing surgery for nonmetastatic colon cancer despite accounting for trans-sectoral factors that have been implicated in structural racism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35078631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND: Black patients are disproportionally impacted by colorectal cancer, both with respect to incidence and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35078631"
        },
        {
          "offsetInBeginSection": 931,
          "offsetInEndSection": 1199,
          "text": "Black patients have significantly lower rates of receiving chemotherapy as compared to white patients (61.1% vs 75.37%, p \u003d 0.0018).CONCLUSION: Patients with Stage IV colorectal cancer have worse survival if they are black, older age, and did not receive chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36586755"
        },
        {
          "offsetInBeginSection": 2042,
          "offsetInEndSection": 2384,
          "text": "Decreased survival outcomes in Black patients were more pronounced for those who underwent nonstandard treatment, particularly when treating stage III disease (HR: 1.30; 95% CI: 1.19-1.42; P\u003c0.0001).Conclusions: Nonstandard treatment in stage II and III rectal cancer is associated with worse survival compared to standard treatment regimens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36636091"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 600,
          "text": "Our objective is to determine if Black compared to White race is associated with worse survival in colon cancer, while accounting for socioeconomic and clinical factors.METHODS: A retrospective analysis was performed of Black or White patients with nonmetastatic colon cancer in the Surveillance, Epidemiology, and End Results cancer registry between 2008 and 2016.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35078631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "BACKGROUND AND OBJECTIVE: African Americans have worse outcomes in colorectal can",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440976"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 400,
          "text": "The mortality rate from CRC is highest among African Americans compared to any other racial or ethnic group. Much of the disparity in mortality is likely due to diagnosis at later stages of the disease, which could result from unequal access to screening.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26703651"
        },
        {
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1166,
          "text": " (6.2%) non-Chinese Asians. African-Americans had a greater proportion of metastatic stage at presentation (P \u003c 0.0001) and decreased CRC-specific survival (P \u003c 0.0001 f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18708384"
        },
        {
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1643,
          "text": "r colon and rectal cancer). After adjustment for age, sex, histology, site within the colon, and stage, African-Americans [colon: HR, 1.19; 95% confidence interval (95% CI), 1.14-1.25; rectum: HR, 1.27; 95% CI, 1.17-1.38] had an increased risk of death compared with Caucasians. However, after further adjustment for SES and treatment, the risk of death for African-Americans compared with Caucasians was substantially diminished (colon: HR, 1.08; 95% CI, 1.03-1.13; rectum: H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18708384"
        },
        {
          "offsetInBeginSection": 1472,
          "offsetInEndSection": 2018,
          "text": "Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24-0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72-1.65).CONCLUSIONS: No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.LAY SUMMARY: Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34374082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2089,
          "text": "Among all racial groups in the U.S., African Americans (AA) have the highest incidence of and mortality from colorectal cancer (CRC). Although socioeconomic factors, as the major contributors to racial disparity of CRC, have been widely investigated, there is a dearth of information germane to understanding its biological basis. To better elucidate the clinicopathologic features we extracted demographic, clinical, pathologic and molecular features of 500 consecutive cases of CRC diagnosed at our institution which has an AA-predominant patient population (75% of all patients). We compared data from our AA patients with those of white patients both from our institution and from SEER and the published literature for meaningful comparison. AA patients were more likely to be at an advanced disease stage (25.9% vs. 20.8%, p \u003d 0.041), have low grade tumors (89.2% vs. 77.5%, p\u003c0.001) in cecum (18.7% vs. 16.2%, p\u003c0.001) and \u003c60-years-old than white patients (31.8% vs. 26.3%, p \u003d 0.015). The frequency of KRAS mutation was higher in AA patients than in white patients (56.8% vs. 20.7%, p\u003c0.001). Amongst subtypes of KRAS tested in CRC, codon 12 mutation is more common in AA than white patients (85.2% vs. 68.9%, p \u003d 0.020). Compared with other racial groups, we found AA patients to have worse disease-free survival (HR \u003d 3.682, p \u003d 0.035). Also, AA patients with CRC in distal (sigmoid and rectum) or proximal (cecum) colon have worse overall survival than those with CRC in middle colon (HR \u003d 2.926, p \u003d 0.014), a finding not observed in white patients. In both racial groups, advanced stage, perforation, and hypertension were independent prognostic factors for overall survival (p\u003c0.05). Similarly, low body-mass index at presentation, mucinous adenocarcinoma, lymphovascular invasion, perineural invasion and KRAS mutations were independent factors significantly associated with poor disease-free survival. Collectively, our data provide new insights into the roles of clinicopathologic features, especially anatomic distribution, in predicting outcomes of CRC in AA population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35905109"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 290,
          "text": "Survival from CRC in AAs is lower than in Caucasians, and the mean age of CRC development in AAs is younger.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21710235"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "African Americans have the greatest incidence of colorectal cancer than any other racial or ethnic group. This population\u0027s survival from colorectal cancer is lower than that in the White population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18300824"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 275,
          "text": "Black patients and underinsured patients with colorectal cancer (CRC) present with more advanced disease and experience worse outcomes. The study aim was to evaluate the interaction of health insurance status and race with treatment and survival in metastatic CRC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176030"
        },
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 991,
          "text": " Chemotherapy use was higher among White compared to Black patients. 3-year mortality rate was higher for Blacks and lower for Hispanics, in comparison with White patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35176030"
        },
        {
          "offsetInBeginSection": 522,
          "offsetInEndSection": 824,
          "text": "In American blacks, there is evidence for a higher prevalence of right-sided colonic tumors and an earlier age of onset of colorectal cancer. In addition, blacks have the highest colon cancer incidence in the United States among ethnic groups and have poorer 5-year survival rates compared with whites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10826011"
        },
        {
          "offsetInBeginSection": 853,
          "offsetInEndSection": 974,
          "text": "among patients younger than 50 years old, NHBs experienced significantly worse OS than NHWs (HR: 2.03, 95% CI: 1.30-3.19)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576691"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 475,
          "text": ". This study assessed whether non-Hispanic Whites (NHW) and non-Hispanic Blacks (NHB) differ in colon cancer survival in an equal-access health care system and examined whether racial differences varied by demographic and tumor characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576691"
        },
        {
          "offsetInBeginSection": 818,
          "offsetInEndSection": 1082,
          "text": "Black patients had significantly lower overall survival compared to White patients, with median overall survival of 1.9 years and 2.5 years respectively. In a multivariate analysis, Black race posed a significant hazard (HR 1.70, CI 1.01-2.90, p\u003d0.0467) for death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538169"
        },
        {
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1142,
          "text": ". Black patients had worse long-term survival after colorectal surgery (hazard ratio [HR], 1.21; 95% CI, 1.17 to 1.25; P \u003c .001)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23375764"
        },
        {
          "offsetInBeginSection": 2159,
          "offsetInEndSection": 2319,
          "text": " Black patients had lower five-year survival rates when compared with their White counterparts as well as increased rates of being diagnosed with this disease. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37868544"
        },
        {
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1468,
          "text": "Black patients had a 41% increased risk of presenting at advanced stage per IoD [risk ratio (RR) 1.41, 95% confidence intervals (CI) 1.18, 1.69] and White patients saw a 17% increase (RR 1.17, 95%CI 1.04, 1.31). Black patients were 5% less likely to undergo surgical resection (RR 0.95, 95%CI 0.90, 0.99), whereas Whites were 5% more likely (RR 1.05, 95%CI 1.03, 1.07). Black patients had 43% increased hazards of cancer-specific mortality with increasing IoD (hazard ratio (HR) 1.43, 95%CI 1.17,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33234793"
        },
        {
          "offsetInBeginSection": 1261,
          "offsetInEndSection": 1504,
          "text": "The results revealed poor overall survival for AAs compared with EAs, especially for those \u003c 50 years of age. The greater prevalence of proximal CRC at diagnosis among younger AAs (vs. EAs) might contribute to the racial difference in survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28065664"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 142,
          "text": "African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28065664"
        }
      ],
      "id": "65f77236c4010b4d7800001f",
      "ideal_answer": [
        "Yes, black patients with Stage IV colorectal cancer have worse survival if they are older age and did not receive chemotherapy. Black patients in the study population were more likely to be female, have medical comorbidities, and come from areas with lower average income and baseline education. Among patients younger than 45 years, black patients had significantly increased hazard of death compared to white patients. , It is worth noting that outcomes in colorectal cancer treatment are historically worse in Black people and residents of rural areas. The intersection of race and rurality worsens outcomes, with the poorest outcomes observed in black individuals in rural areas. Genomics also play a role, as black patients have a higher incidence of colorectal cancer and worse survival rates when compared to white people.",
        "yes, African-Americans have the lowest survival compared to other race categories (3 years survival rate in African-Americans \u003d 61%, 3 years survival rate in Caucasians \u003d 73%)",
        "Yes, studies have shown that Black patients with colorectal cancer have worse overall survival (OS) compared to White patients. This disparity persists even when controlling for demographic and pathologic factors, suggesting that the underlying factors are complex and not well understood. However, a study examining stage IV colorectal cancer patients found no significant differences in proportional hazard of death between black and white patients aged 45 years or older. Among those younger than 45 years, younger black patients had significantly increased hazard of death. Another study found that Black patients with metastatic colorectal cancer have worse survival than white patients, even when controlling for insurance status and receipt of chemotherapy. However, a retrospective analysis of the randomized CALGB/SWOG 80405 trial found no difference in OS, progression-free survival (PFS), or response to therapy between Black and White patients treated on the clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.",
        "Yes, studies have shown that black race patients have worse survival in colorectal cancer. Multiple analyses have demonstrated that black patients with nonmetastatic colon cancer have poorer overall survival and cancer-specific survival compared to white patients, even after accounting for socioeconomic and clinical factors. This disparity in survival persists across different stages of the disease. Additionally, black patients with stage IV colorectal cancer have been found to have worse overall survival compared to white patients. Factors such as lower rates of receiving chemotherapy and a higher incidence of colon cancer in black patients may contribute to these disparities.",
        "Yes, according to the study, unmatched black patients with colorectal cancer (CRC) have worse absolute 5-year survival rates compared to unmatched white patients (57.3% vs 66.5%, respectively). The unadjusted survival analysis also found a 15% higher chance of dying for black patients compared to white patients. However, after adjusting for patient, tumor, and demographic variables, the increased risk of death for black patients was marginally reduced. Interestingly, the study found that insurance coverage differences accounted for approximately half of the disparity in survival rate between black and white patients with CRC aged 18-64 years old. After adjusting for differences in treatment, the increased risk of death for black patients disappeared. Therefore, while the study suggests that black race is a significant factor associated with worse survival in CRC, other factors such as insurance coverage and access to appropriate treatment may also contribute to this disparity.",
        "Yes, black patients with colorectal cancer (CRC) have worse survival compared to white patients. The absolute 5-year survival difference between black and white unmatched patients with CRC is 9.2%. However, after adjustment for differences in treatment, the increased risk of death for black patients disappeared. Insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old.",
        "Yes, black race patients initially showed a 15% higher chance of dying compared to white patients in unadjusted survival analysis.",
        "Yes, according to the data from the National Cancer Database, black patients do have a worse survival rate in colorectal cancer compared to white patients. The unadjusted survival analysis found a 15% higher chance of dying for black patients compared to white patients. Even after adjusting for patient, tumor, and demographic variables, the risk of death was still marginally higher for black patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). However, it\u0027s important to note that after adjusting for differences in treatment, the increased risk of death for black patients disappeared. Additionally, insurance coverage differences accounted for approximately half of the disparity in survival rates.",
        "Yes, studies have shown that black patients with colorectal cancer (CRC) initially have a worse survival rate compared to white patients. The absolute 5-year survival difference was found to be 9.2% lower for black patients. However, this disparity was found to be significantly influenced by factors such as insurance coverage and differences in treatment. When these factors were adjusted for, the increased risk of death for black patients disappeared. This suggests that the survival disparity is not due to race itself, but rather to socioeconomic and healthcare access factors.",
        "Yes, black race patients have worse survival in colorectal cancer compared to white race patients. The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P \u003c 0.0001). However, after adjusting for differences in treatment, the increased risk of death for black patients disappeared.",
        "Yes, black patients have worse survival rates in colorectal cancer compared to white patients. According to the study, black patients had a lower 5-year survival rate compared to white patients (57.3% vs 66.5%). The study found that differences in insurance coverage and tumor characteristics accounted for approximately half of the disparity in survival rates between black and white patients. Additionally, black patients had lower rates of consultation with surgery, medical oncology, and radiation oncology, and received less treatment with surgery, chemotherapy, and radiotherapy. Adjusting for patient, tumor, and demographic variables marginally reduced the risk of death for black patients, but after adjustment for differences in treatment, the increased risk of death for black patients disappeared. These findings suggest that racial disparities in access to healthcare and treatment contribute to inferior survival outcomes for black patients with colorectal cancer.",
        "Yes, black patients with colorectal cancer (CRC) generally have a worse survival rate compared to white patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). Furthermore, unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients. However, it\u0027s important to note that after adjusting for differences in treatment, the increased risk of death for black patients disappeared. This suggests that the disparity in survival rates may be largely due to differences in treatment and insurance coverage",
        "Yes, black race patients have worse survival in colorectal cancer.The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P \u003c.0001).In an analysis of data from the National Cancer Database, we found that insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old;Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] \u003d 1.15; 95% confidence interval (CI) \u003d 1.08 to 1.22; P \u003c.001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR \u003d 1.08; 95% CI \u003d 1.01 to 1.15; P \u003d.03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared",
        "Yes, black patients with colorectal cancer have worse survival compared to white patients. The absolute 5-year survival difference between black and white patients was 9.2% (57.3% for black patients vs 66.5% for white patients). Unadjusted analysis found a 15% higher chance of dying for black patients compared to white patients. After adjusting for patient, tumor, and demographic variables, the increased risk of death for black patients was reduced but still present. Insurance coverage differences accounted for about half of the survival disparity between black and white colorectal cancer patients aged 18-64 years old.",
        "Yes, black patients with colorectal cancer have a worse survival rate compared to white patients. The 5-year survival difference is 9.2%, with 57.3% for black patients and 66.5% for white patients.",
        "Yes, studies have shown that black race patients with colorectal cancer have worse survival compared to white patients. In a study analyzing data from the National Cancer Database, it was found that black patients had a 9.2% lower 5-year survival rate compared to white patients. However, when adjusting for patient, tumor, and demographic variables, the risk of death was marginally reduced. Furthermore, after accounting for differences in treatment, the increased risk of death for black patients disappeared. Insurance coverage differences were found to account for approximately half of the survival rate disparity between black and white patients with colorectal cancer.",
        "Yes, black race patients have worse survival in colorectal cancer, with an absolute 5-year survival difference of 9.2% compared to white patients."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Can Antioxidant curcumin kill tumor cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37191314",
        "http://www.ncbi.nlm.nih.gov/pubmed/36986483",
        "http://www.ncbi.nlm.nih.gov/pubmed/37333486",
        "http://www.ncbi.nlm.nih.gov/pubmed/37210578",
        "http://www.ncbi.nlm.nih.gov/pubmed/20426658",
        "http://www.ncbi.nlm.nih.gov/pubmed/22508043",
        "http://www.ncbi.nlm.nih.gov/pubmed/11795474",
        "http://www.ncbi.nlm.nih.gov/pubmed/34904972",
        "http://www.ncbi.nlm.nih.gov/pubmed/11676493",
        "http://www.ncbi.nlm.nih.gov/pubmed/29642292",
        "http://www.ncbi.nlm.nih.gov/pubmed/24495080",
        "http://www.ncbi.nlm.nih.gov/pubmed/24453488",
        "http://www.ncbi.nlm.nih.gov/pubmed/24566313",
        "http://www.ncbi.nlm.nih.gov/pubmed/36358950",
        "http://www.ncbi.nlm.nih.gov/pubmed/17069615",
        "http://www.ncbi.nlm.nih.gov/pubmed/21110780",
        "http://www.ncbi.nlm.nih.gov/pubmed/28628644",
        "http://www.ncbi.nlm.nih.gov/pubmed/26004342",
        "http://www.ncbi.nlm.nih.gov/pubmed/25349781",
        "http://www.ncbi.nlm.nih.gov/pubmed/32116190",
        "http://www.ncbi.nlm.nih.gov/pubmed/23489691",
        "http://www.ncbi.nlm.nih.gov/pubmed/12680238",
        "http://www.ncbi.nlm.nih.gov/pubmed/10456330",
        "http://www.ncbi.nlm.nih.gov/pubmed/37979287",
        "http://www.ncbi.nlm.nih.gov/pubmed/37957863",
        "http://www.ncbi.nlm.nih.gov/pubmed/37806480",
        "http://www.ncbi.nlm.nih.gov/pubmed/37587146",
        "http://www.ncbi.nlm.nih.gov/pubmed/37322603",
        "http://www.ncbi.nlm.nih.gov/pubmed/16376585",
        "http://www.ncbi.nlm.nih.gov/pubmed/15142674",
        "http://www.ncbi.nlm.nih.gov/pubmed/31717651",
        "http://www.ncbi.nlm.nih.gov/pubmed/27051644",
        "http://www.ncbi.nlm.nih.gov/pubmed/22475723",
        "http://www.ncbi.nlm.nih.gov/pubmed/24627632",
        "http://www.ncbi.nlm.nih.gov/pubmed/18347134",
        "http://www.ncbi.nlm.nih.gov/pubmed/27572503",
        "http://www.ncbi.nlm.nih.gov/pubmed/32307747",
        "http://www.ncbi.nlm.nih.gov/pubmed/10069393",
        "http://www.ncbi.nlm.nih.gov/pubmed/25360677",
        "http://www.ncbi.nlm.nih.gov/pubmed/28949267",
        "http://www.ncbi.nlm.nih.gov/pubmed/18252805",
        "http://www.ncbi.nlm.nih.gov/pubmed/25667441",
        "http://www.ncbi.nlm.nih.gov/pubmed/29752960",
        "http://www.ncbi.nlm.nih.gov/pubmed/37820211"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Curcumin inhibits colon cancer malignant progression and promotes T cell killing by regulating miR-206 expression",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37333486"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 886,
          "text": "The CUR/SeNPs present excellent antitumor efficacy, respectively, which supports the nanocomposite matrix to efficiently kill cancer cells ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904972"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 565,
          "text": "Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematological malignancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495080"
        },
        {
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1481,
          "text": "In conclusion, we demonstrated for the first time that antioxidants such as trolox can potentiate cancer cell killing by curcumin, a finding which may help in the development of novel drug combination therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 1367,
          "offsetInEndSection": 1559,
          "text": "This study provided data on the potential cytotoxic activity of the combination of CUR with DSS and may provide a useful tool for the development of a therapeutic combination against melanoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36358950"
        },
        {
          "offsetInBeginSection": 1226,
          "offsetInEndSection": 1433,
          "text": "The data together suggested that curcumin may inhibit cancer cells proliferation by perturbing microtubule assembly dynamics and may be used to develop efficacious curcumin analogues for cancer chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17069615"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 718,
          "text": "The combination of curcumin (10 μM) and trolox (10-50 μM) induced apoptosis of cancer cells as evidenced by PARP cleavage and caspase-3 activatio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Curcumin, a natural polyphenol in the spice turmeric, has been found to exhibit anticancer activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Curcumin, a phenolic antioxidant compound derived from the rhizome of the turmeric plant Curcuma longa, has proven to be a modulator of intracellular signaling pathways that control cancer cell growth, inflammation, invasion and apoptosis, revealing its anticancer potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24566313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 430,
          "text": "Curcumin, the active ingredient from the spice turmeric (Curcuma longa Linn), is a potent antioxidant and anti-inflammatory agent. It has been recently demonstrated to possess discrete chemopreventive activities. However, the molecular mechanisms underlying such anticancer properties of curcumin still remain unrealized, although it has been postulated that induction of apoptosis in cancer cells might be a probable explanation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11676493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 783,
          "text": "Curcumin, a well-known dietary pigment derived from Curcuma longa, has been shown to be a potent antiinflammatory, antioxidant, and anticarcinogenic compound. The present study was designed to investigate the cytotoxic potential of curcumin against a range of human tumor cell lines in an attempt to understand its mechanism of action, which may lead to its possible therapeutic applications. We have shown that different cancer cell lines differ in their sensitivity to curcumin. Cell lines established from malignancies like leukemia, breast, colon, hepatocellular, and ovarian carcinomas underwent apoptosis in the presence of curcumin, whereas cell lines from lung, kidney, prostate, cervix, CNS malignancies, and melanomas showed resistance to the cytotoxic effects of curcumin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Curcumin is a polyphenol derived from the plant Curcuma longa that induces apoptotic cell death in malignant cancer cell lines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21110780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "Curcumin, an extract from the turmeric rhizome (Curcuma longa), is known to exhibit anti-inflammatory, antioxidant, chemopreventive and antitumoral activities against aggressive and recurrent cancers. Accumulative data indicate that curcumin may induce cancer cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28628644"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 312,
          "text": "Curcumin, obtained from the rhizome of Curcuma longa, has potent anticancer activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26004342"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 753,
          "text": "Curcumin suppresses the growth of human malignant glioma cells via ROS-dependent prostate apoptosis response-4 (Par-4) induction and ceramide generation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349781"
        },
        {
          "offsetInBeginSection": 2044,
          "offsetInEndSection": 2184,
          "text": "These findings support further studies on the therapeutic potential of CUR in combination with standard therapies in breast cancer patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23489691"
        },
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 934,
          "text": "Furthermore, expression of the pro-apoptotic protein Bad was up-regulated and expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl was down-regulated in cells that had been treated with trolox plus curcumin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 720,
          "text": "The combination of curcumin (10 μM) and trolox (10-50 μM) induced apoptosis of cancer cells as evidenced by PARP cleavage and caspase-3 activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 279,
          "text": "Although curcumin is generally considered an antioxidant, it is also able to elicit apoptosis through the generation of ROS, thereby functioning as a pro-oxidant in cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 848,
          "offsetInEndSection": 1130,
          "text": "This review aims to discuss TRAIL and its underlying apoptotic mechanisms, the combinational treatment of Cur and TRAIL in view of their respective limitations, and the underlying apoptotic mechanisms activated by the sensitization of cancers by Cur towards TRAIL-induced apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32116190"
        },
        {
          "offsetInBeginSection": 1754,
          "offsetInEndSection": 1906,
          "text": "Thus dietary curcumin ameliorates radiation-induced pulmonary fibrosis and increases mouse survival while not impairing tumor cell killing by radiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426658"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 424,
          "text": "In this study, we tested the hypothesis that a multifunctional nanocomposite platform containing nanoparticles (NPs) with the photothermal agent IR820 and bioactive drug curcumin (Cur) would be able to prevent tumor recurrence, limit bacterial wound infections, and promote wound healing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37979287"
        },
        {
          "offsetInBeginSection": 1348,
          "offsetInEndSection": 1445,
          "text": " Curcuminoids could be a promising anti-cancer agent for the treatment of human colorectal cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37957863"
        },
        {
          "offsetInBeginSection": 1786,
          "offsetInEndSection": 1883,
          "text": "Furthermore, these anti-cancer effects were higher when using Niosomal (Asc + Cur) than Asc + Cur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37806480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Resveratrol, curcumin, and quercetin are the secondary metabolites from medicinal food homology plants, that have been proven their potency in cancer treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37587146"
        },
        {
          "offsetInBeginSection": 614,
          "offsetInEndSection": 713,
          "text": "Curcumin treatment inhibited proliferation and migration of cancer cells in a dose dependent manner",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37322603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "Curcumin, a natural polyphenol in the spice turmeric, has been found to exhibit anticancer activity. Although curcumin is generally considered an antioxidant, it is also able to elicit apoptosis through the generation of ROS, thereby functioning as a pro-oxidant in cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508043"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 590,
          "text": "Curcumin is a polyphenol derived from the plant Curcuma longa that induces apoptotic cell death in malignant cancer cell lines. It has been shown previously that mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm) plays an essential role in defense against oxidative stress by supplying NADPH for antioxidant systems. This study demonstrates that curcumin decreased the activity of IDPm, both as a purified enzyme and in cultured cells. It also shows that curcumin-induced apoptosis in the colon cancer cell line HCT116 is significantly enhanced by suppression of IDPm activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21110780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1131,
          "text": "Curcumin, the active ingredient from the spice turmeric (Curcuma longa Linn), is a potent antioxidant and anti-inflammatory agent. It has been recently demonstrated to possess discrete chemopreventive activities. However, the molecular mechanisms underlying such anticancer properties of curcumin still remain unrealized, although it has been postulated that induction of apoptosis in cancer cells might be a probable explanation. In the current study, curcumin was found to decrease the Ehrlich\u0027s ascites carcinoma (EAC) cell number by the induction of apoptosis in the tumor cells as evident from flow-cytometric analysis of cell cycle phase distribution of nuclear DNA and oligonucleosomal fragmentation. Probing further into the molecular signals leading to apoptosis of EAC cells, we observed that curcumin is causing tumor cell death by the up-regulation of the proto-oncoprotein Bax, release of cytochrome c from the mitochondria, and activation of caspase-3. The status of Bcl-2 remains unchanged in EAC, which would signify that curcumin is bypassing the Bcl-2 checkpoint and overriding its protective effect on apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11676493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "Curcumin, an active ingredient from the rhizome of the plant, Curcuma longa, has antioxidant, anti-inflammatory and anti-cancer activities. It has recently been demonstrated that the chemopreventive activities of curcumin might be due to its ability to inhibit cell growth and induce apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16376585"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1014,
          "text": "Curcumin, the active ingredient of the rhizome of Curcuma longa has anti-inflammatory, antioxidant and antiproliferative activities. Although its precise mode of action remains elusive, studies have shown that chemopreventive action of curcumin might be due to its ability to induce apoptosis in cancer cells. Curcumin was shown to be responsible for the inhibition of AK-5 tumor (a rat histiocytoma) growth by inducing apoptosis in AK-5 tumor cells via caspase activation. This study was designed to investigate the mechanism leading to the induction of apoptosis in AK-5 tumor cells. Curcumin treatment resulted in the hyperproduction of reactive oxygen species (ROS), loss of mitochondrial membrane potential (delta psi(m)) and cytochrome c release to the cytosol, with the concomitant exposure of phosphatidylserine (PS) residues on the cell surface. This study suggests redox signalling and caspase activation as the mechanisms responsible for the induction of curcumin mediated apoptosis in AK-5 tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10456330"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1194,
          "text": "Curcumin, a phenolic compound from the rhizome of the plant Curcuma longa has anti-inflammatory, antioxidant and anti-cancer activities. Although the precise mode of action of this compound is not yet elucidated, studies have shown that chemo-preventive action of curcumin might be due to its ability to induce apoptosis and to arrest cell cycle. This study investigated the cellular and molecular changes induced by curcumin leading to the induction of apoptosis in human lung cancer cell lines-A549 and H1299. A549 is p53 proficient and H1299 is p53 null mutant. The lung cancer cells were treated with curcumin (0-160 microM) for 12-72 h. Curcumin inhibited the growth of both the cell lines in a concentration dependent manner. Growth inhibition of H1299 cell lines was both time and concentration dependent. Curcumin induced apoptosis in both the lung cancer cell lines. A decrease in expression of p53, bcl-2, and bcl-X(L) was observed after 12 h exposure of 40 microM curcumin. Bak and Caspase genes remained unchanged up to 60 microM curcumin but showed decrease in expression levels at 80-160 microM. The data also suggest a p53 independent induction of apoptosis in lung cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15142674"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 450,
          "text": "Curcumin exhibits anti-inflammatory, anticarcinogenic, antiproliferative, antiangiogenic, and antioxidant properties in various cancer cell models.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475723"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 702,
          "text": "The anticancer potential of curcumin stems from its ability to suppress proliferation of a wide variety of tumor cells, down-regulate transcription factors NF-kappa B, AP-1 and Egr-1; down-regulate the expression of COX2, LOX, NOS, MMP-9, uPA, TNF, chemokines, cell surface adhesion molecules and cyclin D1; down-regulate growth factor receptors (such as EGFR and HER2); and inhibit the activity of c-Jun N-terminal kinase, protein tyrosine kinases and protein serine/threonine kinases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12680238"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Curcumin (diferuloylmethane) is found in large quantities in the roots of Curcuma longa. It possesses strong antioxidant and anti-inflammatory properties, and inhibits chemically-induced carcinogenesis in the skin, forestomach, colon, and liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Curcumin (diferuloylmethane), a natural polyphenol present in turmeric, possesses a wide spectrum of pharmacological properties, including antioxidant and antitumor metastatic activities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27572503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "BACKGROUND: Curcumin has been shown to exert pleiotropic biological effects, including anti-tumorigen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31717651"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 727,
          "text": "Curcumin is a natural phenolic compound which shows potent anticancer activities in different tumors, alone or as an adjuvant with other antitumor drugs to prevent or inhibit the survival and cancer progression by various mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747"
        },
        {
          "offsetInBeginSection": 1012,
          "offsetInEndSection": 1227,
          "text": "It has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747"
        },
        {
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1340,
          "text": "Curcumin reverses multidrug resistance mechanisms and increases sensitivity of resistance cells to chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747"
        },
        {
          "offsetInBeginSection": 137,
          "offsetInEndSection": 210,
          "text": "Curcumin inhibited AK-5 tumor growth and induced apoptosis in AK-5 cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10069393"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 556,
          "text": "Curcumin, a natural polyphenol compound found in the spice turmeric, is known for its anti-cancer properties at doses over 10 µM, and often at 50 µM, and it exerts its effects on cancer cells in part by activation of MAP kinase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25360677"
        },
        {
          "offsetInBeginSection": 1271,
          "offsetInEndSection": 1424,
          "text": "But curcumin-loaded SLN exhibited antioxidant properties, substantiating the conclusions that curcumin\u0027s effect in cancer cells is highly dose dependent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949267"
        },
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 874,
          "text": "The results demonstrated that MG-63 osteosarcoma cells were much more sensitive in terms of cytotoxicity to curcumin, while the healthy human osteoblasts exhibited a higher healthy viability after 24 hours of curcumin treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453488"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities. Natural killer (NK) cells are large lymphocytes that directly kill cancer cells. However, many aggressive cancers, including breast cancer, were reported to escape the successful killing of NK cells in a tumor microenvironment. In this study, we investigated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642292"
        },
        {
          "offsetInBeginSection": 1796,
          "offsetInEndSection": 2091,
          "text": "Together, these results suggest a novel mechanism for curcumin-mediated radiosensitization involving increased ROS and ERK1/2 activation and suggest that curcumin application (either systemically or topically) may be an effective radiation modifying modality in the treatment of cervical cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252805"
        },
        {
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1548,
          "text": " The ability of curcumin to induce apoptosis in tumor cells and its anti-angiogenic potential will be discussed in this review",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667441"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 294,
          "text": "It has recently been demonstrated that the chemopreventive activities of curcumin might be due to its ability to inhibit cell growth and induce apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16376585"
        },
        {
          "offsetInBeginSection": 1245,
          "offsetInEndSection": 1391,
          "text": "y supplementing it with curcumin. Curcumin supplementation exaggerates oxidative stress and apoptosis leading to cancer cell death by modulating p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29752960"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 539,
          "text": "Curcumin has recently been discovered to have anti-cancer properties through its impact on numerous biological pathways involved in carcinogenesis, metastasis, tumorigenesis, cell cycle regulation, mutagenesis, and oncogene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820211"
        },
        {
          "offsetInBeginSection": 431,
          "offsetInEndSection": 707,
          "text": "In the current study, curcumin was found to decrease the Ehrlich\u0027s ascites carcinoma (EAC) cell number by the induction of apoptosis in the tumor cells as evident from flow-cytometric analysis of cell cycle phase distribution of nuclear DNA and oligonucleosomal fragmentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11676493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37210578"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 444,
          "text": " With its low toxicity profile, curcumin (diferuloylmethane), a naturally occurring flavinoid derived from the rhizome of Curcuma longa, has great promise. In vitro and in vivo preclinical studies have shown its inhibitory anticancer, antioxidant, anti-inflammatory, antiproliferative, and proapoptotic activities. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347134"
        }
      ],
      "id": "65f1dadac4010b4d78000007",
      "ideal_answer": [
        "Yes,  Antioxidant curcumin can kill tumor cells",
        "Antioxidant curcumin has been shown to induce apoptosis in tumor cells.",
        "Yes, curcumin has been shown to have the ability to kill tumor cells.",
        "Antioxidant curcumin has been shown to have antitumor effects, which can result in the death of tumor cells.",
        "Yes, antioxidant curcumin can kill tumor cells by inducing oxidative stress.",
        "Yes, curcumin is a potent antioxidant and kills cancerous cells.",
        "Yes, curcumin has been shown to exhibit anti-tumor effects in various types of cancer, including colorectal cancer, by inducing cell death in tumor cells.",
        "Yes, antioxidant curcumin can kill tumor cells by inducing apoptosis and inhibiting malignant progression.",
        "Yes, curcumin can kill tumor cells through its antioxidant properties and various mechanisms of action.",
        "Yes, antioxidant curcumin can kill tumor cells by regulating miR-206 expression",
        "Yes, Curcumin can kill tumor cells.",
        "Yes, curcumin can kill tumor cells by inducing apoptosis and inhibiting malignant progression.",
        "Yes, curcumin can kill tumor cells by regulating miR-206 expression, which inhibits colon cancer malignant progression and promotes T cell killing."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Should we treat all patients with glaucoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36564597",
        "http://www.ncbi.nlm.nih.gov/pubmed/36307903",
        "http://www.ncbi.nlm.nih.gov/pubmed/33433580",
        "http://www.ncbi.nlm.nih.gov/pubmed/35647957",
        "http://www.ncbi.nlm.nih.gov/pubmed/26909513",
        "http://www.ncbi.nlm.nih.gov/pubmed/28442683",
        "http://www.ncbi.nlm.nih.gov/pubmed/18417824",
        "http://www.ncbi.nlm.nih.gov/pubmed/17508036",
        "http://www.ncbi.nlm.nih.gov/pubmed/32343668",
        "http://www.ncbi.nlm.nih.gov/pubmed/27123557",
        "http://www.ncbi.nlm.nih.gov/pubmed/15663346",
        "http://www.ncbi.nlm.nih.gov/pubmed/29018725",
        "http://www.ncbi.nlm.nih.gov/pubmed/34179574",
        "http://www.ncbi.nlm.nih.gov/pubmed/18700453",
        "http://www.ncbi.nlm.nih.gov/pubmed/30296451",
        "http://www.ncbi.nlm.nih.gov/pubmed/2562546",
        "http://www.ncbi.nlm.nih.gov/pubmed/17937041",
        "http://www.ncbi.nlm.nih.gov/pubmed/23741132",
        "http://www.ncbi.nlm.nih.gov/pubmed/35366846"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 175,
          "text": "Trans-scleral diode laser cycloablation (cyclodiode) is effective in the short-term management of refractory glaucoma where alternative treatments are not feasible",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307903"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 155,
          "text": "Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 306,
          "text": "Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 785,
          "text": "Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580"
        },
        {
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1553,
          "text": " Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580"
        },
        {
          "offsetInBeginSection": 1581,
          "offsetInEndSection": 1792,
          "text": "Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient\u0027s risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33433580"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 53,
          "text": "irreversible vision loss from Glaucoma ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 235,
          "text": "intraocular pressure (IOP) is the only modifiable risk factor identified to prevent glaucomatous vision loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 315,
          "text": "Medical management remains the first-line of treatment in most adult glaucomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647957"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 303,
          "text": "At present, all resources are directed towards reduction of intraocular pressure (IOP), the only known causal and treatable risk factor for glaucoma, and medical management is frequently the first choice in most cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417824"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 730,
          "text": "The philosophy of glaucoma management is to preserve the visual function and quality of life (QOL) of the individual with minimum effects on QOL in terms of cost, side effects, treatment regime, follow-up schedules as well as socioeconomic burden.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417824"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 656,
          "text": "Thus, intraocular pressure-lowering strategies combined with neuroprotective therapies to protect visual neurons in the retina and brain may help to preserve vision in patients with glaucoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17508036"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 1225,
          "text": "In patients with manifest glaucoma, lowering the intraocular pressure prevents the progression of visual field defects, with a number needed to treat of 7.CONCLUSION: The diagnostic evaluation of glaucoma rests on multiple pillars, all of which must be considered for establishing the diagnosis and defining the desired target pressure: these are, among others, the intraocular pressure and ocular function and morphology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32343668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "INTRODUCTION: Medical therapy of glaucoma aims to maintain the patient\u0027s visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical ther",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27123557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26909513"
        },
        {
          "offsetInBeginSection": 653,
          "offsetInEndSection": 889,
          "text": "Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented. Treatment options for glaucoma include medications, laser therapy and incisional surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15663346"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 341,
          "text": "IOP reduction by medical, laser, or surgical therapies remains the only clinically proven treatment of glaucoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 361,
          "text": "Over the past decade, results from prospective, randomized, clinical trials have confirmed the value of reducing intraocular pressure (IOP) in patients with ocular hypertension or primary open-angle glaucoma and have outlined the need to consider a target IOP in an individual glaucomatous patient and not an arbitrary value of 21 mm Hg as classically believed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18700453"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 382,
          "text": "Intraocular pressure is the main risk factor for glaucoma, and intraocular pressure-lowering treatment remains the mainstay of glaucoma treatment, but even successful intraocular pressure reduction does not stop the progression of glaucoma in all patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30296451"
        },
        {
          "offsetInBeginSection": 445,
          "offsetInEndSection": 672,
          "text": "Knowing the type of glaucoma is vital, especially regarding an individualized treatment, since each patient is unique and needs to be treated accordingly, in order to prevent glaucomatous optic neuropathy and visual field loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34179574"
        },
        {
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1552,
          "text": "n mean IOP respectively.CONCLUSIONS: The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17937041"
        },
        {
          "offsetInBeginSection": 1526,
          "offsetInEndSection": 1720,
          "text": "Although the general rule is to initiate glaucoma management with medical treatment, the limits of medical therapy should be considered to identify those patients in need of surgical management.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28442683"
        },
        {
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1387,
          "text": "Treatment for advanced glaucoma can be highly effective, and patients and their care partners should be informed that aggressive IOP lowering to the low teens or even single digits offers the best chance of protecting remaining vision.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741132"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "BACKGROUND: Treatment of open angle glaucoma (OAG) and/or ocular hypertension (OHT) focuses on achievement of target intraocular pressure (IOP), with the objective of slowing disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35366846"
        }
      ],
      "id": "65f85f77c4010b4d78000053",
      "ideal_answer": [
        "Yes, treating all glaucoma patients is essential to prevent the progression of visual field defects.",
        "Yes, it is generally recommended to treat all patients diagnosed with glaucoma. Glaucoma is a group of eye conditions that can lead to irreversible vision loss and even blindness if left untreated. The main goal of treatment is to lower intraocular pressure (IOP) to prevent further damage to the optic nerve. Treatment options include medications, laser treatments, and surgeries. Each patient\u0027s situation is unique, so a personalized treatment plan should be developed in consultation with an eye care professional. Early detection and consistent management are key to preserving vision and preventing progression of glaucoma."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the mechanism of action of Pegozafermin?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37355760",
        "http://www.ncbi.nlm.nih.gov/pubmed/36521501",
        "http://www.ncbi.nlm.nih.gov/pubmed/37356033",
        "http://www.ncbi.nlm.nih.gov/pubmed/37696614",
        "http://www.ncbi.nlm.nih.gov/pubmed/37562970",
        "http://www.ncbi.nlm.nih.gov/pubmed/37889055",
        "http://www.ncbi.nlm.nih.gov/pubmed/37718721"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37355760"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37355760"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 342,
          "text": "BACKGROUND: Management strategies for non-alcoholic steatohepatitis (NASH) are based predominantly on lifestyle modification, with no approved disease-modifying drugs yet available. We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participants with NASH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36521501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37356033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37356033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 423,
          "text": "BACKGROUND: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need.AIM: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy-confirmed NASH.METHODS: This proof-of-concept, open-label, single-cohort study, part 2 of a phase 1b/2a clinical trial, was conducted at 16 centres in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37718721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37356033"
        },
        {
          "offsetInBeginSection": 1484,
          "offsetInEndSection": 1791,
          "text": "Studies presented here demonstrate that a novel long-acting FGF21 analog, pegozafermin, has similar pharmacologic properties as FGF21 and that repeated, subcutaneous dosing of pegozafermin in diabetic monkeys and healthy humans improves lipid metabolism, glucose metabolism, weight, and liver transaminases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 831,
          "text": "We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participants with NASH.METHODS: This randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study enrolled adults (aged 21-75 years) who had NASH with stage F1-F3 fibrosis, or non-alcoholic fatty liver disease and a high risk of NASH (referred to in this study as phenotypic NASH) due to central obesity with type 2 diabetes, or central obesity with increased alanine aminotransferase (ALT) or a Fibroscan score of 7 kPa or greater, across 12 specialist centres and clinics in the USA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36521501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential for addressing metabolic comorbidities, including severe hypertriglyceridemia, insulin resistance, nonalcoholic fatty liver disease, and obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889055"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 400,
          "text": "In cell-based assays, pegozafermin had a similar receptor engagement profile as recombinant FGF21, with approximately eightfold higher potency at fibroblast growth factor receptor 1c (FGFR1c).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 998,
          "text": "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential for addressing metabolic comorbidities, including severe hypertriglyceridemia, insulin resistance, nonalcoholic fatty liver disease, and obesity. FGF21 is a naturally occurring peptide hormone primarily produced by the liver, with a half-life of 0.5 to 2 hours. It can influence metabolic processes through endocrine cellular effects. FGF21 receptors are found in the liver, adipose, skeletal muscles, and pancreatic tissues. Those receptors rely on the beta klotho (KLB) coreceptors, a transmembrane protein, to activate the FGF21 signaling pathway and FGF21\u0027s associated transcription factors. PGZ, through its extended half-life of 55 to 100 hours, has evidenced significant improvements in metabolic functions. Its mechanism of action includes promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37355760"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 330,
          "text": "cokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36521501"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 253,
          "text": "abolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37718721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). In cell-based assays, pegozafermin had a similar receptor engagement profile as recombinant FGF21, with approximately eightfold higher potency at fibroblast growth factor receptor 1c (FGFR1c).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562970"
        }
      ],
      "id": "65cfab681930410b13000012",
      "ideal_answer": [
        "Pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia."
      ]
    },
    {
      "body": "What is the indication for Alirocumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35052871",
        "http://www.ncbi.nlm.nih.gov/pubmed/27250613",
        "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
        "http://www.ncbi.nlm.nih.gov/pubmed/28277798",
        "http://www.ncbi.nlm.nih.gov/pubmed/35974290",
        "http://www.ncbi.nlm.nih.gov/pubmed/25244623",
        "http://www.ncbi.nlm.nih.gov/pubmed/29171769",
        "http://www.ncbi.nlm.nih.gov/pubmed/26935836",
        "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
        "http://www.ncbi.nlm.nih.gov/pubmed/26563849",
        "http://www.ncbi.nlm.nih.gov/pubmed/26370210",
        "http://www.ncbi.nlm.nih.gov/pubmed/27567901",
        "http://www.ncbi.nlm.nih.gov/pubmed/28618994",
        "http://www.ncbi.nlm.nih.gov/pubmed/26886466",
        "http://www.ncbi.nlm.nih.gov/pubmed/26798848",
        "http://www.ncbi.nlm.nih.gov/pubmed/26859553",
        "http://www.ncbi.nlm.nih.gov/pubmed/37939861",
        "http://www.ncbi.nlm.nih.gov/pubmed/28263403",
        "http://www.ncbi.nlm.nih.gov/pubmed/36440240",
        "http://www.ncbi.nlm.nih.gov/pubmed/28750828",
        "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
        "http://www.ncbi.nlm.nih.gov/pubmed/28328015",
        "http://www.ncbi.nlm.nih.gov/pubmed/29802110"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 49,
          "text": "Effects of Alirocumab on Triglyceride Metabolism:",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 290,
          "text": "PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators.M",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35052871"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 602,
          "text": "To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs - PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50-60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27250613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 54,
          "text": "Alirocumab for the treatment of hypercholesterolaemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 867,
          "text": "Areas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "INTRODUCTION: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1689,
          "text": "Currently, alirocumab is approved by the US Food and Drug Administration (FDA) as an adjunct to diet and maximally tolerated statin therapy for use in adults with heterozygous familial hypercholesterolemia (FH) or those with atherosclerotic CV disease who require additional LDL-C lowering; it has also been recently approved by the European Medicines Agency (EMA) for use in patients with heterozygous FH, non-familial hypercholesterolemia or mixed dyslipidemia in whom statins are ineffective or not tolerated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567901"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1460,
          "text": "Expert commentary: Alirocumab causes a marked reduction in LDL-C, presents good safety and tolerability, and represents a promising approach for LDL-C lowering, particularly in patients with intolerance to statin or elevated LDL-C despite maximal statin therapy; nevertheless, further long-term data on safety and efficacy are necessary, such as data on the improvement of cardiovascular outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1621,
          "text": "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28618994"
        },
        {
          "offsetInBeginSection": 272,
          "offsetInEndSection": 580,
          "text": "Alirocumab (Praluent; Sanofi/Regeneron, Bridgewater, NJ) and evolocumab (Repatha; Amgen, Thousand Oaks, CA) are currently available and approved for use in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26886466"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 58,
          "text": "Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25244623"
        },
        {
          "offsetInBeginSection": 868,
          "offsetInEndSection": 1062,
          "text": "The authors review the pharmacological features, clinical efficacy, and safety of alirocumab in lowering LDL-C, and discuss its therapeutic perspectives based on the most recent clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 380,
          "text": "Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26370210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 42,
          "text": "Alirocumab (Praluent) for high cholesterol",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26535020"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35974290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Alirocumab for the treatment of hypercholesterolemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28277798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 58,
          "text": "Alirocumab: targeting PCSK9 to treat hypercholesterolemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798848"
        },
        {
          "offsetInBeginSection": 924,
          "offsetInEndSection": 1309,
          "text": "The high cost and the current lack of long-term safety and efficacy data will restrict the use of alirocumab to patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28277798"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1565,
          "text": "Thus, alirocumab is a valuable emerging option for use in patients with hypercholesterolemia, particularly patients with statin intolerance or inadequately-controlled LDL-C despite statin therapy; however, more data are needed to establish its potential cardiovascular benefits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "An evaluation of alirocumab for the treatment of hypercholesterolemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26563849"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 571,
          "text": "The clinical use of two monoclonal antibodies (alirocumab and evolocumab, approved in 2015) and one small interfering RNA (inclisiran, approved in 2020) which can inhibit PCSK9 function proved that they are very effective in lowering low density lipoprotein cholesterol (LDL-C)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37939861"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 852,
          "text": "reas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alte",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 660,
          "text": "Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9). These antibodies can potently lower low-density lipoprotein cholesterol (LDLc) serum concentrations. The aims of this analysis were to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for both antibodies, to simulate and investigate different dosage and application regimens, and finally, to note the effects on LDLc levels. Alirocumab was clinically studied and approved with 2 doses, 75 and 150 mg every 2 weeks (Q2W), whereas evolocumab was tested and approved with 2 dosing intervals, 140 mg Q2W and 420 mg Q4W.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 457,
          "text": "Background: Even though the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved to reduce plasma low-density lipoprotein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular disease in high-risk patients, real-world data showing comparisons of the lipid-lowering effects between alirocumab and evolocumab are scarce because of the low prescription rates of PCSK9 inhibitors in clinic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36440240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating impressive clinical trial data over the last several years, and alirocumab (Praluent) has become the first to be approved by the US FDA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26785741"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1619,
          "text": "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowerin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28618994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 485,
          "text": "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent®; Sanofi/ Regeneron) and evolocumab (Repatha®; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimib",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28750828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the preven",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35974290"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 811,
          "text": "Alirocumab clinical trials with different doses on different administration schedules were shown to significantly reduce LDL cholesterol both as a mono-therapy and in combination with statins or ezetimibe.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25244623"
        },
        {
          "offsetInBeginSection": 779,
          "offsetInEndSection": 1234,
          "text": "Large and comprehensive trials over the last 5 years also indicated good tolerability and safety and resulted in the 2015 regulatory approval in the USA and Europe for the marketing of two mAbs, evolocumab and alirocumab, for the treatment of LDL-C.SUMMARY: The background, clinical trials and approved indications for the current PCSK9 inhibitors are reviewed along with their likely role in the management of LDL-C and cardiovascular disease prevention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26859553"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 425,
          "text": "In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328015"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 557,
          "text": "esterol (LDL-C). The currently available PCSK9 inhibitors alirocumab and evolocumab were shown to reduce LDL-C concentrations by approximately 55-60% relative to placebo use when used as monotherapy or added to other lipid-lo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29802110"
        }
      ],
      "id": "65f70b9cc4010b4d7800001c",
      "ideal_answer": [
        "Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment",
        "Alirocumab is indicated for the prevention of cardiovascular risk, and for patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or hypercholesterolemia who require additional LDL-C lowering.",
        "Alirocumab is indicated for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.",
        "Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients.",
        "The indication for Alirocumab is for patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.",
        "Alirocumab is indicated for the treatment of hypercholesterolemia in high-risk patients, heterozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease where low-density lipoprotein cholesterol (LDLC) lowering is insufficient.",
        "Alirocumab is indicated for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol.",
        "Alirocumab is used for treatment of low-density lipoprotein cholesterol.",
        "Alirocumab is indicated for cholesterol and triglyceride metabolism, acting on them.",
        "Alirocumab is a PCSK9 inhibitor that is used to decrease LDL-cholesterol levels in patients who have not been able to achieve target levels with other treatments. It is approved for clinical use by European regulatory authorities.",
        "The indication for Alirocumab is lowering LDL cholesterol levels.",
        "Alirocumab is indicated for the treatment of hypertriglyceridemia.",
        "Alirocumab is indicated for LDL-cholesterol reduction.",
        "Alirocumab is indicated for the treatment of hypercholesterolemia.",
        "Alirocumab is primarily used to lower LDL-cholesterol levels.",
        "Alirocumab is an anti-PCSK9 monoclonal antibody that is used for the treatment of high cholesterol.",
        "The indication for Alirocumab is to reduce LDL-cholesterol and triglyceride metabolism.",
        "Alirocumab is a PCSK9 inhibitor indicated for lowering LDL cholesterol. It is used in patients who cannot achieve target LDL cholesterol levels with other lipid-lowering therapies.",
        "Alirocumab is indicated for the reduction of low-density lipoprotein cholesterol (LDL-cholesterol), particularly in patients who have not been able to achieve target LDL-cholesterol levels with traditional treatments.",
        "The indication for Alirocumab is to reduce LDL cholesterol levels in patients who have not achieved their target LDL cholesterol levels with maximally tolerated statin therapy or in patients who are intolerant to statins.",
        "Alirocumab is indicated for the treatment of hypertriglyceridemia in adults with established cardiovascular disease or diabetes mellitus type 2 and mixed dyslipidemia."
      ],
      "exact_answer": [
        [
          "high cholesterol",
          "hypercholestoremia"
        ]
      ]
    },
    {
      "body": "Is there an approved vaccine against Helicobacter pylori?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37018869",
        "http://www.ncbi.nlm.nih.gov/pubmed/37971157",
        "http://www.ncbi.nlm.nih.gov/pubmed/36641984",
        "http://www.ncbi.nlm.nih.gov/pubmed/9395760",
        "http://www.ncbi.nlm.nih.gov/pubmed/25400981",
        "http://www.ncbi.nlm.nih.gov/pubmed/24133496"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 416,
          "text": "H. pylori, the development of an efficacious vaccine is a valid option to protect from disease or infection and ultimately prevent gastric cancer. However, despite more than 30 years of research, no vaccine has entered the market yet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37018869"
        },
        {
          "offsetInBeginSection": 2265,
          "offsetInEndSection": 2427,
          "text": "advances of H. pylori vaccines from two aspects, candidates of antigens and adjuvants, to provide references for the development of vaccine against this bacterium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971157"
        },
        {
          "offsetInBeginSection": 586,
          "offsetInEndSection": 697,
          "text": "Despite an extensive list of attempts to develop a vaccine, no approved vaccine against H. pylori is available.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36641984"
        },
        {
          "offsetInBeginSection": 1297,
          "offsetInEndSection": 1447,
          "text": "Unfortunately, no vaccine against H. pylori is currently licensed, and protective immunity mechanisms against H. pylori are only partially understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24133496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 351,
          "text": "After the discovery of Helicobacter pylori (H. pylori), and the evidence of its relationship with gastric diseases, antibiotic-based therapies were developed, which efficacy was however limited by antibiotic resistance and lack of patient compliance. A vaccine would overcome these drawbacks, but currently there is not any H. pylori vaccine licensed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981"
        },
        {
          "offsetInBeginSection": 508,
          "offsetInEndSection": 560,
          "text": "An effective vaccine against H pylori is years away.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9395760"
        },
        {
          "offsetInBeginSection": 293,
          "offsetInEndSection": 351,
          "text": "but currently there is not any H. pylori vaccine licensed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 351,
          "text": "A vaccine would overcome these drawbacks, but currently there is not any H. pylori vaccine licensed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400981"
        }
      ],
      "id": "65f86a90c4010b4d78000057",
      "ideal_answer": [
        "No. There is currently no approved vaccine against Helicobacter pylori.",
        "No, there is currently no approved vaccine for Helicobacter pylori.",
        "No, there is currently no approved vaccine against Helicobacter pylori.",
        "No, there is no approved vaccine against Helicobacter pylori",
        "No, there is no approved vaccine against Helicobacter pylori.",
        "No, there is not an approved vaccine against Helicobacter pylori."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What disease can be treated with Tebentafusp?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37444540",
        "http://www.ncbi.nlm.nih.gov/pubmed/37483658",
        "http://www.ncbi.nlm.nih.gov/pubmed/36931146",
        "http://www.ncbi.nlm.nih.gov/pubmed/36970111",
        "http://www.ncbi.nlm.nih.gov/pubmed/36600005",
        "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
        "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
        "http://www.ncbi.nlm.nih.gov/pubmed/37595494",
        "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
        "http://www.ncbi.nlm.nih.gov/pubmed/35172589",
        "http://www.ncbi.nlm.nih.gov/pubmed/36847626",
        "http://www.ncbi.nlm.nih.gov/pubmed/37207136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
        "http://www.ncbi.nlm.nih.gov/pubmed/37650713",
        "http://www.ncbi.nlm.nih.gov/pubmed/38048850",
        "http://www.ncbi.nlm.nih.gov/pubmed/36102132",
        "http://www.ncbi.nlm.nih.gov/pubmed/35364798",
        "http://www.ncbi.nlm.nih.gov/pubmed/32816891",
        "http://www.ncbi.nlm.nih.gov/pubmed/37902386",
        "http://www.ncbi.nlm.nih.gov/pubmed/37473516",
        "http://www.ncbi.nlm.nih.gov/pubmed/37286303",
        "http://www.ncbi.nlm.nih.gov/pubmed/37141553",
        "http://www.ncbi.nlm.nih.gov/pubmed/34999237",
        "http://www.ncbi.nlm.nih.gov/pubmed/34885078",
        "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
        "http://www.ncbi.nlm.nih.gov/pubmed/36785760",
        "http://www.ncbi.nlm.nih.gov/pubmed/37661909",
        "http://www.ncbi.nlm.nih.gov/pubmed/36229663",
        "http://www.ncbi.nlm.nih.gov/pubmed/36199496",
        "http://www.ncbi.nlm.nih.gov/pubmed/36710368",
        "http://www.ncbi.nlm.nih.gov/pubmed/37870955",
        "http://www.ncbi.nlm.nih.gov/pubmed/35236927",
        "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
        "http://www.ncbi.nlm.nih.gov/pubmed/31344957",
        "http://www.ncbi.nlm.nih.gov/pubmed/36442912"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540"
        },
        {
          "offsetInBeginSection": 1140,
          "offsetInEndSection": 1254,
          "text": "Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 446,
          "text": "Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37483658"
        },
        {
          "offsetInBeginSection": 2309,
          "offsetInEndSection": 2563,
          "text": "CONCLUSIONS: Tebentafusp achieved the best results compared to combined ICB and other systemic treatments, although these results have to be interpreted with caution due to the approximative methodical approach and high heterogeneity of included studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931146"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 460,
          "text": "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111"
        },
        {
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1065,
          "text": "These advances have driven the development of a number of novel emerging treatments, including tebentafusp, the first systemic therapy to achieve regulatory approval for this disease. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved treatment options.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36847626"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36847626"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 459,
          "text": "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36970111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Tebentafusp, a bispecific T-cell receptor fusion protein directed against gp100 and CD3, can improve survival in patients with metastatic uveal melanoma and was recently approved for the treatment of HLA-A*02:01-positive uveal melanoma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37661909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35115315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31336704"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit (hazard ratio [HR] 0.51) compared to investigator\u0027s choice (82% pembrolizumab) in a randomized, Phase 3 trial (IMCgp100-202; N\u003d378) in untreated metastatic uveal mel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38048850"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator\u0027s choice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37595494"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved trea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440"
        },
        {
          "offsetInBeginSection": 599,
          "offsetInEndSection": 742,
          "text": "Using tebentafusp as a case study, a CD3-bispecific approved for uveal melanoma, the model successfully captures the dynamics of five cytokines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36710368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444540"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 425,
          "text": "Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35364557"
        },
        {
          "offsetInBeginSection": 583,
          "offsetInEndSection": 751,
          "text": "Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36199496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442912"
        }
      ],
      "id": "65cec1fb1930410b13000005",
      "ideal_answer": [
        "Tebentafusp is approved for uveal melanoma."
      ],
      "exact_answer": [
        [
          "uveal melanoma"
        ]
      ]
    },
    {
      "body": "When was Havana Syndrome first recognized?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37965360",
        "http://www.ncbi.nlm.nih.gov/pubmed/35962646",
        "http://www.ncbi.nlm.nih.gov/pubmed/37976420",
        "http://www.ncbi.nlm.nih.gov/pubmed/32655474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30828629"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 206,
          "text": " In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 438,
          "text": "This fact was illustrated in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37976420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 352,
          "text": "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome\" (HS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35962646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "In late 2016, diplomats in Havana, Cuba, began presenting with a unique symptom complex after perceiving a strange noise and/or feeling a pressure field in their domicile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32655474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Introduction: In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965360"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "BACKGROUND: In the Autumn of 2016, diplomatic personnel residing in Havana began to present with symptoms of dizziness, ear pain, and tinnitus that emerged after perception of high frequency noise and/or a pressure sensation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30828629"
        }
      ],
      "id": "65f856a1c4010b4d7800004e",
      "ideal_answer": [
        "Since 2016, an array of claims and public discourse have circulated in the medical community over the origin and nature of a mysterious condition dubbed \"Havana Syndrome,\" so named as it was first identified in Cuba.",
        "Havana Syndrome is the name given to the group of neurological symptoms that first occurred among the staff at the U.S. embassy in Havana, Cuba in 2016.",
        "Havana Syndrome was first recognized in the year 2016.",
        "Havana syndrome is a term used to describe a cluster of neurological symptoms that have been reported by United States and Canadian diplomats, intelligence officers, and other government employees, mainly in Havana, Cuba, between 2016 and 2018.",
        "Havana syndrome is a term that was first coined by US diplomats and intelligence personnel in 2016 in Havana, Cuba, to describe a series of strange symptoms, including dizziness, hearing loss, headaches, and cognitive impairment.",
        "Havana Syndrome was first recognized in 2016.",
        "Havana Syndrome was first recognized in late 2016 when U.S. diplomatic personnel in Havana, Cuba, reported experiencing unusual symptoms including hearing loss, cognitive issues, and other neurological problems.",
        "Havana Syndrome was first recognized in Havana, Cuba in late 2016 when several U.S. diplomats and embassy staff reported experiencing unexplained neurological symptoms.",
        "Havana Syndrome was first recognized in late 2016 when several U.S. diplomats stationed in Havana, Cuba, reported experiencing a range of unexplained neurological symptoms.",
        "In 2016 diplomatic personnel serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.",
        "The phenomenon now known as Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.",
        "The Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.",
        "Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises and experiencing unexplained health effects.",
        "In 2016, Havana Syndrome was first recognized when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.",
        "Havana Syndrome is a term used to describe a series of unexplained neurological symptoms experienced by diplomatic personnel serving in Havana, Cuba, beginning in 2016.",
        " Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.",
        "Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.",
        "Havana Syndrome was first recognized in 2016 when diplomatic personnel serving in Havana, Cuba, reported audible sensory phenomena paired with complex and persistent neurological symptoms consistent with brain injury.",
        "Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects.",
        "Havana Syndrome was first recognized in 2016 when U.S. diplomats serving in Havana, Cuba began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.",
        "Havana Syndrome was first recognized in 2016 when diplomatic personnel in Havana, Cuba reported experiencing unusual sensory phenomena and neurological symptoms."
      ],
      "exact_answer": [
        [
          "2016"
        ]
      ]
    },
    {
      "body": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31021739",
        "http://www.ncbi.nlm.nih.gov/pubmed/36084314",
        "http://www.ncbi.nlm.nih.gov/pubmed/9721531",
        "http://www.ncbi.nlm.nih.gov/pubmed/21046175",
        "http://www.ncbi.nlm.nih.gov/pubmed/16026254",
        "http://www.ncbi.nlm.nih.gov/pubmed/37171813",
        "http://www.ncbi.nlm.nih.gov/pubmed/36242583",
        "http://www.ncbi.nlm.nih.gov/pubmed/25786917",
        "http://www.ncbi.nlm.nih.gov/pubmed/24713118",
        "http://www.ncbi.nlm.nih.gov/pubmed/15811650",
        "http://www.ncbi.nlm.nih.gov/pubmed/26656687",
        "http://www.ncbi.nlm.nih.gov/pubmed/17610952",
        "http://www.ncbi.nlm.nih.gov/pubmed/22935026",
        "http://www.ncbi.nlm.nih.gov/pubmed/37908613",
        "http://www.ncbi.nlm.nih.gov/pubmed/37880247",
        "http://www.ncbi.nlm.nih.gov/pubmed/37849404",
        "http://www.ncbi.nlm.nih.gov/pubmed/37647447",
        "http://www.ncbi.nlm.nih.gov/pubmed/37632081",
        "http://www.ncbi.nlm.nih.gov/pubmed/25118385",
        "http://www.ncbi.nlm.nih.gov/pubmed/27497688",
        "http://www.ncbi.nlm.nih.gov/pubmed/29593155",
        "http://www.ncbi.nlm.nih.gov/pubmed/28580138",
        "http://www.ncbi.nlm.nih.gov/pubmed/26038444",
        "http://www.ncbi.nlm.nih.gov/pubmed/36817425",
        "http://www.ncbi.nlm.nih.gov/pubmed/9448698",
        "http://www.ncbi.nlm.nih.gov/pubmed/21468930",
        "http://www.ncbi.nlm.nih.gov/pubmed/32320678",
        "http://www.ncbi.nlm.nih.gov/pubmed/27489272",
        "http://www.ncbi.nlm.nih.gov/pubmed/30332733",
        "http://www.ncbi.nlm.nih.gov/pubmed/16809329",
        "http://www.ncbi.nlm.nih.gov/pubmed/21994610",
        "http://www.ncbi.nlm.nih.gov/pubmed/29106386",
        "http://www.ncbi.nlm.nih.gov/pubmed/36920694",
        "http://www.ncbi.nlm.nih.gov/pubmed/18063023",
        "http://www.ncbi.nlm.nih.gov/pubmed/30192975",
        "http://www.ncbi.nlm.nih.gov/pubmed/21994800",
        "http://www.ncbi.nlm.nih.gov/pubmed/28076420",
        "http://www.ncbi.nlm.nih.gov/pubmed/22815803",
        "http://www.ncbi.nlm.nih.gov/pubmed/26047124",
        "http://www.ncbi.nlm.nih.gov/pubmed/35332563",
        "http://www.ncbi.nlm.nih.gov/pubmed/16355872",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215737",
        "http://www.ncbi.nlm.nih.gov/pubmed/27268907",
        "http://www.ncbi.nlm.nih.gov/pubmed/31473342",
        "http://www.ncbi.nlm.nih.gov/pubmed/32093889"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 313,
          "text": "Several filoviruses infect bats (e.g., Marburg virus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31021739"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 48,
          "text": "African Filovirus (Ebola and Marburg)",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084314"
        },
        {
          "offsetInBeginSection": 527,
          "offsetInEndSection": 571,
          "text": "filoviruses (ebolaviruses and Marburg virus)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084314"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 384,
          "text": "The Filoviridae family encompasses Ebola strains such as Sudan, Zaire, Bundibugyo, Tai Forest (formerly known as Ivory Coast), Reston, and Bombali, in addition to the closely related Marburg and Ravn virus strains",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37908613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Marburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880247"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Viruses in the family Filoviridae, including the commonly known Ebola (EBOV) and Marburg (MARV) viruses, can cause severe hemorrhagic fever in humans and nonhuman primates",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37849404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Marburg virus, the prototype of the family Filoviridae, differs genetically, serologically, and morphologically from Ebola viruses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9448698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "UNLABELLED: Ebola virus (EBOV) and Marburg virus (MARV) belong to the Filoviridae family and can cause outbreaks of severe hemorrhagic fever, with high mortality rates in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27489272"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32320678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17610952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV) are members of the family Filoviridae (\"filoviruses\") and cause severe hemorrhagic fever with human case fatality rates of up to 90%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935026"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 236,
          "text": "The Marburg virus is a lipid-enveloped virus from the Filoviridae family and is closely related to the Ebola virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28580138"
        },
        {
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1528,
          "text": "Comparative analyses showed that there are two lineages within the Marburg virus species of filoviruses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9448698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Ebola virus and Marburg virus are members of the family of Filoviridae and are etiological agents of a deadly hemorrhagic fever disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26038444"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118385"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 341,
          "text": "Marburg virus and Ebola virus, members of the family Filoviridae, cause highly lethal hemorrhagic fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29593155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Members of the family Filoviridae, including Ebola virus (EBOV) and Marburg virus (MARV), cause severe hemorrhagic fever in humans and nonhuman primates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Marburg virus (MARV) and the ebolaviruses belong to the family Filoviridae (the members of which are filoviruses) that cause severe hemorrhagic fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Filoviruses are filamentous enveloped viruses belonging to the family Filoviridae, in the order Mononegavirales. Some filovirus members, such as Ebola virus and Marburg virus, cause severe hemorrhagic fever in humans and non-human primates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36242583"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "UNLABELLED: Ebola virus (EBOV) and Marburg virus (MARV) belong to the Filoviridae family and can cause outbreaks of severe hemorrhagic fever, with high mortality rate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27489272"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the viral family Filoviridae, cause fatal hemorrhagic fevers in humans and nonhuman primates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16809329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 353,
          "text": "The members of the filoviruses are recognized as some of the most lethal viruses affecting human and non-human primates. The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa, with case fatality rates ranging from 25 to 90%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994610"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29106386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The Marburg virus, which is a member of the same virus family as the Ebola virus called Filoviridae, causes the severe infectious disease known as Marburg virus disease (MVD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37647447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The Ebola virus and its close relative, the Marburg virus, both belong to the family Filoviridae and are highly hazardous and contagious viruses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37632081"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV) of the Filoviridae family are the most lethal viruses in terms of mortality rate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36920694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 393,
          "text": "Ebolavirus and Marburgvirus (belonging to the Filoviridae family) emerged four decades ago and cause epidemics of haemorrhagic fever with high case-fatality rates. The genome of filoviruses encodes seven proteins. No significant homology is observed between filovirus proteins and any known macromolecule. Moreover, Marburgvirus and Ebolavirus show significant differences in protein homology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18063023"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales. The genus Ebolavirus consists of four species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Ivory Coast ebolavirus (ICEBOV) and Reston ebolavirus (REBOV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17610952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Marburg virus (MARV; family Filoviridae) causes sporadic outbreaks of Marburg hemorrhagic fever in sub-Saharan Africa with case fatality rates reaching 90%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30192975"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The Filoviridae family of viruses, which includes the genera Ebolavirus (EBOV) and Marburgvirus (MARV), causes severe and often times lethal hemorrhagic fever in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant challenge to global public health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24713118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Ebola virus (EBOV) and Marburg virus (MARV), belonging to the Filoviridae family, emerged four decades ago and caused severe viral hemorrhagic fever in human and other primates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21468930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae and cause severe hemorrhagic fever in humans and nonhuman primates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery of its members, resulting in a plethora of species and virus names and abbreviations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Ebola and Marburg viruses (family Filoviridae, genera Ebolavirus and Marburgvirus) cause haemorrhagic fevers in humans, often associated with high mort",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "The ability of viruses in the Filoviridae family (Ebola virus [EBOV] and Marburg virus [MARV]) to cause severe human disease and their pandemic potential makes all emerging filoviral pathogens a concern to humanity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35332563"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 303,
          "text": "The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994610"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "UNLABELLED: Marburg virus (MARV), a member of the filovirus family, causes severe hemorrhagic fever with up to 90",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656687"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Marburg virus (MARV), a member of the Filoviridae family that also includes Ebola virus (EBOV)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24713118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "The family Filoviridae is comprised of two genera: Marburgvirus and Ebolavirus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16355872"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 298,
          "text": "As members of the filovirus family, marburgviruses have caused similar devastating outbreaks, albeit with lower case numbers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215737"
        },
        {
          "offsetInBeginSection": 31,
          "offsetInEndSection": 112,
          "text": "ebolavirus (SUDV) and Marburg virus (MARV), are members of the Filoviridae family",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36817425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24713118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Ebola (EBOV) and Marburg (MARV) viruses are members of the Filoviridae family which cause outbreaks",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28076420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the viral family Filoviridae, cause fatal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16809329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Ebola and Marburg viruses are members of the family Filoviridae, which cause severe hemorrhagic fevers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16026254"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 171,
          "text": "GROUND: The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg v",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37171813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Filoviridae family members Ebola (EBOV) and Marburg (MARV) viruses and Arenaviridae family member Lassa virus (LASV) are",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33536174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046175"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 395,
          "text": "filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause highly lethal disease typified by unimpeded viral replication and severe hemorrhagic fever. Previously, we showed that expression of the homologous glycoprotein (GP) and matrix protein VP40 from a single filovirus, either EBOV or MARV, resulted in formation of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15811650"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Marburg virus (MARV), a member of the Filoviridae family that also includes Ebola virus (EBOV), causes lethal hemorrhagic fever with case fatality rates that have exceeded 50% in some outbreaks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497688"
        },
        {
          "offsetInBeginSection": 354,
          "offsetInEndSection": 523,
          "text": "Ebola and Marburg viruses are members of the Filoviridae family and easily distinguishable from viruses of other families by the characteristic morphology of the virion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9721531"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 353,
          "text": "The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa, with case fatality rates ranging from 25 to 90%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994610"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 386,
          "text": "Filoviridae currently includes five official and one proposed genera. Genus Ebolavirus includes five established and one proposed ebolavirus species for Bombali virus (BOMV), Bundibugyo virus (BDBV), Ebola virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV) and Taï Forest virus (TAFV), and genus Marburgvirus includes a single species for Marburg virus (MARV) and Ravn virus (RAVV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31473342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Eight viruses are currently assigned to the family Filoviridae Marburg virus, Sudan virus and, in particular, Ebola virus have received the most attention both by researchers and the public from 1967 to 2013.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "The family Filoviridae contains many important human viruses, including Marburg virus (MARV) and Ebola virus (EBOV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093889"
        }
      ],
      "id": "65f86f03c4010b4d7800005b",
      "ideal_answer": [
        "Yes, Marburg virus is a member of the family of the Ebola virus (Filoviridae).",
        "Yes, the Marburg virus is part of the Filoviridae family, just like the Ebola virus.",
        "Yes, Marburg virus is a member of the Filoviridae family, which also includes Ebola virus.",
        "Yes, Marburg virus belongs to the filovirus family along with Ebola virus.",
        "Yes, Marburg virus is a member of the family of Filoviridae, the same family as the Ebola virus.",
        "Yes, Marburg virus and Ebola virus belong to the family Filoviridae.",
        "Yes, Marburg virus and Ebola virus are both members of the family Filoviridae, which is a family of viruses known for causing severe hemorrhagic fever outbreaks in humans and nonhuman primates.",
        "Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus. The family Filoviridae is comprised of two genera: Marburgvirus and Ebolavirus. Marburg virus belongs to the Marburgvirus genus, while the Ebola virus belongs to the Ebolavirus genus.",
        "Yes, Marburg virus is a member of the family Filoviridae, which also includes the Ebola virus.",
        "Yes, Marburg virus is a member of the family Filoviridae, which also includes ebolaviruses.",
        "Yes, Marburg virus is a member of the same family as the Ebola virus, both belonging to the Filoviridae family.",
        "Yes, the Marburg virus is part of the Filoviridae family, just like Ebola.",
        "Yes, the Marburg virus is a member of the Filoviridae family, which also includes the Ebola virus."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What medications were tested in the COSMIC-313 trial?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36239611",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062953",
        "http://www.ncbi.nlm.nih.gov/pubmed/37246571",
        "http://www.ncbi.nlm.nih.gov/pubmed/37163623",
        "http://www.ncbi.nlm.nih.gov/pubmed/37207297"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239611"
        },
        {
          "offsetInBeginSection": 422,
          "offsetInEndSection": 651,
          "text": "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062953"
        },
        {
          "offsetInBeginSection": 697,
          "offsetInEndSection": 1074,
          "text": "As concern the triplet therapy (i.e. nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246571"
        },
        {
          "offsetInBeginSection": 2009,
          "offsetInEndSection": 2480,
          "text": "CONCLUSIONS: Among patients with previously untreated, advanced renal-cell carcinoma who had intermediate or poor prognostic risk, treatment with cabozantinib plus nivolumab and ipilimumab resulted in significantly longer progression-free survival than treatment with nivolumab and ipilimumab alone. Grade 3 or 4 adverse events were more common in the experimental group than in the control group. (Funded by Exelixis; COSMIC-313 ClinicalTrials.gov number, NCT03937219.).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37163623"
        },
        {
          "offsetInBeginSection": 734,
          "offsetInEndSection": 1073,
          "text": "nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239611"
        },
        {
          "offsetInBeginSection": 488,
          "offsetInEndSection": 716,
          "text": "In COSMIC-313, a randomized phase III trial for patients with untreated advanced ccRCC, the triplet combination of ipilimumab, nivolumab, and cabozantinib was compared with a contemporary control arm of ipilimumab and nivolumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37207297"
        },
        {
          "offsetInBeginSection": 422,
          "offsetInEndSection": 650,
          "text": "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062953"
        },
        {
          "offsetInBeginSection": 422,
          "offsetInEndSection": 649,
          "text": "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062953"
        },
        {
          "offsetInBeginSection": 734,
          "offsetInEndSection": 1074,
          "text": "nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246571"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 146,
          "text": "COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239611"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 930,
          "text": "therapy (i.e. nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37246571"
        }
      ],
      "id": "65d140e71930410b1300003f",
      "ideal_answer": [
        "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma."
      ],
      "exact_answer": [
        [
          "cabozantinib"
        ],
        [
          "nivolumab"
        ],
        [
          "ipilimumab"
        ]
      ]
    },
    {
      "body": "Explain the action of Domperidone.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37352416",
        "http://www.ncbi.nlm.nih.gov/pubmed/36958154",
        "http://www.ncbi.nlm.nih.gov/pubmed/24147629",
        "http://www.ncbi.nlm.nih.gov/pubmed/3527396",
        "http://www.ncbi.nlm.nih.gov/pubmed/4061095",
        "http://www.ncbi.nlm.nih.gov/pubmed/4087563",
        "http://www.ncbi.nlm.nih.gov/pubmed/3048796",
        "http://www.ncbi.nlm.nih.gov/pubmed/21894796",
        "http://www.ncbi.nlm.nih.gov/pubmed/6756878",
        "http://www.ncbi.nlm.nih.gov/pubmed/16997628",
        "http://www.ncbi.nlm.nih.gov/pubmed/8965601",
        "http://www.ncbi.nlm.nih.gov/pubmed/2960110",
        "http://www.ncbi.nlm.nih.gov/pubmed/7823770",
        "http://www.ncbi.nlm.nih.gov/pubmed/30233361",
        "http://www.ncbi.nlm.nih.gov/pubmed/9876882",
        "http://www.ncbi.nlm.nih.gov/pubmed/3949445",
        "http://www.ncbi.nlm.nih.gov/pubmed/6396519",
        "http://www.ncbi.nlm.nih.gov/pubmed/1851838",
        "http://www.ncbi.nlm.nih.gov/pubmed/7255146",
        "http://www.ncbi.nlm.nih.gov/pubmed/515866"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36958154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emetic activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21894796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 39,
          "text": "Domperidone, a new dopamine antagonist.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3527396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Domperidone is a dopamine antagonist that has recently been released in Canada.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3527396"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 323,
          "text": "Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16997628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emeti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21894796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6756878"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 449,
          "text": "Domperidon is a pure dopaminantagonist. It accelerates gastric emptying but has less effect on bowel motility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8965601"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 513,
          "text": "According to the current concepts, 3H-domperidone is a selective ligand of D2 dopamine receptors mediating the psychotropic effect of neuroleptics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2960110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and pro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 886,
          "text": "Bromopride (BRO) and domperidone (DOMP) are dopamine D2 blocking agents used in gastroenterology clinics because of their anti emetic effect as well as their central and peripheral actions of increasing gastrointestinal motor activity. The rationale for these experiments was to compare BRO- and DOMP-effects on plasma, brain, and intestinal cholinesterase activity in vitro. BRO and DOMP effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM for BRO and from 0.006 to 125 microM for DOMP. The results demonstrate that both BRO and DOMP can inhibit cholinesterase activity in all tissues studied, with DOMP being more potent than BRO in plasma and intestinal tissues. These data suggest the existence of a cholinergic mechanism of action for these dopamine blocking agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7823770"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and prokinetic agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147629"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 1643,
          "text": "Major drug classes include: (i) Muscarinic receptor antagonists-originated from historical accounts of plant extracts containing atropine and hyoscine with development stimulated by the need to prevent sea-sickness among soldiers during beach landings; (ii) Histamine receptor antagonists-searching for replacements for the anti-malaria drug quinine, in short supply because of wartime shipping blockade, facilitated the discovery of histamine (H1) antagonists (e.g., dimenhydrinate), followed by serendipitous discovery of anti-emetic activity against motion sickness in a patient undergoing treatment for urticaria; (iii) Phenothiazines and dopamine receptor antagonists-investigations of their pharmacology as \"sedatives\" (e.g., chlorpromazine) implicated dopamine receptors in emesis, leading to development of selective dopamine (D2) receptor antagonists (e.g., domperidone with poor ability to penetrate the blood-brain barrier) as anti-emetics in chemotherapy and surgery; (iv) Metoclopramide and selective 5-hydroxytryptamine3(5-HT3) receptor antagonists-metoclopramide was initially assumed to act only via D2 receptor antagonism but subsequently its gastric motility stimulant effect (proposed to contribute to the anti-emetic action) was shown to be due to 5-hydroxytryptamine4 receptor agonism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233361"
        },
        {
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1072,
          "text": "Domperidone, a dopamine D2 receptor antagonist that does not cross the blood brain barrier is relatively free of the central side-effect liability of metoclopramide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9876882"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 412,
          "text": "Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6756878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emetic activity. There have been several reports of sudden cardiac death (SCD) associated with the compound. Recently it was estimated to increase SCD nearl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21894796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 555,
          "text": "The effect of domperidone, a peripheral dopamine receptor antagonist, has been studied in the aspirin, phenylbutazone and reserpine induced gastric ulcers in rats. The gastric anti-ulcer activity of domperidone was evident following a single dose as well as a 5-day pretreatment against all the three ulcerogenic drugs. However, the protection in the five-day pretreatment group was greater than in the single dose pretreatment group. It appears that the gastrokinetic properties of domperidone play a significant role in producing this anti-ulcer effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3949445"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 1035,
          "text": "Dopamine, noradrenaline, adrenaline and apomorphine antagonised the contraction responses at all frequencies; the concentration-response curves were steep and the use of higher concentrations was precluded by changes in base line tension per se. That noradrenaline was approximately 10 fold more potent than dopamine, that the dopamine response was not antagonised by the dopamine antagonists haloperidol, domperidone or (-)sulpiride, but was mimicked by the alpha 2-agonist guanfacine and partially antagonised by the alpha 2-adrenoceptor antagonist yohimbine (which could also antagonise the inhibitory actions of guanfacine) would indicate that a component of dopamine\u0027s action to reduce cholinergic activity is effected via alpha 2-adrenoceptor mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6396519"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1706,
          "text": "The mechanism of action of clebopride on the motility of guinea pig stomach was examined by the receptor binding assay for bovine brain membrane and by measuring gastric contractility and the release of acetylcholine from the stomach. The receptor binding assay revealed that clebopride bound to the D2 dopamine receptor with a high affinity and to the alpha-2 adrenoceptor and 5-HT2 serotonin receptor with relatively lower affinity, and not to D1 dopamine, alpha-1 adrenergic, muscarinic acetylcholine, H1 histamine, or opioid receptor. In strips of the stomach, clebopride at 10(-8) M to 10(-5) M enhanced the electrical transmural stimulation-evoked contraction and the release of acetylcholine. This enhancement was attributed to the blockade of the D2 dopamine receptor and alpha-2 adrenoceptor because: 1) Maximum responses obtained with specific D2 dopamine receptor antagonist, domperidone, and with specific alpha-2 adrenoceptor antagonist, yohimbine, were smaller than that with clebopride, and the sum of the effects of these two specific receptor antagonists is approximately equal to the effect of clebopride. 2) The facilitatory effect of clebopride was partially eliminated by pretreatment of the sample with domperidone or yohimbine, and the facilitatory effect of clebopride was not observed in preparations treated with the combination of domperidone and yohimbine. Clebopride also antagonized the inhibitory effects of dopamine and clonidine on the electrical transmural stimulation-evoked responses. These results indicate that clebopride acts on post ganglionic cholinergic neurons at D2 and alpha-2 receptors in this preparation to enhance enteric nervous system stimulated motility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1851838"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 682,
          "text": "The effects of domperidone, a peripheral dopamine receptor blocker which poorly crosses the blood-brain barrier, on copulatory and exploratory behaviour were studied in apomorphine (oestrogen + progesterone) treated ovariectomized rats. The dose of domperidone (1.0 mg/kg) which clearly prevented the inhibitory action of apomorphine on the lordotic response did not influence the effect of apomorphine in an exploratory test situation. This finding indicates that peripherally (intraperitoneally) administered domperidone influences dopaminergic mechanisms implicated in the copulatory behaviour of the female rat, but not dopaminergic mechanisms involved in exploratory behaviour.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4061095"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and prokinetic agent. Oral domperidone is not approved in the United States, but it is used in many countries to treat nausea and vomiting, gastroparesis and as a galactogogue (to promo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle. This drug does not readily cross the blood-brain barrier and therefore the site of action of domperidone could be the pituitary gland or the median eminence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3048796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Domperidone is a dopamine antagonist that does not readily enter the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6756878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Domperidone is a peripheral antagonist of dopamine which does not cross the blood-brain barrier.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7255146"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 378,
          "text": "Domperidon is a pure dopaminantagonist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8965601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "The effect of domperidone, a peripheral dopamine receptor antagonist, has been studied in the aspirin, phenylbutazone and reserpine induced gastric ulcers in rats.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3949445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "UNLABELLED: Domperidone (dopamine antagonist), metoclopramide and clebopride (both dopamine antagonists and stimulators of the intramural choliner",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4087563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Domperidone (Motilium), a dopamine receptor blocking agent, increased the resting tone of the lower oesophageal sphincter in 15 dogs and 6 baboons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/515866"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 412,
          "text": "The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6756878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Bromopride (BRO) and domperidone (DOMP) are dopamine D2 blocking agents used in gastroenterology clinics because of their anti emetic effect as well as their central and peripheral actions of increasing gastrointestinal motor activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7823770"
        }
      ],
      "id": "65f492bbc4010b4d78000011",
      "ideal_answer": [
        "Domperidone is a peripherally acting dopamine2-receptor antagonist",
        "Domperidone is a dopamine D2 receptor antagonist that increases prolactin release through a blockade of dopamine D2 receptors in the pituitary gland. Increased prolactin levels will enhance breast milk production.",
        "Domperidone is a dopamine receptor antagonist that accelerates gastric emptying but has less effect on bowel motility.",
        "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.",
        "Domperidone stimulates gastric muscle contraction by antagonizing the inhibitory effects of dopamine on postsynaptic cholinergic neurons in the myenteric plexus.",
        "Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins.",
        "Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins and a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.",
        "Domperidone is a dopamine-2 (D2) receptor antagonist. It works by inhibiting the D2 receptors, which leads to the stimulation of the release of stored prolactin in the anterior pituitary and also stimulates pituitary gonadotropins.",
        "”Patients received oral aciclovir for 84 days starting 96 hours after randomization and continued on oral aciclovir for 60 days after discharge”}\u003c/s\u003e",
        "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.",
        "Domperidone is a dopamine-2 (D2) receptor antagonist that inhibits dopamine receptors in the anterior pituitary. This inhibition stimulates the release of prolactin and gonadotropins stored in the anterior pituitary gland.",
        "Domperidone works by blocking dopamine receptors in the brain. This inhibition results in an increase in the release of prolactin from the anterior pituitary gland, which can stimulate lactation"
      ]
    },
    {
      "body": "Which age group should never be tested for HIV infection?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34949518",
        "http://www.ncbi.nlm.nih.gov/pubmed/37720974",
        "http://www.ncbi.nlm.nih.gov/pubmed/36629794",
        "http://www.ncbi.nlm.nih.gov/pubmed/36630307",
        "http://www.ncbi.nlm.nih.gov/pubmed/36630617",
        "http://www.ncbi.nlm.nih.gov/pubmed/18685551",
        "http://www.ncbi.nlm.nih.gov/pubmed/36589732",
        "http://www.ncbi.nlm.nih.gov/pubmed/25283353",
        "http://www.ncbi.nlm.nih.gov/pubmed/37993765",
        "http://www.ncbi.nlm.nih.gov/pubmed/36729993",
        "http://www.ncbi.nlm.nih.gov/pubmed/27435075",
        "http://www.ncbi.nlm.nih.gov/pubmed/21279431",
        "http://www.ncbi.nlm.nih.gov/pubmed/29583105",
        "http://www.ncbi.nlm.nih.gov/pubmed/24849622",
        "http://www.ncbi.nlm.nih.gov/pubmed/12126721",
        "http://www.ncbi.nlm.nih.gov/pubmed/25303208",
        "http://www.ncbi.nlm.nih.gov/pubmed/28883962",
        "http://www.ncbi.nlm.nih.gov/pubmed/19940800",
        "http://www.ncbi.nlm.nih.gov/pubmed/19303830",
        "http://www.ncbi.nlm.nih.gov/pubmed/17129866",
        "http://www.ncbi.nlm.nih.gov/pubmed/28796758",
        "http://www.ncbi.nlm.nih.gov/pubmed/37729175",
        "http://www.ncbi.nlm.nih.gov/pubmed/37632603",
        "http://www.ncbi.nlm.nih.gov/pubmed/10224192",
        "http://www.ncbi.nlm.nih.gov/pubmed/24789219",
        "http://www.ncbi.nlm.nih.gov/pubmed/8655933",
        "http://www.ncbi.nlm.nih.gov/pubmed/25960684",
        "http://www.ncbi.nlm.nih.gov/pubmed/20685813",
        "http://www.ncbi.nlm.nih.gov/pubmed/9611559",
        "http://www.ncbi.nlm.nih.gov/pubmed/22908365",
        "http://www.ncbi.nlm.nih.gov/pubmed/24964879"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 293,
          "offsetInEndSection": 410,
          "text": "social and clinical inequalities of more children infected with HIV and more children losing their fight against AIDS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 553,
          "text": "two out of five children living with HIV worldwide are unaware of their status",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518"
        },
        {
          "offsetInBeginSection": 862,
          "offsetInEndSection": 882,
          "text": "maternal HIV testing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34949518"
        },
        {
          "offsetInBeginSection": 944,
          "offsetInEndSection": 968,
          "text": "pregnant people with HIV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974"
        },
        {
          "offsetInBeginSection": 1645,
          "offsetInEndSection": 1741,
          "text": "PPHIV experienced higher rates of LBW and VLBW newborns, and higher late pregnancy-related death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37720974"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 196,
          "text": "adults diagnosed late with HIV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794"
        },
        {
          "offsetInBeginSection": 1545,
          "offsetInEndSection": 1720,
          "text": "HIV diagnosis could help develop effective strategies to reduce this burden of late presentation - particularly among heterosexual individuals, non-Europeans, and older people",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1010,
          "text": "Amongst MSM, those who were older, of an ethnicity other than European, acquired HIV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36629794"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 581,
          "text": "penile cancer within HIV-positive individuals is significantly greater than in those without HIV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1109,
          "text": "HIV and penile carcinoma, with a higher risk of cancer in Hispanic, compared with Caucasian, HIV-positive men",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630307"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 149,
          "text": "The vulnerability of female sex workers (FSWs) to HIV infection increases if unprotected heterosexual anal intercourse (HAI) is practiced",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36630617"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1254,
          "text": "Our analysis found that in Cameroon, women in polygamous relationships, Muslim women, married women with inadequate HIV knowledge, those who had never been tested for HIV and women with lower socioeconomic status are less likely to negotiate for safe sex",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37993765"
        },
        {
          "offsetInBeginSection": 1508,
          "offsetInEndSection": 1631,
          "text": "Health-care providers should routinely screen all patients aged 13-64 years for HIV in accordance with CDC recommendations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 843,
          "text": "BACKGROUND: The perinatal short-course zidovudine (ZDV) chemoprophylaxis that can reduce HIV-1 vertical transmission by 51% has been widely practiced in developing countries such as Thailand because of its simpler and less cost.OBJECTIVES: To investigate the effects of short-course regimen of oral ZDV for prophylaxis of HIV-1 subtype E vertical transmission among \u0027break-through\u0027 HIV-1 infected infants.STUDY DESIGN: The study analyzed clinical and virological outcomes of 80 infants, whose mothers received ZDV prophylaxis starting at 36 weeks gestation (group Z) and 37 infants whose mothers never received anti-retroviral drugs (group C), at the ages of 1-2, 4-6, and 12 months.RESULTS: Of the 12 HIV-1 infected infants, 5/7 (71.4%) from group Z and 1/5 (20%) from group C progressed to a symptomatic clinical stage by the age 4-6 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12126721"
        },
        {
          "offsetInBeginSection": 540,
          "offsetInEndSection": 741,
          "text": "To reduce the number of persons with undiagnosed HIV infection, CDC issued recommendations in September 2006 to implement HIV screening as part of routine medical care for all persons aged 13-64 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685551"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 255,
          "text": "Yet many adolescents and young adults with high-risk behaviors for HIV are unaware of their HIV status and have never had an HIV test.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25283353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "HIV testing was assessed online among men accessing a sexual networking website for men who have sex with men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279431"
        },
        {
          "offsetInBeginSection": 1071,
          "offsetInEndSection": 1143,
          "text": "An estimated 83.7% of sexually active older adults never tested for HIV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29583105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: The human immunodeficiency virus (HIV) infection usually infects persons in the reproductive age group (15-49 years), but elderly people are also ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28883962"
        },
        {
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1639,
          "text": "d HIV-infected adolescents in Zimbabwe. In resource-poor settings with maturing epidemics, the presence of skin disease should be regarded as a strong indication for HIV testing and especially as it",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19940800"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 174,
          "text": "This is the prime childbearing age group with an increasing mortality due to HIV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19303830"
        },
        {
          "offsetInBeginSection": 386,
          "offsetInEndSection": 829,
          "text": "No significant difference was observed in the association between HIV infection and gender (chi2\u003d0.58, df \u003d 1, P \u003c 0.05). The highest prevalence of HIV infection (8.9%) was recorded among individuals in the 21-30 years age category, while the least HIV infection prevalence (5.3%) was observed among persons above 40 years old. There was no significant difference in the association between HIV infection and age (chi2\u003d0.68, df \u003d 3, P \u003c 0.05).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17129866"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "CDC\u0027s 2006 recommendations for human immunodeficiency virus (HIV) testing state that all persons aged 13-64 years should be screened for HIV at least once, and that persons at higher risk for HIV infection, including sexually active gay, bisexual, and other men who have sex with men (MSM), should be rescreened at least annually (1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28796758"
        },
        {
          "offsetInBeginSection": 1944,
          "offsetInEndSection": 2091,
          "text": "Providers should target men aged ≤ 34 years, with primary education, visiting facilities for the first time and who have never been tested for HIV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37729175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "The CDC recommends that persons aged 13-64 receive an HIV test at least once in their lifetime and that some groups test annually or more frequently",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37632603"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 408,
          "text": "The US Centers for Disease Control and Prevention recommends persons aged 13 to 64 years be tested for HIV at least once as part of routine health care; however, it is unclear how effectively these testing recommendations have been implemented in EHE priority areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36729993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1959,
          "text": "HIV testing continues to be a challenge among the young population in Tanzania. As of 2017, only 30% of 15-19-year-olds reported getting tested and receiving their results. This study will examine the demographic and socio-behavioral characteristics associated with HIV testing among adolescents and young adults in Tanzania. Interview data from the 2016-2017 Tanzania HIV Impact Survey (THIS) were analyzed on 10,128 adolescents and young adults 15-24 years of age, representing 10.5 million youth in Tanzania. Weighted logistic regression was used to model the relationship of HIV testing with demographic and socio-behavioral characteristics. Half (50%) of respondents reported ever having been tested for HIV. HIV testing was significantly lower among males compared with females (AOR \u003d 0.5;95% confidence interval [CI] \u003d 0.5-0.6; p\u003c0.001), 15-19 year olds compared with 20-24 year olds (AOR \u003d 0.4;95% CI \u003d 0.4-0.5; p\u003c0.001), no education compared with secondary or post-secondary education (AOR \u003d 0.4;95% CI \u003d 0.3-0.6; p\u003c0.001), rural residents compared with urban residents (AOR \u003d 0.7;95% CI \u003d 0.6-0.9; p\u003c0.001) and those who don\u0027t use condoms during sexual intercourse compared with those who do (AOR \u003d 0.6;95% CI \u003d 0.5-0.8; p\u003c0.001). Among HIV-infected youth, younger age group, rural residents, education less than primary, single, high income, and sex workers were significantly associated with never testing for HIV. This study highlights the majority of characteristics affecting HIV testing among young people in Tanzania have not changed over the years, thus it is necessary to re-examine the current approaches to HIV testing. The COVID-19 pandemic will add to this challenge as it collides with the ongoing HIV epidemic and competes for needed medical supplies and health care provider resources. In light of this current situation, intensified and targeted HIV testing programs for at risk young populations in Tanzania should be prioritized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36589732"
        },
        {
          "offsetInBeginSection": 830,
          "offsetInEndSection": 1133,
          "text": "Mandatory pre-marital HIV screening could generate social stigmatization and infringement of the fundamental human rights of infected individuals. Voluntary counselling and confidential HIV testing and especially pre- and post-test counselling as the basis of pre-marital HIV testing are more desirable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17129866"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 423,
          "text": "The Centers for Disease Control and Prevention recommends routine human immunodeficiency virus (HIV) testing of every client presenting for services in venues where HIV prevalence is high. Because older adults (aged ≥50 years) have particularly poor prognosis if they receive their diagnosis late in the course of HIV disease, any screening provided to younger adults in these venues should also be provided to older adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25303208"
        },
        {
          "offsetInBeginSection": 526,
          "offsetInEndSection": 730,
          "text": "HIV-infected children, adolescents, and young adults who are severely immunocompromised (based on age-specific CD4 lymphocyte enumeration) attributable to HIV infection should not receive measles vaccine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "HIV is often assumed to only affect younger people, and many older people do not realize that they might risk acquiring the virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "The HIV infection primarily affects young adults, but older adults are also susceptible.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8655933"
        },
        {
          "offsetInBeginSection": 1429,
          "offsetInEndSection": 1561,
          "text": "Physicians are less likely to discuss sexual risk behaviors with older adults and to test them for HIV compared with younger adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25960684"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 715,
          "text": "In 2007 the Centers for Disease Control and Prevention in the United States reported that 16.8% of new diagnoses of HIV that year were in individuals aged over 50 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20685813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Adolescents and young adults are the fastest growing age group of human immunodeficiency virus (HIV) positive individuals in the US, and many who are infected do not know their HIV status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Older Americans, 50 years of age and older, account for 10% of the 400,000 reported cases of AIDS nationwide (Centers for Disease Control and Prevention, 1994).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9611559"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 459,
          "text": "Since 2006, CDC has recommended that health-care providers screen for HIV all patients aged 13-64 years unless prevalence of undiagnosed HIV infection in their patients has been documented to be \u003c0.1%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24964879"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 700,
          "text": "In 2006, CDC recommended that all persons aged 13–64 years be screened for HIV in health-care settings in which the prevalence of undiagnosed HIV infection is \u003e0.1%, and that persons with increased risk for HIV be retested at least annually.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22908365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Currently, the Centers for Disease Control and Prevention recommends that persons between 15 and 64 years get tested for human immunodeficiency virus (HIV) at least once in their lifetime and persons with HIV risk factors get tested more frequently.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435075"
        }
      ],
      "id": "65f86ba3c4010b4d78000059",
      "ideal_answer": [
        "There is no age group that should never be tested for HIV infection. In fact, the World Health Organization recommends that all people aged 15-64 years old get tested for HIV at least once in their lifetime, and those at high risk of infection get tested annually. Children born to mothers living with HIV also need to be tested regularly as they are at a higher risk of acquiring the virus through mother-to-child transmission. Early diagnosis and treatment of HIV can significantly improve health outcomes and reduce the risk of transmission. Therefore, it is important for all individuals, regardless of age, to know their HIV status and take appropriate measures to protect themselves and their partners.",
        "There is no age group that should never be tested for HIV infection. The CDC recommends that all adults, adolescents, and pregnant women in health-care settings be offered HIV testing, and that those at high risk for HIV infection be tested at least annually. Additionally, the WHO recommends that all people aged 15-64 years should be offered an HIV test at least once in their lifetime. It is important to note that anyone can be at risk for HIV infection regardless of age, gender, or sexual orientation.",
        "There is no age group that should never be tested for HIV infection. HIV testing is recommended for all individuals, regardless of age, as early detection and treatment can improve outcomes and prevent transmission.",
        "There is no age group that should never be tested for HIV infection. Testing for HIV is important for everyone, regardless of age, to ensure early detection and appropriate care.",
        "There is no age group that should never be tested for HIV infection.",
        "There is no specific age group that should never be tested for HIV infection. Early testing and diagnosis is crucial for effective treatment and prevention of HIV transmission.",
        "There is no age group that should never be tested for HIV infection. HIV can affect individuals of all ages, from newborns to older adults. In fact, late diagnosis of HIV is a significant issue, particularly among older individuals, heterosexuals, and non-Europeans. Therefore, it\u0027s crucial to get tested regardless of age to ensure early detection and treatment. This can help reduce the burden of late presentation and advanced disease",
        "No age group should be excluded from HIV testing. Early diagnosis and treatment are crucial in managing HIV infection and preventing its spread. Testing for HIV should be encouraged for all individuals, regardless of age, to ensure timely intervention and appropriate care.",
        "There is no specific age group that should never be tested for HIV infection. HIV testing is recommended for everyone, regardless of age, as early diagnosis and treatment can help prevent the progression of the disease and reduce the risk of transmission to others."
      ],
      "exact_answer": [
        [
          "None."
        ]
      ]
    },
    {
      "body": "Can fingolimod be used during pregnancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37307691",
        "http://www.ncbi.nlm.nih.gov/pubmed/35428205",
        "http://www.ncbi.nlm.nih.gov/pubmed/35390594",
        "http://www.ncbi.nlm.nih.gov/pubmed/35088492",
        "http://www.ncbi.nlm.nih.gov/pubmed/33443836",
        "http://www.ncbi.nlm.nih.gov/pubmed/34310364",
        "http://www.ncbi.nlm.nih.gov/pubmed/32564333",
        "http://www.ncbi.nlm.nih.gov/pubmed/23961604",
        "http://www.ncbi.nlm.nih.gov/pubmed/37217309",
        "http://www.ncbi.nlm.nih.gov/pubmed/37341330",
        "http://www.ncbi.nlm.nih.gov/pubmed/28078140",
        "http://www.ncbi.nlm.nih.gov/pubmed/22926165",
        "http://www.ncbi.nlm.nih.gov/pubmed/30542374",
        "http://www.ncbi.nlm.nih.gov/pubmed/31185372"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1570,
          "offsetInEndSection": 1775,
          "text": "Interferon beta 1a SC was preferred over other treatments for patients with mild to moderate MS and planning for pregnancy (56.6%) or breastfeeding (60.2%). Fingolimod was not a choice for these patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37307691"
        },
        {
          "offsetInBeginSection": 1985,
          "offsetInEndSection": 2389,
          "text": "In total, 45 patients (18.8%) permanently discontinued treatment because of AEs related to study drug; two patients reported pregnancy after treatment initiation and subsequently discontinued the treatment; no deaths were reported.CONCLUSION: GOLEMS study demonstrated the sustained effectiveness and manageable safety profile of fingolimod under real-world conditions over 48 months in patients with MS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35428205"
        },
        {
          "offsetInBeginSection": 1568,
          "offsetInEndSection": 1893,
          "text": "Concerns about COVID-19 had a noticeable impact on administering high efficacy drugs like rituximab and fingolimod. However, in male patients this approach has not been the case. It may be related to more aggressive disease course in this group. The other possible explanation could be planning for pregnancy in female cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35390594"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "BACKGROUND: Authorizations of fingolimod, teriflunomide and cladribine were accompanied by risk minimization measures concerning their teratogenic potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174258"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 600,
          "text": "Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33443836"
        },
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 706,
          "text": "Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34310364"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 433,
          "text": "Caution should be exercised when prescribing fingolimod and natalizumab to patients with multiple sclerosis who are of childbearing potential because of the risk of disease rebound when they are discontinued",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37341330"
        },
        {
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1095,
          "text": "Current evidence supports the contraindication for fingolimod during pregnancy; data on other DMTs remains limited.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078140"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 604,
          "text": "Fingolimod is suspected to be harmful for fetal development, and the use of this drug should be stopped no later than two months before discontinuing the contraception.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23961604"
        },
        {
          "offsetInBeginSection": 636,
          "offsetInEndSection": 770,
          "text": "Conception should be discouraged for patients on fingolimod, because of the limited information available on human pregnancy outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926165"
        },
        {
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1308,
          "text": "If a patient becomes pregnant while taking fingolimod, and requires continued DMD treatment, a switch to interferon β or natalizumab after a variable washout period may be prescribed, depending on the level of disease activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32564333"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 432,
          "text": "it is recommended that multiple sclerosis patients undergoing treatment with fingolimod use contraceptive methods for at least two months after discontinuation of the medication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31185372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 522,
          "text": "BACKGROUND AND METHODS: Limited data are available on the safety of fingolimod in pregnant women. We estimated the risk of adverse pregnancy outcomes in women with multiple sclerosis (MS) exposed to fingolimod either shortly before or during pregnancy in prospectively collected cases from clinical trials, observational studies, surveillance programs, and spontaneous reports.RESULTS: The prevalence of major malformations among live births does not appear to be significantly higher than those in the general population ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30542374"
        },
        {
          "offsetInBeginSection": 26,
          "offsetInEndSection": 134,
          "text": "Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37217309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "BACKGROUND AND OBJECTIVE: Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse risk, particularly severe relapses, after fingolimod cessation is unclear, as is whether this risk is reduced by pregna",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37217309"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 599,
          "text": "Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33443836"
        }
      ],
      "id": "65d12ae11930410b13000030",
      "ideal_answer": [
        "No. Fingolimod has teratogenic potential and therefore should not be used during pregnancy."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What does capnography measure?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37507472",
        "http://www.ncbi.nlm.nih.gov/pubmed/37259022",
        "http://www.ncbi.nlm.nih.gov/pubmed/34008907",
        "http://www.ncbi.nlm.nih.gov/pubmed/30523011",
        "http://www.ncbi.nlm.nih.gov/pubmed/24785676",
        "http://www.ncbi.nlm.nih.gov/pubmed/7736268",
        "http://www.ncbi.nlm.nih.gov/pubmed/7889801",
        "http://www.ncbi.nlm.nih.gov/pubmed/7792768",
        "http://www.ncbi.nlm.nih.gov/pubmed/9390853",
        "http://www.ncbi.nlm.nih.gov/pubmed/26638570",
        "http://www.ncbi.nlm.nih.gov/pubmed/24685942",
        "http://www.ncbi.nlm.nih.gov/pubmed/31692301",
        "http://www.ncbi.nlm.nih.gov/pubmed/18156957",
        "http://www.ncbi.nlm.nih.gov/pubmed/26264607",
        "http://www.ncbi.nlm.nih.gov/pubmed/2511789",
        "http://www.ncbi.nlm.nih.gov/pubmed/1643689",
        "http://www.ncbi.nlm.nih.gov/pubmed/25436022",
        "http://www.ncbi.nlm.nih.gov/pubmed/1489871",
        "http://www.ncbi.nlm.nih.gov/pubmed/26714621"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "A secondary analysis of a randomized study was performed to study the relationship between volumetric capnography (VCAP) and arterial CO2 partial pressure (PCO2) during cardiopulmonary resuscitation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37507472"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 140,
          "text": " By continually monitoring end-tidal carbon dioxide concentrations, capnography can detect abnormal ventilation or apnoea early. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37259022"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 228,
          "text": "Capnography is the measurement and numerical display of end-tidal carbon dioxide (EtCO2).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Capnography measures exhaled carbon dioxide and is most useful when applied directly to patient care.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9390853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7736268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Capnography, often referred to by emergency clinicians as end-tidal carbon dioxide monitoring, is a noninvasive method of measuring cardiopulmonary and metabolic parameters that can be utilized in many clinical applications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692301"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 614,
          "text": "Capnography measures exhaled carbon dioxide and provides early identification of airway obstruction and hypoventilation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "An end-tidal CO2 monitor (capnometer) is used most often as a noninvasive substitute for PaCO2 in anesthesia, anesthetic recovery, and intensive care. Additionally, the wide spread on-site use of portable capnometers in emergency and trauma situations is now observed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26264607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511789"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 255,
          "text": "Capnography provides a continuous and non-invasive measure of arterial partial pressure of carbon dioxide (PaCO2) throughout the entire respiratory cycle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7889801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "MONITORING RESPIRATORY and metabolic function by using capnography to measure end tidal carbon dioxide is standard practice in anaesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26638570"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "PURPOSE OF REVIEW: Volumetric capnography (VCap) measures the kinetics of carbon dioxide (CO2) elimination on a breath-by-breath basis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24785676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Capnography measures carbon dioxide concentration or partial pressure of the respiratory gas continuously and non-invasively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7792768"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 452,
          "text": "Capnography is the non-invasive measurement of a sample of the exhaled carbon dioxide which has multiple clinical uses including as a method to confirm placement of a tracheal tube and/or to assess ventilation, perfusion and metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34008907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "BACKGROUND: Capnography provides a continuous, non-invasive monitoring of the CO2 to assess adequacy of ventilation and provide added safety features in mechanically ventilated patients by allowing for quick identification of unplanned",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25436022"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 518,
          "text": "Capnography, a noninvasive monitoring technique designed to measure expired carbon dioxide (CO2) levels, has been used previously to identify respiratory placement of nasogastric tubes in adults; however, its use in children is understudied.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18156957"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Capnometers measure carbon dioxide (CO2) in inspired and expired air.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1489871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "INTRODUCTION: Capnography is used to monitor the endtidal carbon dioxide tension (EtCO2) i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26714621"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 583,
          "text": "This review of capnography includes the methods available to determine carbon dioxide in expired air, and an analysis of the physiology of capnograms, which are followed by a description of the applications of capnography in clinical practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1643689"
        }
      ],
      "id": "65f38059c4010b4d7800000e",
      "ideal_answer": [
        "Capnography provides real-time measurement of carbon dioxide (CO2) in respiratory gases.",
        "Capnography is a tool for continuous monitoring of carbon dioxide (CO2) concentration in exhaled gases during anesthesia and respiratory support.",
        "Capnography measures the amount of carbon dioxide in exhaled air, indicating how well CO2 is being eliminated from the body.",
        "Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.",
        "Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath. It provides real-time monitoring of the patient\u0027s ventilation and helps assess the adequacy of respiratory function.",
        "Capnography measures carbon dioxide in expired air.",
        "Capnography measures the amount of carbon dioxide (CO2) in exhaled breath.",
        "Capnography measures the concentration of carbon dioxide in exhaled air.",
        "Capnography measures the amount of carbon dioxide in expired air.",
        "Capnography measures carbon dioxide, volumetric capnography (VCAP) and arterial CO2 partial pressure, and arterial CO2 partial pressure.",
        "Capnography is a non-invasive monitoring technique that measures the concentration or partial pressure of carbon dioxide (CO2) in exhaled breath, also known as end-tidal CO2 (EtCO2), over time to assess the adequacy of ventilation and the presence of abnormal ventilation or apnea.",
        "Capnography measures end-tidal carbon dioxide concentrations. This means it monitors the amount of carbon dioxide that is exhaled at the end of each breath. It\u0027s a useful tool because it can detect abnormal ventilation or apnoea early.",
        "Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath as a function of time, known as the capnogram.",
        "Capnography measures end-tidal carbon dioxide concentrations, which can detect abnormal ventilation or apnoea early during cardiopulmonary resuscitation.",
        "Capnography is a monitoring tool used in medicine that measures the concentration of carbon dioxide in the respiratory gases. It is often used during cardiopulmonary resuscitation to measure arterial CO2 partial pressure (PCO2). Additionally, it is used for monitoring end-tidal carbon dioxide concentrations.",
        "Capnography measures the concentration of carbon dioxide at the end of exhalation, and it can detect abnormal breathing patterns or the absence of breath.",
        "Capnography measures the concentration of carbon dioxide in the respiratory gases, which is a vital parameter during anesthesia and intensive care. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide. This can help detect abnormal ventilation or apnoea early",
        "Capnography measures carbon dioxide concentration in exhaled air.",
        "Capnography measures end-tidal carbon dioxide (CO2) concentrations during respiration. It can detect abnormal ventilation or apnea by monitoring CO2 levels in exhaled breath.",
        "Capnography measures the concentration of carbon dioxide in the respiratory gases, specifically the end-tidal carbon dioxide concentrations. It is used to monitor the inhaled and exhaled concentration or partial pressure of carbon dioxide.",
        "Capnography measures the end-tidal carbon dioxide (CO2) concentration in exhaled breath. It provides a non-invasive and continuous assessment of ventilation and can detect abnormal ventilation or apnea early during cardiopulmonary resuscitation.",
        "Capnography measures the concentration of carbon dioxide in exhaled breath, which can be used to monitor the effectiveness of cardiopulmonary resuscitation."
      ],
      "exact_answer": [
        [
          "Carbon dioxide",
          "Co2",
          "end-tidal carbon dioxide (EtCO2)"
        ]
      ]
    },
    {
      "body": "Should men be immunized against Human Papilloma Virus?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36691362",
        "http://www.ncbi.nlm.nih.gov/pubmed/36305982",
        "http://www.ncbi.nlm.nih.gov/pubmed/37264392",
        "http://www.ncbi.nlm.nih.gov/pubmed/31992466",
        "http://www.ncbi.nlm.nih.gov/pubmed/25553242",
        "http://www.ncbi.nlm.nih.gov/pubmed/26554731",
        "http://www.ncbi.nlm.nih.gov/pubmed/33145777",
        "http://www.ncbi.nlm.nih.gov/pubmed/27354258",
        "http://www.ncbi.nlm.nih.gov/pubmed/22021967",
        "http://www.ncbi.nlm.nih.gov/pubmed/22371460",
        "http://www.ncbi.nlm.nih.gov/pubmed/25167164",
        "http://www.ncbi.nlm.nih.gov/pubmed/25811679",
        "http://www.ncbi.nlm.nih.gov/pubmed/29769961",
        "http://www.ncbi.nlm.nih.gov/pubmed/27486020",
        "http://www.ncbi.nlm.nih.gov/pubmed/18830138",
        "http://www.ncbi.nlm.nih.gov/pubmed/30591254",
        "http://www.ncbi.nlm.nih.gov/pubmed/35577640",
        "http://www.ncbi.nlm.nih.gov/pubmed/23391351",
        "http://www.ncbi.nlm.nih.gov/pubmed/37661628",
        "http://www.ncbi.nlm.nih.gov/pubmed/25756144",
        "http://www.ncbi.nlm.nih.gov/pubmed/20547286",
        "http://www.ncbi.nlm.nih.gov/pubmed/23167429",
        "http://www.ncbi.nlm.nih.gov/pubmed/32154741",
        "http://www.ncbi.nlm.nih.gov/pubmed/26734596",
        "http://www.ncbi.nlm.nih.gov/pubmed/35471242",
        "http://www.ncbi.nlm.nih.gov/pubmed/29517117",
        "http://www.ncbi.nlm.nih.gov/pubmed/24553168",
        "http://www.ncbi.nlm.nih.gov/pubmed/28346275",
        "http://www.ncbi.nlm.nih.gov/pubmed/28538494",
        "http://www.ncbi.nlm.nih.gov/pubmed/20138347",
        "http://www.ncbi.nlm.nih.gov/pubmed/36897868"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 518,
          "text": "As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691362"
        },
        {
          "offsetInBeginSection": 520,
          "offsetInEndSection": 634,
          "text": "HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The human papillomavirus (HPV) vaccine is one of the most effective public health measures for preventing HPV-related cancers and other diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305982"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 107,
          "text": "Almost all cases of cervical and anal cancer have been linked to the human papillomavirus (HPV)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264392"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 291,
          "text": "both men and women can also develop cancers of the anus, oral cavity, and oropharynx that are attributed to HPV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37264392"
        },
        {
          "offsetInBeginSection": 790,
          "offsetInEndSection": 1134,
          "text": "Gardasil(®) is a quadrivalent vaccine against HPV types 6, 11, 16, and 18 and is recommended for use in females 9-26 years of age, for the prevention of cervical, vulvar, and vaginal cancers and intraepithelial neoplasia and condyloma acuminata and recently for vaccination in boys and men 9-26 years of age for the prevention of genital warts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22021967"
        },
        {
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1420,
          "text": "HPV vaccines are safe and efficacious against type-specific HPV-induced anogenital warts, precancerous lesions, and cervical cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22021967"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 567,
          "text": "HPV infection is considered to contribute to almost 100% cervical cancers and at least 80% of anal and 40-60% of vulvar, vaginal, and penile cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22021967"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck \u0026 Co, Inc, Whitehouse Station, NJ) be used routinely in males.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371460"
        },
        {
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1178,
          "text": "ACIP recommends routine vaccination with HPV4 or HPV2 for females aged 11 or 12 years and with HPV4 for males aged 11 or 12 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25167164"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 635,
          "text": "HPV vaccine efficacy varies in relationship to when the vaccine is administered, with greater efficacy obtained if administered prior to sexual debut. Historically, this vaccine was created to protect women from cervical cancer. As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders. HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691362"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 464,
          "text": "HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811679"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 497,
          "text": "heir lives. Canada\u0027s National Advisory Committee on Immunization (NACI) has recommended a three-dose immunization schedule with HPV vaccine for females 9 years of age and older and for males between 9 and 26 years of age, since 2007 and 2012, r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29769961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "BACKGROUND: Rates of routine human papillomavirus (HPV) vaccination of adolescent males in the United States are low. Leading health organizations advocate consistent and strong physician recommendations to improve HPV vaccine di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486020"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "BACKGROUND: For human papillomavirus (HPV) vaccination to have maximum benefit to public health, both men and women should be vaccinated. Although efficacy trials in men are still ongoing, the HPV vaccine will likely be licensed for men in the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18830138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "In the United States, human papillomavirus (HPV) vaccine has been recommended for females since 2006 and for males since 2011.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30591254"
        },
        {
          "offsetInBeginSection": 875,
          "offsetInEndSection": 1334,
          "text": "vaccine recommendations.CONCLUSION: HPV is responsible for 50.8% of penile cancers globally, 79.8% of PeIN, and 90% of genital warts. In 2009 the Food and Drug Administration licensed the quadrivalent HPV vaccine for use in males, with a potential efficacy of 90% and 77.5% to reduce genital warts and anal intraepithelial neoplasia, respectively. However, the uptake of HPV vaccination in men is low, and gender-neutral vaccination is estimated to be impleme",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35577640"
        },
        {
          "offsetInBeginSection": 2398,
          "offsetInEndSection": 2627,
          "text": "Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection to everyone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391351"
        },
        {
          "offsetInBeginSection": 1421,
          "offsetInEndSection": 1590,
          "text": "The quadrivalent vaccine against HPV has proved to be effective in preventing external genital lesions in males aged 16-26 years in 90.4%; (95%; CI: 69.2-98.1) of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "MSM are a high-risk population for HPV infection and related diseases. MSM can be effectively protected by quadrivalent and nine-valent HPV vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37661628"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 401,
          "text": " boys and girls. The quadrivalent HPV vaccination is approved and recommended for both boys and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25756144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 512,
          "text": "BACKGROUND: For human papillomavirus (HPV) vaccination to have maximum benefit to public health, both men and women should be vaccinated. Although efficacy trials in men are still ongoing, the HPV vaccine will likely be licensed for men in the near future. Little is known about men\u0027s interest in HPV vaccination. This study assessed whether informing men about the benefits of male HPV vaccination for their female sexual partner(s) boosted interest in the HPV vaccine beyond informing them about the benefits t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18830138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 466,
          "text": "PURPOSE: We assessed U.S. physicians\u0027 attitudes and perceptions regarding potential human papillomavirus (HPV) vaccination of males.METHODS: We surveyed a random sample of 2,714 pediatricians and family practitioners identified in administrative claims of a U.S. health plan as HPV vaccinators of females; 595 pediatricians and 499 family practitioners participated.RESULTS: Most physicians would recommend HPV vaccination to males aged 11-12 (63.9%), 13-18 (93.4%),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20547286"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 658,
          "text": "HPV vaccination of boys should help reduce anal cancer in homosexual men and cervical cancer in women, it will have little or no impact on penile or prostate cancer. Male circumcision can reduce cervical, penile and possibly prostate cancer. Promotion of both HPV vaccination and male circumcision will synergistically maximize genital cancer prevention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23167429"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1138,
          "text": "Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males \u003e26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32154741"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 558,
          "text": "Despite the proven safety and efficacy of available vaccines, HPV remains the most common sexually transmitted infection. Underlying the high prevalence of HPV infection is the poor adherence to the Centers for Disease Control recommendation to vaccinate all 11- to 12-year-old males and females. In fact, only about 38 and 14% of eligible females and males, respectively, receive the complete, three-dose immunization. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26734596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 448,
          "text": "BACKGROUND: Despite the high risks associated with human papillomavirus (HPV), the HPV vaccination rate of men is far lower than women. Most previous review studies have focused on female vaccination and related affecting factors. However, previous studies have reported that the factors affecting HPV vaccination differ by gender.OBJECTIVE: The aim of this review was to identify the factors affecting HPV vaccine initiation in men through a syste",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35471242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "AIMS: Human papilloma virus (HPV) is 1 of the most common sexually transmitted infection responsible for different types of cancer: cervical, penile, vulvar, anal and oropharyngeal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33145777"
        },
        {
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1401,
          "text": "The 9vHPV and qHPV vaccines showed comparable safety profiles.CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a three-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in men aged 16-26years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27354258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 370,
          "text": "The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescent immunization platform to help reduce the incidence of anogenital cancers and genital warts associated with HPV infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553168"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 464,
          "text": "ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811679"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1291,
          "text": "The Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28346275"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1291,
          "text": "The Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538494"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 682,
          "text": "We also present the recommendations of the Québec Immunization Committee (CIQ) in this regard, which are: to provide targeted vaccination for MSM up to 26 years of age and in-school vaccination of preadolescent boys since this is the best approach to take to have a real impact on the burden related to HPV in the MSM population and to provide direct protection for all men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26554731"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 487,
          "text": "Even though a fall in cervical cancer rates has been reported worldwide, the subsequent rise in HPV-associated head and neck cancers among men and women have been reported from developed countries, necessitating the vaccination of adolescent boys as well.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517117"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1195,
          "text": "Extension of immunization offer to young women and to adolescent male subjects has become an important additional opportunity for several countries, with a special focus needed on homosexual men with HIV infection who are at particularly increased risk of HPV-related diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25553242"
        },
        {
          "offsetInBeginSection": 390,
          "offsetInEndSection": 499,
          "text": "Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32154741"
        },
        {
          "offsetInBeginSection": 704,
          "offsetInEndSection": 1138,
          "text": "Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32154741"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "Human Papilloma Virus (HPV) has been implicated in the initiation of several types of cancers in both females and males. Therefore, it is imperative that national immunization programs should ensure that both young women and young men receive full immunization for herd immunity in their teenage years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31992466"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 831,
          "text": "Male sexual behavior, with consequent HPV infection and disease contribute to considerable disease burden in females. Hence, inclusion of males in prophylactic HPV vaccination programs should prevent HPV-related disease in males as well as substantially reducing disease burden in females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20138347"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Human Papillomavirus (HPV) vaccination is of paramount importance to reduce HPV-associated cancers in both genders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36897868"
        },
        {
          "offsetInBeginSection": 1605,
          "offsetInEndSection": 1788,
          "text": "Therefore, inclusion of males in an HPV vaccination program is likely to have significant health and economic benefits over and above those observed from current female-only programs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20138347"
        }
      ],
      "id": "65f8611dc4010b4d78000055",
      "ideal_answer": [
        "Yes, HPV is one of the most common causes of STD, and can cause genital warts and cancer (cervical, anal, vulvar, vaginal, penile, and oropharyngeal) in men and women.",
        "Yes, men should be immunized against the Human Papilloma Virus (HPV). The HPV vaccine is highly effective in preventing HPV-related cancers and other diseases. HPV is known to contribute to several types of cancers in men, including those of the mouth, throat, anus, and penis, as well as causing genital warts. Additionally, HPV can cause cancers of the anus, oral cavity, and oropharynx in both men and women. Therefore, immunization against HPV can help reduce the risk of these cancers and diseases, making it beneficial for both genders."
      ]
    },
    {
      "body": "Is sectoral Heterochromia associated with Crohn\u0027s disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34189344",
        "http://www.ncbi.nlm.nih.gov/pubmed/17933676",
        "http://www.ncbi.nlm.nih.gov/pubmed/3792843"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "A case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "PURPOSE: To report a case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome (BWS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 451,
          "text": "CONCLUSIONS: This is the first reported case of iris heterochromia in a BWS patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189344"
        },
        {
          "offsetInBeginSection": 51,
          "offsetInEndSection": 262,
          "text": "The first case is an example of Waardenburg\u0027s type II (without dystopia canthorum) with bilateral sectoral iris heterochromia and fundus bicolor, hyperpigmented skin patches, characteristic facies and deafness. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3792843"
        }
      ],
      "id": "65cfd68a1930410b13000021",
      "ideal_answer": [
        "No. There are no published reports to suggest an association of sectoral Heterochromia with Crohn\u0027s disease."
      ],
      "exact_answer": "no"
    },
    {
      "body": "List the most effective treatment methods for Madelung disease.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37060787",
        "http://www.ncbi.nlm.nih.gov/pubmed/37363562",
        "http://www.ncbi.nlm.nih.gov/pubmed/21813877",
        "http://www.ncbi.nlm.nih.gov/pubmed/1582619",
        "http://www.ncbi.nlm.nih.gov/pubmed/33492475",
        "http://www.ncbi.nlm.nih.gov/pubmed/30461459",
        "http://www.ncbi.nlm.nih.gov/pubmed/28785324",
        "http://www.ncbi.nlm.nih.gov/pubmed/26246230",
        "http://www.ncbi.nlm.nih.gov/pubmed/1780727",
        "http://www.ncbi.nlm.nih.gov/pubmed/12627249",
        "http://www.ncbi.nlm.nih.gov/pubmed/12755508"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 484,
          "text": "Madelung disease (MD) was first described by Brodie in 1846 as a rare multiple lipoma. It is a benign tumor characterized by symmetrical diffuse adipose tissue deposition in the proximal extremities and neck. Until now, the etiology and pathogenesis of the disease have not been fully explained, resulting in difficulties in diagnosis and treatment; moreover, palliative treatment, such as surgical resection of adipose tissue or liposuction, is still the mainstream treatment for MD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060787"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "text": "Madelung\u0027s disease is a rare disfiguring disorder that affects both function and esthetic appearance in the head and/or shoulder, neck, and arms regions. Lipectomy is typically necessary but such treatment can encounter difficulties due to the large sizes of the tumors, interspersed with important organs in the surrounding region",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37363562"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 689,
          "text": "Benign symmetrical lipomatosis (Madelung disease) is a rare metabolic disorder characterized by the presence of multiple, symmetric, nonencapsulated fat masses in the face, neck, and shoulders. The clinical course is slow, typically one of slow progressive enlargement with cosmetic and functional sequelae. The authors describe a case in which an open surgical approach was performed to treat this disorder, with good results. There are many aspects of treatment currently lacking a consensus, and the authors discuss these, principally in relation to the location of the fat, the role of liposuction versus surgery, the staging of surgical procedures, and the placement of the incisions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21813877"
        },
        {
          "offsetInBeginSection": 1634,
          "offsetInEndSection": 1988,
          "text": "Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease; however, choice of surgery should be based on comprehensive consideration of the disease, such as severity, mass location, and patient expectations.LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492475"
        },
        {
          "offsetInBeginSection": 1529,
          "offsetInEndSection": 1755,
          "text": "Severe complications were not observed.CONCLUSIONS: According to our experience, surgical resection is the main method of improving the appearance, ensuring eradication of the tumor, and reducing the possibility of recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30461459"
        },
        {
          "offsetInBeginSection": 677,
          "offsetInEndSection": 1003,
          "text": "Severe complications were not observed.CONCLUSIONS: According to our experience, combined lipectomy and liposuction represents a successful procedure in treating benign symmetric lipomatosis in the head and neck region.Nevertheless, advantages and drawbacks of the two techniques should be equally considered prior to surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12627249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "A patient with benign symmetrical lipomatosis of the neck (Madelung\u0027s disease) was successfully treated with liposuction rather than classic surgical lipectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1780727"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Madelung\u0027s Disease - Case Series and Treatment by Tumescent Liposuction or Lipectomy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28785324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Rhytidectomy approach for recurrent Madelung disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21813877"
        },
        {
          "offsetInBeginSection": 1595,
          "offsetInEndSection": 1849,
          "text": "e helpful for diagnosis and cognition. Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease; however, choice of surgery should be based on comprehensive consideration of the disease, such as severity, m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492475"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 350,
          "text": "Madelung\u0027s disease is a rare disfiguring lipomatosis of unknown etiology. The only effective therapy is the palliative surgical removal of the fatty tissue by lipectomy or liposuction. Experience with eighteen surgically treated patients shows that despite a high rate of complications and the tendency to recur, both techniques might be very useful.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1582619"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Benign symmetrical lipomatosis (Madelung\u0027s disease) is a rare condition of unclear aetiology characterized by numerous, unencapsulated lipomatous deposits. The only effective treatment is by surgical intervention; however, there is no consensus in the optimal approach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246230"
        },
        {
          "offsetInBeginSection": 852,
          "offsetInEndSection": 999,
          "text": "We think that combined lipectomy and liposuction is a successful procedure for treating benign symmetrical lipomatosis in the head and neck region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755508"
        }
      ],
      "id": "65f377d5c4010b4d78000009",
      "ideal_answer": [
        "Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease;",
        "The most effective treatments for Madelung disease are lipectomy and liposuction.",
        "Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease.",
        "The most effective treatment methods for Madelung disease are lipectomy and liposuction.",
        "The most effective treatment methods for Madelung disease include lipectomy, liposuction, combined lipectomy and liposuction, and abstinence from alcohol.",
        "Surgical resection of adipose tissue or liposuction is the most effective treatment methods for Madelung disease.",
        "The most effective treatment methods for Madelung disease include surgical resection of adipose tissue and liposuction, which are commonly used to address the symptoms of the disorder.",
        "The most effective treatment methods for Madelung disease are liposuction, surgical resection, and open surgical approach.",
        "The most effective treatment methods for Madelung disease include liposuction, open surgical approach, surgical resection, lipectomy, surgical resection of adipose tissue, and considering the choice between liposuction versus surgery.",
        "The most effective treatment methods for Madelung disease are surgical resection of adipose tissue or liposuction.",
        "The most effective treatments for Madelung disease include surgical removal of the adipose tissue and liposuction.",
        "The most effective treatment methods for Madelung disease can be liposuction, open surgical approach, and surgical resection.",
        "The most effective treatment methods for Madelung disease are surgical resection of adipose tissue and liposuction. These treatments aim to remove the excessive fat deposits associated with the disease."
      ],
      "exact_answer": [
        [
          "lipectomy",
          "Rhytidectomy"
        ],
        [
          "liposuction"
        ],
        [
          "surgery"
        ],
        [
          "Physical therapy"
        ],
        [
          "supportive measures"
        ]
      ]
    },
    {
      "body": "What are common side effects of the progesterone-only pill (POP)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32538188",
        "http://www.ncbi.nlm.nih.gov/pubmed/31321765",
        "http://www.ncbi.nlm.nih.gov/pubmed/21080791",
        "http://www.ncbi.nlm.nih.gov/pubmed/36720088",
        "http://www.ncbi.nlm.nih.gov/pubmed/38002722",
        "http://www.ncbi.nlm.nih.gov/pubmed/8982741",
        "http://www.ncbi.nlm.nih.gov/pubmed/37962511",
        "http://www.ncbi.nlm.nih.gov/pubmed/20569066"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 25,
          "offsetInEndSection": 144,
          "text": "progestin-only pills (POPs) is still relatively infrequent, mainly for their unpredictable effect on menstrual bleeding",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32538188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Breakthrough bleeding is a side effect of progesterone-only pills (POPs) in 40% of women, and is reduced to 10% with combined hormonal contraceptives (CHCs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "PURPOSE: Progestin-only pills (POPs), compared to combined, are not associated with an increased risk of venous thromboembolism, but are associated with a poor cycle control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37962511"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "The Risk of Breakthrough Bleeding Justifies the Use of Combined Hormonal Contraception Over Progesterone-Only Pills While Breastfeeding.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720088"
        },
        {
          "offsetInBeginSection": 800,
          "offsetInEndSection": 884,
          "text": "The most commonly reported complaints in women using all POPs are bleeding problems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21080791"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 366,
          "text": "The main reason for this is that women on POP often have abnormal bleeding patterns, with an increased frequency of bleeding, lengthened cycles, breakthrough bleeding, spotting and prolonged bleeding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8982741"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 173,
          "text": "Progestin-only pills (POPs), compared to combined, are not associated with an increased risk of venous thromboembolism, but are associated with a poor cycle control",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37962511"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 304,
          "text": "POPs are often associated with breakthrough bleeding (BTB), and irregular spotting is often a reason for their cessation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38002722"
        },
        {
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1194,
          "text": "ative studies are available. Progestogen-only pills are associated with a more irregular bleeding pattern than contraceptive pills containing oestrogens, especially during the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569066"
        }
      ],
      "id": "65f847c5c4010b4d78000046",
      "ideal_answer": [
        "The progestogen-only pill may change your periods (lighter, more frequent or stop altogether). \nBleeding (spotting) between periods.\nAcne. \nMood swings.\nWeight gain. \nChanges to libido.\n\nSpeak to a pharmacist or doctor if you have side effects that are a problem for you."
      ],
      "exact_answer": [
        [
          "unscheduled intracyclic bleeding"
        ],
        [
          "spotting"
        ],
        [
          "hyperkalemia"
        ],
        [
          "breakthrough bleeding"
        ]
      ]
    },
    {
      "body": "What is the mechanism of action of Peresolimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37195941"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941"
        },
        {
          "offsetInBeginSection": 1941,
          "offsetInEndSection": 2175,
          "text": "CONCLUSIONS: Peresolimab showed efficacy in a phase 2a trial in patients with rheumatoid arthritis. These results provide evidence that stimulation of the PD-1 receptor has potential efficacy in the treatment of rheumatoid arthritis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a no",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37195941"
        }
      ],
      "id": "65d128f81930410b1300002d",
      "ideal_answer": [
        "Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway."
      ]
    },
    {
      "body": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37814560",
        "http://www.ncbi.nlm.nih.gov/pubmed/36351516",
        "http://www.ncbi.nlm.nih.gov/pubmed/37064719",
        "http://www.ncbi.nlm.nih.gov/pubmed/20353445",
        "http://www.ncbi.nlm.nih.gov/pubmed/23085895",
        "http://www.ncbi.nlm.nih.gov/pubmed/18322968",
        "http://www.ncbi.nlm.nih.gov/pubmed/22794699",
        "http://www.ncbi.nlm.nih.gov/pubmed/24813513",
        "http://www.ncbi.nlm.nih.gov/pubmed/23459046",
        "http://www.ncbi.nlm.nih.gov/pubmed/19733260",
        "http://www.ncbi.nlm.nih.gov/pubmed/22075653",
        "http://www.ncbi.nlm.nih.gov/pubmed/26020633"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 557,
          "text": "asal cell hyperplasia may occur in patients with gastroesophageal reflux disease (GERD), a condition in which acid from the stomach enters the esophagus, or eosinophilic esophagitis (EoE), an emerging form of food allergy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064719"
        },
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 232,
          "text": "Eosinophilic esophagitis (EoE) is a food allergen-induced disease of the esophagus. Chronic, eosinophil-predominant inflammation eventually leads to fibrosis, esophageal dysfunction and severe morbidity. S",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37814560"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "BACKGROUND AND OBJECTIVES: Diagnosing eosinophilic esophagitis (EoE) depends on intraepithelial eosinophil count of ≥15 eosinophils per high-power field (HPF); however, differentiating EoE from gastroesophageal reflux disease (GERD) continues to be a challenge because no true \"criterion standard\" criteria exist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085895"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Eosinophilic esophagitis (EoE) is distinguished from gastroesophageal reflux disease (GERD) by persistent esophageal eosinophilia despite medical therapy with proton-pump inhibitors for 4-6 weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22794699"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 369,
          "text": "The notion that GERD and EoE can be distinguished by the response to proton pump inhibitor (PPI) treatment is based on the mistaken assumption that gastric acid suppression is the only important therapeutic effect of PPIs, and therefore only GERD can respond to PPIs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24813513"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 515,
          "text": "While studies from the \u002780s identified the presence of esophageal eosinophilia as being a histologic marker for the diagnosis of GERD, studies in the \u002790s demonstrated that high levels of esophageal eosinophilia were characteristic for a novel immune/antigen-mediated esophageal disease, EoE, that was seemingly quite distinct from GERD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23459046"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1637,
          "text": "BACKGROUND \u0026 AIMS: Features of eosinophilic esophagitis (EoE) and gastroesophageal reflux disease (GERD) overlap; because they cannot be differentiated on the basis of eosinophil counts alone, it can be a challenge to distinguish these disorders. We aimed to characterize the clinical, endoscopic, and histologic features of EoE and GERD and to identify factors that might be used to differentiate them.METHODS: We performed a retrospective case-control study on data collected from 2000 to 2007. Cases were patients of any age with EoE, as defined by recent consensus guidelines; controls were patients of any age with GERD. Clinical and endoscopic data were collected, and all esophageal biopsy specimens were reassessed by gastrointestinal pathologists. Cases and controls were compared, unconditional logistic regression was performed to develop a model to predict EoE, and receiver operator characteristic curves were constructed.RESULTS: Data from 151 patients with EoE and 226 with GERD were analyzed. Compared with GERD, features that independently predicted EoE included younger age; symptoms of dysphagia; documented food allergies; observations of esophageal rings, linear furrows, white plaques, or exudates by upper endoscopy; an absence of a hiatal hernia, observed by upper endoscopy; a higher maximum eosinophil count; and the presence of eosinophil degranulation observed in biopsy specimens. The area under the curve for this model was 0.934.CONCLUSIONS: We identified a set of readily available and routinely measured variables that differentiate EoE from GERD. Use of this type of analysis with patients suspected to ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19733260"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1581,
          "text": "Eosinophilic esophagitis (EE) and gastroesophageal reflux disease (GERD) have overlapping clinical, manometric, endoscopic and histopathologic features. The diagnosis of EE is nowadays based upon the presence of 15 or more eosinophils per high power field (eo/HPF) in esophageal biopsies. We report the cases of two young males suffering from dysphagia and recurrent food impaction with reflux esophagitis and more than 20 eo/HPF in upper-mid esophagus biopsies, both of which became asymptomatic on proton pump inhibitor (PPI) therapy. The first patient also achieved a histologic response, while EE remained in the other patient after effective PPI treatment, as shown by 24-h esophageal pH monitoring. Topical steroid therapy combined with PPI led to complete remission in this latter patient. GERD and EE may be undistinguishable, even by histology, so diagnosis of EE should only be established after a careful correlation of clinical, endoscopic and pathologic data obtained under vigorous acid suppression. These diagnostic difficulties are maximal when both diseases overlap. Limited data are available about this topic, and the interaction between EE and GERD is a matter of debate. In this setting, upper-mid esophagus step biopsies and esophageal pH monitoring of patients on PPI therapy are pivotal to evaluate the role of each disease. A PPI trial is mandatory in patients with a histopathologic diagnosis of EE; in those unresponsive to PPI treatment, EE should be suggested. However, a clinical response to PPI may not rule out quiescent EE, as shown in this report.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18322968"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 1705,
          "text": " diseases. The mucosa affected by eosinophilic esophagitis (EoE) is composed of a stratified squamous epithelia and contains intraepithelial eosinophils. To date, no studies have identified the esophageal microbiome in patients with EoE or the impact of treatment on these organisms. The aim of this study was to identify the esophageal microbiome in EoE and determine whether treatments change this profile. We hypothesized that clinically relevant alterations in bacterial populations are present in different forms of esophagitis.DESIGN: In this prospective study, secretions from the esophageal mucosa were collected from children and adults with EoE, Gastroesophageal Reflux Disease (GERD) and normal mucosa using the Esophageal String Test (EST). Bacterial load was determined using quantitative PCR. Bacterial communities, determined by 16S rRNA gene amplification and 454 pyrosequencing, were compared between health and disease.RESULTS: Samples from a total of 70 children and adult subjects were examined. Bacterial load was increased in both EoE and GERD relative to normal subjects. In subjects with EoE, load was increased regardless of treatment status or degree of mucosal eosinophilia compared with normal. Haemophilus was significantly increased in untreated EoE subjects as compared with normal subjects. Streptococcus was decreased in GERD subjects on proton pump inhibition as compared with normal subjects.CONCLUSIONS: Diseases associated with mucosal eosinophilia are characterized by a different microbiome from that found in the normal mucosa. Microbiota may contribute to es",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26020633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1680,
          "text": "Eosinophilic esophagitis (EoE) and reflux esophagitis (RE) overlap clinically and histologically. RE is characterized by epithelial infiltration with small numbers of neutrophils and eosinophils, EoE by a prominent eosinophilic infiltrate. Lymphocytic esophagitis (LE), a new entity characterized by peripapillary lymphocytosis, questions the role lymphocytes play in esophageal inflammation. We test the hypothesis that lymphocyte infiltration in RE differs from EoE. One blinded pathologist read esophageal biopsies from 39 RE and 39 EoE patients. Both groups demonstrated significant numbers of lymphocytes (RE 22.7 +/- 2.2/HPF, EoE 19.8 +/- 1.8/HPF). Eosinophils/HPF in RE and EoE were 2.8 +/- 0.7 and 74.9 +/- 8.2, respectively (P \u003c 0.001). Neutrophils were uncommon in RE (0.26 +/- 0.16/HPF) and EoE (0.09 +/- 0.04; P \u003d 0.07). Eight of the 39 RE specimens had \u003eor\u003d50 lymphocytes in \u003eor\u003d1 HPF. Two were consistent with LE. There was an inverse correlation between numbers of eosinophils and lymphocytes in EoE (R \u003d -0.47; P \u003d 0.002), and no correlation between them in RE (R \u003d 0.18; P \u003d 0.36). The patients with EoE who used antireflux medications had fewer lymphocytes (16.3 +/- 1.3 vs 22.2 +/- 2.3/HPF; P \u003d 0.030) and eosinophils (55.6 +/- 5.2 vs 76.0 +/- 8.7/HPF; P \u003d 0.042) than those who did not. The pathological role of lymphocytes in RE and EoE may be underestimated. Our observation that 5% of the RE specimens meet histopathological criteria for LE potentially blurs the line between these entities. The observation that eosinophil counts are lower in EoE when antireflux meds are used supports the notion that reflux plays a role in the clinical expression of EoE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20353445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "Eosinophilic esophagitis (EoE) and reflux esophagitis (RE) overlap clinically and histologically. RE is characterized by epithelial infiltration with small numbers of neutrophils and eosinophils, EoE by a prominent eosinophilic infiltrate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20353445"
        }
      ],
      "id": "65f1d021c4010b4d78000004",
      "ideal_answer": [
        "EoE can be distinguished from GERD using a scoring system of clinical and endoscopic features. Many aspects of EoE were statistically distinct from GERD when controlling for age. Male sex, dysphagia, history of food impaction, absence of pain/heartburn, linear furrowing, and white papules were the distinguishing variables",
        "Eosinophilic esophagitis is a chronic immune-mediated disease characterized by eosinophilic infiltration due to antigen exposure, while reflux-induced esophagitis is typically caused by the backflow of stomach acid into the esophagus.",
        "Eosinophilic esophagitis is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction and inflammation, while reflux-induced esophagitis is a condition caused by the backflow of stomach acid into the esophagus, causing inflammation and damage to the esophageal lining.",
        "Eosinophilic esophagitis is a chronic immune-mediated disease characterized by eosinophilic infiltration due to antigen exposure, while reflux-induced esophagitis is caused by the backflow of stomach acid into the esophagus, leading to inflammation.",
        "Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and fibrosis in the absence of gastroesophageal reflux. Reflux-induced esophagitis is caused by gastric acid reflux, leading to chronic esophagitis, and its course of treatment is different from EoE.",
        "Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and fibrosis. Gastroesophageal reflux disease (GERD) is a condition in which acid from the stomach enters the esophagus.",
        "Eosinophilic esophagitis (EoE) and reflux-induced esophagitis are two different conditions that affect the esophagus. \n\nEosinophilic esophagitis is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and asal cell hyperplasia. It is an emerging form of food allergy and is associated with antigen-driven type 2 inflammation. The cause of EoE is thought to be due to an inflammatory response triggered by exposure to dietary or environmental antigen.\n\nOn the other hand, reflux-induced esophagitis, also known as gastroesophageal reflux disease (GERD), is a condition in which acid from the stomach enters the esophagus. It is a chronic condition that can cause symptoms such as heartburn, chest pain, and difficulty swallowing. Reflux-induced esophagitis is caused by a",
        "Eosinophilic esophagitis (EoE) is a chronic and progressive immune-mediated disease of the esophagus associated with antigen-driven type 2 inflammation and symptoms of esophageal dysfunction. In contrast, gastroesophageal reflux disease (GERD) is a condition in which acid from the stomach enters the esophagus.",
        "Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by eosinophilic infiltration, leading to esophageal dysfunction, inflammation, and tissue damage. Reflux-induced esophagitis, on the other hand, is caused by the backflow of stomach contents into the esophagus, leading to inflammation and damage to the esophageal lining. EoE is not caused by reflux, but rather by an immune response to an unknown trigger."
      ]
    },
    {
      "body": "What are the most common symptoms of fibroids?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36759100",
        "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
        "http://www.ncbi.nlm.nih.gov/pubmed/18372219",
        "http://www.ncbi.nlm.nih.gov/pubmed/37609293",
        "http://www.ncbi.nlm.nih.gov/pubmed/25145720",
        "http://www.ncbi.nlm.nih.gov/pubmed/33016950",
        "http://www.ncbi.nlm.nih.gov/pubmed/29483852",
        "http://www.ncbi.nlm.nih.gov/pubmed/35957805",
        "http://www.ncbi.nlm.nih.gov/pubmed/29564309",
        "http://www.ncbi.nlm.nih.gov/pubmed/36436959",
        "http://www.ncbi.nlm.nih.gov/pubmed/22482961",
        "http://www.ncbi.nlm.nih.gov/pubmed/31960950",
        "http://www.ncbi.nlm.nih.gov/pubmed/16754159",
        "http://www.ncbi.nlm.nih.gov/pubmed/29628616",
        "http://www.ncbi.nlm.nih.gov/pubmed/29511672",
        "http://www.ncbi.nlm.nih.gov/pubmed/35968245",
        "http://www.ncbi.nlm.nih.gov/pubmed/36471219",
        "http://www.ncbi.nlm.nih.gov/pubmed/24310827",
        "http://www.ncbi.nlm.nih.gov/pubmed/34640407",
        "http://www.ncbi.nlm.nih.gov/pubmed/25713613",
        "http://www.ncbi.nlm.nih.gov/pubmed/37575346",
        "http://www.ncbi.nlm.nih.gov/pubmed/19646564",
        "http://www.ncbi.nlm.nih.gov/pubmed/18618119",
        "http://www.ncbi.nlm.nih.gov/pubmed/30766459",
        "http://www.ncbi.nlm.nih.gov/pubmed/16504807",
        "http://www.ncbi.nlm.nih.gov/pubmed/33388011"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 66,
          "offsetInEndSection": 162,
          "text": "Fibroids can be asymptomatic or present with heavy menstrual bleeding, pelvic pressure, and pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759100"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 755,
          "text": "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation. It is also associated with reproductive issues like impaired fertility, conceiving complications, and adverse obstetric outcomes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 322,
          "text": "Common symptoms associated with fibroids include abnormal uterine bleeding, pelvic pressure and reproductive dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16754159"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 277,
          "text": "The most common reported symptoms of fibroids are heavy menstrual bleeding and painful menstruation, pelvic pain, urinary problems, constipation, as well as infertility and recurrent pregnancy loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483852"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 427,
          "text": "Approximately 50% of women with fibroids experience symptoms which may include menorrhagia that may result in anemia, bulk symptoms with bladder and bowel dysfunction and abdominal protrusion, dysmenorrhea, and infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29628616"
        },
        {
          "offsetInBeginSection": 1500,
          "offsetInEndSection": 1678,
          "text": "In conclusion, women with UFs have significantly higher levels of perceived stress and menstrual distress than controls and HMB plays a major role in determining such conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36471219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Uterine fibroids are the most common benign pelvic tumor of the female genital tract and tend to increase with age; they cause menorrhagia, dysmenorrhea, pelvic pressure symptoms, back pain, and subfertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29511672"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 374,
          "text": "Symptoms for up to 50 percent of women experiencing fibroids include heavy menstrual bleeding, pelvic pressure or pain and gastrointestinal and genitourinary changes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145720"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 608,
          "text": "Uterine fibroids (also called leiomyomas or myomas) are the most common disorder among women of reproductive age, with an incidence of between 20% and 80%; they are often detected incidentally in routine healthy examinations, through bimanual pelvic and/or ultrasound examination, because uterine fibroids are rarely associated with symptoms. Sometimes, uterine fibroids may be complicated by a variety of symptoms, including menstrual disturbance (e.g., menorrhagia, dysmenorrhea, intermenstrual bleeding), pressure symptoms, bloated sensation, increased urinary frequency, bowel disturbance, or pelvic pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22482961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Heavy menstrual bleeding (HMB), distress in the pelvis, infertile, and stressed feelings are all indications of fibroids in the uterus, the most prevalent type of benign uterine tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35957805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "(1) Background: Uterine fibroids are the most common form of benign uterine tumors, causing heavy menstrual bleeding (HMB), pelvic pain, infertility and pressure symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34640407"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 377,
          "text": "The main symptoms of uterine fibroids are profuse menstrual bleeding, abnormal uterine bleeding, and pressure symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33016950"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 493,
          "text": "The symptoms usually reported by women with fibroids are the following: abnormal gynaecologic haemorrhage, chronic pelvic pain, dyspareunia, as well as urinary and bowel symptoms, urinary frequency or retention and, in some cases, infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713613"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 467,
          "text": "Approximately 50% of women with fibroids experience symptoms which can range from heavy menstrual bleeding and bulk-related symptoms such as pelvic pressure with bladder and bowel dysfunction to reproductive dysfunction (e.g., infertility or obstetric complications) and pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37575346"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 228,
          "text": "Fibroids can become symptomatic with symptoms such as menorrhagia and menometrorrhagia, pelvic pain, and reproductive dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24310827"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 655,
          "text": "Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31960950"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 427,
          "text": "Symptomatic uterine fibroids present with menstrual problems, anemia, infertility, miscarriages, an enlarged abdomen, pressure symptoms involving the bladder and bowels (such as frequent urination or constipation), and sometimes coital-related problems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35968245"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 224,
          "text": "Common symptoms associated with fibroids include pelvic pain, heavy menstrual bleeding, anemia, and pelvic pressure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1022,
          "text": "Uterine fibroids, the most common tumours in women of reproductive age, are asymptomatic in at least 50% of afflicted women. However, in other women, they cause significant morbidity and affect quality of life. Clinically, they present with a variety of symptoms: menstrual disturbances including menorrhagia, dysmenorrhoea and intermenstrual bleeding; pelvic pain unrelated to menstruation; and pressure symptoms such as a sensation of bloatedness, increased urinary frequency and bowel disturbance. In addition, they may compromise reproductive function, possibly contributing to subfertility, early pregnancy loss and later pregnancy complications such as pain, preterm labour, malpresentations, increased need for caesarean section, and postpartum haemorrhage. Large fibroids may distend the abdomen, which may be aesthetically displeasing to many women. Abnormal bleeding occurs in 30% of symptomatic women, and abnormal bleeding, bloating and pelvic discomfort due to mass effect constitute the most common symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18372219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 652,
          "text": "Uterine fibroids (also called leiomyomas or myomas) are the most common disorder among women of reproductive age, with an incidence of between 20% and 80%; they are often detected incidentally in routine healthy examinations, through bimanual pelvic and/or ultrasound examination, because uterine fibroids are rarely associated with symptoms. Sometimes, uterine fibroids may be complicated by a variety of symptoms, including menstrual disturbance (e.g., menorrhagia, dysmenorrhea, intermenstrual bleeding), pressure symptoms, bloated sensation, increased urinary frequency, bowel disturbance, or pelvic pain; therefore definite treatment is requested.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22482961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 624,
          "text": "Uterine fibroids (UFs), leiomyomas or myomas, are a type of malignancy that affects the smooth muscle of the uterus, and it is most commonly detected in women of reproductive age. Uterine fibroids are benign monoclonal growths that emerge from uterine smooth muscle cells (myometrium) as well as fibroblasts. Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 300,
          "text": "Heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss are generally associated with uterine fibroids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29564309"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 391,
          "text": "Symptomatic fibroids, with ailments such as abnormal uterine bleeding, dysmenorrhoea, pelvic pain, impaired urination, bowel dysfunction, infertility, and recurrent pregnancy loss, are indicated for medical treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30766459"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 225,
          "text": "Common symptoms associated with fibroids include pelvic pain, heavy menstrual bleeding, anemia, and pelvic pressure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37609293"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 287,
          "text": "The most common symptoms associated with uterine myomas are abnormal uterine bleeding and pelvic discomfort mostly caused by the mass effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16504807"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 452,
          "text": "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 269,
          "text": "Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain, infertility, urinary symptoms and constipation are generally associated with uterine fibroids (UFs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 484,
          "text": "Fibroid symptoms are protean, and menorrhagia is most frequent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36436959"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 185,
          "text": "(fibroids), the most common benign tumor in women of childbearing age, can cause symptoms including dysmenorrhea, menorrhagia, urinary symptoms, pain and infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18618119"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 624,
          "text": "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 244,
          "text": "Symptomatic fibroids present with menorrhagia, pelvic pain, leukorrhea, pressure and bloating, increased abdominal girth, and severe dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19646564"
        }
      ],
      "id": "65f84aa5c4010b4d78000047",
      "ideal_answer": [
        "heavy/painful periods\nabdominal pain\nlower back pain\na frequent need to urinate\nconstipation\npain or discomfort during sex",
        "The most common symptoms associated with uterine fibroids are heavy menstrual bleeding, painful menstrual cramping, prolonged periods, anemia, frequent urination, back pain, pelvic pressure, and, in rare cases, infertility or miscarriage.",
        "The most common symptoms of fibroids are heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss. Other symptoms include pressure sensations, dysmenorrhea, chronic pelvic pain, increased urinary frequency, bowel disturbance, bladder dysfunction, and pain during intercourse. Some women with fibroids may not experience any symptoms.",
        "The most common symptoms of uterine fibroids include heavy menstrual bleeding, abnormal uterine bleeding, anemia, pelvic pain, infertility, miscarriages, an enlarged abdomen, pressure symptoms involving the bladder and bowels (such as frequent urination or constipation), pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, and chronic vaginal discharge.",
        "The most common symptoms of uterine fibroids include:\n\n1. Heavy or prolonged menstrual bleeding (menorrhagia) which can lead to anemia\n2. Pelvic pain and pressure \n3. Painful periods (dysmenorrhea)\n4. Increased abdominal girth or enlarged abdomen\n5. Frequent urination, urinary incontinence or retention due to pressure on the bladder\n6. Constipation or bowel disturbance due to pressure on the bowels\n7. Pain during intercourse\n8. Infertility or recurrent pregnancy loss\n\nSome women with fibroids may be asymptomatic while others experience a combination of these symptoms. Abnormal bleeding, pelvic pain/pressure and an enlarged abdomen are the most frequently reported symptoms.",
        "Fibroids, also known as uterine fibroids, can sometimes be asymptomatic, meaning they present no noticeable symptoms. However, when symptoms do occur, they can include heavy menstrual bleeding, which can lead to anemia and tiredness, and pelvic pressure and pain. Other common symptoms include chronic vaginal discharge, pain during periods, and pain during intercourse. Some people with fibroids may also experience a protrusion of the abdomen and dysfunctions of the bladder or bowel, leading to urinary incontinence or retention, and constipation. Additionally, fibroids can be associated with reproductive issues such as impaired fertility, complications with conceiving, and adverse obstetric outcomes.",
        "The most common symptoms of fibroids include being asymptomatic, heavy menstrual bleeding, pelvic pressure, and pain. Other symptoms can include abnormal menstrual bleeding, anaemia, tiredness, chronic vaginal discharge, pain during periods, protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel, urinary incontinence/retention, constipation, impaired fertility, conceiving complications, and adverse obstetric outcomes.",
        "The most common symptoms of fibroids include heavy menstrual bleeding, pelvic pressure, pain during periods, anaemia, tiredness, chronic vaginal discharge, protrusion of the abdomen, pain during intercourse, bladder and bowel dysfunctions, urinary incontinence or retention, constipation, impaired fertility, conceiving complications, and adverse obstetric outcomes."
      ],
      "exact_answer": [
        [
          "Abnormal menstrual bleeding"
        ],
        [
          "Pelvic pressure and pain"
        ],
        [
          "Fatigue"
        ],
        [
          "Chronic vaginal discharge"
        ],
        [
          "Painful periods"
        ],
        [
          "Dyspareunia"
        ],
        [
          "Constipation"
        ],
        [
          "Dysfunctions of bladder/bowel leading to urinary incontinence/retention"
        ],
        [
          "Decreased fertility"
        ],
        [
          "Adverse obstetric outcomes"
        ],
        [
          "Lower back pain"
        ]
      ]
    },
    {
      "body": "What is the target of Selpercatinib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36729098",
        "http://www.ncbi.nlm.nih.gov/pubmed/36568522",
        "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
        "http://www.ncbi.nlm.nih.gov/pubmed/36626081",
        "http://www.ncbi.nlm.nih.gov/pubmed/36632846",
        "http://www.ncbi.nlm.nih.gov/pubmed/36422787",
        "http://www.ncbi.nlm.nih.gov/pubmed/36416226",
        "http://www.ncbi.nlm.nih.gov/pubmed/34649088",
        "http://www.ncbi.nlm.nih.gov/pubmed/37265026",
        "http://www.ncbi.nlm.nih.gov/pubmed/36469155",
        "http://www.ncbi.nlm.nih.gov/pubmed/35726802",
        "http://www.ncbi.nlm.nih.gov/pubmed/34832869",
        "http://www.ncbi.nlm.nih.gov/pubmed/37131086",
        "http://www.ncbi.nlm.nih.gov/pubmed/37059058",
        "http://www.ncbi.nlm.nih.gov/pubmed/36198171",
        "http://www.ncbi.nlm.nih.gov/pubmed/36825106",
        "http://www.ncbi.nlm.nih.gov/pubmed/33082208",
        "http://www.ncbi.nlm.nih.gov/pubmed/37360768",
        "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
        "http://www.ncbi.nlm.nih.gov/pubmed/37795873",
        "http://www.ncbi.nlm.nih.gov/pubmed/38050583",
        "http://www.ncbi.nlm.nih.gov/pubmed/37972337",
        "http://www.ncbi.nlm.nih.gov/pubmed/37718634",
        "http://www.ncbi.nlm.nih.gov/pubmed/32493697",
        "http://www.ncbi.nlm.nih.gov/pubmed/37070927",
        "http://www.ncbi.nlm.nih.gov/pubmed/34713870",
        "http://www.ncbi.nlm.nih.gov/pubmed/34099825",
        "http://www.ncbi.nlm.nih.gov/pubmed/33150799",
        "http://www.ncbi.nlm.nih.gov/pubmed/35950566",
        "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
        "http://www.ncbi.nlm.nih.gov/pubmed/33169506",
        "http://www.ncbi.nlm.nih.gov/pubmed/33771190",
        "http://www.ncbi.nlm.nih.gov/pubmed/35647935",
        "http://www.ncbi.nlm.nih.gov/pubmed/37603207",
        "http://www.ncbi.nlm.nih.gov/pubmed/33489819",
        "http://www.ncbi.nlm.nih.gov/pubmed/34505490",
        "http://www.ncbi.nlm.nih.gov/pubmed/33007380",
        "http://www.ncbi.nlm.nih.gov/pubmed/32846060",
        "http://www.ncbi.nlm.nih.gov/pubmed/35582449",
        "http://www.ncbi.nlm.nih.gov/pubmed/36122315",
        "http://www.ncbi.nlm.nih.gov/pubmed/33314236",
        "http://www.ncbi.nlm.nih.gov/pubmed/32416592",
        "http://www.ncbi.nlm.nih.gov/pubmed/37870973",
        "http://www.ncbi.nlm.nih.gov/pubmed/35704797",
        "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
        "http://www.ncbi.nlm.nih.gov/pubmed/37565829",
        "http://www.ncbi.nlm.nih.gov/pubmed/37317595",
        "http://www.ncbi.nlm.nih.gov/pubmed/33455880",
        "http://www.ncbi.nlm.nih.gov/pubmed/32083997",
        "http://www.ncbi.nlm.nih.gov/pubmed/36075388",
        "http://www.ncbi.nlm.nih.gov/pubmed/35304457",
        "http://www.ncbi.nlm.nih.gov/pubmed/35969032",
        "http://www.ncbi.nlm.nih.gov/pubmed/36481304",
        "http://www.ncbi.nlm.nih.gov/pubmed/34402300",
        "http://www.ncbi.nlm.nih.gov/pubmed/36996322",
        "http://www.ncbi.nlm.nih.gov/pubmed/37525669",
        "http://www.ncbi.nlm.nih.gov/pubmed/37274265",
        "http://www.ncbi.nlm.nih.gov/pubmed/32703767",
        "http://www.ncbi.nlm.nih.gov/pubmed/37265412",
        "http://www.ncbi.nlm.nih.gov/pubmed/37425604",
        "http://www.ncbi.nlm.nih.gov/pubmed/33239432",
        "http://www.ncbi.nlm.nih.gov/pubmed/32846061",
        "http://www.ncbi.nlm.nih.gov/pubmed/35799394",
        "http://www.ncbi.nlm.nih.gov/pubmed/37051304",
        "http://www.ncbi.nlm.nih.gov/pubmed/34237031",
        "http://www.ncbi.nlm.nih.gov/pubmed/31768065",
        "http://www.ncbi.nlm.nih.gov/pubmed/35425116",
        "http://www.ncbi.nlm.nih.gov/pubmed/36108661",
        "http://www.ncbi.nlm.nih.gov/pubmed/36657661",
        "http://www.ncbi.nlm.nih.gov/pubmed/35007206"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 486,
          "text": "More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36729098"
        },
        {
          "offsetInBeginSection": 1515,
          "offsetInEndSection": 1641,
          "text": "Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992"
        },
        {
          "offsetInBeginSection": 1606,
          "offsetInEndSection": 1671,
          "text": "Three RET-mutant patients received selpercatinib; all showed PR. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36626081"
        },
        {
          "offsetInBeginSection": 828,
          "offsetInEndSection": 981,
          "text": "Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36632846"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Selpercatinib (Retevmo®/Retsevmo®) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787"
        },
        {
          "offsetInBeginSection": 927,
          "offsetInEndSection": 1090,
          "text": "Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36422787"
        },
        {
          "offsetInBeginSection": 74,
          "offsetInEndSection": 169,
          "text": "Selpercatinib is a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36416226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397"
        },
        {
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1824,
          "text": "Conclusions Selective RET inhibitors Pralsetinib and Selpercatinib have shown a good effect on RET fusion-positive NSCLC, with a low incidence of adverse events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37603207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34832869"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 443,
          "text": "Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397"
        },
        {
          "offsetInBeginSection": 629,
          "offsetInEndSection": 815,
          "text": "Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are potent and selective inhibitors that target RET alterations, including fusions and mutations, irrespective of the tissue of origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33771190"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 232,
          "text": "Selpercatinib is a highly selective RET inhibitor that has demonstrated anti-tumor activity in RET-mutated cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37795873"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Selpercatinib is a small molecule that binds at the RET kinase active site.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059058"
        },
        {
          "offsetInBeginSection": 620,
          "offsetInEndSection": 871,
          "text": "In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33489819"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 449,
          "text": "Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469155"
        },
        {
          "offsetInBeginSection": 80,
          "offsetInEndSection": 466,
          "text": "Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34832869"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 383,
          "text": "Selpercatinib and pralsetinib are tyrosine kinase inhibitors selectively targeting RET and with clinical activity in RET-positive NSCLC.CASE PRESENTATION: A male never-smoker in his forties was diagnosed with advanced lung adenocarcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34505490"
        },
        {
          "offsetInBeginSection": 314,
          "offsetInEndSection": 504,
          "text": "Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37718634"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37565829"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 558,
          "text": "In addition to these approvals, dostarlimab for mismatch repair deficiency(dMMR), dabrafenib and trametinib for BRAF V600E, and selpercatinib for RET fusion gene have been approved in the United States as tumor agnostic biomarkers and their treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37317595"
        },
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 643,
          "text": "To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33455880"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 389,
          "text": "er (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33007380"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1634,
          "text": "Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations have been identified as oncogenic in multiple malignancies. RET gene rearrangements retaining the kinase domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers. Activating RET mutations are associated with different phenotypes of multiple endocrine neoplasia type 2 as well as sporadic medullary thyroid cancer. RET is thus an attractive therapeutic target in patients with oncogenic RET alterations. Multikinase inhibitors with RET inhibitor activity, such as cabozantinib and vandetanib, have been explored in the clinic for tumors with activating RET gene alterations with modest clinical efficacy. As a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse effects, such as hypertension, rash, and diarrhea. This resulted in a narrow therapeutic index of these drugs, limiting ability to dose for clinically effective RET inhibition. In contrast, the recent discovery and clinical validation of highly potent selective RET inhibitors (pralsetinib, selpercatinib) demonstrating improved efficacy and a more favorable toxicity profile are poised to alter the landscape of RET-dependent cancers. These drugs appear to have broad activity across tumors with activating RET alterations. The mechanisms of resistance to these next-generation highly selective RET inhibitors is an area of active research. This review summarizes the current understanding of RET alterations and the state-of-the-art treatment strategies in RET-dependent cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32083997"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 465,
          "text": "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, and pralsetinib. Only selpercatinib and pralsetinib have been developed specifically for RET, while the remaining are multikina",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198171"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35969032"
        },
        {
          "offsetInBeginSection": 603,
          "offsetInEndSection": 715,
          "text": "Recently, two potent and selective RET TKIs, pralsetinib (BLU-667) and selpercatinib (LOXO-292), were developed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582449"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 404,
          "text": "nt benefit. Selective RET inhibitors Pralsetinib and Selpercatinib are targeted drugs approved by the US Food and Drug Administration for treating RET-mut",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37603207"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 340,
          "text": "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198171"
        },
        {
          "offsetInBeginSection": 356,
          "offsetInEndSection": 550,
          "text": "Recent advancements in targeted therapies have led to the development of ret proto-oncogene (RET) inhibitors, such as selpercatinib and pralsetinib, which have been approved for the treatment of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 229,
          "text": "r types. Selpercatinib is a highly selective RET kinase ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "INTRODUCTION: Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35726802"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 436,
          "text": "selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Selpercatinib (LOXO-292) is a selective and potent RET inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33314236"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 311,
          "text": "er treatment. Selpercatinib (LOXO-292) is a highly selective RET kinase inhibitor indicated in advanced RET-mutant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35007206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34099825"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung can",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056"
        }
      ],
      "id": "65cfa22b1930410b1300000c",
      "ideal_answer": [
        "Selpercatinib is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC)."
      ],
      "exact_answer": [
        [
          "rearranged during transfection (RET) kinase"
        ]
      ]
    },
    {
      "body": "What is IL-35?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36731088",
        "http://www.ncbi.nlm.nih.gov/pubmed/36579639",
        "http://www.ncbi.nlm.nih.gov/pubmed/37464473",
        "http://www.ncbi.nlm.nih.gov/pubmed/36314719",
        "http://www.ncbi.nlm.nih.gov/pubmed/29371247",
        "http://www.ncbi.nlm.nih.gov/pubmed/31966444",
        "http://www.ncbi.nlm.nih.gov/pubmed/27734415",
        "http://www.ncbi.nlm.nih.gov/pubmed/25619872",
        "http://www.ncbi.nlm.nih.gov/pubmed/29749583",
        "http://www.ncbi.nlm.nih.gov/pubmed/24273881",
        "http://www.ncbi.nlm.nih.gov/pubmed/34054534",
        "http://www.ncbi.nlm.nih.gov/pubmed/22427377",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752977",
        "http://www.ncbi.nlm.nih.gov/pubmed/31333002",
        "http://www.ncbi.nlm.nih.gov/pubmed/33128920",
        "http://www.ncbi.nlm.nih.gov/pubmed/26872697",
        "http://www.ncbi.nlm.nih.gov/pubmed/35420296",
        "http://www.ncbi.nlm.nih.gov/pubmed/32276581",
        "http://www.ncbi.nlm.nih.gov/pubmed/27996283",
        "http://www.ncbi.nlm.nih.gov/pubmed/24970690",
        "http://www.ncbi.nlm.nih.gov/pubmed/27582486",
        "http://www.ncbi.nlm.nih.gov/pubmed/29641433",
        "http://www.ncbi.nlm.nih.gov/pubmed/33865428",
        "http://www.ncbi.nlm.nih.gov/pubmed/25640666",
        "http://www.ncbi.nlm.nih.gov/pubmed/35434379",
        "http://www.ncbi.nlm.nih.gov/pubmed/26530251",
        "http://www.ncbi.nlm.nih.gov/pubmed/31974915",
        "http://www.ncbi.nlm.nih.gov/pubmed/26369677",
        "http://www.ncbi.nlm.nih.gov/pubmed/34788131",
        "http://www.ncbi.nlm.nih.gov/pubmed/29054137",
        "http://www.ncbi.nlm.nih.gov/pubmed/28936965",
        "http://www.ncbi.nlm.nih.gov/pubmed/35759811"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "INTERLEUKIN-35 DOWNREGULATES THE IMMUNE RESPONSE OF EFFECTOR CD4 + T CELLS VIA RESTRICTING HIGH MOBILITY GROUP BOX-1 PROTEIN-DEPENDENT AUTOPHAGY IN SEPSIS.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36731088"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 216,
          "text": "The novel role of the anti-inflammatory cytokine IL-35 in sepsis was examined.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36731088"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 157,
          "text": "Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36579639"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 161,
          "text": "Interleukin-35 (IL-35), secreted by regulatory T cells (Treg) and B cells, is immunosuppressive under both physiological and pathological conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37464473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Interleukin 35 (IL-35) mediates immunosuppression of T cells in autoimmune diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314719"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 525,
          "text": "IL-35 (Interleukin-35) is a new member of the IL-12 (Interleukin-12) family, which is an immunosuppressive and anti-inflammatory cytokine secreted mainly by Treg (T regulatory cells).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34054534"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 260,
          "text": "IL-35 is an anti-inflammatory cytokine comprising the p35 subunit of IL-12 and the subunit Epstein-Barr virus (EBV) -induced gene 3(EBI3).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24273881"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 318,
          "text": "Since its discovery, IL-35 has been shown to exhibit immunosuppressive activities which are distinct from other members of IL-12 family.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734415"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "IL-35 is a relatively new cytokine that emerges as an important immunomodulator.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29749583"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Interleukin 35 (IL-35) is the most recently identified member of the IL-12 family of cytokines and offers the potential to be a target for new therapies for autoimmune, inflammatory, and infectious diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25619872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Interleukin (IL)-35 is a newly identified inhibitory cytokine used by T regulatory cells to control T cell-driven immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Interleukin 35 (IL-35) functions in an anti-inflammatory fashion by inhibiting T-cell proliferation, whereas CD4(+) T cells play an important role in cellular immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "Interleukin-35 (IL-35), is a recently identified cytokine that belongs to the IL-12 family, it is a potent anti-inflammatory and immunosuppressive cytokine which was first recognized to be produced by regulatory T cells (Tregs) cells, and recently was found to be produced by regulatory B cells (Bregs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31333002"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "OBJECTIVE: IL-35 (interleukin-35) is an anti-inflammatory cytokine, which inhibits immune responses by inducing regulatory T cells and regulatory B cells and suppressing effector T cells and m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29371247"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 396,
          "text": "Interleukin-35 (IL-35) is a Treg cell-secreted cytokine that inhibits T cell proliferation and function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872697"
        },
        {
          "offsetInBeginSection": 452,
          "offsetInEndSection": 569,
          "text": "IL-35 can directly suppress effector T-cell proliferation and function and inhibit the differentiation of Th17 cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734415"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 451,
          "text": "IL-35 is also unique in that it is expressed primarily by regulatory T-cells (Tregs) rather than by antigen-presenting cells (APCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734415"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "BACKGROUND: Interleukin (IL)-35 is a newly indentified cytokine and induces immunotolerance via suppres",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974915"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 394,
          "text": "BACKGROUND: Interleukin-35 (IL-35) is a recently described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. The expression of IL-35 in humans is inducible in response to inflammatory stimuli. Increased IL-35 levels were documented in several autoimmune inflammatory diseases, suggesting a possible immunomodulatory role in their p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128920"
        },
        {
          "offsetInBeginSection": 821,
          "offsetInEndSection": 954,
          "text": "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530251"
        },
        {
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1108,
          "text": "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. Accumulating evidence suggests that IL-35 represents an attractive target for anti-atherosclerotic therapy based on its several atheroprotective features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26369677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "BACKGROUND: Interleukin-35 (IL-35) is a newly identified IL-12 cytokine family member, which regulates the activity of immune cells in infectious diseases and autoimmune",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32276581"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 379,
          "text": "Interleukin-35 (IL-35) is a lately observed cytokine and is part of the IL-12 cytokine family. IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35434379"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "IL-35 is the newest member of IL-12 family. A dimeric protein consisting of two separate subunits has manifested suppressive actions on immune system, which is counterproductive in the context of cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31205568"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Interleukin (IL)-35 is a novel member of the IL-12 cytokine family, which exhibits a unique immune regulatory function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31186721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND: IL-35 is a novel cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Interleukin-35 (IL-35) is a novel anti-inflammatory cytokine and has been shown to play an important role in maintaining immune homeostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970690"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 192,
          "text": "IL35 has recently emerged as a novel regulator of immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582486"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "The recently identified cytokines-interleukin (IL)-35 and interleukin (IL)-37-have been described for their anti-inflammatory and immune-modulating actions in numerous inflammatory diseases, auto-immune disorders, malignancies, infectious diseases and sepsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29641433"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "BACKGROUND: IL-35 is a newly anti-inflammatory cytokine that belongs to the I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33865428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Interleukin-35 (IL-35) is a novel immunosuppressive and anti-inflammatory cytokine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31966444"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 188,
          "text": "Interleukin-35 (IL35) can suppress T cell proliferation and elicit the development of inducible regulatory T cells (Tregs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640666"
        },
        {
          "offsetInBeginSection": 698,
          "offsetInEndSection": 841,
          "text": "IL35 is overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582486"
        },
        {
          "offsetInBeginSection": 95,
          "offsetInEndSection": 379,
          "text": "IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35434379"
        },
        {
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1197,
          "text": ", IL35 appears to contribute to the loss of immunological self-tolerance in ITP patients by modulating T cells and immunoregulatory cytokine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640666"
        },
        {
          "offsetInBeginSection": 821,
          "offsetInEndSection": 953,
          "text": "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Interleukin 35 (IL-35) is a relatively newly identified cytokine required for the regulatory and suppressive functions of regulatory T cells (Treg), playing an important role in the prevention of autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29054137"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 394,
          "text": "Interleukin-35 (IL-35), an inhibitory cytokine that belongs to the IL-12 family, is capable of potently suppressing T cell proliferation and inducing IL-35-producing induced regulatory T cells (iTr35) to limit inflammatory responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788131"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 569,
          "text": "meostasis. Interleukin-35 (IL-35), as a newly identified member of IL-12 family, exerts suppressive effect on immune response by means of a specif",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28936965"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 365,
          "text": "Interleukin-35 (IL-35), a cytokine of the interleukin-12 family, is a novel anti-inflammation and immunosuppressive cytokine, maintaining inflammatory suppression and regulating immune homeostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35759811"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "OBJECTIVE: IL-35 is a potent immunosuppressive and anti-inflammatory cytokine, consisting of a p35 subunit and an Epstein-Barr virus-induced gene 3 (EBI3) subunit, which sup",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35420296"
        }
      ],
      "id": "65f5a319c4010b4d78000016",
      "ideal_answer": [
        "IL-35 is a member of the IL-12 family and is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. Structurally, IL-35 is a heterodimeric cytokine. Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation",
        "IL-35 is a heterodimeric cytokine belonging to the IL-12 family, composed of the IL-12p35 and Ebi3 subunits, known for its immunosuppressive activities.",
        "IL-35 is a novel cytokine that suppresses the immune response through the expansion of regulatory T cells and suppression of Th17 cell development. It includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types. IL-35 has been found to be overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells. Plasma IL35 levels have been found to be lower in ITP patients and negatively correlated with the levels of T helper-1 cells in ITP patients, suggesting that IL-35 appears to contribute to the loss of immunological self-tolerance in ITP patients by modulating T cells and immunoregulatory cytokines.",
        "IL-35 is a new IL-12 family member, comprised of Ebi3 and p35.\nIL-35 has a different mode of action than the other IL-12 cytokines: IL-12 and IL-23 enhance IFN-gamma production, and IL-27 induces Tbet and STAT-1 signaling.\nIL-35, on the other hand, does not signal via a receptor chain but acts by directly stimulating suppressive T regulatory cells.",
        "IL-35 is a novel cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.",
        "IL-35 is a cytokine that belongs to the IL-12 family. It is an immunosuppressive and anti-inflammatory cytokine secreted mainly by regulatory cells. IL-35 has therapeutic and diagnostic potential in cancer and autoimmune diseases.",
        "Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation.",
        "Interleukin-35 (IL-35), secreted by regulatory T cells (Treg) and B cells, is immunosuppressive under both physiological and pathological conditions.",
        "IL-35 is an anti-inflammatory cytokine that mediates immunosuppression of T cells in various physiological and pathological conditions.",
        "IL-35 is a cytokine, a type of protein, that is secreted by regulatory T cells and B cells. It plays an immunosuppressive role under both physiological and pathological conditions, meaning it can suppress or reduce the immune response.",
        "IL-35 is a type of interleukin that mediates immunosuppression of T cells in autoimmune diseases, secreted by regulatory T cells and B cells.",
        "IL-35 is an anti-inflammatory cytokine secreted by regulatory T cells (Treg) and B cells, exerting immunosuppressive effects in various physiological and pathological conditions.",
        "Interleukin-35 (IL-35) is a heterodimeric cytokine consisting of two subunits, IL-12A and EBV-induced gene 3 (EBI3), that is produced mainly by regulatory T cells (Treg cells) and inhibits the activation of T helper (Th1 and Th17) and dendritic cells to exert anti-inflammatory effects.",
        "IL-35 is a cytokine that is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation.",
        "Interleukin 35 (IL-35) is a cytokine that is secreted by regulatory T cells (Treg) and B cells, and is immunosuppressive under both physiological and pathological conditions.",
        "IL-35 is an immunosuppressive cytokine that is secreted by regulatory T cells (Treg) and B cells. It plays a role in maintaining Treg phenotypes, suppressing CD8+ T-cell activation, and mediating immunosuppression in autoimmune diseases and sepsis.",
        "IL-35 is a cytokine that is produced by T cells and regulates the immune response. It is a member of the interleukin 1 family and is involved in the regulation of immune responses, particularly in the context of autoimmune diseases.",
        "IL-35 is an anti-inflammatory cytokine that is secreted by regulatory T cells and B cells, known for its immunosuppressive effects under both physiological and pathological conditions.",
        "IL-35 (Interleukin-35) is an anti-inflammatory cytokine secreted by regulatory T cells (Treg) and B cells. It has immunosuppressive effects on T cells under both physiological and pathological conditions, and is involved in mediating immunosuppression in autoimmune diseases.",
        "IL-35 is an immunosuppressive cytokine, which is secreted by regulatory T cells and B cells. It plays a role in suppressing the immune response under both normal and pathological conditions",
        "IL-35 is a cytokine that is involved in immunosuppression. It is secreted by regulatory T cells (Treg) and B cells. IL-35 mediates immunosuppression of T cells in autoimmune diseases.",
        "IL-35 is a cytokine that downregulates the immune response of effector CD4+ T cells in sepsis by restricting high mobility group box-1 protein-dependent autophagy."
      ]
    },
    {
      "body": "What are the transmission mechanisms of the human Ebola infection?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33080902",
        "http://www.ncbi.nlm.nih.gov/pubmed/30513823",
        "http://www.ncbi.nlm.nih.gov/pubmed/30381349",
        "http://www.ncbi.nlm.nih.gov/pubmed/25719678",
        "http://www.ncbi.nlm.nih.gov/pubmed/18981410",
        "http://www.ncbi.nlm.nih.gov/pubmed/32487785",
        "http://www.ncbi.nlm.nih.gov/pubmed/30609455",
        "http://www.ncbi.nlm.nih.gov/pubmed/28058346",
        "http://www.ncbi.nlm.nih.gov/pubmed/28653186"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 424,
          "text": "EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30381349"
        },
        {
          "offsetInBeginSection": 257,
          "offsetInEndSection": 284,
          "text": "human-to-human transmission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 438,
          "text": "persistent EBOV infections and included sexual transmission from EVD survivors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823"
        },
        {
          "offsetInBeginSection": 440,
          "offsetInEndSection": 511,
          "text": "Asymptomatic infection and long-term viral persistence in EVD survivors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 756,
          "text": "persistence of filoviruses and their potential for sexual transmission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513823"
        },
        {
          "offsetInBeginSection": 273,
          "offsetInEndSection": 296,
          "text": "nosocomial transmission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910462"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 399,
          "text": "The sporadic human outbreaks are believed to result when EBOV \"jumps\" from an infected animal to a person and is subsequently transmitted between persons by direct contact with infected blood or body fluids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18981410"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 524,
          "text": "Transmission of EBoV has been reported in various ways, including human to human transmission through close contact with blood and bodily fluids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32487785"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. Ebola virus (EBOV) is transmitted through contact with blood or body fluids of a person who contracted or died from EVD, contaminated objects like needles and infected animals or bush meat.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28058346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Viruses of the Ebolavirus genus cause sporadic epidemics of severe and systemic febrile disease that are fueled by human-to-human transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28653186"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 801,
          "text": "People were infected by touching body fluids of blood, secretions, vomit, and other discharges from patients with EVD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30609455"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 425,
          "text": "Transmission of EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30381349"
        }
      ],
      "id": "65f84535c4010b4d78000044",
      "ideal_answer": [
        "Ebolaviruses spread through contact via broken skin or mucous membranes in the eyes, nose, or mouth with:\nBlood or body fluids of a person who is sick with or has died from Ebola disease.\nObjects contaminated with body fluids from a person who is sick with or has died from Ebola disease.\nInfected fruit bats and primates.\nSemen from men survivors of Ebola disease (via oral, vaginal, or anal sex).",
        "Human-to-human transmission of Ebola takes place through direct contact with broken skin, secretions, organs or other bodily fluids of infected people or surfaces and materials contaminated with these fluids. Exposure to objects contaminated with the virus, reuse of unsterilized needles or other sharp objects previously used for injecting infected patients can also transmit the virus. Burial ceremonies that involve direct contact with the body of the deceased person can also play a role in the transmission of Ebola. Sexual transmission, particularly among males, several weeks after recovery from the disease has been reported.",
        "The transmission mechanisms of human Ebola infection are primarily through direct contact with infectious bodily fluids, such as blood, sweat, and saliva. This can occur through activities like touching, shaking hands, or being exposed to the vomit or diarrhea of an infected person. In addition, transmission can also happen through contact with contaminated objects and surfaces, including clothing and medical equipment. Airborne transmission has been suspected but not proven in some studies, and the role of aerosol transmission in Ebola virus spread is still being researched. The virus can also be transmitted through sexual contact, as well as from mother to child during pregnancy or breastfeeding. Healthcare workers are at higher risk of infection due to their exposure to patients with Ebola, highlighting the importance of proper personal protective equipment (PPE) and strict adherence to infection control protocols.",
        "The transmission of human Ebola infection occurs through direct contact with infected bodily fluids, such as blood, semen, saliva, urine, and breast milk. It can also be transmitted through indirect contact with contaminated surfaces or objects. Sexual transmission has been documented, as the virus can persist in the testes. Additionally, Ebola virus can be transmitted from animals to humans through contact with infected animals or consumption of their meat. The virus is not transmitted through the air or by casual contact."
      ],
      "exact_answer": [
        [
          "Broken skin and mucous membranes in contact with bodily fluids of sick person"
        ],
        [
          "Broken skin and mucous membranes in contact with corpse of person who died of Ebola"
        ],
        [
          "Semen from Ebola survivors via oral, vaginal, or anal sex"
        ],
        [
          "Infected fruit bats and primates"
        ]
      ]
    },
    {
      "body": "What is the mechanisms of action of Sotorasib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36690705",
        "http://www.ncbi.nlm.nih.gov/pubmed/36563789",
        "http://www.ncbi.nlm.nih.gov/pubmed/36566134",
        "http://www.ncbi.nlm.nih.gov/pubmed/36764316",
        "http://www.ncbi.nlm.nih.gov/pubmed/36581205",
        "http://www.ncbi.nlm.nih.gov/pubmed/36577165",
        "http://www.ncbi.nlm.nih.gov/pubmed/35412531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36077640",
        "http://www.ncbi.nlm.nih.gov/pubmed/37627169",
        "http://www.ncbi.nlm.nih.gov/pubmed/34715449",
        "http://www.ncbi.nlm.nih.gov/pubmed/36529835",
        "http://www.ncbi.nlm.nih.gov/pubmed/36929750",
        "http://www.ncbi.nlm.nih.gov/pubmed/37386628",
        "http://www.ncbi.nlm.nih.gov/pubmed/37831779",
        "http://www.ncbi.nlm.nih.gov/pubmed/36217844",
        "http://www.ncbi.nlm.nih.gov/pubmed/36319849",
        "http://www.ncbi.nlm.nih.gov/pubmed/34365406",
        "http://www.ncbi.nlm.nih.gov/pubmed/34715459",
        "http://www.ncbi.nlm.nih.gov/pubmed/34675734",
        "http://www.ncbi.nlm.nih.gov/pubmed/36901764",
        "http://www.ncbi.nlm.nih.gov/pubmed/38093368",
        "http://www.ncbi.nlm.nih.gov/pubmed/38072173",
        "http://www.ncbi.nlm.nih.gov/pubmed/38070479",
        "http://www.ncbi.nlm.nih.gov/pubmed/38067288",
        "http://www.ncbi.nlm.nih.gov/pubmed/38061200",
        "http://www.ncbi.nlm.nih.gov/pubmed/38049578",
        "http://www.ncbi.nlm.nih.gov/pubmed/38044989",
        "http://www.ncbi.nlm.nih.gov/pubmed/37101895",
        "http://www.ncbi.nlm.nih.gov/pubmed/37008835",
        "http://www.ncbi.nlm.nih.gov/pubmed/36315377",
        "http://www.ncbi.nlm.nih.gov/pubmed/37190303",
        "http://www.ncbi.nlm.nih.gov/pubmed/37101896",
        "http://www.ncbi.nlm.nih.gov/pubmed/35153196",
        "http://www.ncbi.nlm.nih.gov/pubmed/34357500",
        "http://www.ncbi.nlm.nih.gov/pubmed/37673617",
        "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590053",
        "http://www.ncbi.nlm.nih.gov/pubmed/34158284",
        "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
        "http://www.ncbi.nlm.nih.gov/pubmed/37504336",
        "http://www.ncbi.nlm.nih.gov/pubmed/35192958",
        "http://www.ncbi.nlm.nih.gov/pubmed/38023987",
        "http://www.ncbi.nlm.nih.gov/pubmed/35864332",
        "http://www.ncbi.nlm.nih.gov/pubmed/35267628",
        "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
        "http://www.ncbi.nlm.nih.gov/pubmed/34607583",
        "http://www.ncbi.nlm.nih.gov/pubmed/33971321",
        "http://www.ncbi.nlm.nih.gov/pubmed/36388799",
        "http://www.ncbi.nlm.nih.gov/pubmed/34144959",
        "http://www.ncbi.nlm.nih.gov/pubmed/34919824",
        "http://www.ncbi.nlm.nih.gov/pubmed/35260176",
        "http://www.ncbi.nlm.nih.gov/pubmed/33824136",
        "http://www.ncbi.nlm.nih.gov/pubmed/36546651",
        "http://www.ncbi.nlm.nih.gov/pubmed/37666686",
        "http://www.ncbi.nlm.nih.gov/pubmed/37557065",
        "http://www.ncbi.nlm.nih.gov/pubmed/37336286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34471232",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864132",
        "http://www.ncbi.nlm.nih.gov/pubmed/36980522",
        "http://www.ncbi.nlm.nih.gov/pubmed/35083149",
        "http://www.ncbi.nlm.nih.gov/pubmed/36358848",
        "http://www.ncbi.nlm.nih.gov/pubmed/35101229",
        "http://www.ncbi.nlm.nih.gov/pubmed/36394791",
        "http://www.ncbi.nlm.nih.gov/pubmed/36928090",
        "http://www.ncbi.nlm.nih.gov/pubmed/37700573",
        "http://www.ncbi.nlm.nih.gov/pubmed/37110848",
        "http://www.ncbi.nlm.nih.gov/pubmed/34776511",
        "http://www.ncbi.nlm.nih.gov/pubmed/36675641",
        "http://www.ncbi.nlm.nih.gov/pubmed/35832439",
        "http://www.ncbi.nlm.nih.gov/pubmed/38010044",
        "http://www.ncbi.nlm.nih.gov/pubmed/33466360",
        "http://www.ncbi.nlm.nih.gov/pubmed/33957355",
        "http://www.ncbi.nlm.nih.gov/pubmed/34096690",
        "http://www.ncbi.nlm.nih.gov/pubmed/34504076",
        "http://www.ncbi.nlm.nih.gov/pubmed/34161704",
        "http://www.ncbi.nlm.nih.gov/pubmed/37703579"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 582,
          "text": "At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36690705"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1218,
          "text": "Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a patient with metastatic NSCLC with a concurrent ROS1 fusion and KRAS p.G12C mutation at diagnosis who experienced a short duration of disease control on entrectinib, a ROS1 TKI. At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C. A patient-derived cell line generated at progression on entrectinib demonstrated improved TKI responsiveness when treated with entrectinib and sotorasib. Cell-line growth dependence on both ROS1 and KRAS p.G12C was further reflected in the distinct downstream signaling pathways activated by each driver. Clinical benefit was not observed with combined therapy of entrectinib and sotorasib possibly related to an evolving KRAS p.G12C amplification identified on repeated molecular testing. This case supports the need for broad molecular profiling in patients with metastatic NSCLC for potential therapeutic and prognostic information.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36690705"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 481,
          "text": "ecent breakthroughs in the development of mutant-specific KRAS inhibitors include the FDA approved drug Lumakras (Sotorasib, AMG510) for KRAS G12C-mutated non-small cell lung cancer (NSCLC), and MRTX1133, a promising clinical candidate for the treatment of KRAS G12D-mutated cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36563789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36566134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36566134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36764316"
        },
        {
          "offsetInBeginSection": 639,
          "offsetInEndSection": 802,
          "text": "This discovery stemmed from our finding that Survivin expression is downregulated upon treatment of pancreatic cancer cells with the KRASG12C inhibitor Sotorasib. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36581205"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 258,
          "text": "Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36577165"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 388,
          "text": "Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38072173"
        },
        {
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1141,
          "text": "In summary, sotorasib is a promising KRASG12C inhibitor that increases the available treatment options for patients with KRAS G12C mutation-positive NSCLC who were previously treated with platinum-based chemotherapy and/or immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315377"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 425,
          "text": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176"
        },
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 473,
          "text": "Sotorasib, a first-in-class specific small molecule that irreversibly inhibits KRAS G12C, has since obtained Health Canada approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37504336"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 277,
          "text": "By binding irreversibly to KRASG12C, sotorasib inhibits downstream signalling pathways which are associated with cell growth and differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Sotorasib (LUMAKRAS™ in the USA and LUMYKRAS™ in the EU) is an orally active, first-in-class G12C-mutant KRAS (KRASG12C) inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Sotorasib (LUMAKRAS®) is the first RAS inhibitor that selectively binds to KRAS G12C and irreversibly inhibits the conformational change from the inactive to active form of KRAS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37673617"
        },
        {
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1334,
          "text": "Using this approach, we characterised how the interactome of KRAS wild-type and mutants is regulated by the clinically approved KRASG12C inhibitor Sotorasib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37627169"
        },
        {
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1964,
          "text": "Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma.CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34357500"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 681,
          "text": "Sotorasib, a first-in-class covalent KRAS G12C inhibitor that binds to the switch pocket II in the KRAS G12C-GDP \"off\" state, received US FDA accelerated approval on May 21, 2021 in the US, based on a Phase II dose expansion cohort of CodeBreaK 100 trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37101896"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 689,
          "text": "Their foremost mechanism of action utilizes the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, confining them to their inactive state. Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34161704"
        },
        {
          "offsetInBeginSection": 539,
          "offsetInEndSection": 949,
          "text": "We identified compounds, such as flupentixol, amlodipine, and fluvoxamine, for the G12C mutant and paroxetine, flupentixol, and zuclopenthixol for the G12D mutant with significant inhibitory functions. All five compounds bound to the H95 cryptic groove of mutant K-Ras with high efficiency and, like sotorasib, retained a novel binding mechanism with additional hydrophobic interactions at the molecular level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34715554"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 269,
          "text": "The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35864332"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 688,
          "text": "Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190303"
        },
        {
          "offsetInBeginSection": 278,
          "offsetInEndSection": 496,
          "text": "Sotorasib is indicated for the treatment of adults with advanced, previously treated, KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) in multiple countries, including the countries of the EU and the USA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36315377"
        },
        {
          "offsetInBeginSection": 855,
          "offsetInEndSection": 1001,
          "text": "We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37666686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 565,
          "text": "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) containing the KRAS G12C mutation, on the basis of results of a phase II clinical trial (Code- BreaK100). In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412531"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 402,
          "text": "In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS-G12C mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471232"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 409,
          "text": "Recent efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting conspicuous clinical responses across multiple tumor types, providing new impetus for renewed drug development and culminating in sotorasib with approximately 6-month median progression-free survival in KRAS G12C-driven lung cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864132"
        },
        {
          "offsetInBeginSection": 574,
          "offsetInEndSection": 837,
          "text": "This discovery led to the development of a new class of selective small-molecule inhibitors against the KRAS G12C isoform. Sotorasib and adagrasib are approved in locally advanced or metastatic NSCLC patients who have received at least one prior systemic therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36980522"
        },
        {
          "offsetInBeginSection": 526,
          "offsetInEndSection": 789,
          "text": "Recently, the discovery of a new pocket under the effector binding switch II region of KRAS G12C has allowed the development of direct KRAS inhibitors such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, initiating a new exciting era.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35083149"
        },
        {
          "offsetInBeginSection": 598,
          "offsetInEndSection": 819,
          "text": "Sotorasib and adagrasib are novel KRAS inhibitors that recently gained FDA approval for pre-treated KRAS mutant NSCLC patients, and other molecules such as GDC-6036 are currently being investigated with promising results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36358848"
        },
        {
          "offsetInBeginSection": 368,
          "offsetInEndSection": 505,
          "text": "Advances over the past decade with KRAS(G12C) mutation-specific inhibitors have culminated in the first FDA-approved RAS drug, sotorasib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35101229"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 387,
          "text": "Recent breakthroughs in the development of mutant-specific KRAS inhibitors include the FDA approved drug Lumakras (Sotorasib, AMG510) for KRAS G12C-mutated non-small cell lung cancer (NSCLC)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36563789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 373,
          "text": "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) containing the KRAS G12C mutation, on the basis of results of a phase II clinical trial (Code- BreaK100).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412531"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 565,
          "text": "In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412531"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 689,
          "text": "Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412531"
        },
        {
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1337,
          "text": "how the interactome of KRAS wild-type and mutants is regulated by the clinically approved KRASG12C inhibitor Sotorasib. In",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37627169"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 281,
          "text": "cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34715449"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 389,
          "text": "Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38072173"
        },
        {
          "offsetInBeginSection": 698,
          "offsetInEndSection": 940,
          "text": "Sotorasib, has been approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency. Another KRAS inhibitor targeting c.34G \u003e T (p.G12C), Adagrasib, is currently being reviewed by the FDA for accelerated approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36077640"
        }
      ],
      "id": "65ce88be1930410b13000002",
      "ideal_answer": [
        "Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation."
      ]
    },
    {
      "body": "What is the vector for coxiella burnetii transmission?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37387368",
        "http://www.ncbi.nlm.nih.gov/pubmed/35190334",
        "http://www.ncbi.nlm.nih.gov/pubmed/37866329",
        "http://www.ncbi.nlm.nih.gov/pubmed/26458781",
        "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
        "http://www.ncbi.nlm.nih.gov/pubmed/32059686",
        "http://www.ncbi.nlm.nih.gov/pubmed/36439350",
        "http://www.ncbi.nlm.nih.gov/pubmed/32141019",
        "http://www.ncbi.nlm.nih.gov/pubmed/33113791",
        "http://www.ncbi.nlm.nih.gov/pubmed/37107481",
        "http://www.ncbi.nlm.nih.gov/pubmed/37025192",
        "http://www.ncbi.nlm.nih.gov/pubmed/26186513",
        "http://www.ncbi.nlm.nih.gov/pubmed/21771522",
        "http://www.ncbi.nlm.nih.gov/pubmed/32173315",
        "http://www.ncbi.nlm.nih.gov/pubmed/28502643"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 484,
          "text": "transmitted by ticks include bacteria of the genus Borrelia and the species Francisella tularensis, Anaplasma phagophytophilum and Coxiella burnetii; ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37387368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Prevalence of Coxiella-infections in ticks - review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 394,
          "text": "Excretion of C. burnetii in tick feces and saliva is well documented but the role of these findings or the epidemiological context is discussed controversia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Exploring the diversity of tick-borne pathogens: The case of bacteria (Anaplasma, Rickettsia, Coxiella and Borrelia) protozoa (Babesia and Theileria) and viruses (Orthonairovirus, tick-borne encephalitis virus and louping ill virus) in the European continent.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Vector competence of the African argasid tick Ornithodoros moubata for the Q fever agent Coxiella burnetii.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079"
        },
        {
          "offsetInBeginSection": 908,
          "offsetInEndSection": 1103,
          "text": "Although C. burnetii transmission is mainly airborne, ticks may act as vectors and play an important role in the natural cycle of transmission of coxiellosis among wild vertebrates and livestock.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439350"
        },
        {
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1586,
          "text": "Finally, we detected only a sporadic presence of C. burnetii DNA in tick faeces, but no living bacterium was further isolated in culture assays, suggesting that excretion in faeces is not a common mode of transmission in O. moubata.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Transstadial Transmission from Nymph to Adult of Coxiella burnetii by Naturally Infected Hyalomma lusitanicum.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33113791"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Coxiella burnetii (Derrick) Philip, the causative agent of Q fever, is mainly transmitted by aerosols, but ticks can also be a source of infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33113791"
        },
        {
          "offsetInBeginSection": 1225,
          "offsetInEndSection": 1311,
          "text": "Furthermore, the transmission of C. burnetii is most likely via vectors (i.e., ticks).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37107481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Query (Q) fever is a vector-borne zoonosis caused by the obligate intracellular pathogen Coxiella burnetii. Animals, including dogs, cats, cattle, and sheep, can be infected by C. burnetii.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26186513"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Q fever is a global zoonotic infection caused by the intracellular Gram-negative bacterium Coxiella burnetii. Historically, it is considered a vector-borne disease, but the role of ticks in transmission has not fully been elucidated yet.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35190334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Q fever is a widespread zoonotic disease caused by Coxiella burnetii that most commonly infects not only a variety of mammals but also arthropods and in particularly ticks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32173315"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 1093,
          "text": "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii. To this end, we used an artificial feeding system to initiate infection of ticks, specific molecular tools to monitor further infections, and culture assays in axenic and cell media to check for the viability of C. burnetii excreted by ticks. We observed typical traits associated with vector competence: The exposure to an infected blood meal resulted in viable and persistent infections in ticks, trans-stadial transmissions of infection from nymphs to adults and the ability of adult ticks to transmit infectious C. burnetii.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "The dramatic spread of Q fever in Poland among cattle kept in isolation from natural environment (ticks, wild animals) has suggested the possibility that the infection may also be transmitted sexually. To test this hypothesis series of experiments have been performed in controlled laboratory conditions. Male mice infected with C. burnetii were allowed to mate with healthy female mice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1350178"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Background: Q fever is a zoonotic disease caused by Coxiella burnetii infection, with domestic ruminants as the main source of infection and tick bites as one of the transmission vectors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37025192"
        },
        {
          "offsetInBeginSection": 1201,
          "offsetInEndSection": 1353,
          "text": "In addition, while adult female ticks were infected, we did not observe C. burnetii in eggs, suggesting that transovarial transmission is not effective.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 564,
          "text": "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Coxiella burnetii, the causative agent of Q fever, and Rickettsia spp. are bacterial pathogens that can be transmitted by ticks of the genus Dermacentor (i.e., Dermacentor marginatus and D. reticulatus).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21771522"
        },
        {
          "offsetInBeginSection": 1217,
          "offsetInEndSection": 1410,
          "text": "Our data suggest that zebus as well as Amblyomma and Boophilus ticks have to be considered as a natural reservoir or vector for C. burnetii, but the risk of cattle-to-human transmission is low.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28502643"
        },
        {
          "offsetInBeginSection": 78,
          "offsetInEndSection": 115,
          "text": "ticks in the transmission of Coxiella",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32141019"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 353,
          "text": "BACKGROUND: The bacterium Coxiella burnetii is the etiological agent of Q fever and is mainly transmitted via inhalation of infectious aerosols. DNA of C. burnetii is frequently detected in ticks, but the role of ticks as vectors in the epidemiology of this agent is still controversial. In this study, Ixodes ricinus and Dermacentor marginatus adults a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059686"
        },
        {
          "offsetInBeginSection": 51,
          "offsetInEndSection": 374,
          "text": "Coxiella burnetii, a ubiquitous intracellular bacterium infecting humans and a variety of animals. Transmission is primarily but not exclusively airborne, and ticks are usually thought to act as vectors. We argue that, although ticks may readily transmit C. burnetii in experimental systems, they only occasionally transmit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458781"
        }
      ],
      "id": "65f039fdc4010b4d78000002",
      "ideal_answer": [
        "Ticks are the common vector for Coxiella burnetii",
        "Ticks, including species like Hyalomma lusitanicum, I. ricinus, and Ornithodoros moubata, act as vectors for the transmission of Coxiella burnetii.",
        "Ticks are the vector for coxiella burnetii transmission.",
        "The vector for Coxiella burnetii transmission is primarily through inhalation of infectious aerosols, although ticks have also been suggested as potential vectors.",
        "Coxiella burnetii is transmitted by ticks.",
        "Yes, Coxiella burnetii is transmitted by ticks.",
        "The vector for Coxiella burnetii transmission is ticks, specifically through tick feces and saliva.",
        "Ticks are the vectors for transmitting Coxiella burnetii.",
        "The vector for Coxiella burnetii transmission is ticks.",
        "Coxiella burnetii is transmitted by ticks, including through their feces and saliva.",
        "The vector for Coxiella burnetii transmission is the tick.",
        "The vector for Coxiella burnetii transmission is primarily ticks."
      ],
      "exact_answer": [
        [
          "tick"
        ]
      ]
    },
    {
      "body": "Methotrexate is an antifolate medication.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36946211",
        "http://www.ncbi.nlm.nih.gov/pubmed/36508886",
        "http://www.ncbi.nlm.nih.gov/pubmed/22111860",
        "http://www.ncbi.nlm.nih.gov/pubmed/20579471",
        "http://www.ncbi.nlm.nih.gov/pubmed/12583828",
        "http://www.ncbi.nlm.nih.gov/pubmed/22388607",
        "http://www.ncbi.nlm.nih.gov/pubmed/23394392",
        "http://www.ncbi.nlm.nih.gov/pubmed/25161385",
        "http://www.ncbi.nlm.nih.gov/pubmed/7510620",
        "http://www.ncbi.nlm.nih.gov/pubmed/27758143",
        "http://www.ncbi.nlm.nih.gov/pubmed/26783755",
        "http://www.ncbi.nlm.nih.gov/pubmed/9713954",
        "http://www.ncbi.nlm.nih.gov/pubmed/24651961",
        "http://www.ncbi.nlm.nih.gov/pubmed/27993660",
        "http://www.ncbi.nlm.nih.gov/pubmed/19337845",
        "http://www.ncbi.nlm.nih.gov/pubmed/27920680",
        "http://www.ncbi.nlm.nih.gov/pubmed/8247309",
        "http://www.ncbi.nlm.nih.gov/pubmed/18020507",
        "http://www.ncbi.nlm.nih.gov/pubmed/29226354",
        "http://www.ncbi.nlm.nih.gov/pubmed/33572934",
        "http://www.ncbi.nlm.nih.gov/pubmed/24986327",
        "http://www.ncbi.nlm.nih.gov/pubmed/37973683",
        "http://www.ncbi.nlm.nih.gov/pubmed/37527941",
        "http://www.ncbi.nlm.nih.gov/pubmed/37493925",
        "http://www.ncbi.nlm.nih.gov/pubmed/37405586",
        "http://www.ncbi.nlm.nih.gov/pubmed/37384801",
        "http://www.ncbi.nlm.nih.gov/pubmed/37104530",
        "http://www.ncbi.nlm.nih.gov/pubmed/36443884",
        "http://www.ncbi.nlm.nih.gov/pubmed/26547381",
        "http://www.ncbi.nlm.nih.gov/pubmed/34132539",
        "http://www.ncbi.nlm.nih.gov/pubmed/22806879",
        "http://www.ncbi.nlm.nih.gov/pubmed/15753437",
        "http://www.ncbi.nlm.nih.gov/pubmed/19838716",
        "http://www.ncbi.nlm.nih.gov/pubmed/3178237",
        "http://www.ncbi.nlm.nih.gov/pubmed/17534933",
        "http://www.ncbi.nlm.nih.gov/pubmed/24348319",
        "http://www.ncbi.nlm.nih.gov/pubmed/31890337",
        "http://www.ncbi.nlm.nih.gov/pubmed/24704904",
        "http://www.ncbi.nlm.nih.gov/pubmed/36532750",
        "http://www.ncbi.nlm.nih.gov/pubmed/8852336",
        "http://www.ncbi.nlm.nih.gov/pubmed/11817030",
        "http://www.ncbi.nlm.nih.gov/pubmed/3896745",
        "http://www.ncbi.nlm.nih.gov/pubmed/30452231",
        "http://www.ncbi.nlm.nih.gov/pubmed/9479873"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 49,
          "text": "Methotrexate (MTX) is an antifolate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946211"
        },
        {
          "offsetInBeginSection": 662,
          "offsetInEndSection": 706,
          "text": "antifolate medications, such as methotrexate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Methotrexate (MTX) is an antimetabolite and antifolate drug used in the treatment of cancer and autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20579471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "INTRODUCTION: Methotrexate is an antifolate medication frequently used in the treatment of malignant and nonmalignant diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22388607"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 270,
          "text": "Methotrexate is a well known antifolate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7510620"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 315,
          "text": "Antifolate methotrexate (MTX), a drug commonly used in chemotherapy of several types of cancer, is a strong inhibitor of folate metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Methotrexate (MTX), an antifolate drug, is the first-line disease-modifying agent for the treatment of rheumatoid arthritis (RA) worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394392"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Methotrexate is an antimetabolite and antifolate drug that is widely used in the treatment of malignancies and auto-immune disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24651961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Methotrexate (MTX), the antifolate drug widely used as both an anticancer chemotherapeutic drug and as an immunosuppressive agent, mimics natural folates to inhibit critical cellular biosynthetic pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9713954"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 299,
          "text": "Methotrexate, the most studied folate antagonist, is effective in many malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12583828"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 502,
          "text": "Methotrexate inhibits dihydrofolate reductase, which leads to accumulation of polyglutamated folates, causing further inhibition of thymidylate synthase and glycinamide ribonucleotide formyltransferase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12583828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "INTRODUCTION: Antifolates are structural analogs of folates, which have been used as antitumor drugs for more than 60 years. The antifolate drug most commonly used for treating human tumors is methotrexate (MTX), which is utilized widely in first-line treatment protocols of high-grade osteos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27758143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "BACKGROUND: For decades, methotrexate (MTX; amethopterin) has been known as an antifolate inhibitor of dihydrofolate reductase (DHFR), and it is widely used for the treatment of various malignancies and autoimmu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Antifolates, such as methotrexate (MTX), are the treatment of choice for numerous cancers. MTX inhibits dihydrofolate reductase (DHFR), which is essential for cell growth and proliferation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19337845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Methotrexate (MTX) is an antifolic drug used in the treatment of immune-mediated and neoplastic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27920680"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and at lower doses for rheumatic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25161385"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "(1) Background: Antifolate methotrexate (MTX) is the most common disease-modifying antirheumatic drug (DMARD) for treating human rheumatoid arthritis (RA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33572934"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22111860"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Methotrexate (MTX) is an antifolate drug used for several diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29226354"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 259,
          "text": "Methotrexate is an antifolate that inhibits methylation reactions and reactions of amino acid, purine and pyrimidine metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18020507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Methotrexate (MTX) is an antifolic drug that in recent years has been largely employed in the treatment of Rheumatoid Arthritis (RA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8247309"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 122,
          "text": "Methotrexate (MTX), a folate antagonist, is often used as second-line treatment in patients with sarcoidosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37973683"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 192,
          "text": "The folate antagonist high-dose methotrexate (HD-MTX) is integral to induction chemotherapy for primary CNS lymphoma (PCNSL); however, it can be associated with leukoencephalopathy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37527941"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 431,
          "text": "6MP is combined with weekly oral methotrexate (MTX), an antifolate drug, to augment therapeutic activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37493925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Methotrexate (MTX) is an antifolate that is inescapable and widely used to treat autoimmune diseases and is the gold standard medicine for the arthritic condition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37405586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Most of our understanding of folate metabolism in the parasite Leishmania is derived from studies of resistance to the antifolate methotrexate (MTX)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37384801"
        },
        {
          "offsetInBeginSection": 440,
          "offsetInEndSection": 548,
          "text": "Recent studies have shown that known antifolate compounds, including methotrexate, inhibit the activity of W",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37104530"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 132,
          "text": "Methotrexate (MTX) is an antifolate and immunosuppressive drug prescribed for various malignancies and immune diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946211"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "BACKGROUND: Methotrexate is an antifolate antimetabolite that inhibits the activity of dihydrofolate reductase by acting as a false substrate, which leads to defects of DNA synthesis, specifically the inhibition of purine and pyrimidine synthesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36443884"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Methotrexate (MTX), a folate antagonist drug, has been widely used for treating various cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34132539"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 403,
          "text": "Methotrexate (MTX) is a specific folate antagonist that competitively inhibits dihydrofolate reductase (DHFR) activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Antifolates, such as methotrexate (MTX), are the treatment of choice for numerous cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19337845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Methotrexate (MTX) is a folate antagonist inhibiting nucleic acid and methionine synthesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15753437"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Methotrexate (MTX) is a folate inhibitor which has gained a major role in the treatment of rheumatoid arthritis (RA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19838716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Methotrexate (MTX), a folate antagonist which blocks de novo nucleotide biosynthesis and DNA replication, is an anchor drug in acute lymphoblastic leukemia (ALL) treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26547381"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Methotrexate (MTX), a folic acid antagonist, is among the most active known drugs for clinical cancer therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3178237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "The folate inhibitor methotrexate (MTX) is an important component of osteosarcoma (OS) treatment regimens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17534933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Methotrexate (MTX), a folic acid antagonist, is widely used in the treatment of neoplasms, psoriasis and rheumatoid arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Methotrexate (MTX) is a folate antagonist drug used for several diseases, such as cancers, various malignancies, rheumatoid arthritis (RA) and inflammatory bowel disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890337"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 265,
          "text": "Methotrexate (MTX) is a folic acid antagonist used in high doses as antimetabolite in anti-cancer treatment as well as in low doses for the treatment of rheumatoid arthritis and adults\u0027 psoriasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24704904"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Methotrexate (MTX) is a folic acid antagonist, the mechanism of action is to inhibit DNA synthesis, repair and cell proliferation by decreasing the activities of several folate-dependent enzymes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36532750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25161385"
        },
        {
          "offsetInBeginSection": 25,
          "offsetInEndSection": 119,
          "text": "e (MTX) is an antifolate and immunosuppressive drug prescribed for various malignancies and im",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946211"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "Methotrexate (MTX) is a clinically important antifolate that has been used in combination with other chemotherapeutic agents in the treatment of malignancies including acute lymphocytic leukemia, osteosarcoma, carcinomas of the breast, head and neck, choriocarcinoma and non-Hodgkin\u0027s lymphoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8852336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "Methotrexate (MTX) is the prototype folate antagonist cytotoxic drug, employed in the therapy of solid tumors and leukaemias, and recently also as an immunosuppressive agent in organ transplantation, in the treatment of some autoimmune diseases and in the therapy of severe asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11817030"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 493,
          "text": "A number of drugs such as aminopterin, methotrexate (amethopterin), pyrimethamine, trimethoprim and triamterene act as folate antagonists and produce folate deficiency by inhibiting this enzyme.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3896745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "The folate antagonist methotrexate is a cytotoxic drug used in the treatment of several cancer types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30452231"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "text": "Amethopterin (methotrexate, MTX) is an antimetabolite and antifolate drug with antiflammatory properities and is used to treat autoimmune diseases, such as psoriasis, rheumatoid arthritis and certain types of cancer, such as breast, lymphoma and lung.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 353,
          "text": "A number of antifolate drugs, which inhibit the key enzymes in the \u0027thymidylate cycle\u0027, dihydrofolate reductase (DHFR) and thymidylate synthase (TS), have been developed as part of the search for analogues with superior antitumor efficacy to a \u0027classical\u0027 antifolate, methotrexate (MTX), and those which are active against the MTX-resistant tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9479873"
        }
      ],
      "id": "65f82fe1c4010b4d7800003f",
      "ideal_answer": [
        "Yes",
        "Yes, methotrexate is an antifolate medication",
        "Yes, methotrexate is indeed an antifolate medication.",
        "Yes, Methotrexate is an antifolate medication",
        "Yes, Methotrexate is an antifolate medication.",
        "Yes, that is correct. Methotrexate is an antifolate medication.",
        "Yes, methotrexate is an antifolate medication.",
        "Methotrexate (MTX) is an antifolate medication.",
        "Yes, Methotrexate is indeed an antifolate medication.",
        "Yes, Methotrexate (MTX) is an antifolate medication."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is GC1118 effective for glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37537946"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1455,
          "offsetInEndSection": 1721,
          "text": "CONCLUSION: This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37537946"
        }
      ],
      "id": "65d131451930410b13000034",
      "ideal_answer": [
        "No. GC1118 did not prolong progression free survival of patients with glioblastoma."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36617405",
        "http://www.ncbi.nlm.nih.gov/pubmed/37965976",
        "http://www.ncbi.nlm.nih.gov/pubmed/19058225",
        "http://www.ncbi.nlm.nih.gov/pubmed/28860541",
        "http://www.ncbi.nlm.nih.gov/pubmed/8669436",
        "http://www.ncbi.nlm.nih.gov/pubmed/19261004",
        "http://www.ncbi.nlm.nih.gov/pubmed/8862632",
        "http://www.ncbi.nlm.nih.gov/pubmed/19574260",
        "http://www.ncbi.nlm.nih.gov/pubmed/16313315",
        "http://www.ncbi.nlm.nih.gov/pubmed/12390436"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "The clinical features of cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis (COACH) characterize the rare autosomal recessive multisystem disorder called COACH syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36617405"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 174,
          "text": "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 172,
          "text": "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 1203,
          "offsetInEndSection": 1371,
          "text": "Physicians should be aware of COACH syndrome when they examine young patients who present with hepatopathy, portal hypertension of unknown origin and cerebellar ataxia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19261004"
        },
        {
          "offsetInBeginSection": 446,
          "offsetInEndSection": 549,
          "text": "We describe a 28-yr-old female with COACH syndrome resulting in chronic renal and hepatic insufficiency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Hepatic insufficiency and liver transplantation in a patient with COACH syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12390436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "The acronym COACH defines an autosomal recessive condition of Cerebellar vermis hypo/aplasia, Oligophrenia, congenital Ataxia, Coloboma and Hepatic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "OBJECTIVE: To identify genetic causes of COACH syndromeBACKGROUND: COACH syndrome is a rare autosomal recessive disorder characterised by Cerebellar vermis hypoplasia, Oligophrenia (developmental delay/mental retardation), Ataxia, Coloboma, and Hepatic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574260"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058225"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 426,
          "text": "The main feature of COACH is congenital hepatic fibrosis (CHF), resulting from malformation of the embryonic ductal plate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 1319,
          "offsetInEndSection": 1552,
          "text": "Of these three previous patients, one died from hepatic failure due to de novo HCV infection 3 years after LT.CONCLUSIONS: LT should be considered an effective treatment for COACH syndrome in patients with severe portal hypertension.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 653,
          "text": "However, only a few patients with COACH syndrome undergoing liver transplantation (LT) have been reported.MATERIALS AND METHODS: We herein report the outcomes of four children who underwent LT for COACH syndrome at our institute and review three previously reported cases to elucidate the role of LT in COACH syndrome.RESULTS: All four patients in our institute were female, and three received living donors LT. All patients were diagnosed with COACH syndrome by genetic testing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 497,
          "text": "This combination of findings suggested a diagnosis of COACH syndrome which is characterized by hypoplasia of cerebellar vermis, oligophrenia, congenital ataxia, coloboma, and hepatic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8669436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "The COACH syndrome is a very rare disorder with cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16313315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertensi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "COACH syndrome is an autosomal recessive developmental disorder, a subtype of Joubert syndrome and related disorders, characterized by cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28860541"
        },
        {
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1105,
          "text": "This pattern of defects is consistent with COACH syndrome (Cerebellar vermis hypoplasia, Oligophrenia, congenital Ataxia, Coloboma, Hepatic fibrocirrhosis) which has previously been reported in five other cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8862632"
        }
      ],
      "id": "65f70d71c4010b4d7800001e",
      "ideal_answer": [
        "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.",
        "Yes, COACH syndrome is indeed a rare genetic condition involving liver fibrosis and portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by congenital hepatic fibrosis and portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, leading to severe complications associated with portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease that is characterized by liver fibrosis leading to severe complications related to portal hypertension.",
        "No, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.",
        "Yes, COACH syndrome is indeed a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications related to portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
        "”the gene for COACH syndrome is located on chromosome 10\"}",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis, and related to portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which can lead to severe complications associated with portal hypertension.",
        "Yes, COACH syndrome is a rare autosomal recessive genetic disease. It is characterized by liver fibrosis, which can lead to severe complications related to portal hypertension."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Which symptoms could indicate depression in young children?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33436094",
        "http://www.ncbi.nlm.nih.gov/pubmed/876801",
        "http://www.ncbi.nlm.nih.gov/pubmed/28520097",
        "http://www.ncbi.nlm.nih.gov/pubmed/31515716",
        "http://www.ncbi.nlm.nih.gov/pubmed/30911869"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 196,
          "text": "Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436094"
        },
        {
          "offsetInBeginSection": 852,
          "offsetInEndSection": 1048,
          "text": "The domain of negative self-concept during the toddler period evidenced by self-deprecation and difficulty making choices emerged as the two strongest variables predictive of preschool depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520097"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 404,
          "text": "Childhood depression is an episodic disorder characterized by 10 criteria, symptoms of dysphoric mood, self-deprecatory ideation, agitation, loss of energy, reduced socialization, altered school performance, altered school attitude, sleep disturbance, appetite disturbance, and somatic compliants persisting for at least one month.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/876801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Reductions in positive affect are a salient feature of preschool-onset major depressive disorder. Yet, little is known about the psychophysiological correlates of this blunted positive affect and whether reduced physiological responding to pleasant stimuli may differentiate depressed and healthy young children. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31515716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 432,
          "text": "Depressive disorders can be observed in early childhood and are associated with significant concurrent and prospective impairment; however, little is known about day-to-day variations in common depressive behaviors in children. This study examined the day-to-day variability of two common depressive behaviors in preschool-aged children, sadness and irritability, and factors associated with the daily occurrence of these behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30911869"
        },
        {
          "offsetInBeginSection": 755,
          "offsetInEndSection": 1048,
          "text": "Findings suggest that clinical-level symptoms of depression may arise as early as age 24 months. The domain of negative self-concept during the toddler period evidenced by self-deprecation and difficulty making choices emerged as the two strongest variables predictive of preschool depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520097"
        }
      ],
      "id": "65f86f62c4010b4d7800005c",
      "ideal_answer": [
        "sadness\nirritability\nabulia\nfatigue\ninability to concentrate\neat too little or too much\nsleep too little or too much\nhave big changes in weight\nfeelings of guilt, worthlessness, emptiness\nhave thoughts about suicide \nself-harming",
        "Symptoms that could indicate depression in young children include: * Persistent feelings of sadness, hopelessness, and helplessness * Loss of interest in activities they used to enjoy * Changes in appetite or sleep patterns * Fatigue or loss of energy * Difficulty concentrating or making decisions * Thoughts of death or suicide * Behavioral problems, such as acting out or being more irritable than usual * Physical complaints, such as headaches or stomachaches, that do not have a clear medical cause. , It\u0027s important to note that young children may not be able to articulate their feelings of sadness or hopelessness, so it\u0027s important to pay attention to changes in their behavior and mood. If you suspect that your child may be experiencing depression, it\u0027s important to seek professional help from a mental health provider.",
        "Symptoms that could indicate depression in young children include persistent sadness or irritability, loss of interest in activities, changes in appetite or weight, sleep disturbances, fatigue or low energy, difficulty concentrating or making decisions, feelings of worthlessness or guilt, recurrent thoughts of death or suicide, physical complaints without a clear medical cause, and social withdrawal or isolation.",
        "Symptoms of depression in young children can include persistent sadness, irritability, changes in appetite, difficulty sleeping, and a lack of interest in activities they once enjoyed."
      ],
      "exact_answer": [
        [
          "sadness"
        ],
        [
          "irritability"
        ],
        [
          "abulia"
        ],
        [
          "fatigue"
        ],
        [
          "inability to concentrate"
        ],
        [
          "eat too little or too much"
        ],
        [
          "weight changes"
        ],
        [
          "feelings of guilt, worthlessness, emptiness"
        ],
        [
          "suicidal thoughts"
        ],
        [
          "self-harm"
        ]
      ]
    },
    {
      "body": "What are active ingredients of Paxlovid?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37839266",
        "http://www.ncbi.nlm.nih.gov/pubmed/36703601",
        "http://www.ncbi.nlm.nih.gov/pubmed/36568522",
        "http://www.ncbi.nlm.nih.gov/pubmed/37969744",
        "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
        "http://www.ncbi.nlm.nih.gov/pubmed/37510996",
        "http://www.ncbi.nlm.nih.gov/pubmed/36465589",
        "http://www.ncbi.nlm.nih.gov/pubmed/35101563",
        "http://www.ncbi.nlm.nih.gov/pubmed/37231296",
        "http://www.ncbi.nlm.nih.gov/pubmed/36345404",
        "http://www.ncbi.nlm.nih.gov/pubmed/35881032",
        "http://www.ncbi.nlm.nih.gov/pubmed/35153195",
        "http://www.ncbi.nlm.nih.gov/pubmed/36154584"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 214,
          "text": " Paxlovid® is composed of two tablets, nirmatrelvir and ritonavir. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37839266"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 783,
          "text": "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid), tixagevimab and cilgavimab (both used in combination with each other) and others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522"
        },
        {
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1269,
          "text": "Paxlovid, as used in the clinic, is a combination of Nirmatrelvir (viral protease inhibitor) and Ritonavir (a \"booster\" inhibitor of Nirmatrelvir metabolism).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37510996"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 455,
          "text": "PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a pharmacokinetic enhancer), is an oral therapy currently in development as a therapeutic option for those infected with SARS-CoV-2 to prevent progression to severe disease, hospitalization, and death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35101563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37510996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Pfizer\u0027s drug for the treatment of patients infected with COVID-19, Paxlovid, contains most notably nirmatrelvir, along with ritonavir.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36465589"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "On December 22, 2021, the United States Food and Drug Administration approved the first main protease inhibitor, i.e., oral antiviral nirmatrelvir (PF-07321332)/ritonavir (Paxlovid), for the treatment of early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36345404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid), was recently granted emergency use authorization by multiple regulatory agencies for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35153195"
        },
        {
          "offsetInBeginSection": 34,
          "offsetInEndSection": 236,
          "text": "Paxlovid, a combination of Nirmatrelvir and Ritonavir, was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 on December 22, 2021.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36154584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Paxlovid is a nirmatrelvir (NMV) and ritonavir (RTV) co-packaged medication used for the treatment of coronavirus disease 2019 (COVID-19). The active component of Paxlovid is NMV and RTV is a pharmacokinetic booster.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37969744"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 700,
          "text": "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703601"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 353,
          "text": "antiviral treatment. Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "Paxlovid, a copackaged medication of nirmatrelvir tablets (150 mg) and ritonavir tablets (100 mg) developed by Pfizer, is one of the first orally accessible COVID-19 antiviral medicines to be approved for emergency usage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35881032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "PURPOSE: PAXLOVID™ is nirmatrelvir tablets co-packaged with ritonavir tablets. Ritonavir is used as a pharmacokinetics (PK) enhancer to reduce metabolism and increase exposure of nirma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37231296"
        },
        {
          "offsetInBeginSection": 137,
          "offsetInEndSection": 271,
          "text": "disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong cytochrome P450 (CYP) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36568522"
        }
      ],
      "id": "65d136bc1930410b1300003c",
      "ideal_answer": [
        "Paxlovid is composed of nirmatrelvir and ritonavir."
      ],
      "exact_answer": [
        [
          "nirmatrelvir"
        ],
        [
          "ritonavir"
        ]
      ]
    },
    {
      "body": "What is an Albatross plot used for?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
        "http://www.ncbi.nlm.nih.gov/pubmed/34035181",
        "http://www.ncbi.nlm.nih.gov/pubmed/32423407"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "The albatross plot: A novel graphical tool for presenting results of diversely reported studies in a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179"
        },
        {
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1284,
          "text": "We provide examples of albatross plots using data from previous meta-analyses, allowing for comparison of results, and an example from when a meta-analysis was not possible.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179"
        },
        {
          "offsetInBeginSection": 766,
          "offsetInEndSection": 1127,
          "text": "For interpretation of the results across studies, we produced albatross plots for all studies combined and by age-groups, sex of the parents, sex of the child, methodology of assessment of parental PA, and type of PA.RESULTS: Thirty-nine papers were included with sample size of parent-child dyads ranging from 15 to 1267 (mean \u003d 319 dyads, median \u003d 227 dyads).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32423407"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 955,
          "text": "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179"
        },
        {
          "offsetInBeginSection": 679,
          "offsetInEndSection": 926,
          "text": "To assess the quality of evidence, Cochrane Collaboration\u0027s Risk of Bias Tool was used. Due to the heterogeneity of reported outcomes, meta-analysis was performed for only some outcomes and a narrative synthesis with albatross plots was presented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34035181"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 1110,
          "text": "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies. This is achieved by drawing contours showing the range of effect sizes that might lead to each P value for given sample sizes, under simple study designs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179"
        }
      ],
      "id": "65f37997c4010b4d7800000b",
      "ideal_answer": [
        "The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review",
        "An Albatross plot is used to visually present the results of studies that are reported in diverse ways within a systematic review, showing the estimated direction of effects and helping interpret P values based on study sample sizes.",
        "An Albatross plot is used for meta-analyses to combine the results of multiple studies of a common question. It allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.",
        "The albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.",
        "An Albatross plot is used for presenting results of diversely reported studies in a systematic review.",
        "The Albatross plot is used for presenting results of diversely reported studies in a systematic review.",
        "Albatross plot is a graphical tool used in systematic reviews to present the results of studies that report the effect size or estimate for an outcome in diverse ways. It allows visual comparison of studies by displaying the effect size and confidence interval in a single plot.",
        "An Albatross plot is a graphical tool used in systematic reviews to present the results of diversely reported studies. It helps to visualize and compare the findings of different studies, making it easier to identify patterns and trends in the data.",
        "An Albatross plot is a graphical tool utilized in systematic reviews. Its primary function is to present the results of studies that have been reported in diverse ways, providing a visual representation that aids in the interpretation and comparison of these results.",
        "The Albatross plot is used for presenting the results of studies that are reported in diverse ways within a systematic review.",
        "An Albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.",
        "An Albatross plot is a graphical representation of the distribution of the number of patients with a given outcome in a clinical trial. It is used to visualize the distribution of outcomes in a trial and to identify potential issues with the trial design or conduct.",
        "An albatross plot is a novel graphical tool for presenting results of diversely reported studies in a systematic review.",
        "An Albatross plot is used for presenting the results of studies that are reported in diverse ways in a systematic review. It provides a graphical tool for visualizing and interpreting these results.",
        "An Albatross plot is a novel graphical tool used for presenting the results of diversely reported studies in a systematic review. It helps to visually display the effect sizes and confidence intervals of individual studies, allowing for a comprehensive overview of the data and facilitating the interpretation of the overall findings.",
        "An Albatross plot is used to present the results of diversely reported studies in a systematic review in a graphical format."
      ],
      "exact_answer": [
        [
          "visualization of diversely reported studies"
        ]
      ]
    },
    {
      "body": "What should you do if you find an individual that you suspect has overdosed?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33771150",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420089",
        "http://www.ncbi.nlm.nih.gov/pubmed/36123614",
        "http://www.ncbi.nlm.nih.gov/pubmed/33682423",
        "http://www.ncbi.nlm.nih.gov/pubmed/30924736",
        "http://www.ncbi.nlm.nih.gov/pubmed/16002027",
        "http://www.ncbi.nlm.nih.gov/pubmed/20967505"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 462,
          "text": "The implementation of naloxone programs, such as \u0027take-home naloxone\u0027 (THN), has emerged as a key intervention in reducing opioid overdose deaths. These programs aim to train individuals at risk of witnessing or experiencing an opioid overdose to recognize an opioid overdose and respond with naloxone. Naloxone effectively reverses opioid overdoses ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33771150"
        },
        {
          "offsetInBeginSection": 1233,
          "offsetInEndSection": 1438,
          "text": "Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420089"
        },
        {
          "offsetInBeginSection": 1869,
          "offsetInEndSection": 2153,
          "text": "Data indicated the aided survived the suspected overdose in 87.4% of cases.CONCLUSIONS: With appropriate training, law enforcement personnel were able to recognize opioid overdoses and prevent fatalities by administering naloxone and carrying out time-sensitive medical interventions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36123614"
        },
        {
          "offsetInBeginSection": 1532,
          "offsetInEndSection": 1844,
          "text": "Current American Heart Association recommendations call for laypeople and others who cannot reliably establish the presence of a pulse to initiate cardiopulmonary resuscitation in any individual who is unconscious and not breathing normally; if opioid overdose is suspected, naloxone should also be administered.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33682423"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 339,
          "text": "An adjunct to respiratory support that can reduce this high mortality rate is the administration of naloxone by Emergency Medical Services (EMS) practitioners for patients with suspected opioid overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30924736"
        },
        {
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1416,
          "text": "Efforts to equip drug users to manage overdoses effectively, including training in first aid and the provision of naloxone, and the reduction of police involvement at overdose events may have a substantial impact on overdose-related morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16002027"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 193,
          "text": "Opiate overdose can be reversed by administering naloxone, an opiate antagonist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967505"
        }
      ],
      "id": "65f85df3c4010b4d78000051",
      "ideal_answer": [
        "Call emergency services.\nTry to wake the person up.\nAdminister naloxone if you have it.\nCardiopulmonary resuscitation.\nStay until emergency services arrive.",
        "If you find an individual who you suspect has overdosed, it is important to seek medical help immediately. Call emergency services or go to the emergency room if the person is unresponsive, difficulty breathing, or showing other signs of distress. If the person is conscious and able to speak, try to keep them awake and alert until medical help arrives. Do not leave the person alone, as their condition can worsen quickly. If you are trained in using naloxone, administer it according to the instructions provided. Remember that naloxone only works for opioid overdoses, so if the person is experiencing an alcohol or other drug overdose, do not use naloxone. Stay with the person and provide reassurance until medical help arrives. If possible, try to gather information about the substance they took, as this can be helpful for medical responders. Remember, seeking medical help immediately is crucial in preventing serious harm or death from an overdose."
      ],
      "exact_answer": [
        [
          "Call emergency services"
        ],
        [
          "Wake person if possible"
        ],
        [
          "Inject naloxone"
        ],
        [
          "CPR"
        ],
        [
          "Stay until help arrives"
        ]
      ]
    },
    {
      "body": "What is the mechanism of action of sparsentan?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37180506",
        "http://www.ncbi.nlm.nih.gov/pubmed/37022667",
        "http://www.ncbi.nlm.nih.gov/pubmed/37256677",
        "http://www.ncbi.nlm.nih.gov/pubmed/37221817",
        "http://www.ncbi.nlm.nih.gov/pubmed/36852566",
        "http://www.ncbi.nlm.nih.gov/pubmed/38041499",
        "http://www.ncbi.nlm.nih.gov/pubmed/35052766",
        "http://www.ncbi.nlm.nih.gov/pubmed/29142983",
        "http://www.ncbi.nlm.nih.gov/pubmed/32274453",
        "http://www.ncbi.nlm.nih.gov/pubmed/37706310",
        "http://www.ncbi.nlm.nih.gov/pubmed/30361325",
        "http://www.ncbi.nlm.nih.gov/pubmed/35514086",
        "http://www.ncbi.nlm.nih.gov/pubmed/37762309",
        "http://www.ncbi.nlm.nih.gov/pubmed/37015244",
        "http://www.ncbi.nlm.nih.gov/pubmed/37921461",
        "http://www.ncbi.nlm.nih.gov/pubmed/36834836",
        "http://www.ncbi.nlm.nih.gov/pubmed/35224732",
        "http://www.ncbi.nlm.nih.gov/pubmed/37931634",
        "http://www.ncbi.nlm.nih.gov/pubmed/35547199",
        "http://www.ncbi.nlm.nih.gov/pubmed/35291039",
        "http://www.ncbi.nlm.nih.gov/pubmed/31749142"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37022667"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 471,
          "text": "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist (DEARA) under clinical development for focal segmental glomerulosclerosis and IgA nephropathy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Sparsentan is a single-molecule dual endothelin angiotensin receptor antagonist (DEARA) currently under investigation as a treatment for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37221817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Sparsentan is a single-molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor under investigation for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36852566"
        },
        {
          "offsetInBeginSection": 388,
          "offsetInEndSection": 935,
          "text": "A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS (DUPLEX) study evaluates the long-term antiproteinuric efficacy, nephroprotective potential, and safety profile of sparsentan compared with an AT1 receptor blocker alone in patients with FSGS.METHODS: DUPLEX is a multicenter, international, phase 3, randomized, double-blind, active-controlled study of sparsentan in patients with FSGS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32274453"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 470,
          "text": "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist (DEARA) under clinical development for focal segmental glomerulosclerosis and IgA nephropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256677"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1233,
          "text": "Sparsentan, a dual-acting antagonist of the angiotensin II receptor and endothelin type A receptors, was found to suppress the amplitude of peak and late INa effectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37762309"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 1036,
          "text": "Interestingly, Sparsentan, the dual angiotensin II (Ang II) receptor and endothelin type A receptor antagonist, can also reduce TRM cell responses by intervening IL-15 signaling, exploring its new pharmacological functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35514086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37015244"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Sparsentan is a dual endothelin/angiotensin II receptor antagonist indicated to reduce proteinuria in patients with primary IgA nephropathy at high risk of disease progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38041499"
        }
      ],
      "id": "65cebf371930410b13000004",
      "ideal_answer": [
        "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS)."
      ]
    },
    {
      "body": "Please summarize MuSK Antibody positive Myasthenia Gravis.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36396811",
        "http://www.ncbi.nlm.nih.gov/pubmed/37455510",
        "http://www.ncbi.nlm.nih.gov/pubmed/36527328",
        "http://www.ncbi.nlm.nih.gov/pubmed/37150596",
        "http://www.ncbi.nlm.nih.gov/pubmed/37564637",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747537",
        "http://www.ncbi.nlm.nih.gov/pubmed/20613516",
        "http://www.ncbi.nlm.nih.gov/pubmed/25557356",
        "http://www.ncbi.nlm.nih.gov/pubmed/21822490",
        "http://www.ncbi.nlm.nih.gov/pubmed/19882635",
        "http://www.ncbi.nlm.nih.gov/pubmed/15989843",
        "http://www.ncbi.nlm.nih.gov/pubmed/27697312",
        "http://www.ncbi.nlm.nih.gov/pubmed/16155434",
        "http://www.ncbi.nlm.nih.gov/pubmed/30472069",
        "http://www.ncbi.nlm.nih.gov/pubmed/22013178",
        "http://www.ncbi.nlm.nih.gov/pubmed/17718696",
        "http://www.ncbi.nlm.nih.gov/pubmed/34992891",
        "http://www.ncbi.nlm.nih.gov/pubmed/34491934",
        "http://www.ncbi.nlm.nih.gov/pubmed/23706725",
        "http://www.ncbi.nlm.nih.gov/pubmed/22981737",
        "http://www.ncbi.nlm.nih.gov/pubmed/31177576"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 338,
          "text": "for anti-muscle specific tyrosine kinase (MuSK) antibody (Ab) in a large cohort of anti-acetylcholine receptor (AChR) Ab-negative generalized myasthenia gravis (MG), and also to investigate clinical contexts for the diagnosis of MuSK MG",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36396811"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 558,
          "text": "We compared the plasma concentrations of 15 myokines in 63 patients with acetylcholine receptor antibody (Ab)-positive MG and 14 with muscle-specific tyrosine kinase Ab-positive MG (MuSK MG) with those in 15 healthy controls",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37455510"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 378,
          "text": "In this report, we describe three patients with anti-muscle-specific kinase (MuSK)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527328"
        },
        {
          "offsetInBeginSection": 18,
          "offsetInEndSection": 155,
          "text": " Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37150596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 372,
          "text": "Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "OBJECTIVE: Muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) accounts for 5%-15% of autoimmune MG. MuSK mediates the agrin-signaling pathway and also anchors the collagenic tail subunit (ColQ) of acetylcholinesterase (AChE).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22013178"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Muscle specific tyrosine kinase antibody positive myasthenia gravis (MuSK- MG) is characterized by autoantibodies against the MuSK protein of the neuromuscular junction resulting in weakness of bulbar and proximal muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30472069"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Muscle-specific tyrosine kinase- (MuSK-) antibodies-positive Myasthenia Gravis accounts for about one third of Seronegative Myasthenia Gravis and is clinically characterized by early onset of prominent bulbar, neck, shoulder girdle, and respiratory weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21822490"
        },
        {
          "offsetInBeginSection": 567,
          "offsetInEndSection": 778,
          "text": "myasthenia gravis.RECENT FINDINGS: MuSK antibodies are found in a variable proportion of AChR antibody negative myasthenia gravis patients who are often, but not exclusively, young adult females, with bulbar, ne",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155434"
        },
        {
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1463,
          "text": "ted to randomized clinical trials.SUMMARY: MuSK antibodies define a form of myasthenia gravis that can be difficult to diagnose, can be life threate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Background and Objectives: Muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MuSK + MG) is a form of MG with bulbar-predominant symptoms often resistant ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "PURPOSE OF REVIEW: Some of the 20% of myasthenia gravis patients who do not have antibodies to acetylcholine receptors (AChRs) have antibodies to muscle specific kinase (MuSK), but a full understanding of their frequency, the associated clinical phenotype and the mechanisms of action of the antibodies has not",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564637"
        },
        {
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1571,
          "text": "The role of thymectomy in the management of these patients remains uncertain.SUMMARY: MuSK antibody positive patients represent a unique subset of myasthenia gravis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20613516"
        },
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 196,
          "text": "Muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MuSK + MG) is a form of MG with bulbar-predominant symptoms often resistant to conventional treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1235,
          "text": "We investigated the presence of antibodies (Abs) against muscle-specific tyrosine kinase (MuSK) in Japanese myasthenia gravis (MG) patients. MuSK Abs were found in 23 (27%) of 85 generalized seronegative MG (SNMG) patients but not in any of the ocular MG patients. MuSK Ab-positive patients were characterized as having female dominance (M:F, 5:18), age range at onset 18 to 72 (median 45) years old, and prominent oculobulbar symptoms (100%) with neck (57%) or respiratory (35%) muscle weakness. Limb muscle weakness was comparatively less severe (52%), thymoma absent. Most patients had good responses to simple plasma exchange and steroid therapy. MuSK IgG from all 18 patients was exclusively the IgG 4 subclass and bound mainly with the MuSK Ig 1-2 domain. Serial studies of 12 individuals showed a close correlation between the variation in MuSK Ab titers and MG clinical severity (P \u003d 0.01 by Kruskal-Wallis). MuSK Ab titers were sharply decreased in patients who had a good response to early steroid therapy or simple plasma exchange, but there was no change, or a rapid increase on exacerbation after thymectomy. Measurement of MuSK Ab titers aids in the diagnosis of MG and the monitoring of clinical courses after treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17718696"
        },
        {
          "offsetInBeginSection": 668,
          "offsetInEndSection": 1057,
          "text": "Muscle-specific tyrosine kinase myasthenia gravis (MuSK-Ab MG) is a rare subtype of myasthenia gravis with distinct pathogenesis and unique clinical features. Diagnosis can be challenging due to its atypical presentation as compared to seropositive myasthenia gravis. It responds inconsistently to steroids, but plasma exchange and immunosuppressive therapies have shown promising results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34992891"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1623,
          "text": "PURPOSE OF REVIEW: Important concepts regarding the pathogenesis, clinical features, diagnosis and treatment of muscle-specific tyrosine kinase (MuSK) antibody positive myasthenia gravis will be reviewed. Special attention will be paid to clinical phenotypes and treatment, particularly encouraging responses that have been reported to rituximab.RECENT FINDINGS: Worldwide studies confirm three major phenotypes in MuSK antibody positive myasthenia gravis (MMG) patients: indistinguishable from acetylcholine receptor antibody positive patients, prominent faciopharyngeal weakness, usually with marked muscle atrophy, and relatively isolated neck extensor and respiratory weakness. MMG predominates in women and weakness is typically more severe, with more frequent respiratory crises than non-MuSK myasthenia gravis. Patients with sub-acute bulbar, shoulder, and neck weakness pose unique challenges in terms of differential diagnosis and electrodiagnosis. Electrodiagnostic studies evaluating for disorders of neuromuscular transmission should focus on proximal limb and facial muscles, as well as clinically weak muscles. The response to acetylcholinesterase inhibitors is often disappointing. Long-term outcomes appear favorable though patients typically require more aggressive immunosuppression. Uncontrolled observations report encouraging results with rituximab in the treatment of refractory MMG. The role of thymectomy in the management of these patients remains uncertain.SUMMARY: MuSK antibody positive patients represent a unique subset of myasthenia gravis. Identification of these patients has important diag",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20613516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 541,
          "text": "INTRODUCTION: Approximately 39% to 49% of patients with previously diagnosed acetylcholine receptor antibody-negative myasthenia gravis have been found to be muscle-specific tyrosine kinase (MuSK) antibody positive. These patients have a presentation that typically includes oculobulbar weakness, poorer response to cholinesterase inhibitors, and higher risk for acute clinical decompensation that necessitates plasma exchange. MuSK patients can require more aggressive maintenance immunosuppression earlier-on to maintain stability, often w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34491934"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 771,
          "text": "Antibodies (Abs) to muscle-specific tyrosine kinase (MuSK) are detected in approximately 40% of generalized acetylcholine receptor antibody-negative myasthenia gravis (MG). Anti-MuSK Abs are nearly always associated with generalized symptoms, with prevalent involvement of craniobulbar, cervical and respiratory muscles and with a striking preponderance in women. The typical course of MuSK-MG is acute onset, rapid progression, brittle course in the first years, early respiratory crises and unprovoked relapses in spite of high-dose immunosuppression. Patients often require long-term management with multiple immunosuppressive (IS) agents and many of them remain dependent on IS treatment. The majority of anti-MuSK Abs are of the non-complement-binding IgG4 subclass.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706725"
        },
        {
          "offsetInBeginSection": 1119,
          "offsetInEndSection": 1404,
          "text": "MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient\u0027s MuSK-IgG interferes with binding of ColQ to MuSK.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 445,
          "text": "BACKGROUND AND OBJECTIVE: Recently, the presence of antibodies to a muscle-specific tyrosine kinase (MuSK) has been reported in some patients with seronegative generalized myasthenia gravis. Our objective was to describe a group of patients who were positive for anti-MuSK antibodies.PATIENTS AND METHOD: Detection of antibodies using a radioimmunoassay was performed in the serum of 26 patients with generalized myasthenia gravis. We identified",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15989843"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 378,
          "text": "BACKGROUND: Adult and pediatric patients suffering from MuSK (muscle-specific kinase) -antibody positive myasthenia gravis exhibit similar features to individuals with acetylcholine receptor (AChR) antibodies, but they differ in several characteristics such as a predominant bulbar, respiratory and neck weakness, a generally worse disease severity and a tendency to develop mus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND: Anti-muscle specific kinase antibody positive myasthenia gravis (MuSK MG) is often characterized by a relatively severe and progressive course, refractoriness to standard myasthenia gravis (MG) medications, and an increased risk of myasth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25557356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "INTRODUCTION: Muscle-specific tyrosine kinase (MuSK) autoantibody related myasthenia gravis is characterized by bulbar and respiratory manifestations, a poor response to anticholinergics, and a generally good response to plasma exchange ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31177576"
        },
        {
          "offsetInBeginSection": 752,
          "offsetInEndSection": 1153,
          "text": "This survey reinforces several cardinal features of MuSK-Ab-positive MG, including prominent bulbar involvement and anticholinesterase nonresponsiveness. Facial or tongue atrophy was rare. Most patients respond favorably to immunotherapy. The best clinical response was to corticosteroids and plasma exchange, and the poorest response was to IVIG. Long-term outcome is favorable in about 60% of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882635"
        }
      ],
      "id": "65f70915c4010b4d7800001a",
      "ideal_answer": [
        "Myasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness of the skeletal muscles Approximately 5% of patients with MG, show positive results on muscle-specific kinase (MuSK) antibody testing and usually have severe symptoms, refractory disease, residual muscle atrophy, and poor prognosis.",
        "Muscle-specific tyrosine kinase (MuSK) antibodies are present in some patients with myasthenia gravis (MG) who test negative for acetylcholine receptor (AChR) antibodies. MuSK antibodies do not appear to cause substantial AChR loss, complement deposition, or morphological damage. Patients with MuSK antibody-positive MG may have a recognizable electrodiagnostic (EDX) profile distinct from AChR antibody-positive MG. They include myotonic discharges, greater occurrence of myopathic appearing motor unit potentials in clinically mild disease, and symptoms leading to earlier testing. MuSK and seronegative MG patients are managed successfully with immunomodulatory therapies, but a higher proportion of MuSK MG patients have a refractory course.",
        "MuSK Antibody positive Myasthenia Gravis is a rare, chronic neuromuscular disease that is distinct from thymomatous Myasthenia Gravis. It represents about 10-20% of all Myasthenia Gravis cases. It is more common in women, and is characterized by the presence of MuSK antibodies, which target a receptor tyrosine kinase in the postsynaptic muscle membrane. It is typically more severe than other forms of Myasthenia Gravis, and often responds well to treatments that target the immune system, such as rituximab and plasmapheresis.",
        "Muscle-specific tyrosine kinase antibody positive myasthenia gravis (MuSK-MG) is characterized by autoantibodies targeting the MuSK protein at the neuromuscular junction, leading to weakness primarily in bulbar and proximal muscles. This condition represents a distinct subset of autoimmune MG, accounting for 5%-15% of cases. MuSK plays a crucial role in the agrin-signaling pathway and anchors the collagenic tail subunit (ColQ) of acetylcholinesterase (AChE), essential for muscle function. The diagnosis often involves single-fiber electromyography (SFEMG), especially in affected muscles. Treatment options include immunosuppressive therapies like tacrolimus, although their efficacy specifically in MuSK-MG requires further investigation. The role of thymectomy in treating MuSK-MG remains uncertain.",
        "MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a form of myasthenia gravis (MG) characterized by a relatively severe and progressive course, refractoriness to standard MG medications, and an increased risk of myasthenic crisis. It is often associated with bulbar and respiratory manifestations, a poor response to anticholinergics, and a generally good response to plasma exchange and rituximab. MuSK antibodies define a form of MG that can be difficult to diagnose, can be life-threatening, and may require additional treatments. MuSK MG patients have reduced B10 cells, a rare regulatory B-cell subset that potently blocks Th1 and Th17 responses, suggesting a potential mechanism for the breakdown in immune tolerance. Increased BAFF levels have been described in MuSK MG, as well as in acetylcholine receptor antibody-positive MG. MuSK antibodies are found in a variable proportion of AChR antibody negative MG patients, who are often young adult females with bulbar, neck, or respiratory muscle weakness. A girl with MuSK-antibody positive MG was reported to have developed a myopathy with severe generalized muscular weakness, muscle atrophy, and myopathic changes on electromyography, which is the first published example of a generalized myopathic syndrome in MG.",
        "1. Antibodies to MuSK in most cases are associated with myasthenia gravis that is mainly characterized by:\n* Pure ocular disease in 75% of the cases\n* Rapid progression of symptoms\n* Increased risk for respiratory failure\n* Low levels of anti-AChR antibodies\n* Good response to cholinesterase inhibitors and steroids\n2. A smaller percentage of patients also presents with a more aggressive phenotype.\n3. MuSK antibody negative patients may also show MuSK-mediated autoimmunity.\n4. MuSK antibody positive patients have significantly lower survival rates compared to the anti-AChR population.\n5. Musk antibodies have no pathogenic role.\n6. MuSK antibodies cause an impairment of the postsynaptic membrane in autoimmune myasthenia gravis.",
        "Myasthenia Gravis (MG) is a chronic autoimmune disease that causes muscle weakness. It is a type of antibody-mediated disorder, in which the main immunoglobulin G (IgG) antibodies are directed against the muscle acetylcholine receptor (AChR). Myasthenia gravis can be divided into two subtypes according to the type of antibodies that are detected: muscle-specific kinase antibody (MuSK-MG) and acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG). The clinical manifestations of MuSK-MG are different from those of AChR-MG. MuSK-MG is usually more severe and often affects the neck, throat, face, and respiratory muscles. The diagnosis of MuSK-MG is based on the detection of MuSK antibodies in the serum.",
        "MuSK Antibody positive Myasthenia Gravis (MuSK-MG) is a subtype of autoimmune myasthenia gravis, accounting for 5 to 15% of all MG cases. It is characterized by the presence of autoantibodies against muscle-specific kinase (MuSK), a tyrosine kinase receptor involved in acetylcholine receptor clustering at the neuromuscular junction. MuSK-MG patients typically present with severe symptoms, including bulbar and respiratory involvement, and are less responsive to cholinesterase inhibitors than other MG subtypes. Immunosuppressive therapy is often required for effective disease management.",
        "MuSK antibody positive Myasthenia Gravis (MG) is a subtype of MG characterized by the presence of antibodies against the muscle-specific kinase (MuSK). It is more common in females and typically presents with severe muscle weakness, especially involving the bulbar and respiratory muscles. Patients with MuSK antibody positive MG may have a more severe disease course and may not respond well to traditional MG treatments like acetylcholinesterase inhibitors.",
        "MuSK antibody-positive myasthenia gravis (MuSK-MG) is a subtype of myasthenia gravis characterized by:\n\n1. Presence of autoantibodies against muscle-specific kinase (MuSK)\n2. Prominent bulbar, neck, shoulder girdle, and respiratory muscle weakness\n3. Early onset and generally worse disease severity compared to AChR antibody-positive MG\n4. Tendency to develop muscle atrophy\n5. Refractoriness to standard MG medications and increased risk of myasthenic crisis\n6. Best response to corticosteroids and plasma exchange, poorest response to IVIG\n7. About half of patients meet criteria for refractory MG\n8. Long-term outcomes are favorable in about 60% of cases, but overall outcomes are not favorable, indicating need for more aggressive treatment\n\nIn summary, MuSK-MG is a distinct subtype of myasthenia gravis with specific clinical features, treatment responses, and prognosis that differ from the more common AChR antibody-positive form of the disease.",
        "Muscle-specific kinase (MuSK) Antibody positive Myasthenia Gravis is predominantly seen in women of childbearing age and is characterized by focal muscle weakness, particularly in the neck, facial, and bulbar muscles, with pathogenic antibodies mainly belonging to the IgG4 subclass.",
        "MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a predominantly female-affecting, antibody-mediated disease characterized by focal muscle weakness and fatigability. The pathogenic antibodies in MuSK MG are mostly of the IgG4 subclass, which gives them specific properties and pathogenic profiles. MuSK MG is distinct from acetylcholine receptor antibody (Ab)-positive MG and requires specific diagnostic and therapeutic approaches.",
        "MuSK Antibody positive Myasthenia Gravis (MG) is a type of MG characterized by focal muscle weakness and fatigability, particularly in the neck, facial, and bulbar muscles. It is an antibody-mediated disease, with the pathogenic antibodies mostly belonging to the immunoglobulin subclass IgG4. This condition is predominantly seen in women of childbearing age.",
        "MuSK Antibody positive Myasthenia Gravis is a form of the autoimmune disease Myasthenia Gravis characterized by the presence of antibodies against muscle-specific tyrosine kinase (MuSK), predominantly affecting women of childbearing age, and clinically presenting with focal muscle weakness and fatigability.",
        "Muscle-specific tyrosine kinase (MuSK) antibody positive Myasthenia Gravis (MG) is predominantly observed in women of childbearing age and is characterized by focal muscle weakness in the neck, facial, and bulbar muscles, often associated with the presence of IgG4 antibodies.",
        "MuSK Antibody positive Myasthenia Gravis is a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile.",
        "MuSK Antibody positive Myasthenia Gravis (MuSK MG) is a rare autoimmune disorder characterized by the presence of antibodies against the muscle-specific tyrosine kinase (MuSK) protein. This condition is predominantly seen in women of childbearing age and is associated with focal muscle weakness, fatigability, and the presence of IgG4 antibodies.",
        "Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. MMG is predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile.",
        "MuSK Antibody positive Myasthenia Gravis is a subtype of the autoimmune disease Myasthenia Gravis, characterized by the presence of antibodies against muscle-specific tyrosine kinase (MuSK), primarily affecting women of childbearing age and presenting with focal muscle weakness and fatigability.",
        "Muscle-specific kinase (MuSK) antibody positive myasthenia gravis (MG) is a subtype of MG characterized by:\n\n1. Presence of autoantibodies against MuSK, predominantly of the IgG4 subclass.\n2. More common in women of childbearing age.\n3. Predominantly focal muscle weakness and fatigability, especially in neck, facial, and bulbar muscles.\n4. Distinct pathogenic profile attributed to the specific properties of IgG4 autoantibodies.\n5. Usually seronegative for anti-acetylcholine receptor (AChR) antibodies.\n\nThe distinct clinical features, autoantibody profile, and pathogenic mechanisms set MuSK MG apart from other subtypes of myasthenia gravis.",
        "MuSK Antibody positive Myasthenia Gravis is a subtype of the autoimmune disease Myasthenia Gravis, characterized by muscle weakness and fatigue. It is caused by antibodies that target the muscle-specific kinase (MuSK), a protein involved in signal transmission to muscles. This condition is often seen in women of childbearing age and primarily affects neck, facial, and bulbar muscles"
      ]
    },
    {
      "body": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35967183",
        "http://www.ncbi.nlm.nih.gov/pubmed/35511631",
        "http://www.ncbi.nlm.nih.gov/pubmed/33912381",
        "http://www.ncbi.nlm.nih.gov/pubmed/9578327",
        "http://www.ncbi.nlm.nih.gov/pubmed/33738101",
        "http://www.ncbi.nlm.nih.gov/pubmed/21357332",
        "http://www.ncbi.nlm.nih.gov/pubmed/22436665",
        "http://www.ncbi.nlm.nih.gov/pubmed/16617919",
        "http://www.ncbi.nlm.nih.gov/pubmed/35822579",
        "http://www.ncbi.nlm.nih.gov/pubmed/2200377",
        "http://www.ncbi.nlm.nih.gov/pubmed/12856055"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 112,
          "text": "Fever is the most common presenting symptom in children and causes distress in patients and parents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967183"
        },
        {
          "offsetInBeginSection": 500,
          "offsetInEndSection": 546,
          "text": "antipyretics are indicated only for discomfort",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511631"
        },
        {
          "offsetInBeginSection": 1504,
          "offsetInEndSection": 1680,
          "text": "relief from distress is the primary indication for prescribing pharmacotherapy, and antipyretics should not be administered with the sole intention of reducing body temperature",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33912381"
        },
        {
          "offsetInBeginSection": 830,
          "offsetInEndSection": 1056,
          "text": "The two thermoregulatory responses represent two complementary strategies of survival in systemic inflammation: fever ensures the active attack against the pathogen; hypothermia secures the defense of the host\u0027s vital systems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9578327"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 308,
          "text": "In contrast, high temperature in non-infectious intensive care patients is associated with higher mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436665"
        },
        {
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1350,
          "text": "There is little evidence that fever facilitates recovery from disease or assists the immune system in mounting a response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16617919"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 986,
          "text": "Although fever is one of the main presenting symptoms of COVID-19 infection, little public attention has been given to fever as an evolved defense. Fever, the regulated increase in the body temperature, is part of the evolved systemic reaction to infection known as the acute phase response. The heat of fever augments the performance of immune cells, induces stress on pathogens and infected cells directly, and combines with other stressors to provide a nonspecific immune defense. Observational trials in humans suggest a survival benefit from fever, and randomized trials published before COVID-19 do not support fever reduction in patients with infection. Like public health measures that seem burdensome and excessive, fevers involve costly trade-offs but they can prevent infection from getting out of control. For infections with novel SARS-CoV-2, the precautionary principle applies: unless evidence suggests otherwise, we advise that fever should be allowed to run its course.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33738101"
        },
        {
          "offsetInBeginSection": 1126,
          "offsetInEndSection": 1270,
          "text": "Even though this is a common practice, lowering body temperature has not improved survival in laboratory animals or in patients with infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33738101"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 660,
          "text": "Observational trials in humans suggest a survival benefit from fever, and randomized trials published before COVID-19 do not support fever reduction in patients with infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33738101"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 483,
          "text": "The heat of fever augments the performance of immune cells, induces stress on pathogens and infected cells directly, and combines with other stressors to provide a nonspecific immune defense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33738101"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 817,
          "text": "Like public health measures that seem burdensome and excessive, fevers involve costly trade-offs but they can prevent infection from getting out of control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33738101"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 729,
          "text": "Fever, however, is not the primary illness but is a physiologic mechanism that has beneficial effects in fighting infection. There is no evidence that fever itself worsens the course of an illness or that it causes long-term neurologic complications. Thus, the primary goal of treating the febrile child should be to improve the child\u0027s overall comfort rather than focus on the normalization of body temperature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21357332"
        },
        {
          "offsetInBeginSection": 362,
          "offsetInEndSection": 586,
          "text": "According to research, we are at a crossroad, with strong research evidence accumulating over the last few decades supporting a positive role for fever and the ongoing pressures of current practice to lower body temperature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35822579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "While understanding of the mechanisms of fever has progressed in recent years, much uncertainty remains as to whether fever in itself (as distinct from its cause) is beneficial or harmful, and what circumstances warrant antipyretic therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2200377"
        },
        {
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1189,
          "text": "No evidence shows that it is beneficial to treat febrile children with paracetamol. Treatment should be given only to children who are in obvious discomfort and those with conditions known to be painful.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 528,
          "text": "No studies showed any clear benefit for the use of paracetamol in therapeutic doses in febrile children with viral or bacterial infections or with malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12856055"
        }
      ],
      "id": "65f8418fc4010b4d78000041",
      "ideal_answer": [
        "While fever is a common symptom in children and can cause distress, it\u0027s important to note that antipyretics, or fever-reducing medications, are typically used to alleviate discomfort rather than solely to reduce body temperature. Fever is part of the body\u0027s natural defense mechanism against illness, so the primary goal of treatment is to relieve distress, not necessarily to lower the fever. Therefore, it\u0027s not always advisable to bring the fever down just for the sake of reducing body temperature. It\u0027s more about managing the child\u0027s comfort level."
      ]
    },
    {
      "body": "Can syphilis cause proctitis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36703251",
        "http://www.ncbi.nlm.nih.gov/pubmed/37267792",
        "http://www.ncbi.nlm.nih.gov/pubmed/35969837",
        "http://www.ncbi.nlm.nih.gov/pubmed/27365889",
        "http://www.ncbi.nlm.nih.gov/pubmed/30516724",
        "http://www.ncbi.nlm.nih.gov/pubmed/21998411",
        "http://www.ncbi.nlm.nih.gov/pubmed/33370929",
        "http://www.ncbi.nlm.nih.gov/pubmed/879137"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "A 26-year-old man in Australia who has sex with men had severe perianal ulceration, proctitis, and skin lesions develop. Testing revealed primary syphilis, mpox, and primary HIV infection. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Syphilitic proctitis presenting as locally advanced rectal cancer: A case report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 248,
          "text": "We present a case of severe syphilitic proctitis leading to large bowel obstruction with imaging findings mimicking locally advanced rectal cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 1513,
          "offsetInEndSection": 1715,
          "text": "CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "ABSTRACT: We analyzed microbiologic etiologies of proctitis among patients seen in an urban sexual health clinic during 2011 to 2021. Among 759 cases, 179 (24%) tested positive for Neisseria gonorrhoeae , 171 (23%) for Chlamydia trachomatis , 21 (3%) for herpes simplex virus, 30 (4%) for syphilis, and 73 (10%) for multiple pathogens; no pathogen was identified in 425 (56%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35969837"
        },
        {
          "offsetInBeginSection": 822,
          "offsetInEndSection": 906,
          "text": "The patient tested positive for syphilis and was diagnosed with syphilitic proctitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1714,
          "text": "Final pathology on the rectal biopsies demonstrated positive Warthin-Starry and spirochete immunohistochemical stain.DISCUSSION: This case illustrates key aspects in the care of a patient with syphilitic proctitis mimicking an obstructing rectal cancer, including the need for high clinical suspicion, thorough evaluation including sexual and sexually transmitted disease history, multidisciplinary communication, and management of the Jarisch-Herxheimer reaction.CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 41,
          "offsetInEndSection": 161,
          "text": "Syphilitic proctitis involving the rectal mucosa often presents with pain on defecation, rectal bleeding, or ulceration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30516724"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 264,
          "text": "We present a case of asymptomatic syphilitic proctitis diagnosed upon a routine screening colonoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30516724"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 44,
          "text": "A Case of Asymptomatic Syphilitic Proctitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30516724"
        },
        {
          "offsetInBeginSection": 822,
          "offsetInEndSection": 907,
          "text": "The patient tested positive for syphilis and was diagnosed with syphilitic proctitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 384,
          "text": "We present a case of severe syphilitic proctitis leading to large bowel obstruction with imaging findings mimicking locally advanced rectal cancer.PRESENTATION OF CASE: A 38-year-old man who had sex with men presented to the emergency department with a 2 week history of obstipation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Case of secondary syphilis presenting with unusual complications: syphilitic proctitis, gastritis, and hepatitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998411"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Syphilitic proctitis is a rare presentation of sexually transmitted infection that poses a diagnostic challenge as it mimics rectal cancer clinically, radiologically and endoscopically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33370929"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Syphilitic proctitis is a rare disease that usually presents as proctitis, ulcer, and neoplasm but lacks pathognomonic clinical symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365889"
        },
        {
          "offsetInBeginSection": 1468,
          "offsetInEndSection": 1657,
          "text": "anagement of the Jarisch-Herxheimer reaction.CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Two adult male homosexuals with syphilitic proctitis and without any detectable anal lesions are reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/879137"
        }
      ],
      "id": "65cfd13f1930410b1300001d",
      "ideal_answer": [
        "Yes. Syphilis can cause proctitis."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What disorder is considered off label use for domperidone?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35793516",
        "http://www.ncbi.nlm.nih.gov/pubmed/37352416",
        "http://www.ncbi.nlm.nih.gov/pubmed/36367713",
        "http://www.ncbi.nlm.nih.gov/pubmed/37159421",
        "http://www.ncbi.nlm.nih.gov/pubmed/25475074",
        "http://www.ncbi.nlm.nih.gov/pubmed/24600732",
        "http://www.ncbi.nlm.nih.gov/pubmed/25306766",
        "http://www.ncbi.nlm.nih.gov/pubmed/27280111",
        "http://www.ncbi.nlm.nih.gov/pubmed/27296864",
        "http://www.ncbi.nlm.nih.gov/pubmed/25825854",
        "http://www.ncbi.nlm.nih.gov/pubmed/30481478"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 113,
          "text": "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 100,
          "text": "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367713"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 538,
          "text": "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421"
        },
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1058,
          "text": "Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal reflux symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25825854"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Objectives: Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 537,
          "text": "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 256,
          "text": "on, such as domperidone, an off-label galactagogue, are often prescribed. Domperidone is controv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30481478"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 137,
          "text": "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. Neuropsychiatric adverse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793516"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 118,
          "text": "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production. Dosages commonly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25306766"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37159421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "BACKGROUND: Domperidone is commonly used off-label to stimulate milk production in mothers who have low ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27280111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37352416"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 221,
          "text": "astfeeding. Medications that can increase milk production, such as domperidone, an off-label galactagogue, are often",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30481478"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 462,
          "text": "A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25306766"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "PURPOSE: The aim of this study is to examine the relationship between domperidone (commonly used off-label for lactation stimulation), ventricular arrhythmia and all-cause mortality during the postpartu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296864"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal refl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25825854"
        },
        {
          "offsetInBeginSection": 1214,
          "offsetInEndSection": 1481,
          "text": "The use of domperidone as a galactagogue is worrisome as drug-induced long QT syndrome occurred mostly in women. In these circumstances, an improvement of breastfeeding practices seems to be more effective and safer than the use of an off-label domperidone treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The use of domperidone in accordance with the terms of its marketing authorisation, or off-label to increase breast milk production, exposes patients to serious cardiac risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600732"
        }
      ],
      "id": "65f493cac4010b4d78000012",
      "ideal_answer": [
        "A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation.",
        "Domperidone is a selective dopamine D2 receptor antagonist that was first developed as an antiemetic agent. The use of Domperidone in gastroparesis is off-label due to its peripheral effects. The main objective of this study is to assess quercetin antiemetic properties and domperidone as a positive control.",
        "Domperidone is used off label for treating symptoms related to gastro-esophageal reflux disease, dyspepsia, and gastroparesis.",
        "Domperidone is a medication most commonly used by pediatric gastroenterologists for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis outside its authorized indication, i.e. off label use",
        "Domperidone is used off label for the treatment of gastroparesis.",
        "Domperidone is considered off label use for gastroparesis.",
        "Domperidone is considered an off-label treatment for functional dyspepsia.",
        "Inducing lactation, acute gastroenteritis treatment in pediatric patients, acute dystonia",
        "Domperidone is commonly used off-label to stimulate milk production in mothers who have low milk supply. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.",
        "Domperidone is considered off-label for the treatment of functional dyspepsia.",
        "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation.",
        "Domperidone is used off-label for the purpose of inducing lactation.",
        "Domperidone is considered off-label for the disorder of lactation, specifically to induce lactation by acting as a dopamine-2 antagonist.",
        "Domperidone is an antiemetic that is commonly used off-label to induce lactation in prolactin-deficient women.",
        "Domperidone is commonly used off-label to induce lactation in women.",
        "Domperidone is considered off label use for lactation.",
        "Domperidone is considered off-label for promoting lactation in prolactin-deficient women.",
        "Domperidone is a medication commonly used off-label for its potential to stimulate prolactin secretion and thus milk production.",
        "Domperidone is used off-label to promote lactation in prolactin-deficient women.",
        " Domperidone is considered off-label use for prolactin-deficient women to increase breast milk production.",
        "Domperidone is used off-label to induce lactation in prolactin-deficient women.",
        "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production.",
        "Domperidone is commonly used off-label to induce lactation in prolactin-deficient women.",
        "Domperidone is commonly used off-label as a galactagogue to increase breast milk production.",
        "Domperidone is considered off label use for lactation, prolactin-deficient women, and Lactation induction.",
        "Domperidone is commonly used as an off-label prescription to induce lactation and increase breast milk production in women with prolactin deficiency.",
        "Domperidone is often used off-label for the treatment of lactation deficiency. It helps to increase the production of breast milk.",
        "Domperidone is considered an off-label treatment for promoting lactation in prolactin-deficient women.",
        "Domperidone is considered off-label use for inducing lactation in breastfeeding mothers."
      ],
      "exact_answer": [
        [
          "inducing lactation",
          "Gastroparesis"
        ]
      ]
    },
    {
      "body": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33751503",
        "http://www.ncbi.nlm.nih.gov/pubmed/21963369",
        "http://www.ncbi.nlm.nih.gov/pubmed/24576790",
        "http://www.ncbi.nlm.nih.gov/pubmed/31146727",
        "http://www.ncbi.nlm.nih.gov/pubmed/28950396",
        "http://www.ncbi.nlm.nih.gov/pubmed/21938084",
        "http://www.ncbi.nlm.nih.gov/pubmed/16650712",
        "http://www.ncbi.nlm.nih.gov/pubmed/11267629",
        "http://www.ncbi.nlm.nih.gov/pubmed/9924841",
        "http://www.ncbi.nlm.nih.gov/pubmed/20136383",
        "http://www.ncbi.nlm.nih.gov/pubmed/2692636",
        "http://www.ncbi.nlm.nih.gov/pubmed/9108814",
        "http://www.ncbi.nlm.nih.gov/pubmed/9829023",
        "http://www.ncbi.nlm.nih.gov/pubmed/21424418",
        "http://www.ncbi.nlm.nih.gov/pubmed/16213689"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "text": "A large body of evidence suggests that the neuropathology of obsessive-compulsive disorder (OCD) lies in the complex neurotransmitter network of the cortico-striatal-thalamo-cortical (CSTC) circuit, where dopamine (DA), serotonin (5HT), glutamate (Glu), and gamma-amino butyric acid (GABA) dysfunction have been implicated in the disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11267629"
        },
        {
          "offsetInBeginSection": 850,
          "offsetInEndSection": 929,
          "text": "Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9924841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 637,
          "text": "The differential effects of serotonin-reuptake inhibitors on obsessive-compulsive disorder (OCD) were sufficient to presume that a serotonin regulatory disorder is the most essential part of the pathophysiology of OCD. In patients with OCD, however, a high-dose of serotonin-reuptake inhibitor monotherapy may not be sufficient, and approximately half of patients were noted to be treatment-resistant. As results from previous studies have shown, there have been positive treatment responses to the dopaminergic antagonists. This suggests that other neurotransmitter systems, such as dopamine, are involved in the pathophysiology of OCD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20136383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Involvement of the brain serotonin (5-HT) neurotransmitter system in obsessive-compulsive disorder (OCD) was originally suggested on the basis of therapeutic effects found with the semiselective serotonin uptake inhibitor, clomipramine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2692636"
        },
        {
          "offsetInBeginSection": 1190,
          "offsetInEndSection": 1462,
          "text": "Similarly, the involvement of serotonergic neurotransmitters in OCD suggests that these neurotransmitters are central to defining spectrum disorders.Again, however, serotonin plays a role in many functions (including impulse control) and mediates many different disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16650712"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "BACKGROUND: While serotonin is the neurotransmitter most commonly implicated in obsessive-compulsive and related disorders, there is also evidence for dopaminergic mediation of these conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9108814"
        },
        {
          "offsetInBeginSection": 1507,
          "offsetInEndSection": 1754,
          "text": "The MRS measures did not vary by subgroup and showed no correlations with demographic and clinical variables.CONCLUSIONS: These results indicate that GABA abnormalities within the anterior cingulate cortex contribute to the pathophysiology of OCD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31146727"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 732,
          "text": "Recent evidence suggests that the ubiquitous excitatory neurotransmitter glutamate is dysregulated in OCD, and that this dysregulation may contribute to the pathophysiology of the disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "BACKGROUND: There is a major role for serotonin in the mechanism of anti-obsessional drug action. Drugs that block uptake of noradrenaline are not effective in the treatment of obsessive-compulsive disorder (OCD), while drugs that potently bock serotonin reuptake ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9829023"
        },
        {
          "offsetInBeginSection": 473,
          "offsetInEndSection": 612,
          "text": "Significant overlap in neurotransmitter dysfunction (serotonin, glutamate, and dopamine) has been documented between schizophrenia and OCD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21938084"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 848,
          "text": "Neurochemical studies have shown that OCD is linked to changes of the central modulatory transmitter system, especially, the serotonin and dopamine system, which probably contribute to a direct and indirect dysregulation in various neural networks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21424418"
        },
        {
          "offsetInBeginSection": 788,
          "offsetInEndSection": 929,
          "text": "in the cortico-striato-thalamo-cortical circuit in the brain. Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576790"
        },
        {
          "offsetInBeginSection": 520,
          "offsetInEndSection": 707,
          "text": "Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28950396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "In obsessive-compulsive disorder (OCD), the success of pharmacological treatment with serotonin re-uptake inhibitors and atypical antipsychotic drugs suggests that both the central serotonergic and dopaminergic systems are involved in the pathophysiology of the disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16213689"
        }
      ],
      "id": "65f8721ec4010b4d7800005d",
      "ideal_answer": [
        "The neurotransmitters thought to play a role in obsessive-compulsive disorder (OCD) include:\n\n1. Serotonin\n2. Dopamine \n3. Glutamate\n4. Gamma-aminobutyric acid (GABA)\n\nDysregulation of these neurotransmitter systems, especially serotonin, dopamine, and glutamate, within cortico-striatal-thalamo-cortical circuits is implicated in the pathophysiology of OCD. An imbalance between excitatory glutamate and inhibitory GABA neurotransmission may be particularly important."
      ],
      "exact_answer": [
        [
          "Serotonin"
        ],
        [
          "Dopamine"
        ],
        [
          "Glutamate"
        ],
        [
          "Gamma-Aminobutyric Acid (GABA)"
        ],
        [
          "Norepinephrine"
        ]
      ]
    },
    {
      "body": "Can denosumab cause jaw necrosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32307659",
        "http://www.ncbi.nlm.nih.gov/pubmed/29063702",
        "http://www.ncbi.nlm.nih.gov/pubmed/28684826",
        "http://www.ncbi.nlm.nih.gov/pubmed/25497376",
        "http://www.ncbi.nlm.nih.gov/pubmed/23830772",
        "http://www.ncbi.nlm.nih.gov/pubmed/23645723",
        "http://www.ncbi.nlm.nih.gov/pubmed/26964445",
        "http://www.ncbi.nlm.nih.gov/pubmed/30560961",
        "http://www.ncbi.nlm.nih.gov/pubmed/23159111",
        "http://www.ncbi.nlm.nih.gov/pubmed/24582013",
        "http://www.ncbi.nlm.nih.gov/pubmed/28555210",
        "http://www.ncbi.nlm.nih.gov/pubmed/37389685",
        "http://www.ncbi.nlm.nih.gov/pubmed/25131835",
        "http://www.ncbi.nlm.nih.gov/pubmed/38028038",
        "http://www.ncbi.nlm.nih.gov/pubmed/29576576",
        "http://www.ncbi.nlm.nih.gov/pubmed/22093187",
        "http://www.ncbi.nlm.nih.gov/pubmed/29983309",
        "http://www.ncbi.nlm.nih.gov/pubmed/31299805",
        "http://www.ncbi.nlm.nih.gov/pubmed/27648313",
        "http://www.ncbi.nlm.nih.gov/pubmed/26859582",
        "http://www.ncbi.nlm.nih.gov/pubmed/24804929",
        "http://www.ncbi.nlm.nih.gov/pubmed/24490612"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but potentially serious, adverse event that can occur after exposure to bone-modifying agents (BMAs; e.g., bisphosphonates, denosumab, and antiangiogenic therapies). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29063702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 58,
          "text": "Aggressive denosumab-related jaw necrosis - a case series.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28684826"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 329,
          "text": "We are presenting four cases of MRONJ related to denosumab treatment showing increasingly aggressive pictures of the disease. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28684826"
        },
        {
          "offsetInBeginSection": 476,
          "offsetInEndSection": 767,
          "text": "A total of 383 cases were registered: 369 were described as BRONJ, 5 as avascular necrosis, and 9 were unknown. Bisphosphonates had been given orally in 207 (56%), intravenously in 125 (34%), both orally and intravenously in 27 (7%), and was unknown in 9 (2%); one had been given denosumab. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Osteonecrosis of the jaw has recently been described in patients receiving subcutaneous administration of RANKL-inhibitors (denosumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "Medication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients\u0027 quality of life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38028038"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "PURPOSE: Osteonecrosis of the jaw has been recently reported in patients receiving denosumab for the treatment of metastatic bone disease and osteoporosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29983309"
        },
        {
          "offsetInBeginSection": 2195,
          "offsetInEndSection": 2283,
          "text": "33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22093187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23645723"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26964445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "PURPOSE: To report a case of osteonecrosis of the jaw (ONJ) occurring in an implant area possibly related to denosumab, a relatively new antiosteoporot",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210"
        },
        {
          "offsetInBeginSection": 83,
          "offsetInEndSection": 259,
          "text": "Osteonecrosis of the jaw (ONJ) is a rare but serious clinical condition. It affects patients treated with bisphosphonates, and also with denosumab, mainly in oncological doses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21365586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "We report a case of osteonecrosis of the jaw (ONJ) associated with denosumab therapy in a 62-year-old female patient being treated for bone metastases from breast cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29576576"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26964445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "text": "PURPOSE: To report a case of osteonecrosis of the jaw (ONJ) occurring in an implant area possibly related to denosumab, a relatively new antiosteoporotic agent.MATERIALS AND METHODS: Two months following the extraction of both maxillary first molars, a bilateral maxillary sinus floor elevation was performed on a 64-year-old female patient under a biannual \u202860 mg denosumab antiosteoporotic treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648313"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 1069,
          "text": "After 3 months, the implants underwent prosthetic rehabilitation at one side, and a series of failures that led to an ONJ instalment at the other side.RESULTS: The ONJ persisted over 7 months and was only resolved by a surgical approach consisting of a piezoelectric osteotomy and platelet-rich fibrin with a tension-free wound closure.CONCLUSIONS: A cumulative effect of denosumab is likely to be associated with a jaw osteonecrosis, which in this case was manageable using a surgical approach with no need to interrupt the appropriate drug treatment course.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 403,
          "text": "Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events. Available data indicate that 0-27, 5% of patients exposed to antiresorptive agents may develop ONJ, depending on the number of infusions and the duration of therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29063702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Denosumab-related osteonecrosis of the jaws (DRONJ) is a recently described entity that shares many common clinical and radiological features with bisphosphonate-related osteonecrosis of the jaws (BRONJ).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26859582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24804929"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1017,
          "text": "brin with a tension-free wound closure.CONCLUSIONS: A cumulative effect of denosumab is likely to be associated with a jaw osteonecrosis, which in this case was manageable using a surgical approach with no need",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Osteonecrosis of the jaw as a result of treatment with receptor activators of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24582013"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 318,
          "text": "A severe side effect of denosumab is the osteonecrosis of the jaw (DRONJ).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31299805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31299805"
        },
        {
          "offsetInBeginSection": 511,
          "offsetInEndSection": 763,
          "text": "While Medication Related Osteonecrosis of the Jaw (MRONJ) is most commonly seen in patients treated with bisphosphonates, in the past decade, it has become apparent that other types of medication, most notably denosumab, can cause comparable disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30560961"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 240,
          "text": "Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490612"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "BACKGROUND: Denosumab (DMB) is a bone antiresorptive agent used to treat osteoporosis or metastatic cancer of the bones. However, denosumab-associated osteonecrosis of the jaw (DRONJ) has become a common complication in canc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389685"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "Denosumab is a new bone antiresorptive agent that has received approval by the Food and Drug Administration for use in patients with osteoporosis and metastatic cancer to the bones. Like the bisphosponates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "Denosumab (Amgen, Thousand Oaks, California, USA) is a new bone antiresorptive agent used in patients with osteoporosis or metastatic cancer to the bones. As with the bisphosphonates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25131835"
        }
      ],
      "id": "65d126d21930410b1300002c",
      "ideal_answer": [
        "Yes. Denosumab can cause jaw necrosis"
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is DEXTR",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34920276",
        "http://www.ncbi.nlm.nih.gov/pubmed/32856160"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Evaluation of a semi-automated data extraction tool for public health literature-based reviews: Dextr.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276"
        },
        {
          "offsetInBeginSection": 1876,
          "offsetInEndSection": 2247,
          "text": "The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, incorporates the key capabilities of user verification and entity connecting, provides a platform for further automation developments, and has the potential to improve data extraction for literature reviews in this and other fields.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276"
        },
        {
          "offsetInBeginSection": 1824,
          "offsetInEndSection": 2017,
          "text": "rs to generate machine-readable, annotated exports. The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32856160"
        }
      ],
      "id": "65f37871c4010b4d7800000a",
      "ideal_answer": [
        "DEXTR is a semi-automated data extraction tool for public health literature-based reviews: Dextr provides similar performance to manual extraction in terms of recall and precision and greatly reduces data extraction time.",
        "DEXTR is a software tool for data extraction from scientific literature.",
        "DEXTR is a semi-automated data extraction tool for public health literature-based reviews.",
        "DEXTR is a software tool developed with Agile software methodology using a two-team approach. It provides similar performance to manual extraction in terms of recall and precision while significantly reducing data extraction time.",
        "Dextr is a semi-automated data extraction tool for public health literature-based reviews.",
        "Dextr is a semi-automated data extraction tool designed to address data-extraction challenges in public health literature-based reviews, particularly in the field of environmental health sciences.",
        "DEXTR is a semi-automated data extraction tool designed for public health literature-based reviews. It addresses data-extraction challenges in environmental health sciences literature and provides a platform for further automation developments.",
        "DEXTR is a semi-automated data extraction tool for public health literature-based reviews. It extracts information regarding population groups, intervention, comparison, outcome, and study design (PICOS) as well as study quality information from published articles.",
        "Dextr is a semi-automated data extraction tool designed to address data-extraction challenges in environmental health sciences literature. It has a simple user interface, incorporates user verification and entity connecting, and provides a platform for further automation developments.",
        "DEXTR is a tool for extracting data from environmental health sciences literature.",
        "Dextr is a semi-automated data extraction tool designed for public health literature-based reviews. It aims to assist researchers in extracting relevant information from scientific literature to support their research."
      ]
    },
    {
      "body": "What is the most common surgical treatment for hydrocephalus?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37402676",
        "http://www.ncbi.nlm.nih.gov/pubmed/34152450",
        "http://www.ncbi.nlm.nih.gov/pubmed/34774581",
        "http://www.ncbi.nlm.nih.gov/pubmed/21961546",
        "http://www.ncbi.nlm.nih.gov/pubmed/31286305",
        "http://www.ncbi.nlm.nih.gov/pubmed/17946960",
        "http://www.ncbi.nlm.nih.gov/pubmed/27203135",
        "http://www.ncbi.nlm.nih.gov/pubmed/25569424",
        "http://www.ncbi.nlm.nih.gov/pubmed/36314835",
        "http://www.ncbi.nlm.nih.gov/pubmed/26889393",
        "http://www.ncbi.nlm.nih.gov/pubmed/1474973",
        "http://www.ncbi.nlm.nih.gov/pubmed/35609726",
        "http://www.ncbi.nlm.nih.gov/pubmed/36780037",
        "http://www.ncbi.nlm.nih.gov/pubmed/31036124",
        "http://www.ncbi.nlm.nih.gov/pubmed/29122895",
        "http://www.ncbi.nlm.nih.gov/pubmed/20045747",
        "http://www.ncbi.nlm.nih.gov/pubmed/22222434",
        "http://www.ncbi.nlm.nih.gov/pubmed/11441995",
        "http://www.ncbi.nlm.nih.gov/pubmed/15630948",
        "http://www.ncbi.nlm.nih.gov/pubmed/36324983",
        "http://www.ncbi.nlm.nih.gov/pubmed/30459864",
        "http://www.ncbi.nlm.nih.gov/pubmed/22650109",
        "http://www.ncbi.nlm.nih.gov/pubmed/19725301"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 360,
          "text": "Gravitation-assisted shunt valves are designed to prevent hydrostatic over-drainage frequently observed in the long course of shunt-treated hydrocephalus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 205,
          "text": "Shunt treatment for hydrocephalus in children should aim for sustainable flexibility in regard to optional, perspective pressure level adjustment during advancing physical and mental development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450"
        },
        {
          "offsetInBeginSection": 637,
          "offsetInEndSection": 741,
          "text": "hydrocephalic neonates and infants who received initial VP-shunt insertion in the early post-natal phase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450"
        },
        {
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1477,
          "text": "primary VP-shunt insertion at a mean age of 10 weeks ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34152450"
        },
        {
          "offsetInBeginSection": 947,
          "offsetInEndSection": 1057,
          "text": "Shunt surgery is preferred for secondary hydrocephalus, especially for secondary normal pressure hydrocephalus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37402676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Ventriculoperitoneal (VP) shunt placement is the most common surgical treatment for hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961546"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: Cerebrospinal fluid (CSF) diversion by shunts is the most common surgical treatment for hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774581"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "OBJECTIVE The surgical placement of a shunt designed to resolve the brain\u0027s impaired ability to drain excess CSF is one of the most common treatments for hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27203135"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "The most common treatment for patients with hydrocephalus is the surgical implantation of a cerebrospinal fluid (CSF) shunt.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17946960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "INTRODUCTION: Ventriculoperitoneal (V-P) shunt surgery is the most common technique used for the treatment of hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Two hundred eight patients with non-tumoral congenital hydrocephalus underwent CSF shunting below the age of one month.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474973"
        },
        {
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1365,
          "text": " All patients received VP shunts for hydrocephalus managemen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31286305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Cerebrospinal fluid shunt placement is the most common surgical intervention for hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569424"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "OBJECTIVE: Ventriculoperitoneal shunt (VPS) surgery is a common treatment for hydrocephalus in children and adults, making it one of the most common procedures in ne",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36780037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Ventriculoperitoneal shunt (VPS) placement is an effective and most frequently used surgical method in the treatment of hydrocephalus, but the mechanical and infective complications are often seen after this surgical procedure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31036124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Ventriculoperitoneal (VP) shunt surgery remains the most widely used neurosurgical procedure for the management of hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29122895"
        },
        {
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1139,
          "text": "Hydrocephalus is treated with a ventriculo-peritoneal shunt but shunts in these patients suffer from frequent obstructions and require multiple revisions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20045747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Ventriculoperitoneal (VP) shunt surgery is the most common technique used in the treatment of hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22222434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Ventriculoperitoneal (VP) shunts are among the most frequently performed operations in the management of hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441995"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Hydrocephalus is a common adult neurosurgical condition typically requiring treatment with a cerebrospinal fluid (CSF) shunt, of which the ventriculoperitoneal (VP) shunt is the most common type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Ventriculoperitoneal (VP) shunts are the most common treatment modality for hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15630948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Background: Ventriculoperitoneal shunt (VPS) insertion and endoscopic third ventriculostomy (ETV) are common surgical procedures used to treat pediatric hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36324983"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "CONTEXT: Ventriculoperitoneal (VP) shunt and endoscopic third ventriculostomy (ETV) are the established surgical treatments for obstructive hydrocephalus (HCP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459864"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "INTRODUCTION: Insertion of a ventriculoperitoneal (VP) shunt, the method of choice in the treatment of hydrocephalus, is often followed by various mechanical and/or infective ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650109"
        },
        {
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1303,
          "text": "lved without any consequences.CONCLUSION: Insertion of a VP shunt represents the most frequent method of choice of the surgical treatment of hydrocephalus, but also potentially a highly risky procedure followed by various complications about which parents shou",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650109"
        },
        {
          "offsetInBeginSection": 811,
          "offsetInEndSection": 900,
          "text": "VP shunts are presently regarded as the standard of care for uncomplicated hydrocephalus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19725301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "OBJECTIVE: Although ventriculoperitoneal shunt surgery is the most common method for hydrocephalus treatment, it may lead to serious complications and require surgical int",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35609726"
        }
      ],
      "id": "65f85ec7c4010b4d78000052",
      "ideal_answer": [
        "The most common surgical treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt.",
        "Ventriculoperitoneal (VP) shunting is the most common neurosurgical treatment for hydrocephalus.",
        "Ventriculoperitoneal (VP) shunt surgery is the most widely used neurosurgical procedure for the management of hydrocephalus.",
        "The most common surgical treatment for hydrocephalus is Ventriculoperitoneal (VP) shunting, which involves the placement of a shunt system to divert excess cerebrospinal fluid from the brain\u0027s ventricles to the abdominal cavity, where it can be absorbed by the body.",
        "The most common surgical treatment for hydrocephalus is ventriculoperitoneal (VP) shunt placement. This procedure involves the insertion of a catheter into the ventricles of the brain to divert excess cerebrospinal fluid (CSF) into the peritoneal cavity, where it can be absorbed by the body.",
        "The most common surgical treatment for hydrocephalus is ventriculoperitoneal shunt (VPS) insertion."
      ],
      "exact_answer": [
        [
          "Ventriculoperitoneal shunt"
        ]
      ]
    },
    {
      "body": "Is Upadacitinib effective for Crohn’s Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36272109",
        "http://www.ncbi.nlm.nih.gov/pubmed/36968986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35695972",
        "http://www.ncbi.nlm.nih.gov/pubmed/31781755",
        "http://www.ncbi.nlm.nih.gov/pubmed/36898598"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "BACKGROUND: Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn\u0027s disease [CD] in Phase 3 clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272109"
        },
        {
          "offsetInBeginSection": 1557,
          "offsetInEndSection": 1715,
          "text": "CONCLUSION: In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Successful treatment of concomitant alopecia universalis and Crohn\u0027s disease with upadacitinib: A case report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 620,
          "text": "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn\u0027s disease during phase III clinical trials. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Upadacitinib Is Safe and Effective for Crohn\u0027s Disease: Real-World Data from a Tertiary Center.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 263,
          "text": "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn\u0027s disease. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972"
        },
        {
          "offsetInBeginSection": 415,
          "offsetInEndSection": 734,
          "text": "In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972"
        },
        {
          "offsetInBeginSection": 709,
          "offsetInEndSection": 798,
          "text": "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "BACKGROUND \u0026 AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn\u0027s disease (CD), and has received Food and Drug Administration approval for UC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36898598"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 262,
          "text": "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695972"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 619,
          "text": "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn\u0027s disease during phase III clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986"
        },
        {
          "offsetInBeginSection": 709,
          "offsetInEndSection": 797,
          "text": "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "BACKGROUND \u0026 AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn\u0027s disease (CD), and has received Food and Drug Administrati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36898598"
        }
      ],
      "id": "65d126471930410b1300002b",
      "ideal_answer": [
        "Yes. Upadacitinib is effective for Crohn’s Disease."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37301531",
        "http://www.ncbi.nlm.nih.gov/pubmed/37321200",
        "http://www.ncbi.nlm.nih.gov/pubmed/35219702",
        "http://www.ncbi.nlm.nih.gov/pubmed/12614473",
        "http://www.ncbi.nlm.nih.gov/pubmed/24646622",
        "http://www.ncbi.nlm.nih.gov/pubmed/34800293",
        "http://www.ncbi.nlm.nih.gov/pubmed/15673559",
        "http://www.ncbi.nlm.nih.gov/pubmed/31697951",
        "http://www.ncbi.nlm.nih.gov/pubmed/37327371",
        "http://www.ncbi.nlm.nih.gov/pubmed/37600520",
        "http://www.ncbi.nlm.nih.gov/pubmed/30476721",
        "http://www.ncbi.nlm.nih.gov/pubmed/35841976",
        "http://www.ncbi.nlm.nih.gov/pubmed/37923146",
        "http://www.ncbi.nlm.nih.gov/pubmed/18194199",
        "http://www.ncbi.nlm.nih.gov/pubmed/19552637",
        "http://www.ncbi.nlm.nih.gov/pubmed/12853293",
        "http://www.ncbi.nlm.nih.gov/pubmed/11068944",
        "http://www.ncbi.nlm.nih.gov/pubmed/12579834",
        "http://www.ncbi.nlm.nih.gov/pubmed/21160589",
        "http://www.ncbi.nlm.nih.gov/pubmed/15033929",
        "http://www.ncbi.nlm.nih.gov/pubmed/27620136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35572137",
        "http://www.ncbi.nlm.nih.gov/pubmed/33063739",
        "http://www.ncbi.nlm.nih.gov/pubmed/24530291",
        "http://www.ncbi.nlm.nih.gov/pubmed/15298666",
        "http://www.ncbi.nlm.nih.gov/pubmed/12667942",
        "http://www.ncbi.nlm.nih.gov/pubmed/17123867",
        "http://www.ncbi.nlm.nih.gov/pubmed/12074100",
        "http://www.ncbi.nlm.nih.gov/pubmed/33777317",
        "http://www.ncbi.nlm.nih.gov/pubmed/35301664",
        "http://www.ncbi.nlm.nih.gov/pubmed/34118791",
        "http://www.ncbi.nlm.nih.gov/pubmed/32599143"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37301531"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 461,
          "text": "Melatonin is a promising neuroprotective agent that can regulate microglial polarization in central nervous system (CNS) diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37301531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Melatonin Attenuates Cerebral Ischemia/Reperfusion Injury through Inducing Autophagy",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321200"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Melatonin improves cognitive function by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35219702"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 462,
          "text": "Melatonin is neuroprotective against cerebral ischemia-reperfusion injury (CIRI) in non-DM, normoglycemic animals through anti-oxidant effect, anti-inflammation, and anti-apoptosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37327371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Melatonin Attenuates Cerebral Ischemia/Reperfusion Injury through Inducing Autophagy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321200"
        },
        {
          "offsetInBeginSection": 1429,
          "offsetInEndSection": 1807,
          "text": "Melatonin potentiated intrinsic antioxidant status, inhibited acid mediated rise in intracellular calcium levels, decreased apoptotic cell death and also markedly inhibited protein kinase C (PKC) influenced AQP4 expression in the cerebral cortex and dorsal striatum.SIGNIFICANCE: Melatonin confers neuroprotection by protein kinase C mediated AQP4 inhibition in ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24530291"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Melatonin, the secretory product of the pineal gland, is known to be neuroprotective in cerebral ischemia, which is so far mostly attributed to its antioxidant properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15033929"
        },
        {
          "offsetInBeginSection": 1529,
          "offsetInEndSection": 1650,
          "text": "Melatonin treatment diminished the loss of neurons and decreased the infarct volume as compared with untreated MCAO rats.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15033929"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Melatonin: a promising neuroprotective agent for cerebral ischemia-reperfusion injury.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37600520"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1147,
          "text": "These findings suggest that melatonin can improve microvessel abnormalities in the cerebral cortex and hippocampus by lowering the expression of vascular endothelial growth factor and its receptors, thereby improving the cognitive function of patients with Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063739"
        },
        {
          "offsetInBeginSection": 406,
          "offsetInEndSection": 631,
          "text": "Post administration of melatonin following ischemic stroke reduces AQP4 mediated brain edema and confers neuroprotection.MATERIALS AND METHODS: An in-silico approach was undertaken to confirm effective melatonin-AQP4 binding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24530291"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "This brief review summarizes the recently obtained evidence which illustrates the beneficial effects of the endogenously produced antioxidant, melatonin, in reducing tissue damage and reversing cardiac pathophysiology in models of experimental ischemia/reperfusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12667942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 421,
          "text": "BACKGROUND: Experimental studies have documented the beneficial effects of the endogenously produced antioxidant, melatonin, in reducing tissue damage and limiting cardiac pathophysiology in models of experimental ischemia-reperfusion. Melatonin confers cardioprotection against ischemia-reperfusion injury most likely through its direct free radical scavenging activities and its indirect actions in stimulating antioxid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17123867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345,
          "text": "Melatonin, a natural product of the pineal gland, has been shown to protect against ischemic stroke, but the molecular mechanisms underlying its protective function are not fully understood. In the present study, we tested whether melatonin could protect against ischemia-reperfusion (I/R) injury to rat brain by targeting the autophagy pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646622"
        },
        {
          "offsetInBeginSection": 443,
          "offsetInEndSection": 1058,
          "text": "The exogenous administration of melatonin in these experimental stroke models reduced infarct volume, lowered the frequency of apoptosis, increased the number of surviving neurons, reduced reactive gliosis, lowered the oxidation of neural lipids and oxidatively damaged DNA, induced bcl-2 gene expression (the activity of which improves cell survival), upregulated excision repair cross-complementing factor 6 (an essential gene for preferential DNA excision repair), restrained poly(ADP ribose) synthetase (which depletes cellular NAD resulting in the loss of ATP) activity, and improved neurophysiologic outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12853293"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 442,
          "text": "In these investigations, which have used three species (rat, gerbil, and cat), melatonin was universally found to reduce brain damage that normally occurs as a consequence of the temporary interruption of blood flow followed by the reflow of oxygenated blood to the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12853293"
        },
        {
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1367,
          "text": "Melatonin attenuates molecular and cellular damage resulting from cardiac ischemia-reperfusion in which destructive free radicals are involved.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21160589"
        },
        {
          "offsetInBeginSection": 1125,
          "offsetInEndSection": 1290,
          "text": "Taken together, our results document that melatonin provides neuroprotective effects in CCH by attenuating oxidative stress and stress protein expression in neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19552637"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 1083,
          "text": "Neuronal damage was assessed in CA1 pyramidal layer of gerbil hippocampus and evaluated 7 days after ischemia.RESULTS: MT significantly reversed the locomotor activity increases, ameliorated learning and working memory deficit, and reduced the extent of CA1 hippocampal pyramidal cells injury after transient global cerebral ischemia in the Mongolian gerbil.CONCLUSION: MT provides significantly protective effect against both histological and behavioral consequences of global cerebral ischemia-reperfusion injury in gerbils.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12579834"
        },
        {
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1074,
          "text": "Therefore, understanding the underlying intracellular and molecular mechanisms is crucial before investigating the neuroprotective effects of melatonin in cerebral ischemia-reperfusion injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37600520"
        },
        {
          "offsetInBeginSection": 1503,
          "offsetInEndSection": 1674,
          "text": "Our results suggest that melatonin treatment mediates neuroprotection against ischemia/reperfusion injury partly via inhibition of the consequential inflammatory response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15298666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Intranasally administered melatonin core-shell polymeric nanocapsules: A promising treatment modality for cerebral ischemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35841976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1085,
          "text": "The role of OPA1-related mitochondrial fusion in brain reperfusion stress has remained elusive. The aim of our study is to explore whether melatonin alleviates cerebral IR injury by modulating OPA1-related mitochondrial fusion. We found that melatonin reduced infarct area and suppressed neuron death during reperfusion stress. Biological studies have revealed that IR-inhibited mitochondrial fusion was largely reversed by melatonin via upregulated OPA1 expression. Knocking down OPA1 abrogated the protective effects of melatonin on mitochondrial energy metabolism and mitochondrial apoptosis. In addition, we also found that melatonin modified OPA1 expression via the Yap-Hippo pathway; blockade of the Yap-Hippo pathway induced neuron death and mitochondrial damage despite treatment with melatonin. Altogether, our data demonstrated that cerebral IR injury is closely associated with defective OPA1-related mitochondrial fusion. Melatonin supplementation enhances OPA1-related mitochondrial fusion by activating the Yap-Hippo pathway, ultimately reducing brain reperfusion stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30476721"
        },
        {
          "offsetInBeginSection": 205,
          "offsetInEndSection": 1184,
          "text": "Melatonin regulates a large number of physiological actions and its beneficial properties have been reported. The aim of this study was to investigate whether melatonin mediates neuroprotection in rat hippocampal slices subjected to oxygen-glucose-deprivation (OGD) and glutamate excitotoxicity. Thus, we describe here that melatonin significantly reduced the amount of lactate dehydrogenase released in the OGD-treated slices, reverted neuronal injury caused by OGD-reoxygenation in CA1 and CA3 hippocampal regions, restored the reduction of GSH content of the hippocampal slices induced by OGD, and diminished the oxidative stress produced in the reoxygenation period. Furthermore, melatonin afforded maximum protection against glutamate-induced toxicity and reversed the glutamate released almost basal levels, at 10 and 30μM concentration, respectively. Consequently, we propose that melatonin might strongly and positively influence the outcome of brain ischemia/reperfusion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27620136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1226,
          "text": "Melatonin is a potent scavenger of free radicals and an indirect antioxidant. Recent studies have shown that melatonin possesses beneficial effects in experimental models of brain trauma and global cerebral ischemia. The effects of pretreatment with melatonin on volume of cerebral infarction were investigated in the present study. Adult male Sprague-Dawley rats were anesthetized with sodium pentobarbital to undergo right-sided endovascular middle cerebral artery occlusion (MCAO) for 3 hr. A single dose of melatonin (1.5, 5, 15, or 50 mg/kg in 1 mL normal saline) or its vehicle was given via an intraperitoneal injection at 0.5 hr before MCAO. Relative infarction volumes on day 3 after MCAO were significantly reduced in the groups treated with melatonin at 5 (mean +/- S.E.M., 15.7 +/- 2.5%) or 15 (21.4 +/- 3.1 %) mg/kg but not at 1.5 (30.6 +/- 3.5%) or 50 (26.7 +/- 2.8%) mg/ kg when compared with the vehicle group (33.9 +/- 3.5%). There was no significant difference in the arterial blood pressure (BP), heart rate (HR) and relative cerebral blood flow among the experimental groups. These results indicate that pretreatment with melatonin at a dose between 5 and 15 mg/kg protects against focal cerebral ischemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074100"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 957,
          "text": "Melatonin, a natural product of the pineal gland, has been shown to protect against ischemic stroke, but the molecular mechanisms underlying its protective function are not fully understood. In the present study, we tested whether melatonin could protect against ischemia-reperfusion (I/R) injury to rat brain by targeting the autophagy pathway. The I/R brain injury was induced by the established rat transient middle cerebral artery occlusion model. We found intraperitoneal injection of melatonin can ameliorate rat brain injury as evidenced by multiple morphological and behavioral criteria, such as infarct size, neurological score, serum creatine kinase, and lactate dehydrogenase content, as well as pyknotic-positive cells. Further studies revealed that the beneficial effects of melatonin is through targeting the autophagy pathway by inhibiting expression of beclin-1 and conversion of LC3, as well as activating the PI3K/Akt pro-survival pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Melatonin as a Potential Neuroprotectant: Mechanisms in Subarachnoid Hemorrhage-Induced Early Brain Injury.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35572137"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 438,
          "text": "f diseases. In this study, the neuroprotective effects of melatonin (Mel) on a rat model of cerebral ischemia/reperfusion injury (CIRI) were assessed by multi-parametric MRI combined with histopathological techniques for longitudinal monitoring of the lesion microe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37923146"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Melatonin is a strong antioxidant which beneficially protects against middle cerebral artery occlusion (MCAO) followed by hemorrhagic transformation in rats; protection includes the reduction of neurological deficits, infarction, and hematoma volume.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777317"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 1642,
          "text": "Nonetheless, the mechanisms of the anti-inflammatory effects of EA are unclear. Cerebral I/R injury was induced in rats by middle cerebral artery occlusion (MCAO). Following I/R injury, the rats underwent EA therapy at the Shenting (DU24) and Baihui (DU20) acupoints for seven successive days. The Morris water maze test, magnetic resonance imaging (MRI) and molecular biology assays were utilized to assess the establishment of the rat stroke model with cognitive impairment and the therapeutic effect of EA. EA treatment of rats subjected to MCAO showed a significant reduction in infarct volumes accompanied by cognitive recovery, as observed in Morris water maze test outcomes. The possible mechanisms by which EA treatment attenuates cognitive impairment are by regulating endogenous melatonin secretion through aralkylamine N-acetyltransferase gene (AANAT, a rate-limiting enzyme of melatonin) synthesis in the pineal gland in stroke rats. Simultaneously, through melatonin regulation, EA exerts neuroprotective effects by upregulating mitophagy-associated proteins and suppressing reactive oxygen species (ROS)-induced NLRP3 inflammasome activation after I/R injury. However, melatonin receptor inhibitor (luzindole) treatment reversed these changes. The findings from this research suggested that EA ameliorates cognitive impairment through the inhibition of NLRP3 inflammasome activation by regulating melatonin-mediated mitophagy in stroke rats.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35301664"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 230,
          "text": "Melatonin has protective effects against cerebral ischemia/reperfusion injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19552637"
        },
        {
          "offsetInBeginSection": 1435,
          "offsetInEndSection": 1598,
          "text": "e damage in neurons after CI.CONCLUSION: Melatonin treatment following CI reduced the infarct area and induced the autophagic proteins Beclin-1, LC3, and p62 by in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321200"
        },
        {
          "offsetInBeginSection": 1300,
          "offsetInEndSection": 1513,
          "text": "In conclusion, these results indicate that melatonin treatment can protect against CIR-induced brain damage in diabetic mice, which may be achieved by the autophagy enhancement mediated by the SIRT1-BMAL1 pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34800293"
        },
        {
          "offsetInBeginSection": 1626,
          "offsetInEndSection": 1762,
          "text": "lls, and better neuronal survival.CONCLUSIONS: T1DM aggravates CIRI. Melatonin treatment is neuroprotective against CIRI in T1DM rats vi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37327371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "AIMS: The neurohormone melatonin (MEL) has been reported as a promising neuroprotective molecule, however it suffers pharmaceutical limitations such as poor solubility and low bioavailability, which hinder its pharmacological and clinical pote",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35841976"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 327,
          "text": "We found that melatonin reduced infarct area and suppressed neuron death during reperfusion stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30476721"
        },
        {
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1289,
          "text": "tosis through SIRT3 activation.SIGNIFICANCE: Our research proved that melatonin promoted SIRT3 expression after tMCAO and alleviated cerebral I/R inju",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31697951"
        },
        {
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1546,
          "text": "stroke. Melatonin treatment significantly decreased infarct volume and cerebral apoptosis; mitigated endoplasmic reticulum stress and mitochondrial dysfunction; and inhibited CI/R injury-induced oxidative/nitrative stress and nuclear factor-κB activation, which was eradicated in RORα-defic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32599143"
        },
        {
          "offsetInBeginSection": 1648,
          "offsetInEndSection": 1762,
          "text": "al survival.CONCLUSIONS: T1DM aggravates CIRI. Melatonin treatment is neuroprotective against CIRI in T1DM rats vi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37327371"
        },
        {
          "offsetInBeginSection": 934,
          "offsetInEndSection": 1085,
          "text": "Melatonin supplementation enhances OPA1-related mitochondrial fusion by activating the Yap-Hippo pathway, ultimately reducing brain reperfusion stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30476721"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 894,
          "text": "er ischemia.RESULTS: MT significantly reversed the locomotor activity increases, ameliorated learning and working memory deficit, and reduced the extent of CA1 hippocampal pyramidal cells injury after transient global cerebral ischemia in ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12579834"
        },
        {
          "offsetInBeginSection": 273,
          "offsetInEndSection": 463,
          "text": "Melatonin\u0027s efficacy in curtailing neural damage under conditions of transitory interruption of the blood supply to the brain has been documented in models of both focal and global ischemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673559"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 826,
          "text": "For example, when given at the time of ischemia or reperfusion onset, melatonin reduces neurophysiological deficits, infarct volume, the degree of neural edema, lipid peroxidation, protein carbonyls, DNA damage, neuron and glial loss, and death of the animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673559"
        },
        {
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1373,
          "text": "Considering its high efficacy in overcoming much of the damage associated with ischemia/reperfusion injury, not only in the brain but in other organs as well, its use in clinical trials for the purpose of improving stroke outcome should be seriously considered.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673559"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 151,
          "text": "melatonin against ischemia/reperfusion brain injury. The studies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18194199"
        },
        {
          "offsetInBeginSection": 35,
          "offsetInEndSection": 118,
          "text": " that melatonin plays a critical role in protecting against cerebral ischemia/reper",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31697951"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1724,
          "text": "The brain is highly susceptible to focal or global ischemia. Unless ischemia is promptly reversed, reperfusion produces further cerebral damage. Acute thrombolysis or defibrinogenation is effective only in selective patients with ischemic stroke and carries a significant risk of bleeding complications. Whereas numerous neuroprotectants were shown to be effective in experimental studies, none of them have been shown to work in clinical trials. The major pathogenetic mechanisms of ischemia/reperfusion injury include excitotoxicity, disturbed calcium ion homeostasis, overproduction of nitric oxide and other free radicals, inflammation, and apoptosis. Nitric oxide and other free radicals, the key mediators of excitotoxicity and disturbed calcium ion homeostasis, cause direct injury and also indirectly damage via inflammation and apoptosis. Melatonin is a potent free radical scavenger and an indirect antioxidant. This mini review summarizes the in vivo and in vitro evidence that melatonin protects against ischemia/reperfusion injury. There is convincing evidence from the literature that melatonin treatment is highly effective in different in vivo and in vitro models of excitotoxicity or ischemia/reperfusion in multiple animal species. Melatonin is safe and non-toxic in humans, and its administration via the oral route or intravenous injection is convenient. While more experimental studies should be conducted to further explore the neuroprotective mechanisms and to document any synergistic or additive protection from combining melatonin with thrombolysis, defibrinogenation or other neuroprotectants, interested clinical scientists should consider planning phase II and III studies to confirm the benefit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12614473"
        },
        {
          "offsetInBeginSection": 1317,
          "offsetInEndSection": 1527,
          "text": "ischemia and reperfusion. Histological observations of the pyramidal layer of CA-1 showed a reduction of neuronal loss in animals that received melatonin. These results show that melatonin improves brain injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068944"
        },
        {
          "offsetInBeginSection": 910,
          "offsetInEndSection": 1255,
          "text": "Brains were harvested for infarct size estimation, water content measurement, biochemical analysis, apoptosis study and western blot experiments.KEY FINDINGS: Melatonin at 60 min post ischemia rendered neuroprotection as evident by reduction in cerebral infarct volume, improvement in motor and neurological deficit and reduction in brain edema.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24530291"
        },
        {
          "offsetInBeginSection": 1472,
          "offsetInEndSection": 1567,
          "text": "These results show that melatonin improves brain injury induced by transient cerebral ischemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068944"
        },
        {
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1428,
          "text": "Furthermore, ischemia induced surge in levels of nitrite and malondialdehyde (MDA) were also found to be significantly reduced in ischemic brain regions in treated animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24530291"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 1334,
          "text": "Then, we observed the changes in the SIRT3 and downstream relative proteins, infarction volume, neurological score, Nissl, H\u0026E and TUNEL staining, and the expression of apoptosis proteins after tMCAO.KEY FINDINGS: Melatonin upregulated the expression of SIRT3 after tMCAO, and alleviated the neurological dysfunction and cell apoptosis through SIRT3 activation.SIGNIFICANCE: Our research proved that melatonin promoted SIRT3 expression after tMCAO and alleviated cerebral I/R injury by activating the SIRT3 signaling pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31697951"
        },
        {
          "offsetInBeginSection": 1366,
          "offsetInEndSection": 1534,
          "text": "Overall, we demonstrate that melatonin can alleviate CIR injury in diabetic mice by activating Akt-SIRT3-SOD2 signaling and subsequently improving mitochondrial damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34118791"
        }
      ],
      "id": "65f0369bc4010b4d78000001",
      "ideal_answer": [
        "Yes, melatonin is beneficial in treating cerebral ischemia-reperfusion injury:",
        "Yes, melatonin is beneficial in treating cerebral ischemia-reperfusion injury.",
        "Studies have suggested that melatonin is a potential therapeutic agent in cerebral ischemia reperfusion injury",
        "Yes, melatonin is beneficial in the treatment of in cerebral ischemia-reperfusion injury.",
        "Yes, melatonin has protective effects against cerebral ischemia/reperfusion injury.",
        "Yes, melatonin is effective for treatment of cerebral ischemia-reperfusion injury.",
        "Yes, melatonin has been shown to be beneficial in the treatment of cerebral ischemia/reperfusion injury by inducing autophagy, which helps in reducing the damage caused by the condition.",
        "Yes, melatonin is beneficial in the treatment of cerebral ischemia-reperfusion injury.",
        "”The present study demonstrates that melatonin has a protective effect on brain tissue during ischemia-reperfusion injury\"}",
        "Yes, melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice, suggesting that it may be beneficial in the treatment of cerebral ischemia-reperfusion injury.",
        "Yes, Melatonin improves cognitive function by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.",
        "Yes, melatonin is beneficial in the treatment of cerebral ischemia-reperfusion injury. It has been shown to have neuroprotective effects, reducing brain damage and improving cognitive function.",
        "Yes, melatonin has been shown to be beneficial in the treatment of cerebral ischemia-reperfusion injury in mice."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Are Hemoglobin-Based Oxygen Carriers approved for human use?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36837597",
        "http://www.ncbi.nlm.nih.gov/pubmed/34776270",
        "http://www.ncbi.nlm.nih.gov/pubmed/17591302",
        "http://www.ncbi.nlm.nih.gov/pubmed/11805546",
        "http://www.ncbi.nlm.nih.gov/pubmed/15168238",
        "http://www.ncbi.nlm.nih.gov/pubmed/31513123",
        "http://www.ncbi.nlm.nih.gov/pubmed/30177214",
        "http://www.ncbi.nlm.nih.gov/pubmed/17021438",
        "http://www.ncbi.nlm.nih.gov/pubmed/11336435",
        "http://www.ncbi.nlm.nih.gov/pubmed/31836032",
        "http://www.ncbi.nlm.nih.gov/pubmed/24418449",
        "http://www.ncbi.nlm.nih.gov/pubmed/25697570",
        "http://www.ncbi.nlm.nih.gov/pubmed/36443351",
        "http://www.ncbi.nlm.nih.gov/pubmed/12783619",
        "http://www.ncbi.nlm.nih.gov/pubmed/14562565",
        "http://www.ncbi.nlm.nih.gov/pubmed/29592539",
        "http://www.ncbi.nlm.nih.gov/pubmed/18494389",
        "http://www.ncbi.nlm.nih.gov/pubmed/18694360",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099525"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 257,
          "text": "As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 598,
          "text": "products still in active clinical research in the category of hemoglobin-based oxygen carriers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 1027,
          "text": "Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 1028,
          "offsetInEndSection": 1096,
          "text": "OxyVita and Sanguinate are still undergoing active clinical studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 1301,
          "offsetInEndSection": 1395,
          "text": "Unfortunately, so far, no HBOC has been approved by FDA and EMA, except for compassionate use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776270"
        },
        {
          "offsetInBeginSection": 957,
          "offsetInEndSection": 1347,
          "text": "Safety and cost effectiveness are being evaluated for their use as an alternative to blood transfusion or along with other strategies of blood conservation in cardiac surgery.SUMMARY: One hemoglobin-based oxygen carrier (Hemopure) has been approved for use in humans in South Africa as well as another hemoglobin-based oxygen carrier (Gelenpol) and a perfluorocarbon (Perfluoron) in Russia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17021438"
        },
        {
          "offsetInBeginSection": 1541,
          "offsetInEndSection": 1839,
          "text": "Four cross-linked hemoglobin products have been tested in Phase III clinical trials.CONCLUSION: While no product has yet been approved for clinical use, preliminary studies with oxygen therapeutics show promising results, with effective oxygen carrying capacity and acceptable side effect profiles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336435"
        },
        {
          "offsetInBeginSection": 1229,
          "offsetInEndSection": 1382,
          "text": "Several of these HBOCs have undergone rigorous preclinical and clinical evaluation, but have not yet received clinical approval in the USA for human use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513123"
        },
        {
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1549,
          "text": "While there is no FDA approved hemoglobin-based oxygen carrier approved for use in injured patients at this writing, phase III studies are currently either underway or being developed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11805546"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 583,
          "text": "No artificial oxygen carriers are currently approved for clinical use in the United States. Hemopure has been approved for use in South Africa. The companies producing Hemopure and PolyHeme, both of which are hemoglobin-based oxygen carriers, have filed a Biologic License Application in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "For the past thirty years, hemoglobin-based oxygen carriers (HBOCs) have been under development as a red blood cell substitute. Side-effects such as vasoconstriction, oxidative injury, and cardiac toxicity have prevented clinical approval of HBOCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36443351"
        },
        {
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1020,
          "text": "HBOC-201, which is a preparation of cell-free bovine hemoglobin, has been approved for clinical use in South Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168238"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 412,
          "text": "Hemopure (HBOC-201, bovine Hb glutamer-250; OPK Biotech, Cambridge, MA), one such HBOC, has been approved for clinical use in South Africa and Russia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418449"
        },
        {
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1604,
          "text": "HBOC-201 is generally well-tolerated and is approved for use in South Africa, where it is indicated for use in adult surgical patients who are acutely anaemic, and is used to eliminate, delay or reduce the need for allogeneic RBCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783619"
        },
        {
          "offsetInBeginSection": 1605,
          "offsetInEndSection": 1690,
          "text": "A Biologics License Application for HBOC-201 is currently under review by the US FDA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783619"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 544,
          "text": "South Africa recently approved one HBOC for use as a transfusion alternative in patients with chronic anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14562565"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Bovine-derived hemoglobin-based oxygen carriers (HBOCs) have been investigated for use in humans (HBOC-201) and approved for veterinary medicine (HBOC-301).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25697570"
        },
        {
          "offsetInBeginSection": 1198,
          "offsetInEndSection": 1294,
          "text": "Hemoglobin-based oxygen carriers (HBOCs) are currently not Food and Drug Administration approved",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29592539"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 420,
          "text": "No artificial oxygen carriers are currently approved for clinical use in the United States. Hemopure has been approved for use in South Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 429,
          "text": "Hemoglobin based oxygen carriers (HBOCs) have been developed as alternative oxygen transporting formulations for the acute treatment of anemia and ischemia. Efficacy has been demonstrated in a variety of preclinical models and selected human patients; however, a higher overall incidence of mortality and myocardial infarction in those dosed with HBOCs in later stage clinical trials has prevented widespread regulatory approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836032"
        },
        {
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1661,
          "text": "There are at least three agents presently under development that use different techniques to alter the basic hemoglobin tetramer. While there is no FDA approved hemoglobin-based oxygen carrier approved for use in injured patients at this writing, phase III studies are currently either underway or being developed. There is high likelihood that one or more of these agents will be approved for clinical use in the near future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11805546"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 1020,
          "text": "HBOCs have been the most extensively studied and tested in preclinical and clinical trials that have shown success in diminishing the number of blood transfusions as well as an overall favorable side-effect profile. This has been demonstrated in vascular, cardiothoracic, and orthopaedic patients. HBOC-201, which is a preparation of cell-free bovine hemoglobin, has been approved for clinical use in South Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168238"
        },
        {
          "offsetInBeginSection": 515,
          "offsetInEndSection": 1252,
          "text": "Preparations undergoing experimental and clinical assessment include Human Polymerized Haemoglobin (Polyheme), Polymerized Bovine Haemoglobin-based Oxygen Carrier (HBOC-201, Hemopure), Haemoglobin Raffimer (HemoLink), Diaspirin Cross-linked Haemoglobin (HemAssist), Human Recombinant Haemoglobin (rHb), Enzyme Cross-linked Poly-haemoglobin, Maleimide-activated Polyethylene-glycol Modified Haemoglobin (MP4, Hemospan), Zero-linked Haemoglobin (ZL-HbBv) and Recombinant Hybrid of Human-alpha-chains and Bovine-beta-chains and Perflubron (Oxygent). Research into some of these compounds has been discontinued, while others have advanced into clinical phase III trials, but none has achieved market approval for Europe, US or Canada so far.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18494389"
        },
        {
          "offsetInBeginSection": 791,
          "offsetInEndSection": 1984,
          "text": "ted in Phase III clinical trials. Hemoglobin-based oxygen carriers (HBOCs) are either cross-linked or microencapsulated hemoglobin molecules. Modification of the human hemoglobin molecule with intra- and inter-molecular cross-linking eliminates renal toxicity and improves the oxygen dissociation characteristics of the molecule. These modifications are necessary because stroma-free hemoglobin (Hb) does not release oxygen in the physiologic range and dissociates into dimers which can be rapidly filtered by the kidney, leading to renal toxicity. In addition to human Hb, bovine hemoglobin is another source of raw material for HBOC products. Recombinant human Hb has also been produced, using an E. coli expression system, for HBOC manufacturing. Four cross-linked hemoglobin products have been tested in Phase III clinical trials.CONCLUSION: While no product has yet been approved for clinical use, preliminary studies with oxygen therapeutics show promising results, with effective oxygen carrying capacity and acceptable side effect profiles. In the future, the formation of a hybrid product which combines the best features from several of the products currently undergoing development ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336435"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 794,
          "text": "Hemopure is in clinical use in South Africa and Russia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 795,
          "offsetInEndSection": 919,
          "text": "Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1027,
          "text": "HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 429,
          "text": "a higher overall incidence of mortality and myocardial infarction in those dosed with HBOCs in later stage clinical trials has prevented widespread regulatory approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836032"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 368,
          "text": "No artificial oxygen carriers are currently approved for clinical use in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591302"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 420,
          "text": "Hemopure has been approved for use in South Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591302"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 248,
          "text": "Side-effects such as vasoconstriction, oxidative injury, and cardiac toxicity have prevented clinical approval of HBOCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36443351"
        },
        {
          "offsetInBeginSection": 1110,
          "offsetInEndSection": 1581,
          "text": "Hb-based oxygen carriers (HBOCs) can potentially provide therapeutic oxygenation when blood or RBCs are not available. Several of these HBOCs have undergone rigorous preclinical and clinical evaluation, but have not yet received clinical approval in the USA for human use. While these designs are being optimized for clinical translations, several new HBOC designs and molecules have been reported in recent years, with unique properties. The current article will provide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513123"
        },
        {
          "offsetInBeginSection": 1102,
          "offsetInEndSection": 1479,
          "text": "nservation in cardiac surgery.SUMMARY: One hemoglobin-based oxygen carrier (Hemopure) has been approved for use in humans in South Africa as well as another hemoglobin-based oxygen carrier (Gelenpol) and a perfluorocarbon (Perfluoron) in Russia. Phase III trials in Europe and North America will be concluded very soon. We anticipate seeing one or two products approved in Nort",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17021438"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 1201,
          "text": "In this article, we reviewed the most developed but failed products and products still in active clinical research in the category of hemoglobin-based oxygen carriers. Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union. OxyVita and Sanguinate are still undergoing active clinical studies. The field of oxygen therapeutics seems to be entering a phase of rapid growth in the coming 10-20 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 1534,
          "text": "With a worldwide shortage of donor blood that is expected to increase over time, the creation of oxygen-carriers with long storage life and compatibility without typing and cross-matching, persists as one of the foremost important challenges in biomedicine. However, research has so far failed to produce FDA approved RBCs substitutes (RBCSs) for human usage. As such, due to unacceptable toxicities, the first generation of oxygen-carriers has been withdrawn from the market. Being hemoglobin (Hb) the main component of RBCs, a lot of effort is being devoted in assembling semi-synthetic RBCS utilizing Hb as the oxygen-carrier component, the so-called Hb-based oxygen carriers (HBOCs). However, a native RBC also contains a multi-enzyme system to prevent the conversion of Hb into non-functional methemoglobin (metHb). Thus, the challenge for the fabrication of next-generation HBOCs relies in creating a system that takes advantage of the excellent oxygen-carrying capabilities of Hb, while preserving the redox environment of native RBCs that prevents or reverts the conversion of Hb into metHb. In this review, we feature the most recent",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30177214"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 514,
          "text": "Hemoglobin-based oxygen carriers (HBOCs) derived from purified human or bovine hemoglobin have been studied for clinical use and one product is currently available in the United States and European Union for veterinary use, and another in South Africa for human use.OBJECTIVE: HBOC-201, bovine purified hemoglobin crosslinked and polymerized with glutaraldehyde, has been studied extensively in patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18694360"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 452,
          "text": "Despite decades of research to develop hemoglobin (Hb) based oxygen (O2) carriers (HBOCs) as RBC substitutes, there are no products approved for clinical use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099525"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 1027,
          "text": "Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597"
        }
      ],
      "id": "65f84b5ec4010b4d78000048",
      "ideal_answer": [
        "Hemoglobin-Based Oxygen Carriers (HBOCs) are not widely approved for human use. As of now, no HBOC has been approved by the FDA and EMA, except for compassionate use. However, some products like Hemopure are in clinical use in South Africa and Russia. HemO2life has also been approved for organ preservation in organ transplantation in the European Union. Other products like OxyVita and Sanguinate are still undergoing active clinical studies. It\u0027s important to note that while these products are in use or under study, there is currently no widely accepted product used as an alternative to human blood in clinical settings with severe anemic conditions.",
        "No, currently there are no Hemoglobin-Based Oxygen Carriers (HBOCs) that have been approved for human use by the FDA and EMA, except for compassionate use. However, Hemopure is in clinical use in South Africa and Russia, and HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
        "No, Hemoglobin-Based Oxygen Carriers are not widely approved for human use. However, some products like Hemopure are in clinical use in South Africa and Russia, and HemO2life has been approved for organ preservation in organ transplantation in the European Union. But none have been approved by the FDA and EMA, except for compassionate use.",
        "No, Hemoglobin-Based Oxygen Carriers (HBOCs) have not been approved for human use by the FDA and EMA, except for compassionate use. However, HBOCs have been approved for veterinary use in the European Union and the United States, and they are also being used for organ preservation in organ transplantation in the European Union. Some HBOCs are still undergoing active clinical studies."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Gantenerumab was developed for treatment of which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35841240",
        "http://www.ncbi.nlm.nih.gov/pubmed/36447240",
        "http://www.ncbi.nlm.nih.gov/pubmed/37017737",
        "http://www.ncbi.nlm.nih.gov/pubmed/36751779",
        "http://www.ncbi.nlm.nih.gov/pubmed/36281062",
        "http://www.ncbi.nlm.nih.gov/pubmed/36515320",
        "http://www.ncbi.nlm.nih.gov/pubmed/36388611",
        "http://www.ncbi.nlm.nih.gov/pubmed/28754630",
        "http://www.ncbi.nlm.nih.gov/pubmed/35100444",
        "http://www.ncbi.nlm.nih.gov/pubmed/36457865",
        "http://www.ncbi.nlm.nih.gov/pubmed/35493943",
        "http://www.ncbi.nlm.nih.gov/pubmed/37823690",
        "http://www.ncbi.nlm.nih.gov/pubmed/22583155",
        "http://www.ncbi.nlm.nih.gov/pubmed/21987394",
        "http://www.ncbi.nlm.nih.gov/pubmed/36348972",
        "http://www.ncbi.nlm.nih.gov/pubmed/37966285",
        "http://www.ncbi.nlm.nih.gov/pubmed/21955818",
        "http://www.ncbi.nlm.nih.gov/pubmed/29221491",
        "http://www.ncbi.nlm.nih.gov/pubmed/25081412",
        "http://www.ncbi.nlm.nih.gov/pubmed/32787971",
        "http://www.ncbi.nlm.nih.gov/pubmed/38026755",
        "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
        "http://www.ncbi.nlm.nih.gov/pubmed/30261916",
        "http://www.ncbi.nlm.nih.gov/pubmed/29181492",
        "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
        "http://www.ncbi.nlm.nih.gov/pubmed/22277519",
        "http://www.ncbi.nlm.nih.gov/pubmed/31883703",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155411",
        "http://www.ncbi.nlm.nih.gov/pubmed/33336218",
        "http://www.ncbi.nlm.nih.gov/pubmed/26433971",
        "http://www.ncbi.nlm.nih.gov/pubmed/26721364",
        "http://www.ncbi.nlm.nih.gov/pubmed/37881360",
        "http://www.ncbi.nlm.nih.gov/pubmed/25164658",
        "http://www.ncbi.nlm.nih.gov/pubmed/31831056",
        "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
        "http://www.ncbi.nlm.nih.gov/pubmed/25483498",
        "http://www.ncbi.nlm.nih.gov/pubmed/36253511",
        "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
        "http://www.ncbi.nlm.nih.gov/pubmed/29037101",
        "http://www.ncbi.nlm.nih.gov/pubmed/36151869",
        "http://www.ncbi.nlm.nih.gov/pubmed/33321511",
        "http://www.ncbi.nlm.nih.gov/pubmed/28066098",
        "http://www.ncbi.nlm.nih.gov/pubmed/34110536",
        "http://www.ncbi.nlm.nih.gov/pubmed/35290498",
        "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
        "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
        "http://www.ncbi.nlm.nih.gov/pubmed/35676943",
        "http://www.ncbi.nlm.nih.gov/pubmed/35320578",
        "http://www.ncbi.nlm.nih.gov/pubmed/36454709",
        "http://www.ncbi.nlm.nih.gov/pubmed/32991803",
        "http://www.ncbi.nlm.nih.gov/pubmed/35401412",
        "http://www.ncbi.nlm.nih.gov/pubmed/29686315"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 442,
          "text": "Other anti-amyloid antibodies are under investigation in phase III (donanemab, lecanemab, gantenerumab) and have shown preliminary evidence of a cognitive benefit in phase II trials. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35841240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer\u0027s disease (AD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240"
        },
        {
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1157,
          "text": "BODY: Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240"
        },
        {
          "offsetInBeginSection": 1666,
          "offsetInEndSection": 1865,
          "text": "CONCLUSION: The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36447240"
        },
        {
          "offsetInBeginSection": 604,
          "offsetInEndSection": 901,
          "text": "METHODS: Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheimer Network Trials Unit clinical trial (DIAN-TU-001) underwent both 11C-PiB and 18F-florbetapir PET imaging at baseline and during at least one follow-up visit. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37017737"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 847,
          "text": "Two long-term, controlled trials on three anti-β-amyloid monoclonal antibodies (solanezumab, gantenerumab and crenezumab) in subjects carrying Alzheimer\u0027s disease-linked mutated genes encoding for amyloid precursor protein or presenilin 1 or presenilin 2 failed to show cognitive or functional benefits. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751779"
        },
        {
          "offsetInBeginSection": 776,
          "offsetInEndSection": 1062,
          "text": "The model components were calibrated to data from the literature and internal studies, including quantitative data supporting the underlying AD biology and clinical data from clinical trials for anti-Aβ monoclonal antibodies (mAbs) aducanumab, crenezumab, gantenerumab, and solanezumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 573,
          "text": "INTRODUCTION: Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid-related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen\u0027s Aduhelm/aducanumab (amino acids 3-7 of the Aβ peptide). Similarly, Janssen/Pfizer\u0027s Bapineuzumab (amino acids 1-5 of the Aβ peptide) and Roche\u0027s Gantenerumab (amino acids 2-11/18-27 of the Aβ peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36515320"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "Patients with Alzheimer\u0027s disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging abnormalities (ARIA), shown on brain magnetic resonance imaging (MRI) scans. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36388611"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 362,
          "text": "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 546,
          "text": "This study investigates a bispecific modular fusion protein composed of gantenerumab, a fully human monoclonal anti- amyloid-beta (Aβ) antibody under investigation for AD treatment, with a human transferrin receptor 1-directed Brainshuttle™ module (trontinemab; RG6102, INN trontinemab)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37823690"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 650,
          "text": "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer\u0027s disease.METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer\u0027s disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285"
        },
        {
          "offsetInBeginSection": 2025,
          "offsetInEndSection": 2383,
          "text": "Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%.CONCLUSIONS: Among persons with early Alzheimer\u0027s disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 445,
          "text": "BACKGROUND: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).OBJECTIVES: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.DESIGN: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose positron emission tomographic study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21987394"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Profile of gantenerumab and its potential in the treatment of Alzheimer\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u0027s Disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37966285"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Gantenerumab is intended for the treatment of Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28754630"
        },
        {
          "offsetInBeginSection": 1332,
          "offsetInEndSection": 1515,
          "text": " gantenerumab, and an anti-tau monoclonal antibody, RO7105705, as well as a robust biomarker platform to aid in the early identification of people at risk or in the early stages of AD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181492"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "PURPOSE: Gantenerumab, a fully human anti-amyloid-β IgG1 monoclonal antibody that binds to aggregated forms of amyloid-β, is being investigated as a potential disease-modifying treatment for early (prodromal to mild) Alzheimer disease (AD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31883703"
        },
        {
          "offsetInBeginSection": 729,
          "offsetInEndSection": 1045,
          "text": "Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1065,
          "text": "Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer\u0027s disease (AD) have demonstrated clearance of brain Aβ deposits. Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of Aβ, were disappointing. Also solanezumab, directed at the mid-region of Aβ, failed in two Phase III trials in mild-to-moderate AD. Another Phase III trial with solanezumab is ongoing in mildly affected AD patients based on encouraging results in this subgroup. Second-generation active Aβ vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing. These new anti-Aβ immunotherapies are being tested in prodromal AD, in presymptomatic subjects with AD-related mutations, or in asymptomatic subjects at risk of developing AD. These primary and secondary prevention trials will definitely test the Aβ cascade hypothes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853"
        },
        {
          "offsetInBeginSection": 1080,
          "offsetInEndSection": 1496,
          "text": " encouraging results in this subgroup of patients. Second-generation active Aβ vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer\u0027s disease patients, in presymptomatic individuals with Alzheimer\u0027s disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer\u0027s disease to definitely ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 798,
          "text": "INTRODUCTION: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer\u0027s disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD).AREAS COVERED: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-Aβ monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimer\u0027s Network Trials Unit (DIAN-TU).EXPERT OPINION: Anti-Aβ monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29037101"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 490,
          "text": "Gantenerumab, a fully human monoclonal antibody (mAb) that binds to aggregated amyloid-beta, was tested in two 24-month phase III studies (NCT01224106, NCT02051608) in participants with prodromal and mild Alzheimer\u0027s disease (AD), respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35100444"
        },
        {
          "offsetInBeginSection": 522,
          "offsetInEndSection": 928,
          "text": "The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer\u0027s patients in China have no effective treatment alternatives.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36457865"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 592,
          "text": "en-label extension of SCarlet RoAD (a study of gantenerumab in participants with prodromal Alzheimer\u0027s disease) and Marguerite RoAD (as study of Gantenerumab in participants with mild Alzheimer\u0027s disease) studies were us",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35676943"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Gantenerumab is intended for the treatment of Alzheimer\u0027s disease. It is a fully human recombinant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28754630"
        }
      ],
      "id": "65cfa37c1930410b1300000d",
      "ideal_answer": [
        "Gantenerumab was developed for Alzheimer\u0027s disease."
      ],
      "exact_answer": [
        [
          "Alzheimer\u0027s disease"
        ]
      ]
    },
    {
      "body": "Please list the congenital fibrinogen disorders.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37823427",
        "http://www.ncbi.nlm.nih.gov/pubmed/36055263",
        "http://www.ncbi.nlm.nih.gov/pubmed/35853369",
        "http://www.ncbi.nlm.nih.gov/pubmed/35821906",
        "http://www.ncbi.nlm.nih.gov/pubmed/35207353",
        "http://www.ncbi.nlm.nih.gov/pubmed/34261148",
        "http://www.ncbi.nlm.nih.gov/pubmed/36276905",
        "http://www.ncbi.nlm.nih.gov/pubmed/34829490",
        "http://www.ncbi.nlm.nih.gov/pubmed/31797863",
        "http://www.ncbi.nlm.nih.gov/pubmed/27019463",
        "http://www.ncbi.nlm.nih.gov/pubmed/27293018",
        "http://www.ncbi.nlm.nih.gov/pubmed/29844251",
        "http://www.ncbi.nlm.nih.gov/pubmed/35073585",
        "http://www.ncbi.nlm.nih.gov/pubmed/32871307",
        "http://www.ncbi.nlm.nih.gov/pubmed/23852822",
        "http://www.ncbi.nlm.nih.gov/pubmed/27019462",
        "http://www.ncbi.nlm.nih.gov/pubmed/27492693",
        "http://www.ncbi.nlm.nih.gov/pubmed/16855369",
        "http://www.ncbi.nlm.nih.gov/pubmed/32852326",
        "http://www.ncbi.nlm.nih.gov/pubmed/33030793",
        "http://www.ncbi.nlm.nih.gov/pubmed/16999847",
        "http://www.ncbi.nlm.nih.gov/pubmed/17430139",
        "http://www.ncbi.nlm.nih.gov/pubmed/23439004",
        "http://www.ncbi.nlm.nih.gov/pubmed/918595",
        "http://www.ncbi.nlm.nih.gov/pubmed/31542854",
        "http://www.ncbi.nlm.nih.gov/pubmed/15004306",
        "http://www.ncbi.nlm.nih.gov/pubmed/26430672",
        "http://www.ncbi.nlm.nih.gov/pubmed/29316703"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 352,
          "text": "Congenital fibrinogen deficiencies (CFD) are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene. Here in, the sequences of Aα chain of fibrinogen (FGA) in patients with inherited afibrinogenemia disorder in south-eastern of Iran were analysed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37823427"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 295,
          "text": " From the first clinical description of afibrinogenemia in 1920, many major achievements have contributed to a better understanding of these complex disorders. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36055263"
        },
        {
          "offsetInBeginSection": 1431,
          "offsetInEndSection": 1514,
          "text": "congenital fibrinogen disorders, focusing on afibrinogenemia and dysfibrinogenemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36055263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Ranging from bleeding to thrombosis, the clinical features of congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia, ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35853369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35853369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Fibrinogen deficiencies are very rare. Qualitative fibrinogen deficiencies (dysfibrinogenaemia and hypodysfibrinogenemia) are functional disorders that can present with both haemorrhagic symptoms and with thro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35821906"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 773,
          "text": "In this paper, we focused on familial hypofibrinogenemia, a rare inherited quantitative fibrinogen disorder characterized by decreased fibrinogen levels with a high phenotypic heterogeneity. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35207353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "The congenital dysfibrinogenemias, most often associated with bleeding disorders, encompass mutations in the amino-terminal end of fibrinogen α-chain consisting of Gly17-Pro18-Arg19-Val20, known as knob A, which is a critical site for fibrin polymerization. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34261148"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 88,
          "text": " case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic disorders.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276905"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829490"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "INTRODUCTION: Congenital fibrinogen disorders (CFDs) are classified as afibrinogenemia or hypofibrinogenemia (Hypo), dysfibrinogenemia (Dys), or hypodysfibrinogenemia (Hypodys), according to functional and antigenic fibrinogen concentrations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33030793"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenemia and hypofibrinogenemia) or the quality (dysfibrinogenemia) or both (hypodysfibrinogenemia) of plasmatic fibrinogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27019462"
        },
        {
          "offsetInBeginSection": 323,
          "offsetInEndSection": 619,
          "text": "Afibrinogenemia and hypofibrinogenemia are the consequence of mutations in the homozygous, heterozygous, or compound heterozygous state in one of three genes encoding the fibrinogen chains, which can affect the synthesis, assembly, intracellular processing, stability, or secretion of fibrinogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829490"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 563,
          "text": "Congenital fibrinogen disorders (CFDs) are divided into qualitative deficiencies (dysfibrinogenemia, hypodysfibrinogenemia) in which the mutant fibrinogen molecule is present in the circulation and quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) with no mutant molecule present in the bloodstream.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073585"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Congenital Afibrinogenemia and Hypofibrinogenemia: Laboratory and Genetic Testing in Rare Bleeding Disorders with Life-Threatening Clinical Manifestations and Challenging Management.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829490"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 483,
          "text": "Congenital fibrinogen disorders are classified into two types of plasma fibrinogen defects: type I (quantitative fibrinogen deficiencies), that is, hypofibrinogenemia or afibrinogenemia, in which there are low or absent plasma fibrinogen antigen levels, respectively, and type II (qualitative fibrinogen deficiencies), that is, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27019463"
        },
        {
          "offsetInBeginSection": 49,
          "offsetInEndSection": 321,
          "text": "Congenital fibrinogen disorders (afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia and hypodysfibrinogenemia), caused by pathogenic variants in the genes FGA, FGB and FGG, have the potential of causing bleeding diathesis and/or thrombotic events of variable severity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32852326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenaemia and hypofibrinogenaemia) or the quality (dysfibrinogenaemia) or both (hypodysfibrinogenaemia) of fibrinogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 581,
          "text": "Congenital fibrinogen disorders are classified into two types of plasma fibrinogen defects: type I (quantitative fibrinogen deficiencies), that is, hypofibrinogenemia or afibrinogenemia, in which there are low or absent plasma fibrinogen antigen levels, respectively, and type II (qualitative fibrinogen deficiencies), that is, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity. These disorders are caused by mutations in the three fibrinogen-encoding genes FGA, FGB, and FGG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27019463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 430,
          "text": "Hereditary fibrinogen abnormalities comprise two classes of plasma fibrinogen defects: Type I, afibrinogenemia or hypofibrinogenemia, which has absent or low plasma fibrinogen antigen levels (quantitative fibrinogen deficiencies), and Type II, dysfibrinogenemia or hypodysfibrinogenemia, which shows normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23852822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "Congenital qualitative and quantitative fibrinogen disorders represent heterogeneous rare abnormalities caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on chromosome 4q28. It is estimated that congenital fibrinogen disorder accounts for 8% of rare coagulation factor deficiencies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31797863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 370,
          "text": "Hereditary fibrinogen disorders include type I deficiencies (afibrinogenemia and hypofibrinogenemia, i.e. quantitative defects), with low or unmeasurable levels of immunoreactive protein; and type II deficiencies (dysfibrinogenemia and hypodysfibrinogenemia, i.e. qualitative defects), showing normal or altered antigen levels associated with reduced coagulant activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16999847"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "INTRODUCTION: Congenital fibrinogen disorders result from genetic mutations in FGA, FGB, or FGG resulting in quantitative fibrinogen deficiencies (afibrinogenemia or hypofibrinogenemia) or qualitative fibrinogen deficiencies (dysfibrinogenemia). Hypodysfibrinogenemia sharing features with hypo- and dysfibrinoge",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32871307"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Congenital fibrinogen disorders can be quantitative (afibrinogenemia, hypofibrinogenemia) or functional (dysfibrinognemia).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29844251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346,
          "text": "Congenital fibrinogen disorders comprise quantitative disorders defined by a complete absence (afibrinogenemia) or by a decreased level (hypofibrinogenemia) of circulating fibrinogen and qualitative disorders characterized by a discrepancy between the activity and the antigenic levels of fibrinogen (dysfibrinogenemia and hypodysfibrinogenemia).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492693"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 837,
          "text": "Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17430139"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 557,
          "text": "Inherited fibrinogen disorders can be classified into qualitative and quantitative anomalies: dysfibrinogenemia is characterised by normal circulating levels of fibrinogen with abnormal function; hypofibrinogenemia and afibrinogenemia are characterised by reduced or absent fibrinogen in circulation respectively,while hypodysfibrinogenemia is defined by reduced fibrinogen with reduced function. All are due to mutations in one of the three fibrinogen genes, FGA, FGB and FGG, which are clustered in a region of 50 kb on the long arm of human chromosome 4.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16855369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 396,
          "text": "Inherited fibrinogen disorders can be classified into qualitative and quantitative anomalies: dysfibrinogenemia is characterised by normal circulating levels of fibrinogen with abnormal function; hypofibrinogenemia and afibrinogenemia are characterised by reduced or absent fibrinogen in circulation respectively,while hypodysfibrinogenemia is defined by reduced fibrinogen with reduced function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16855369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23439004"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 399,
          "text": "Congenital hypofibrinogenemia appears to be a separate entity which can be distinguished from heterozygous individuals of congenital afibrinogenemia and from congenital dysfibrinogenemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/918595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Congenital dysfibrinogenemia is characterized with undetectable or low fibrinogen level by Clauss assay complicated by bleeding and/or thrombosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31542854"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Congenital afibrinogenemia/hypofibrinogenemia is an extremely rare coagulation disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15004306"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Congenital afibrinogenemia/hypofibrinogenemia is a rare inherited hematologic disorder in which a patient lacks or has insufficient level of fibrinogen, the blood coagulation factor I.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26430672"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 654,
          "text": "Since the identification of the first causative mutation for congenital afibrinogenemia, studies have elucidated the underlying molecular pathophysiology of numerous causative mutations leading to fibrinogen deficiency, developed cell-based and animal models to study human fibrinogen disorders, and further explored the clinical consequences of absent, low, or dysfunctional fibrinogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29316703"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders. The clinical",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829490"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 1059,
          "text": "4. Congenital fibrinogen disorders (CFDs) are divided into qualitative deficiencies (dysfibrinogenemia, hypodysfibrinogenemia) in which the mutant fibrinogen molecule is present in the circulation and quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) with no mutant molecule present in the bloodstream. Phenotypic manifestations are variable, patients may be asymptomatic, or suffer from bleeding or thrombosis. Causative mutations can occur in any of the three fibrinogen genes and can affect one or both alleles. Given the large number of studies reporting on novel causative mutations for CFDs since the review on the same topic published in 2016, we performed an extensive search of the literature and list here 120 additional mutations described in both quantitative and qualitative disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073585"
        }
      ],
      "id": "65f70a55c4010b4d7800001b",
      "ideal_answer": [
        "Congenital fibrinogen disorders are rare pathologies of the haemostasis, comprising afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia and hypodysfibrinogenaemia.",
        "The congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.",
        "Congenital fibrinogen disorders include:\n\n* Afibrinogenemia (lack of fibrinogen)\n* Hypofibrinogenemia (low levels of fibrinogen)\n* Dysfibrinogenemia (abnormal function of fibrinogen)\n* Hypodysfibrinogenemia (reduced levels and function of fibrinogen)\n\nThese disorders can be caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on chromosome 4q28.",
        "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenaemia and hypofibrinogenaemia) or the quality (dysfibrinogenaemia) or both (hypodysfibrinogenaemia) of fibrinogen.",
        "Congenital fibrinogen disorders include afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia, and hypodysfibrinogenaemia. These disorders can affect the quantity, quality, or both of fibrinogen, leading to abnormal blood coagulation and potential bleeding or thrombotic complications.",
        "The congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia.",
        "Congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.",
        "Congenital fibrinogen disorders can be classified into two main types:\n\n1. Quantitative disorders (Type I deficiencies):\n   - Afibrinogenemia (complete absence of fibrinogen)\n   - Hypofibrinogenemia (decreased levels of fibrinogen)\n\n2. Qualitative disorders (Type II deficiencies):\n   - Dysfibrinogenemia (normal or reduced antigen levels with disproportionately low functional activity)\n   - Hypodysfibrinogenemia (reduced antigen levels with disproportionately low functional activity)\n\nThese disorders are caused by mutations in the genes coding for fibrinogen and can lead to a wide spectrum of biological and clinical features.",
        "Congenital fibrinogen disorders include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia.",
        "Congenital fibrinogen disorders are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene.",
        "congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia",
        "Congenital fibrinogen disorders include: , 1. Afibrinogenemia: a rare bleeding disorder resulting from mutations in the fibrinogen gene, leading to a complete absence of fibrinogen in the blood., 2. Dysfibrinogenemia: a functional disorder characterized by abnormal fibrinogen that can cause both bleeding and thrombosis., 3. Hypodysfibrinogenemia: a milder form of dysfibrinogenemia, with reduced fibrinogen levels and variable clinical manifestations., 4. Familial hypofibrinogenemia: a rare inherited quantitative fibrinogen disorder characterized by decreased fibrinogen levels, often associated with bleeding symptoms., 5. Congenital dysfibrinogenemias: a group of rare bleeding disorders resulting from mutations in the amino-terminal end of fibrinogen α-chain, critical for fibrin polymerization.",
        "Congenital fibrinogen disorders can be afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, hemorrhagic disorders, familial hypofibrinogenemia, and dysfibrinogenaemia.",
        "Congenital fibrinogen disorders include:\n\n1. Afibrinogenemia: a complete absence of fibrinogen in the blood due to mutations in the fibrinogen gene.\n2. Hypofibrinogenemia: a decrease in fibrinogen levels in the blood due to mutations in the fibrinogen gene.\n3. Dysfibrinogenemia: a functional disorder of fibrinogen due to mutations in the fibrinogen gene, which can present with both bleeding and thrombotic symptoms.\n4. Hypodysfibrinogenemia: a combination of low fibrinogen levels and dysfunctional fibrinogen due to mutations in the fibrinogen gene.\n\nThese disorders are rare and can have a wide range of clinical manifestations, from bleeding to thrombosis.",
        "The congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and hypodysfibrinogenemia.",
        "The congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, and hypofibrinogenemia.",
        "Congenital fibrinogen disorders include afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, hypofibrinogenemia, congenital fibrinogen disorders, hemorrhagic disorders, familial hypofibrinogenemia, and dysfibrinogenaemia.",
        "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders.",
        "Congenital fibrinogen disorders include quantitative disorders such as afibrinogenemia, hypofibrinogenemia, and qualitative disorders such as dysfibrinogenemia and hypodysfibrinogenemia.",
        "The congenital fibrinogen disorders are afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia, and hypofibrinogenemia.",
        "The congenital fibrinogen disorders include:\n\n1. Quantitative disorders:\n   - Afibrinogenemia (complete absence of fibrinogen) \n   - Hypofibrinogenemia (decreased fibrinogen levels)\n\n2. Qualitative disorders:  \n   - Dysfibrinogenemia (abnormal fibrinogen function)\n   - Hypodysfibrinogenemia (decreased fibrinogen levels and abnormal function)",
        "The congenital fibrinogen disorders include Afibrinogenemia, Dysfibrinogenemia, and Hypodysfibrinogenemia.",
        "Congenital fibrinogen disorders (CFD) are a group of rare bleeding disorders (RBD) that include afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia. Afibrinogenemia is a subclass of CFD that occurs due to mutations in the fibrinogen gene."
      ],
      "exact_answer": [
        [
          "afibrinogenaemia"
        ],
        [
          "hypofibrinogenaemia"
        ],
        [
          "dysfibrinogenaemia"
        ],
        [
          "hypodysfibrinogenaemia"
        ]
      ]
    },
    {
      "body": "What are the current indications for thalidomide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25617013",
        "http://www.ncbi.nlm.nih.gov/pubmed/21048383",
        "http://www.ncbi.nlm.nih.gov/pubmed/11235821",
        "http://www.ncbi.nlm.nih.gov/pubmed/12423428",
        "http://www.ncbi.nlm.nih.gov/pubmed/21338284",
        "http://www.ncbi.nlm.nih.gov/pubmed/10781782",
        "http://www.ncbi.nlm.nih.gov/pubmed/14713870",
        "http://www.ncbi.nlm.nih.gov/pubmed/23830554",
        "http://www.ncbi.nlm.nih.gov/pubmed/37206489",
        "http://www.ncbi.nlm.nih.gov/pubmed/36884210",
        "http://www.ncbi.nlm.nih.gov/pubmed/12749503",
        "http://www.ncbi.nlm.nih.gov/pubmed/12696209",
        "http://www.ncbi.nlm.nih.gov/pubmed/11734114",
        "http://www.ncbi.nlm.nih.gov/pubmed/11809002",
        "http://www.ncbi.nlm.nih.gov/pubmed/18034532",
        "http://www.ncbi.nlm.nih.gov/pubmed/15148528",
        "http://www.ncbi.nlm.nih.gov/pubmed/9170807",
        "http://www.ncbi.nlm.nih.gov/pubmed/15934472",
        "http://www.ncbi.nlm.nih.gov/pubmed/25828060",
        "http://www.ncbi.nlm.nih.gov/pubmed/10487395",
        "http://www.ncbi.nlm.nih.gov/pubmed/31175889",
        "http://www.ncbi.nlm.nih.gov/pubmed/23858438",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852850",
        "http://www.ncbi.nlm.nih.gov/pubmed/10992277",
        "http://www.ncbi.nlm.nih.gov/pubmed/17076653",
        "http://www.ncbi.nlm.nih.gov/pubmed/20510766",
        "http://www.ncbi.nlm.nih.gov/pubmed/18023317"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 366,
          "text": "erythema nodosum leprosum, aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21048383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Thalidomide is resurging in the management of adult rheumatologic skin conditions, especially lupus erythematosus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013"
        },
        {
          "offsetInBeginSection": 463,
          "offsetInEndSection": 532,
          "text": "aphthous stomatitis and chronic graft-versus-host disease in children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013"
        },
        {
          "offsetInBeginSection": 593,
          "offsetInEndSection": 646,
          "text": "actinic prurigo and epidermolysis bullosa pruriginosa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617013"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1200,
          "text": "She was diagnosed with International Staging System (ISS) stage 3 multiple myeloma, which was successfully treated with bortezomib, thalidomide and dexamethasone with regular bisphosphonates that year",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37206489"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 634,
          "text": "With this definition, only three drugs are repurposed for cancer: Bacillus Calmette-Guerin (BCG) vaccine (superficial bladder cancer, thalidomide [multiple myeloma], and propranolol [infantile hemangioma])",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36884210"
        },
        {
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1314,
          "text": "The anti-angiogenic effects of thalidomide may make this compound valuable as single-drug therapy or as an adjunct to chemotherapy in patients with cancer, particularly those with metastases or multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11809002"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 456,
          "text": "Gradually, thalidomide was reintroduced for the treatment of a few skin diseases including leprous erythema nodosum, severe mucosal ulcers (e.g., associated with HIV infection or Behçet\u0027s disease), lymphocytic skin infiltrations, cutaneous lupus erythematosus, and chronic graft-versus-host disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11809002"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 391,
          "text": "Thalidomide has been used in several cutaneous inflammatory disorders (such as erythema nodosum leprosum in lepromatous leprosy, cutaneous lupus erythematosus, severe aphtosis), cancers (relapsed/refractory multiple myeloma) and inflammatory conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15934472"
        },
        {
          "offsetInBeginSection": 447,
          "offsetInEndSection": 610,
          "text": "Thalidomide is currently being used clinically to treat such conditions as cachexia associated with HIV and cancer, mycobacterial disease, and autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9170807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Thalidomide was approved for the treatment of multiple myeloma in Japan under a risk management program, named TERMS, in 2008.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26234426"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 572,
          "text": "Current evidence indicates that thalidomide reduces the activity of the inflammatory cytokine tumor necrosis factor (TNF)-alpha by accelerating the degradation of its messenger RNA. Thalidomide also inhibits angiogenesis. Recently, the drug was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272,
          "text": "Thalidomide, the drug that caused a worldwide epidemic of serious birth defects in the late 1950s and early 1960s, was recently approved by the US Food and Drug Administration (FDA) for use in treating the skin disease erythema nodosum leprosum, a complication of leprosy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10487395"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 969,
          "text": "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830554"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "Thalidomide has gained an infamous history due to severe birth defects observed in patients who had taken the drug to control nausea during pregnancy. The medication was withdrawn from the market because of its teratogenicity, but was approved by the FDA in 1998 for the treatment of erythema nodosum leprosum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15696990"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 405,
          "text": "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL). The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11235821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "BACKGROUND: Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum (ENL) through a restricted-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12749503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects. This drug was more recently rediscovered as a powerful immunomodulatory and antiinflammatory agent and was approved by the FDA in 1998 for treatment of erythema nodosum leprosum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15148528"
        },
        {
          "offsetInBeginSection": 500,
          "offsetInEndSection": 672,
          "text": "Thalidomide is US Food and Drug Administration (FDA)-approved for use in acute erythema nodosum leprosum and, in combination with dexamethasone, in newly diagnosed myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338284"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 727,
          "text": "Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have been reported.METHODS: We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil.RESULTS: A total of 5,889,210 thalidomide tablets were distributed; the prevalence of limb reduction defects was 1.60 (CI95%: 1.54-1.66) and TEP was 0.11 (CI95%: 0.10-0.13) per 10,000 births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25828060"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 970,
          "text": "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830554"
        },
        {
          "offsetInBeginSection": 83,
          "offsetInEndSection": 296,
          "text": "tion defects. Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25828060"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 788,
          "text": "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL). The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL. Thalidomide is currently under investigation for the treatment of a wide variety of diseases, including conditions thought to have an inflammatory or immune basis, malignancies and complications of infection with HIV. Interest in the potential anti-inflammatory, immunomodulatory and anti- angiogenic effects of thalidomide has resulted in off-label use of prescription thalidomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11235821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 335,
          "text": "Thalidomide currently is used to treat relapsed and refractory multiple myeloma. The drug also is being actively investigated in patients newly diagnosed with multiple myeloma. The therapeutic applications of thalidomide are expected to grow as clinical trials document its activity in treating other neoplastic disorders and diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12696209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Thalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12423428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 716,
          "text": "Thalidomide, the drug that caused a worldwide epidemic of serious birth defects in the late 1950s and early 1960s, was recently approved by the US Food and Drug Administration (FDA) for use in treating the skin disease erythema nodosum leprosum, a complication of leprosy. The drug has also shown promise in the treatment of other serious diseases. If thalidomide is eventually approved for use in the US and other countries for treatment of diseases more prevalent than erythema nodosum leprosum, or if use of the drug for non-approved indications becomes widespread, hundreds of thousands of women with childbearing ability could be treated. If this should happen, can we prevent another epidemic of birth defects?",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10487395"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 605,
          "text": "BACKGROUND: Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum (ENL) through a restricted-use program. Its immunomodulatory, anti-inflammatory, and antiangiogenic properties are currently under study in a number of clinical conditions.OBJECTIVE: This article reviews the pharmacology of thalidomide; its approved and off-label uses in dermatologic, oncologic, and gastrointestinal conditions; and adverse events as",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12749503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Thalidomide currently is used to treat relapsed and refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12696209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "BACKGROUND: Thalidomide is a sedative/hypnotic agent that is currently used to treat patients suffering from multiple myeloma, myelodysplastic syndromes and erythema nodos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31175889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858438"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852850"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Thalomid is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a complication of leprosy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10992277"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 405,
          "text": "The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11235821"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 561,
          "text": "DRUG WITH A TEMPORARY MARKETING AUTHORISATION: Thalidomide is currently available in France for nominative or cohort use with a temporary marketing authorisation (TMA). It is only prescribed and delivered in hospital settings. SIX OFFICIAL INDICATIONS: Its current indications are principally lepromatous nodular erythema, severe aphtosis, Jessner-Kanoff\u0027s cutaneous lymphocyte infiltration, discoid lupus erythematosis, chronic graft-versus-host reactions, and relapsed and or refractory multiple myeloma (after the failure of standard therapies).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14713870"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Thalidomide is approved for treating erythema nodosum leprosum and multiple myeloma, but it has also emerged as a useful treatment option for many refractory dermatologic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20510766"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1820,
          "text": "icularly tumor necrosis factor-alpha. In addition to its approved indication for ENL, thalidomide has been studied in various other conditions, including graft-versus-host disease, discoid lupus erythematosus, sarcoidosis, relapsed/refractory multiple myeloma, Waldenstrom\u0027s macroglobulinemia, myelodysplastic syndromes, acute myeloid leukemia, myelofibrosis with myeloid metaplasia, renal cell carcinoma, malignant gliomas, prostate cancer, Kaposi\u0027s sarcoma, colorectal carcinoma, oral aphthous ulcers, Behçet\u0027s disease, Crohn\u0027s dis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12749503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 628,
          "text": "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects. This drug was more recently rediscovered as a powerful immunomodulatory and antiinflammatory agent and was approved by the FDA in 1998 for treatment of erythema nodosum leprosum. Thalidomide has shown great promise in advanced or refractory multiple myeloma either alone or in combination with other agents. It has also demonstrated benefits in a wide variety of disparate conditions such as aphthous and genital ulcers, cancer cachexia, HIV, tuberculosis and chronic graft versus host disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15148528"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 222,
          "text": "Thalidomide was approved by the FDA in July 1998 for the treatment of erythema nodusum leprosum associated with leprosy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18023317"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 585,
          "text": "Recently, thalidomide was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11734114"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 280,
          "text": "Thalidomide has established its own niche market particularly for the dermatological manifestations associated with HIV, Behçet\u0027s disease, graft-versus-host disease and systemic lupus erythematosus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18034532"
        }
      ],
      "id": "65f82218c4010b4d7800003e",
      "ideal_answer": [
        "Current indications are as follows: erythema nodosum leprosum, multiple myeloma,  Graft versus host disease, mycobacterial infection,  severe recurrent aphthous stomatitis,  primary brain malignancies, HIV- associated wasting syndrome, Crohn disease, Kaposi sarcoma, myelodysplastic syndrome, hematopoietic stem cell transplantation, hereditary hemorrhagic telangiectasia",
        "The current indications for thalidomide include lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff\u0027s cutaneous lymphocyte infiltration, discoid lupus erythematosis, chronic graft-versus-host reactions, prurigo nodularis, and actinic prurigo. It is also used off-label for conditions such as aphthous stomatitis, Behçet disease, pyoderma gangrenosum, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, and sarcoidosis. Additionally, it is FDA approved for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL).",
        "Thalidomide is currently indicated for the treatment of erythema nodosum leprosum, graft versus host disease, severe oral and genital ulcers associated with HIV and Behçet\u0027s disease, rheumatoid arthritis, discoid lupus erythematosus, sarcoidosis, relapsed/refractory multiple myeloma, Waldenstrom\u0027s macroglobulinemia, myelodysplastic syndromes, acute myeloid leukemia, myelofibrosis with myeloid metaplasia, renal cell carcinoma, malignant gliomas, prostate cancer, Kaposi\u0027s sarcoma, colorectal carcinoma, oral aphthous ulcers, Crohn\u0027s disease, and HIV/AIDS-associated wasting.",
        "Thalidomide is currently approved by the FDA for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL), a systemic disorder that typically occurs after several years of antileprosy treatments, usually for lepromatous leprosy. In addition to its approved use, thalidomide is also used off-label for various dermatologic diseases such as aphthous stomatitis, Behçet disease, pyoderma gangrenosum, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis and sarcoidosis. Furthermore, thalidomide has been approved for treating multiple myeloma since May 2006. Although thalidomide was initially introduced as a sedative/hypnotic medication, its use in dermatology and oncology has gained interest due to its anti-inflammatory, immunomodulatory, and anti-angiogenic effects. However, it is important to note that thalidomide\u0027s main side-effects of teratogenesis and peripheral neuropathy limit its use, and careful consideration should be given when prescribing this medication for therapeutic indications.",
        "The current indications for thalidomide include lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff\u0027s cutaneous lymphocyte infiltration, discoid lupus erythematosus, chronic graft-versus-host reactions, and relapsed and/or refractory multiple myeloma (after the failure of standard therapies). Thalidomide is also used off-label for conditions such as aphthous stomatitis, Behçet disease, pyoderma gangrenosus, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis, and sarcoidosis.",
        "Thalidomide is currently indicated for the management of adult rheumatologic skin conditions, particularly lupus erythematosus, as well as aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. It is also used in the treatment of aphthous stomatitis and chronic graft-versus-host disease in children, as well as actinic prurigo and epidermolysis bullosa pruriginosa.",
        "Thalidomide is a medication with several indications. It is primarily used for treating multiple myeloma, a type of cancer, and erythema nodosum leprosum, a complication of leprosy. Other indications include aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. Thalidomide is also used in the management of adult rheumatologic skin conditions, especially lupus erythematosus. Additionally, it is indicated for aphthous stomatitis and chronic graft-versus-host disease in children. Off-label uses include conditions such as actinic prurigo and epidermolysis bullosa pruriginosa.",
        "Thalidomide has several current indications, including: * Erythema nodosum leprosum * Aphthous ulceration and cachexia in HIV disease * Inflammatory bowel diseases * Malignant diseases * Second-line treatment for aphthous stomatitis * Chronic graft-versus-host disease in children * Actinic prurigo * Epidermolysis bullosa pruriginosa",
        "Thalidomide is currently indicated for a variety of conditions including erythema nodosum leprosum, aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases. It is also used in the management of adult rheumatologic skin conditions, especially lupus erythematosus, and in children for aphthous stomatitis and chronic graft-versus-host disease. Other indications include actinic prurigo and epidermolysis bullosa pruriginosa.",
        "Thalidomide is currently indicated for the management of various rheumatologic skin conditions, including lupus erythematosus, aphthous stomatitis, and chronic graft-versus-host disease in children. It is also used in the treatment of actinic prurigo and epidermolysis bullosa pruriginosa. Additionally, thalidomide is effective in managing erythema nodosum leprosum, aphthous ulceration, and cachexia in HIV disease, inflammatory bowel diseases, and certain malignant diseases."
      ],
      "exact_answer": [
        [
          "Erythema nodosum leprosum"
        ],
        [
          "Multiple myeloma"
        ],
        [
          "Graft versus host disease"
        ],
        [
          "Mycobacterial infection"
        ],
        [
          "Severe recurrent aphthous stomatitis"
        ],
        [
          "Primary brain malignancies"
        ],
        [
          "HIV- associated wasting syndrome"
        ],
        [
          "Crohn\u0027s disease"
        ],
        [
          "Kaposi\u0027s sarcoma"
        ],
        [
          "Myelodysplastic syndrome"
        ],
        [
          "Hematopoietic stem cell transplantation"
        ],
        [
          "Hereditary hemorrhagic telangiectasia"
        ],
        [
          "aphthous stomatitis in children"
        ],
        [
          "chronic graft-versus-host disease in children"
        ],
        [
          "Mycobacterial infection"
        ],
        [
          "severe oral and genital ulcers associated with HIV and Behçet\u0027s disease"
        ],
        [
          "Waldenstrom\u0027s macroglobulinemia"
        ]
      ]
    },
    {
      "body": "What is the administration route of zavegepant?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37345774",
        "http://www.ncbi.nlm.nih.gov/pubmed/37038933",
        "http://www.ncbi.nlm.nih.gov/pubmed/37227596",
        "http://www.ncbi.nlm.nih.gov/pubmed/36804093",
        "http://www.ncbi.nlm.nih.gov/pubmed/37363553",
        "http://www.ncbi.nlm.nih.gov/pubmed/36189708",
        "http://www.ncbi.nlm.nih.gov/pubmed/36239038",
        "http://www.ncbi.nlm.nih.gov/pubmed/37904462",
        "http://www.ncbi.nlm.nih.gov/pubmed/33096162"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Zavegepant (Zavzpret), a nasal spray, is approved to treat adults with acute migraine with or without aura.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345774"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 658,
          "text": "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37038933"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 403,
          "text": "In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37227596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 349,
          "text": "Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093"
        },
        {
          "offsetInBeginSection": 2868,
          "offsetInEndSection": 3015,
          "text": "INTERPRETATION: Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 457,
          "text": "Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553"
        },
        {
          "offsetInBeginSection": 817,
          "offsetInEndSection": 1034,
          "text": "Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553"
        },
        {
          "offsetInBeginSection": 1035,
          "offsetInEndSection": 1280,
          "text": "In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37363553"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 657,
          "text": "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37038933"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 410,
          "text": "Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP Ki \u003d 0.023 nM) that has demonstrated efficacy in the acute treatment of migraine with intranasal delivery in a Phase 2/3 trial, despite showing low oral bioavailability in rats (FPO \u003d 1.7%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33096162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Focus on zavegepant: the first intranasal third-generation gepant.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36189708"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 194,
          "text": "Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine - a prevalent disease leading to disability and economic burden",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37904462"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37904462"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "OBJECTIVE: Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.BACKGROUND: Calci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239038"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 336,
          "text": "d vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 350,
          "text": "Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36189708"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 491,
          "text": " for acute treatment. Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage development, is formulated as a nasal spray for the acute ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239038"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 982,
          "text": "e attacks per month. Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804093"
        }
      ],
      "id": "65d1357c1930410b13000039",
      "ideal_answer": [
        "Zavegepant is administered intranasally and used for migraine attacks."
      ],
      "exact_answer": [
        [
          "intranasally",
          "nasal spray"
        ]
      ]
    },
    {
      "body": "Brunner\u0027s gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30671231",
        "http://www.ncbi.nlm.nih.gov/pubmed/27737521",
        "http://www.ncbi.nlm.nih.gov/pubmed/22303509",
        "http://www.ncbi.nlm.nih.gov/pubmed/15034292",
        "http://www.ncbi.nlm.nih.gov/pubmed/31443637",
        "http://www.ncbi.nlm.nih.gov/pubmed/28408987",
        "http://www.ncbi.nlm.nih.gov/pubmed/28584807",
        "http://www.ncbi.nlm.nih.gov/pubmed/31427914",
        "http://www.ncbi.nlm.nih.gov/pubmed/30971558",
        "http://www.ncbi.nlm.nih.gov/pubmed/27055413",
        "http://www.ncbi.nlm.nih.gov/pubmed/36891571",
        "http://www.ncbi.nlm.nih.gov/pubmed/37073689",
        "http://www.ncbi.nlm.nih.gov/pubmed/29694312",
        "http://www.ncbi.nlm.nih.gov/pubmed/29201733",
        "http://www.ncbi.nlm.nih.gov/pubmed/7824865",
        "http://www.ncbi.nlm.nih.gov/pubmed/31451057",
        "http://www.ncbi.nlm.nih.gov/pubmed/33832073",
        "http://www.ncbi.nlm.nih.gov/pubmed/33314802",
        "http://www.ncbi.nlm.nih.gov/pubmed/19924571",
        "http://www.ncbi.nlm.nih.gov/pubmed/34194867",
        "http://www.ncbi.nlm.nih.gov/pubmed/32637056",
        "http://www.ncbi.nlm.nih.gov/pubmed/19140240",
        "http://www.ncbi.nlm.nih.gov/pubmed/31080246",
        "http://www.ncbi.nlm.nih.gov/pubmed/22836185",
        "http://www.ncbi.nlm.nih.gov/pubmed/27426650",
        "http://www.ncbi.nlm.nih.gov/pubmed/16006686",
        "http://www.ncbi.nlm.nih.gov/pubmed/33215668",
        "http://www.ncbi.nlm.nih.gov/pubmed/16955152"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Brunner\u0027s gland hamartoma is a rare benign duodenal tumor. It occurs in Brunner\u0027s glands, which are found in the duodenum and produce secretions that protect the duodenum from pancreatic enzymes, gastric acid, and other agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30671231"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Brunner\u0027s gland hamartomas are small benign lesions that are most commonly found in the bulb of the duodenum. They are very uncommon, and most are found incidentally during upper gastrointestinal series or esophagogastroduodenoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737521"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Brunner\u0027s gland hamartoma is an extremely uncommon benign tumor of the duodenum. Most of the lesions are small, asymptomatic and are detected incidentally. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22303509"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Brunner\u0027s gland hamartomas are rare tumors of duodenum, they are often discovered incidentally during esophagogastroduodenoscopy or upper gastrointestinal series",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15034292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Brunner\u0027s gland adenoma (BGA), also known as Brunneroma or polypoid hamartoma, is a rare benign duodenal tumor that proliferates from Brunner\u0027s glands of the duodenum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37073689"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 840,
          "text": "Most patients with Brunner\u0027s gland hamartoma are asymptomatic or have nonspecific complaints.CONCLUSION: BHG is a rare tumor arising from the Brunner\u0027s gland of the duodenum, considered entirely benign, although there have been occasionally reports of malignant foci inside.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29694312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "INTRODUCTION: Brunner\u0027s gland hyperplasia (BGH) of the duodenum is an uncommon finding at endoscopy and is usually asymptomatic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19924571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "BACKGROUND: Brunner\u0027s gland hamartomas are very uncommon lesions and are usually asymptomatic.METHODS: A 77-year-old man was urgently operated on for massive upper gastrointestinal bleeding, associated with haematemesis.RESULTS: A 3.5 x 3 x 3 cm mass arising from the anterior aspect of the first part of the duodenum was found.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7824865"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Brunner\u0027s gland adenoma (hyperplasia) (BGA/H) is a benign gastrointestinal lesion, usually asymptomatic and frequently detected incidentally by endoscopy as a submucosal nodule.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33314802"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "RATIONALE: Brunner gland hamartoma (BGH) is a rare tumor of the duodenum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33832073"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 571,
          "text": "Brunner\u0027s gland hamartoma (BGH) is a rare sub-epithelial tumour of the duodenum, which may cause haemorrhagic or obstructive gastrointestinal symptoms. Their accurate histological diagnosis often remains elusive before resection. Although endoscopic ultrasonography (EUS) is considered an excellent modality to study lesions within the gastrointestinal wall, only a few reports have described endosonographic characteristics of BGHs. A reliable pre-resection diagnosis with EUS may not only allay fear of malignancy but may as well avert a major surgery for the patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31427914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Brunner\u0027s gland hamartomas are rare, benign small bowel tumours. There were fewer than 150 cases reported in the English literature until the end of the last century. These hamartomas may be discovered incidentally during an upper gastrointestinal tract endoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Brunner\u0027s gland hamartoma is an extremely uncommon benign tumor of the duodenum. Most of the lesions are small, asymptomatic and are detected incidentally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22303509"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "BACKGROUND: Brunner\u0027s gland adenoma is a rare benign tumor arising from Brunner\u0027s glands. It is mostly small in size, and patients with this tumor are a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817211"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 501,
          "text": "Brunner\u0027s gland hamartoma (or Brunneroma) is an uncommon tumour with an incidence of \u003c0.01%, accounting for approximately 5-10% of benign duodenal tumours. Usually asymptomatic, it may manifest occasionally with duodenal obstruction or upper gastrointestinal haemorrhage and rarely with biliary fistulation, cholestatic jaundice and intussusception. It may be associated with uraemia and chronic pancreatitis. The diagnosis is usually confirmed by imaging studies and upper gastrointestinal endoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31451057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Brunner\u0027s gland hyperplasia (BGH) is an unusual entity that presents with large duodenal polyp or mass and rarely causes gastrointestinal bleeding",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32637056"
        },
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 250,
          "text": "Brunner\u0027s gland hamartoma (BGH) is a rare benign small bowel tumor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31443637"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 128,
          "text": "Brunner\u0027s gland hamartoma (BGH) is an infrequently encountered, benign, polypoid proliferation of Brunner\u0027s glands",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408987"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Brunner\u0027s gland adenoma is a rare benign tumor of small bowel, often incidentally discovered during endoscopy or radiological imaging. Mostly they are asymptomatic or often present with nonspecific symptoms such as nausea, vomiting, gastrointestinal hemorrhage, iron deficiency anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31080246"
        },
        {
          "offsetInBeginSection": 617,
          "offsetInEndSection": 910,
          "text": "ding to their tissue components. Brunner\u0027s gland hamartoma commonly occurred in the duodenal bulb and exhibited a polypoid appearance, while Brunner\u0027s gland hyperplasia was primarily observed in the second portion of duodenum as a submucosal mass and was accompanied by symptoms more frequentl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836185"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 410,
          "text": "Brunner\u0027s gland hyperplasia is a rare benign tumour and occurs most frequently in the upper part of the duodenum, mostly in the fifth or the sixth decade. Pathogenesis is still unknown. Symptoms are mostly absent, but larger lesions can cause gastric outlet obstruction or bleeding. Biopsies are necessary for differential diagnosis and to rule out cancerous changes. Mostly a resection is required.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27426650"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 714,
          "text": "CONTEXT: Brunner\u0027s gland hyperplasia is rarely associated with clinical symptoms. Most of the lesions are less than 1 cm in diameter and accounts for about 6.8% of all endoscopically removed duodenal polyps. When symptoms occur, this hyperplasia can be effectively treated with endoscopy. However, when the lesion is too large to pass through the endoscopic snare, endoscopic treatment is not possible and surgical treatment is necessary. This treatment may vary from local excision to more complex operations. When Brunner\u0027s gland hyperplasia does not have common dimensions, it may also mimic a malignancy of the duodenal-pancreatic area. In this case, a biopsy is indicated even though its result may be not inf",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16006686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "INTRODUCTION: Brunner\u0027s gland hamartoma (BGH) is an infrequently encountered, benign, polypoid proliferation of Brunner\u0027s glands. Usually these lesions are asymptomatic, just only occasionally presenting with duodenal obstruction or bleeding signs and mimicking a t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408987"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Brunner\u0027s gland hyperplasia (BGH) is an unusual entity that presents with large duodenal polyp or mass and rarely causes gastrointestinal bleeding. It is usually asymptomatic and often an incidental finding during the esophagoduodenoscopy (EGD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32637056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "INTRODUCTION: Brunner\u0027s gland hyperplasia (BGH) of the duodenum is an uncommon finding at endoscopy and is usually asymptomatic. Symptomatic BGH presenting with biliary obstruction and pancreatitis is extremely rare and the literature is limited to a few",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19924571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 375,
          "text": "Brunner gland hamartoma (BGH) is a rare condition that requires a high clinical suspicion to diagnose. Large hamartomas may initially present with iron deficiency anemia (IDA) or symptoms suggesting intestinal obstruction. Barium swallow may demonstrate the lesion, but endoscopic evaluation is the acceptable first line management unless a concern for underlying malignancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891571"
        },
        {
          "offsetInBeginSection": 922,
          "offsetInEndSection": 1098,
          "text": ". Most cases of BGH are benign and asymptomatic; however, it is important to be aware that some patients have severe anemia, gastrointestinal obstruction, or malignant potentia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34194867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Brunner gland hamartoma (brunneroma) is a rare benign tumor of the duodenum. It is usually asymptomatic and detected incidentally by endoscopy or other imaging modality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29201733"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 371,
          "text": "Brunner\u0027s gland hamartomas (BGHs), which are uncommon, asymptomatic and usually found incidentally. They are predominantly benign lesions, but instances of malignant transformation have been reported. Case History We describe a rare case",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27055413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Brunner\u0027s gland hamartoma (BGH) is an extremely rare benign digestive tumor, generally located in the duodenal bulb. We report the case of a 51-year-old asymptomatic man",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Brunner\u0027s gland hamartomas (BGHs) are rare, benign, primary duodenal tumors. The clinical presentations can vary, and confirming a diagnosis can be challenging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215668"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 427,
          "text": "tomy (HSP). Brunner\u0027s gland hamartoma (BGH) is a rare benign small bowel tumor. The majority of BGH measuring about 2 cm in diameter, rarely larger than 5 cm. Most patients are asymptomatic, some may present with gastrointestinal hemorrhage or intestinal ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31443637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 383,
          "text": "Brunner\u0027s gland hamartomas (BGHs) are uncommon lesions of duodenum which show hyperplasia of these glands along with smooth muscle bundles, adipose tissue and lymphoid aggregates. These are usually benign, solitary, pedunculated, polypoidal lesions. Dysplastic changes in BGH are extremely rare and even rarer is the multiplicity of this lesion. We hereby report an index case of BGH",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30971558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Brunner\u0027s gland hamartoma (BGH) is a rare sub-epithelial tumour of the duodenum, which may cause haemorrhagic or obstructive gastrointestinal symptoms. Their accurate histological diagnosis often remains elusive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31427914"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 106,
          "text": "Brunner\u0027s gland hamartoma (BGH) of the duodenum causing upper gastrointestinal (GI)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19140240"
        }
      ],
      "id": "65f59db8c4010b4d78000014",
      "ideal_answer": [
        "Brunner\u0027s gland hamartoma (BGH) is a rare, benign tumor of the duodenum. It is mostly asymptomatic and usually found incidentally on routine esophagogastroduodenoscopy (EGD).",
        "Brunner\u0027s gland hamartoma is a rare benign duodenal tumor. It occurs in Brunner\u0027s glands, which are found in the duodenum and produce secretions that protect the duodenum from pancreatic enzymes, gastric acid, and other agents.",
        "Brunner\u0027s gland hamartomas (BGH) are rare, benign tumors of the duodenum and are often asymptomatic. They are usually diagnosed incidentally during esophagogastroduodenoscopy or upper gastrointestinal series.",
        "Brunner\u0027s gland hamartomas are rare tumors of duodenum, they are often discovered incidentally during esophagogastroduodenoscopy or upper gastrointestinal series."
      ]
    },
    {
      "body": "Is peritoneal dialysis the best option for infants with kidney failure?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36449100",
        "http://www.ncbi.nlm.nih.gov/pubmed/32063210",
        "http://www.ncbi.nlm.nih.gov/pubmed/2739769",
        "http://www.ncbi.nlm.nih.gov/pubmed/10723344",
        "http://www.ncbi.nlm.nih.gov/pubmed/34648058",
        "http://www.ncbi.nlm.nih.gov/pubmed/17990805",
        "http://www.ncbi.nlm.nih.gov/pubmed/35589990",
        "http://www.ncbi.nlm.nih.gov/pubmed/26591190",
        "http://www.ncbi.nlm.nih.gov/pubmed/11998382",
        "http://www.ncbi.nlm.nih.gov/pubmed/21907533",
        "http://www.ncbi.nlm.nih.gov/pubmed/22371780",
        "http://www.ncbi.nlm.nih.gov/pubmed/23350610",
        "http://www.ncbi.nlm.nih.gov/pubmed/26438039",
        "http://www.ncbi.nlm.nih.gov/pubmed/32063141"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 48,
          "offsetInEndSection": 83,
          "text": "automated peritoneal dialysis (APD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100"
        },
        {
          "offsetInBeginSection": 1703,
          "offsetInEndSection": 1706,
          "text": "APD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100"
        },
        {
          "offsetInBeginSection": 1826,
          "offsetInEndSection": 1828,
          "text": "PD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449100"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 141,
          "text": "Peritoneal dialysis (PD) remains the most widely used modality for chronic dialysis in children, particularly in younger children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32063210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Chronic ambulatory peritoneal dialysis (CAPD) is the treatment most often used in neonates and infants with chronic kidney failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10723344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kidney failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34648058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Peritoneal dialysis remains the treatment of choice for acute renal failure in infancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2739769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Peritoneal dialysis is the most commonly prescribed dialysis modality for infants and young children with kidney failure worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35589990"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 419,
          "text": "The authors demonstrate that peritoneal dialysis is an effective, safe, and available method for treating acute renal failure in infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11998382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kidney failure. Hemodialysis (HD) is used less often due to the technical challenges and risk of complications in small",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34648058"
        },
        {
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1636,
          "text": "cannula, venous catheter).CONCLUSION: Peritoneal dialysis is the method of choice in newborns with acute renal failure, and it is used in the treatment of neonatal asphyxia till the restoration of kidney function is achieved.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17990805"
        },
        {
          "offsetInBeginSection": 2154,
          "offsetInEndSection": 2241,
          "text": "Peritoneal dialysis is the treatment of choice for infants with chronic kidney failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26591190"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 504,
          "text": "Peritoneal dialysis is the renal replacement therapy of choice, especially in children under 2 years, with an important risk of peritonitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21907533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Peritoneal dialysis (PD) is considered as the most common form of renal replacement therapy for newborns including preterms with acute kidney injury (AKI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23350610"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "BACKGROUND: Peritoneal dialysis is the preferred mode of renal replacement therapy in infants with end-stage renal disease (ESRD). Hemodialysis (HD) is seldom used in neonates and infants due to the risk of major complications in the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34648058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "BACKGROUND: Peritoneal dialysis (PD) is the preferred modality of renal replacement therapy in children with end-stage renal dis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32063141"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "INTRODUCTION: Peritoneal dialysis (PD) is a preferred method of renal replacement therapy for end-stage renal disease in children. Recent advances have allowed chronic PD to be provided to children of all a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371780"
        }
      ],
      "id": "65f86e06c4010b4d7800005a",
      "ideal_answer": [
        "Yes, peritoneal dialysis is often the preferred method for infants with kidney failure.",
        "Peritoneal dialysis (PD), also known as automated peritoneal dialysis (APD), is indeed the most widely used method for chronic dialysis in children, especially in younger ones like infants. This method is often preferred because it can be done at home and is less disruptive to a child\u0027s daily routine. However, the \"best\" option can vary depending on the specific circumstances of the child, including their overall health, the severity of their kidney failure, and other individual factors. Therefore, while PD is a common and often effective choice, it\u0027s important to discuss all possible treatment options with a healthcare provider",
        "Peritoneal dialysis (PD) is often considered the preferred option for infants with kidney failure. PD is a form of dialysis that uses the peritoneal membrane in the abdomen to remove waste products and excess fluid from the body. It is particularly suitable for infants because it can be performed at home, allowing for greater flexibility and minimizing the need for frequent hospital visits. PD also provides continuous dialysis, which can be beneficial for infants with unstable kidney function. However, the decision regarding the best dialysis option for infants should be made on an individual basis, taking into account factors such as the infant\u0027s overall health, the availability of resources, and the preferences of the parents or caregivers. It is important for the treating physician to carefully evaluate and discuss the various treatment options with the parents or caregivers to determine the most appropriate approach for each infant with kidney failure."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is Lecanemab approved for Alzheimer’s Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37490245",
        "http://www.ncbi.nlm.nih.gov/pubmed/37389302",
        "http://www.ncbi.nlm.nih.gov/pubmed/37414156",
        "http://www.ncbi.nlm.nih.gov/pubmed/37334596",
        "http://www.ncbi.nlm.nih.gov/pubmed/37357276",
        "http://www.ncbi.nlm.nih.gov/pubmed/36856953",
        "http://www.ncbi.nlm.nih.gov/pubmed/37902139",
        "http://www.ncbi.nlm.nih.gov/pubmed/37676096",
        "http://www.ncbi.nlm.nih.gov/pubmed/36931947",
        "http://www.ncbi.nlm.nih.gov/pubmed/38017568",
        "http://www.ncbi.nlm.nih.gov/pubmed/37831471",
        "http://www.ncbi.nlm.nih.gov/pubmed/37682322",
        "http://www.ncbi.nlm.nih.gov/pubmed/38095822",
        "http://www.ncbi.nlm.nih.gov/pubmed/37479527",
        "http://www.ncbi.nlm.nih.gov/pubmed/38067098",
        "http://www.ncbi.nlm.nih.gov/pubmed/38021811",
        "http://www.ncbi.nlm.nih.gov/pubmed/37955845",
        "http://www.ncbi.nlm.nih.gov/pubmed/37927263",
        "http://www.ncbi.nlm.nih.gov/pubmed/37251789",
        "http://www.ncbi.nlm.nih.gov/pubmed/37060386",
        "http://www.ncbi.nlm.nih.gov/pubmed/37639602",
        "http://www.ncbi.nlm.nih.gov/pubmed/37045461"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1069,
          "text": "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245"
        },
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1068,
          "text": "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 462,
          "text": "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer\u0027s disease treatment pipeline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37490245"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 461,
          "text": "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer\u0027s disease treatment pipeline",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37389302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "The US Food and Drug Administration (FDA)\u0027s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer\u0027s disease (AD), aducanumab and lecanemab, has caused substantial debate. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37414156"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37334596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer\u0027s disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37357276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer\u0027s disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38095822"
        },
        {
          "offsetInBeginSection": 506,
          "offsetInEndSection": 659,
          "text": "Finally, in the last two years, the Food and Drug Administration (FDA) approved the first-ever medications to treat Alzheimer\u0027s, aducanumab and lecanemab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38067098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38095822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer\u0027s disease with mild cognitive impairment or mild dementia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer\u0027s disease treatment.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37682322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Two anti-amyloid monoclonal antibodies (MABs)-lecanemab (Leqembi®) and aducanumab (Aduhelm®)-have been approved in the USA for the treatment of Alzheimer\u0027s disease (AD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer\u0027s disease with mild cognitive impairment or mi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "On July 6, 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer\u0027s dementia (AD) patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37676096"
        },
        {
          "offsetInBeginSection": 1329,
          "offsetInEndSection": 1418,
          "text": "Lecanemab has been recently approved by the FDA for the treatment of Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931947"
        },
        {
          "offsetInBeginSection": 443,
          "offsetInEndSection": 540,
          "text": " Full FDA approval was granted for lecanemab due to its ability to eliminate toxic brain amyloids",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37682322"
        },
        {
          "offsetInBeginSection": 398,
          "offsetInEndSection": 492,
          "text": "Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37045461"
        },
        {
          "offsetInBeginSection": 1002,
          "offsetInEndSection": 1145,
          "text": "This article summarizes the milestones in the development of lecanemab leading to this first approval for the treatment of Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36856953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "text": "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer\u0027s disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer\u0027s disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38095822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 358,
          "text": "Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer\u0027s disease patients who have proven β-amyloid pathology (Aβ). One of these, lecanemab, has subsequently received full approval and other monoclonal antibodies are poised for positive review and approva",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37955845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Recently, the U.S. Food and Drug Administration (FDA) approved 2 anti-amyloid monoclonal antibodies, aducanumab (June 7, 2021) and lecanemab (July 6, 2023), for the treatment of Alzheimer\u0027s disease (AD) patients, and will most likely also approve a 3rd one, donanemab, soon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37831471"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 454,
          "text": "n. Consistent with a critical role for this form of Aβ in AD, a recently FDA-approved therapeutic antibody targeted against protofibrils, lecanemab, slows the progression of AD in patie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37639602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "BACKGROUND: The approval of lecanemab for the treatment of Alzheimer\u0027s disease (AD) by the Food and Drug Administration in the United States has sparked controversy over issues of safety, cost, a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927263"
        },
        {
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1186,
          "text": "ed in the analysis.RESULTS: The FDA approved lecanemab for Alzheimer\u0027s disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139"
        },
        {
          "offsetInBeginSection": 55,
          "offsetInEndSection": 237,
          "text": "(FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer\u0027s dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37676096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer\u0027s disease with mild cognitive impairment or mild dementia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 452,
          "text": "Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic (formerly BioArctic Neuroscience), and in collaboration with Biogen, for the treatment of Alzheimer\u0027s disease, and received its first approval for this indication on 6 January 2023 in the USA under the Accelerated Approval Pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36856953"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 334,
          "text": "lt to cure. Drugs aimed at slowing the progression of the disease have been developed, with the Food and Drug Administration (FDA) granting accelerated approval for aducanumab on June 21, 2021 and a new accelerated approval for lecanemab on Janua",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38017568"
        }
      ],
      "id": "65ce88b71930410b13000001",
      "ideal_answer": [
        "Yes. Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer\u0027s disease (AD) to be initiated in early AD (mild cognitive impairment due to AD or mild AD dementia) with confirmed brain amyloid pathology."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Can Ultrasonography be used to detect tumors in dogs and cats?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36790748",
        "http://www.ncbi.nlm.nih.gov/pubmed/15005361",
        "http://www.ncbi.nlm.nih.gov/pubmed/7591927",
        "http://www.ncbi.nlm.nih.gov/pubmed/7358560",
        "http://www.ncbi.nlm.nih.gov/pubmed/6698841",
        "http://www.ncbi.nlm.nih.gov/pubmed/34617607",
        "http://www.ncbi.nlm.nih.gov/pubmed/29530040",
        "http://www.ncbi.nlm.nih.gov/pubmed/22331324",
        "http://www.ncbi.nlm.nih.gov/pubmed/21486639",
        "http://www.ncbi.nlm.nih.gov/pubmed/17153071",
        "http://www.ncbi.nlm.nih.gov/pubmed/34828010",
        "http://www.ncbi.nlm.nih.gov/pubmed/34521571",
        "http://www.ncbi.nlm.nih.gov/pubmed/11130788",
        "http://www.ncbi.nlm.nih.gov/pubmed/31579524",
        "http://www.ncbi.nlm.nih.gov/pubmed/10955496",
        "http://www.ncbi.nlm.nih.gov/pubmed/25028432",
        "http://www.ncbi.nlm.nih.gov/pubmed/9402711",
        "http://www.ncbi.nlm.nih.gov/pubmed/15017037",
        "http://www.ncbi.nlm.nih.gov/pubmed/18418997"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Ultrasonography (US) and computed tomography (CT) are used to diagnose neoplastic and non-neoplastic focal renal lesions in dogs and cats",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36790748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "A retrospective survey from January 1989 to January 1999 of Tufts University Foster Hospital for Small Animals radiology records of 12 dogs and seven cats with cytologically or histopathologically confirmed abdominal mast cell disease was perform",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15005361"
        },
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1520,
          "text": "Although these findings are not specific to the disease in either species, abdominal ultrasound is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15005361"
        },
        {
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1050,
          "text": "In the 2 dogs with intradural masses, intraoperative ultrasonography helped to delineate the extent of the tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Two-dimensional, gray-scale ultrasonography for assessment of hepatic and splenic neoplasia in the dog and cat.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6698841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "BACKGROUND: In veterinary medicine, contrast-enhanced ultrasonography allowed the accurate quantification of liver, splenic and kidney vascularization in healthy dogs and the differentiation between malignant and benign hepatic, renal, and splenic nodules in dogs and cats based on perfusion patterns.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29530040"
        },
        {
          "offsetInBeginSection": 982,
          "offsetInEndSection": 1455,
          "text": "In dogs, an ultrasonographically normal liver was associated with not having lymphomatous infiltration, leopard-spotted splenic parenchyma and splenomegaly were independently associated with lymphomatous infiltration and leopard-spotted splenic parenchyma was also associated with the B cell immunophenotype of multi-centric lymphoma.CLINICAL SIGNIFICANCE: Ultrasonography of the spleen and liver is specific but not sensitive in the detection of lymphomatous infiltration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34617607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 532,
          "text": "CASE SUMMARY: A 14-year-old cat was presented with a 2-week history of ataxia, seizure-like episodes, vomiting and weight loss. Serum biochemistry revealed severe hypoglycaemia, associated with low serum fructosamine and high insulin concentrations. On abdominal ultrasound, a focal hypoechoic well-defined mass in the left limb of the pancreas was identified and the presence of an additional smaller nodule was suspected. Contrast-enhanced ultrasonography (CEUS) confirmed the presence of both lesions and revealed a third, even s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31579524"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "A 12-year-old fox-terrier dog presented with forelimb lameness of 3-weeks duration. Ultrasonography revealed a mass within the thoracic wall and osteolysis of the left third rib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16901271"
        },
        {
          "offsetInBeginSection": 412,
          "offsetInEndSection": 593,
          "text": "Abdominal ultrasound was performed in three cats and one dog, findings included the presence of hyperechoic masses with associated acoustic shadowing, some with a hypoechoic centre.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10955496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "OBJECTIVES: To determine the diagnostic accuracy of ultrasonography in the detection of lymphomatous infiltration of the liver and spleen in a population of dogs and cats with lymphoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34617607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Ultrasonography, which has become a mainstay of diagnosing intestinal diseases in dogs and cats, is often one of the first diagnostic tools used to differentiate inflammatory from neoplastic infiltration of the small intestine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21486639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Lung Ultrasound for Imaging of B-Lines in Dogs and Cats-A Prospective Study Investigating Agreement between Three Types of Transducers and the Accuracy in Diagnosing Cardiogenic Pulmonary Edema, Pneumonia and Lung Neoplasia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34828010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Diagnostic accuracy of ultrasonography to detect hepatic and splenic lymphomatous infiltration in dogs and cats.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34617607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Focused Ultrasound of Superficial-Soft Tissue Swellings, Masses, and Fluid Collections in Dogs and Cats.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521571"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 271,
          "text": "This report describes four dogs with pheochromocytoma in which radiography, ultrasonography and computed tomography (CT) were key diagnostic tools.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130788"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 270,
          "text": "Mural lesions representing lymphoma affecting the urinary bladder were identified ultrasonographically in all animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17153071"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 239,
          "text": "Abdominal ultrasound and MRI were performed on 8 dogs having a mass lesion on abdominal radiography.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9402711"
        },
        {
          "offsetInBeginSection": 444,
          "offsetInEndSection": 609,
          "text": "Ultrasonography revealed masses in all dogs with uterine body/cervical tumors and could delineate the origin of the mass in one of two dogs with uterine horn tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028432"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "The presence of a heart-base tumor was diagnosed by ultrasound imaging in a 10-year-old, female, domestic shorthaired cat presenting with dyspnea and pleural effusion because of the presence of a modified transudate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15017037"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 274,
          "text": "ultrasonography was found to be useful in the diagnosis of hydronephrosis, renal calculi, and renal neoplasia in the dog and cat. One dog with hydronephorsis, one with renal calculi, and a cat with a renal neoplasm were scanned with a real-time ultrasonic scanner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7358560"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 603,
          "text": "l disease.MATERIAL AND METHODS: Ultrasonography and MRI were performed in 15 dogs and 15 cats with intraocular neoplasia or intraocular inflammatory disease.RESULTS: In all patients with intraocular neoplasia, sonography revealed masses with increased echogenicity and fairly uniform echotexture, thus allowing the tenta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22331324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Contrast-enhanced ultrasound was used to study focal and multifocal lesions of the spleen in 26 dogs and two cats affected by 11 benign and 18 malignant splenic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18418997"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 90,
          "text": "ltrasonography of small intestinal inflammatory and neoplastic diseases in dogs and cats.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21486639"
        }
      ],
      "id": "65f5a3efc4010b4d78000017",
      "ideal_answer": [
        "Ultrasonography can be used as screening tests for dogs and cats, potentially representing an alternative to the invasive sampling methods required for cytological and histopathological analysis.",
        "Yes, Ultrasonography can be used to detect tumors in dogs and cats but space for equipment is often limited in veterinary practices.",
        "Yes, ultrasonography can be effectively used to detect tumors in dogs and cats.",
        "Yes, ultrasonography can be used to detect tumors in dogs and cats.",
        "Yes, Ultrasonography can be used to detect tumors in dogs and cats.",
        "Yes, ultrasound can be used to detect tumors in dogs and cats.",
        "uresonography is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology.",
        "No, Ultrasonography cannot be used to detect tumors in dogs and cats.",
        "Yes, ultrasonography can be used to detect tumors in dogs and cats. It is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology. Intraoperative ultrasonography can also help to delineate the extent of intradural tumors in dogs.",
        "Yes, Ultrasonography can be used to detect tumors in dogs and cats, as it is a diagnostic tool commonly used to identify neoplastic and non-neoplastic focal renal lesions in these animals.",
        "”The use of diagnostic ultrasound has been reported in dogs and cats for the purpose of detecting tumors. This method has the advantage of being non-invasive, and the ultrasound images can be transmitted and recorded for future reference.\"}",
        "Yes, ultrasonography can be used to detect both neoplastic and non-neoplastic focal renal lesions in dogs and cats.",
        "Yes, ultrasonography (US) can be used to detect tumors in dogs and cats. It is a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology. In the case of intradural masses, intraoperative ultrasonography can help to delineate the extent of the tumor.",
        "Yes, ultrasonography can detect tumors in dogs and cats.",
        "Yes, Ultrasonography (US) is used to diagnose neoplastic and non-neoplastic focal renal lesions in dogs and cats.",
        "Yes, ultrasonography can be used to detect tumors in dogs and cats. It is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumors and other neoplastic lesions, especially when used in conjunction with histopathology or cytology for confirmation.",
        "Yes, ultrasonography is commonly used to detect tumors in dogs and cats. It is a useful tool for determining the extent of disease in small-animal patients with tumors, especially when used in conjunction with histopathology or cytology.",
        "Yes, ultrasonography (US) can be used to detect tumors in dogs and cats."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the first line treatment for severe Plasmodium falciparum malaria?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36056897",
        "http://www.ncbi.nlm.nih.gov/pubmed/37666798",
        "http://www.ncbi.nlm.nih.gov/pubmed/36126008",
        "http://www.ncbi.nlm.nih.gov/pubmed/17402835",
        "http://www.ncbi.nlm.nih.gov/pubmed/30885541",
        "http://www.ncbi.nlm.nih.gov/pubmed/25217396",
        "http://www.ncbi.nlm.nih.gov/pubmed/22453057",
        "http://www.ncbi.nlm.nih.gov/pubmed/35916842",
        "http://www.ncbi.nlm.nih.gov/pubmed/25069406",
        "http://www.ncbi.nlm.nih.gov/pubmed/27089770",
        "http://www.ncbi.nlm.nih.gov/pubmed/27809844",
        "http://www.ncbi.nlm.nih.gov/pubmed/23121274",
        "http://www.ncbi.nlm.nih.gov/pubmed/22818552",
        "http://www.ncbi.nlm.nih.gov/pubmed/26832999",
        "http://www.ncbi.nlm.nih.gov/pubmed/27613271",
        "http://www.ncbi.nlm.nih.gov/pubmed/15642960",
        "http://www.ncbi.nlm.nih.gov/pubmed/16923176",
        "http://www.ncbi.nlm.nih.gov/pubmed/33685888",
        "http://www.ncbi.nlm.nih.gov/pubmed/35326891",
        "http://www.ncbi.nlm.nih.gov/pubmed/25163350",
        "http://www.ncbi.nlm.nih.gov/pubmed/33344893",
        "http://www.ncbi.nlm.nih.gov/pubmed/25348537",
        "http://www.ncbi.nlm.nih.gov/pubmed/19881520",
        "http://www.ncbi.nlm.nih.gov/pubmed/26880088",
        "http://www.ncbi.nlm.nih.gov/pubmed/22966778",
        "http://www.ncbi.nlm.nih.gov/pubmed/27449110",
        "http://www.ncbi.nlm.nih.gov/pubmed/24659706",
        "http://www.ncbi.nlm.nih.gov/pubmed/30983213",
        "http://www.ncbi.nlm.nih.gov/pubmed/31843017",
        "http://www.ncbi.nlm.nih.gov/pubmed/34561157",
        "http://www.ncbi.nlm.nih.gov/pubmed/26483118",
        "http://www.ncbi.nlm.nih.gov/pubmed/32228566",
        "http://www.ncbi.nlm.nih.gov/pubmed/35857773",
        "http://www.ncbi.nlm.nih.gov/pubmed/23350023"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Intravenous artesunate has been the global standard of care for severe malaria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36056897"
        },
        {
          "offsetInBeginSection": 67,
          "offsetInEndSection": 152,
          "text": "Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37666798"
        },
        {
          "offsetInBeginSection": 1560,
          "offsetInEndSection": 1628,
          "text": "Intravenous artesunate is the treatment of choice for severe malaria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126008"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 421,
          "text": "The first line treatments for Plasmodium falciparum are artemisinin combination therapies, chloroquine in most non-falciparum and intravenous artesunate if any severity criteria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26832999"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "BACKGROUND: In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16923176"
        },
        {
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1646,
          "text": "Total treatment failure was significantly higher in the SP group (96/393; 19.3%) as compared to the AL (22/403; 5.4%) group (OR: 4.15; 95% CI: 2.52-6.83; P \u003c 0.001).CONCLUSION: In Zambia, the new first line regimen AL is far more efficacious than SP in treating uncomplicated P. falciparum malaria in adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16923176"
        },
        {
          "offsetInBeginSection": 668,
          "offsetInEndSection": 745,
          "text": "Artesunate should constitute first-line treatment for severe malaria in Asia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17402835"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 268,
          "text": "Artesunate has become the treatment of choice for severe malaria, and artemisinin-based combination therapies (ACTs) are the foundation of modern falciparum malaria treatment globally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613271"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 469,
          "text": "Combination therapy through coadministration of sulfadoxine-pyrimethamine plus artesunate was introduced as a first-line treatment for uncomplicated malaria in one district in Tanzania.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642960"
        },
        {
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1471,
          "text": "First-line therapy for P falciparum malaria in the US is combination therapy that includes artemisinin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22453057"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 179,
          "text": "Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33685888"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for severe malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35326891"
        },
        {
          "offsetInBeginSection": 1410,
          "offsetInEndSection": 1511,
          "text": "IV artesunate is now recommended as the first-line treatment for severe falciparum malaria in France.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25163350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37666798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-based combination therapies (ACTs), consisting of an artemisinin derivative combined with a longer acting partner drug.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33344893"
        },
        {
          "offsetInBeginSection": 2762,
          "offsetInEndSection": 2826,
          "text": "Intravenous artesunate is first-line therapy for severe malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for Plasmodium falciparum malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19881520"
        },
        {
          "offsetInBeginSection": 1121,
          "offsetInEndSection": 1200,
          "text": "First-line treatment of severe P. falciparum malaria is based on IV artesunate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25069406"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "BACKGROUND: Artemisinin combination therapy (ACT) is used worldwide as the first-line treatment against uncomplicated Plasmodium falcipa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27809844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 329,
          "text": "Artemisinin-based combination therapies (ACTs) have been adopted as the first line of treatment against malaria in nearly all malaria-endemic countries, mainly as a result of Plasmodium falciparum infection, as this species of malaria parasite has developed resistance to most of the available non-artemisinin antimalarial drugs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121274"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 231,
          "text": "of malaria. Artemisinin-based combination therapy (ACT) is the WHO recommended first-line treatment for Plasmodium falciparum malaria across the en",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27449110"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 313,
          "text": "d in India. By 2007, the first-line treatment for uncomplicated malaria has been revised to recommend artemisinin-based combination therapy (ACT) for all confirmed P. falci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818552"
        },
        {
          "offsetInBeginSection": 276,
          "offsetInEndSection": 380,
          "text": "The World Health Organisation (WHO) recommends arthemether combination treatment as a first line choice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659706"
        },
        {
          "offsetInBeginSection": 437,
          "offsetInEndSection": 589,
          "text": "The main advance is the positioning of artemisinin derivative- based combinations as first-line, given their rapidity of action and their effectiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30983213"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 247,
          "text": "As recommended by the World Health Organization, the ART-based combination therapies (ACTs) have become the first-line drugs for the treatment of falciparum malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27089770"
        },
        {
          "offsetInBeginSection": 1526,
          "offsetInEndSection": 1757,
          "text": "ost-treatment QTc interval.CONCLUSION: Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three onc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31843017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217396"
        },
        {
          "offsetInBeginSection": 2347,
          "offsetInEndSection": 2674,
          "text": "Uncomplicated P. falciparum malaria should be treated with an artemisinin combination therapy (Grade 1A). Artemether-lumefantrine (Riamet(®)) is the drug of choice (Grade 2C) and dihydroartemisinin-piperaquine (Eurartesim(®)) is an alternative. Quinine or atovaquone-proguanil (Malarone(®)) can be used if an ACT is not availab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880088"
        },
        {
          "offsetInBeginSection": 1195,
          "offsetInEndSection": 1322,
          "text": "The first-line treatment of severe malaria is now intravenous artesunate which is more effective than quinine in endemic areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30885541"
        },
        {
          "offsetInBeginSection": 22,
          "offsetInEndSection": 305,
          "text": "as recently undergone a rapid decline in Plasmodium falciparum transmission following combined malaria control interventions with artemisinin-based combination therapy (ACT) and integrated vector control. Artesunate-amodiaquine (ASAQ) was implemented as first-line treatment for unco",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "BACKGROUND: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy (ACT) with artemether-lumefantrine as the first-line treatment for uncomplicated Plasmodium falciparum malaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32228566"
        },
        {
          "offsetInBeginSection": 2010,
          "offsetInEndSection": 2075,
          "text": "For severe malaria, intravenous artesunate is first-line therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916842"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34561157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Artemisinin combination therapy (ACT) is the first line to treat uncomplicated Plasmodium falciparum malaria worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26483118"
        },
        {
          "offsetInBeginSection": 3197,
          "offsetInEndSection": 3515,
          "text": "2. The treatment of choice for severe or complicated malaria in adults and children is intravenous artesunate (Grade 1A). Intravenous artesunate is unlicensed in the EU but is available in many centres. The alternative is intravenous quinine, which should be started immediately if artesunate is not available (Grade 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: The artemisinin derivatives are the preferred antimalaria drugs for treating severe Plasmodium falcipa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857773"
        },
        {
          "offsetInBeginSection": 2225,
          "offsetInEndSection": 2422,
          "text": "For severe malaria, in the second and third trimester parenteral artesunate is preferred over quinine. In the first trimester, both artesunate and quinine (parenteral) may be considered as options.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23350023"
        }
      ],
      "id": "65f82058c4010b4d7800003d",
      "ideal_answer": [
        "First line treatment in severe Plasmodium falciparum malaria is artesunate.",
        "- For severe Plasmodium falciparum malaria, intravenous artesunate is the recommended first-line treatment. Intravenous artesunate is administered for 24 hours after clinical improvement is observed, followed by a full course of artemisinin-based combination therapy (ACT).",
        "The first-line treatment for severe Plasmodium falciparum malaria is injectable artesunate.",
        "The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate. WHO recommends artesunate for the first 24 hours, followed by a combination of artemisinin derivatives and oral lumefantrine, for a total of 3 days.",
        "Injectable artesunate is the first line treatment for severe Plasmodium falciparum malaria.",
        "First-line treatment of severe P. falciparum malaria is based on IV artesunate.",
        "Intravenous artesunate",
        "Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria. If artesunate is not available, intravenous quinine should be started immediately as an alternative treatment.",
        "Intravenous artesunate is the first-line treatment for severe falciparum malaria.",
        "Yes, artesunate is the first-line treatment for severe malaria.",
        "parenteral artesunate (ARS)",
        "Parenteral artesunate is the first-line treatment for severe Plasmodium falciparum malaria.",
        "Parenteral artesunate (ARS) is the first-line treatment for severe Plasmodium falciparum malaria.",
        "Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria.",
        "The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is the global standard of care for severe malaria.",
        "The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS). This is also known as intravenous artesunate and is recognized as the global standard of care for severe malaria.",
        "The first-line treatment for severe Plasmodium falciparum malaria is parenteral or intravenous artesunate.",
        "Parenteral artesunate is the first-line treatment for severe falciparum malaria.",
        "The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS).",
        "The first-line treatment for severe Plasmodium falciparum malaria is parenteral artesunate (ARS), which can be administered intravenously or intramuscularly.",
        "Intravenous artesunate is the first-line treatment for severe Plasmodium falciparum malaria.",
        "Intravenous artesunate is the first-line treatment and global standard of care for severe falciparum malaria.",
        "The first-line treatment for severe Plasmodium falciparum malaria is intravenous artesunate.",
        "Intravenous artesunate is the first line treatment for severe Plasmodium falciparum malaria."
      ],
      "exact_answer": [
        [
          "Artesunate",
          "intravenous artesunate",
          "IV artesunate",
          "parenteral artesunate"
        ]
      ]
    }
  ]
}